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Abstract
The hypothalamo-pituitary-adrenal (HPA) axis plays a vital role in restoring homeostasis
following stress; responsiveness of the axis can change however. The
adrenocorticotropic hormone (ACTH) and corticosterone secretory responses to
emotional and physical stressors are reduced in late pregnancy. Here, experiments were
designed to investigate changes in the brain mechanisms underlying these reduced
responses, with particular focus on adaptations at the level of the hypothalamus. The
responsiveness of the HPA axis to the emotional stressors, restraint and maternal
aggression were markedly reduced in late pregnant (day 21) rats. This was at least partly
a result of reduced activation of the parvocellular paraventricular nucleus (pPVN)
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) neurones, as
revealed by quantitative in situ hybridisation for NGFI-B mRNA and AVP hnRNA
expression. To seek changes in responses to immune challenge, lipopolysaccharide
(LPS) and interleukin-1P (IL-ip) were given acutely. Blood sampling from conscious
rats revealed that the ACTH and corticosterone secretory responses to peripheral
immune challenge are strongly attenuated in late pregnant rats. This was found to be a
consequence of the CRH neurones being stimulated less by the stressor in pregnancy,
resulting in reduced drive to the anterior pituitary by CRH. IL-lp has been shown to act
via a brainstem pathway from the nucleus of the tractus solitarus (NTS) to the PVN. IL-
1P was found to activate Fos expression in NTS neurones similarly in virgin and
pregnant rats, indicating that signalling between the NTS and the PVN neurones is
interrupted in pregnancy, resulting in reduced activation of the HPA axis. Endogenous
opioids are involved in this attenuation of HPA axis responses to IL-lp in pregnancy, as
removing opioid inhibition by pre-treatment with the opioid receptor antagonist,
naloxone, largely reinstated the ACTH response to IL-ip in the pregnant rats, and
resulted in CRH mRNA responses that were not different between virgin and pregnant
rats. Oxytocin is also a "stress hormone" in rats. Oxytocin secretory responses to
systemic IL-ip were attenuated in late pregnant rats, which was shown to be also a
consequence of strong opioid restraint. To test if CRH neurones were also non-
responsive in pregnancy to excitatory stimuli concerned with regulating metabolism and
arousal, the effects of orexin-A on HPA activity was measured. Intracerebroventricular
administration of orexin-A evoked a response at all levels of the HPA axis in virgin rats,
but failed to activate the HPA axis in late pregnant rats, indicating a "global reduction"
in the responsiveness of the CRH neurones to stimuli in late pregnancy. A possible role
for enhanced slow and rapid corticosterone negative feedback mechanisms was
investigated. In pregnancy, slow glucocorticoid feedback appears to be enhanced so that
the CRH and AVP neurones in the PVN are more sensitive to removal of this feedback
signal. In contrast, sensitivity to rapid corticosterone feedback in response to stress is
reduced, and is unlikely to underlie the attenuated HPA axis responses to stressors in
pregnant rats. A comparative study demonstrated that mice also display attenuated HPA
axis responses to stress in late pregnancy. Thus changes in central drive to the PVN
neurones and their responsiveness to excitatory inputs seems to be the most important
factor in the reduced responsiveness of the HPA axis in late pregnancy, though enhanced
slow glucocorticoid negative feedback may contribute. The significance of the
suppression of CRH/AVP pPVN neurone responsiveness, and hence reduced HPA
responses in rats and mice following exposure to stress in pregnancy is that it will limit
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General Introduction Chapter I
1.1. Introduction
The successful existence of an organism is dependent upon its ability to mount an
appropriate response when faced with a physiological challenge such as stress. Stress
is a widely used term, with meanings in many disciplines. In the medical field, Hans
Selye (Selye H., 1936) first defined stress as the generalised effort of the organism to
adapt to a critical situation and termed this response "general adaptation syndrome".
Today the popular perception of stress recognised by most civilisations around the
world is that of social and/or work pressures that are often associated with increased
frequency of illnesses. However, stress is not all bad. Responding to stress is a vital
defence mechanism, without which an organism's life may be threatened. Exposure
to adverse events results in a series of orchestrated responses often referred to as
'stress responses'. These responses act to preserve homeostasis and involve complex
behavioural, autonomic and endocrine adaptations, which are all aimed at enhancing
the chances of survival. Problems occur when an organism fails to tenninate a
response to an acute stress and can result in chronic stress syndrome, characterised
by elevated secretion of glucocorticoids with consequent immunosuppression and
vulnerability to disease (Jessop, 1999). Thus, health relies on an organism's ability to
respond to a stressful situation but also on its ability to switch off the stress response
appropriately, when the stress no longer poses a threat.
1.2. Stress and 'Fight-Flight' Responses
The hypothalamo-pituitary-adrenal (HPA) axis and the sympathetic adrenomedullary
systems are the key players in expressing stress responses. Activation of the HPA
axis as a result of stress triggers a neuroendocrine cascade of events, the final
outcome of which is increased production and secretion of glucocorticoids (e.g.
corticosterone in the rat) from the adrenal cortex. The principal action of
glucocorticoids is to promote mobilisation of glucose and fat stores and stimulate
gluconeogenesis (Jeanrenaud & Rohner-Jeanrenaud, 2001). Glucocorticoids also
play an important role in restraining the effectors of the stress response. During
stress, the sympathetic adrenomedullary system is also activated, leading to release
2
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of catecholamines (for review see (McCarty, 1994) e.g. adrenaline and noradrenaline
from the adrenal medulla. In 1930 Walter Cannon (Cannon, 1930) described actions
of the "involuntary" (autonomic) nervous system in response to changes in the
internal environment. The autonomic nervous system plays its part by actions upon
the cardiovascular and respiratory systems, smooth muscles and glands.
Glucocorticoids and catecholamines act together to mobilise energy stores and
redistribute resources. They raise blood pressure and cardiac output and enhance the
delivery of substrates to tissues that are critical to the immediate defence of the
organism, thus enabling the organism to cope with emergency situations and
facilitate "fight or flight" responses. The function of these adaptations is to preserve
homeostasis and defend the stability of the internal environment.
1.3. The Hypothalamo-Pituitary-Adrenal Axis
The major endocrine response to stress occurs via activation of the hypothalamo-
pituitary-adrenal (HPA) axis (see figure 1.1.), which functions to restore deviations
from homeostasis and employs complex negative and positive feedback mechanisms
(Campeau et al, 1998). Stress activates neurosecretory neurones in the parvocellular
region of the hypothalamic paraventricular nucleus (pPVN). These neurones
synthesise two neuropeptides: corticotropin-releasing hormone (CRH) and arginine
vasopressin (AVP). Upon activation of these neurones CRH and AVP is released
from nerve terminals at the external zone of the median eminence into the
hypophysial portal blood system (see figure 1.2.). CRH and AVP act synergistically
at the level of the anterior pituitary to evoke the release of adrenocorticotropic
hormone (ACTH). Specialised cells termed corticotrophs secrete ACTH, which in
turn stimulates secretion of glucocorticoids (corticosterone in rodents or Cortisol in
humans) from the adrenal cortex. Glucocorticoids restrain their own release by
providing feedback inhibition at several levels including the pituitary, hypothalamus
and the hippocampus (see section 1.14.4.).
3
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Hypothalamus
Figure 1.1. The Hypothalamo-Pituitary-Adrenal (HPA) Axis
Neurones in the parvocellular division of the paraventricular nucleus (pPVN)
in the hypothalamus secrete corticotropin-releasing hormone (CRH) and
arginine vasopressin (AVP) in response to stress. CRH stimulates the release
of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland,
which in turn triggers the release of corticosterone from the adrenal cortex.
Corticosterone has a negative feedback effect at the level of both the anterior
pituitary and the hypothalamus to restrain the HPA axis. Blue arrows indicate
stimulation; red arrows indicate inhibition.
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Figure 1.2. Hypothalamo-Pituitary Interactions
Stress activates CRH/AVP neurones in the parvocellular division of the
paraventricular nucleus (pPVN). CRH/AVP neurones terminate at the median
eminence, where they release their respective peptides into the hypophysial portal
blood system. This portal system connects the hypothalamus and the pituitary. On
binding with receptors on anterior pituitary corticotrophs, CRH and AVP
stimulate release of ACTH. The diagram also shows oxytocin neurones which
project directly from the PVN to the posterior pituitary. Oxytocin's role in stress is
discussed in section 1.11. Abbreviations: CRH, corticotropin-releasing hormone;
AVP, arginine vasopressin; ACTH, adrenocorticotropic hormone; OXT, oxytocin.
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1.4. The Paraventricular Nucleus
The hypothalamus is situated at the base of the forebrain below the thalamus, and is
divided in two by the third ventricle (see figure 1.3). Attached to the hypothalamus
by the hypophysial stalk is the pituitary gland. The hypothalamus plays a critical role
in the coordination of autonomic, endocrine and behavioural responses that maintain
homeostasis (Morgane & Panksepp, 1980). In mammals the hypothalamus is
involved in regulation of body temperature (Kanosue et al, 1998), the cardiovascular
system (Ganten et al, 1985), body fluid homeostasis (Denton et al, 1996) and feeding
(Lawrence et al, 1999) , as well as sexual and maternal behaviours (Naruse, 1997;
Pfaus, 1999); all of which aid survival of the species. The neural mechanisms
responsible for these adaptive responses are not completely understood and the
neuroanatomical circuitry involved has been in the past difficult to study since the
hypothalamus gives rise to and is traversed by complex fibre systems. Technological
advancements in the methods used to study neuroanatomy have considerably
benefited those researching the hypothalamus (for review see (Jones & Hatman,
1978)). For example, the development of fluorescent labelled markers for
anterograde and retrograde labelling have provided information about neuronal
axonal projections to and from the hypothalamus, and immunocytochemical
techniques provide information about the identity of these cells.(Lawrence et al ,
1999)
The primary hypothalamic region involved in neuroendocrine responses to stress is
the paraventricular nucleus (PVN). The PVN is found on either side of the third
ventricle (see figure 1.4.) and is composed of distinct magnocellular (large cell) and
parvocellular (small cell) divisions (Gurdjian, 1927; Kreig, 1932). These two major
areas of the PVN can be further divided into a total of eight distinct subdivisions
based on cell structure, cell connections and cell type (Swanson & Kuypers, 1980),
three of which are magnocellular and five of which are parvocellular. The three
subdivisions of the magnocellular PVN are the (i) anterior magnocellular (amPVN),
(ii) medial magnocellular (mmPVN) and (iii) posterior magnocellular (pmPVN)
areas (Swanson & Sawchenko, 1980; Swanson & Sawchenko, 1983). Cells located in
6
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these regions project primarily to the posterior lobe of the pituitary gland (Sherlock
et al, 1975). Cells in the parvocellular division of the PVN (pPVN) generally project
to the external lamina of the median eminence (Swanson et al, 1980; Wiegand &
Price, 1980b) where they influence anterior pituitary function and to the brainstem
and spinal cord (Hosoya & Matsushita M., 1979; Swanson & Kuypers, 1980). As
mentioned above the parvocellular division can be divided into five distinct parts,
these are: anterior, (ap); medial, (mp); lateral, (lp); dorsal, (dp) and periventricular,
(pv) (Swanson & Sawchenko, 1980; Swanson & Sawchenko, 1983).
The PVN of the hypothalamus is the site of CRH/AVP producing cells and thus
plays a crucial role for central control of the HPA axis. Lesions to this region
markedly reduce portal blood CRH levels and stress induced ACTH and
corticosterone secretion (Antoni, 1986).
7
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Figure 1.4. Coronal section through a rat brain, showing location of the
paraventricular nucleus (PVN).
Section representative of one taken approximately -2.0 mm from Bregma.
Abbreviations: PVN, paraventricular nucleus; 3V, third ventricle; OT, optic tract;
LV, lateral ventricle; SON, supraoptic nucleus.
1.5.1. The Pituitary Gland
The pituitary gland is also called the hypophysis and is attached to the median
eminence of the hypothalamus at the base of the brain. Secretion of the hormones of
the pituitary gland is regulated by the hypothalamus. The pituitary gland is divided
into three parts: the anterior lobe {pars distalis), the intermediate lobe {pars
intermedia) and the posterior lobe {pars nervosa). Together the anterior and
intermediate lobes form a true endocrine gland, called the adenohypophysis.
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The posterior lobe, also called the neurohypophysis is a neural extension of the
hypothalamus. The pituitary is attached to the hypothalamus by the hypophyseal
stalk.
1.5.2. The Adenohypophysis
The adenohypophysis is attached to the hypothalamus by the portion of the
hypophyseal stalk called the pars tuberalis which contains the hypophyseal portal
system of blood vessels. The nerve endings of the neurosecretory cells of the
hypothalamus terminate at the median eminence, where their honnones are released
into the hypophyseal portal system and are then carried to the adenohypophysis. The
anterior lobe synthesises and releases six hormones namely adrenocorticotropic
hormone (ACTH), growth hormone (GH), follicle stimulating hormone (FSH),
luteinising hormone (LH), prolactin (PRL) and thyroid stimulating hormone (TSH),
while the intermediate lobe synthesises one hormone: alpha-melanocyte stimulating
hormone (a-MSH).
1.5.3. The Neurohypophysis
The neurohypophysis consists of the posterior lobe of the pituitary and the portion of
the hypophyseal stalk termed the infundibulum. The infundibulum contains axons of
the hypothalamic neurosecretory cells whose cell bodies are located in the
magnocellular regions of the PVN and SON of the hypothalamus and synthesise
oxytocin and vasopressin.
1.6.1. Pathways Involved in Mediating Stress-Induced HPA Axis Activation
The PVN receives a rich and diverse afferent supply, which are potential routes by
which stressful stimuli may influence the HPA axis. Specific central brain circuits
drive excitation of the HPA axis in response to stress.
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1.6.2. Systemic and Neurogenic Stressors
The stress-processing circuit activated by a particular stressor is dependent upon the
nature of the stressor. Generally stress models are divided into two basic categories,
referred to as systemic (also termed physiological or physical) and neurogenic (also
referred to as emotional, psychological or processive) paradigms (Fortier C., 1951)
(for review see (Sawchenko et al, 2000)). Systemic stressors are generally conceived
as physiological threats, which are not necessarily consciously appreciated. Systemic
stress models commonly employed include cardiovascular, osmotic and immune
challenge, as well as ether stress and hypoxia. These stressors have common
properties: they are relayed directly to the PVN by visceral afferent pathways and all
represent a direct threat to survival. Therefore in these situations it is advantageous to
bypass cognitive processing and rapidly relay information to the PVN. In contrast,
neurogenic stressors involve sensory processing and a distinct cognitive component.
Restraint, immobilisation, novel environment and footshock are often employed as
neurogenic stress models. These stressors again have common features: they require
processing of signals from somatosensory pathways prior to initiation of a stress
response and further, none of the neurogenic stressors represent an immediate threat
to homeostasis.
Since lesions to limbic structures (including the prefrontal cortex, hippocampus and
amygdala) disrupt HPA responses to neurogenic stressors but have no effect on HPA
responses to systemic stressors, Herman & Cullinan (Herman & Cullinan, 1997)
have postulated the existence of two generalised stress pathways: "limbic-sensitive"
and "limbic insensitive". The former requires processing and integration by the
limbic system. The limbic system is then capable of augmenting or attenuated the
HPA response depending on prior experience. Limbic insensitive stressors are of
immediate survival value and therefore do not require interpretation by the limbic
system and instead activate the PVN by a relatively direct pathway.
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Transcription of immediate early genes (IEGs) is switched on when a cell is activated
and therefore provides a good indicator of neuronal activation. C-fos, in particular,
has been employed to identify neuronal pathways involved in response to various
stressors (Chan et al, 1993b) (Hoffman et al, 1993). Both neurogenic and systemic
stressors activate cells in the pPVN (reflected by c-fos induction) (Pezzone et al,
1992; Imaki et al, 1993; Ericsson et al, 1994) with indistinguishable patterns of
activation. The patterns of cellular activation in response to these different types of
stressor only become distinct when brain areas beyond the PVN are examined.
1.6.3. Brainstem and Medullary Pathways
Brainstem catecholaminergic pathways are known to project directly to CRH
producing neurones in the PVN. The nucleus of the solitary tract (NTS) in the
brainstem is the principal recipient of sensory information carried by the vagus and
glossopharyngeal nerves. Catecholamine synthesising neurones located here project
to the PVN both directly and indirectly via the ventrolateral medulla (Cunningham &
Sawchenko, 1988; Cunningham et al, 1990). Acute stress causes rapid induction of
IEG expression in brainstem catecholamine neurones, supporting their involvement
in activation of HPA stress responses (Chan et al , 1993b; Cullinan et al, 1995;
Sawchenko et al, 1996). Several studies have demonstrated catecholaminergic drive
appears to promote HPA activity in response to haemorrhage, hypertension,
respiratory distress (Plotsky et al, 1989) and immune challenge (Ericsson et al ,
1994). Further supporting the role of brainstem catecholamine neurones with an
excitatory influence on the HPA axis is evidence that deafferentation of ascending
brainstem pathways to the PVN inhibits induction of c-fos mRNA and Fos protein in
pPVN neurones following immune challenge (Li et al, 1996). However brainstem
deafferentations are ineffective in blocking PVN c-fos induction by footshock. These
inconsistencies suggest alternative circuitry for different stressors.
Evidence also suggests that ascending aminergic inputs may influence HPA activity
following stress. Noradrenergic and serotoninergic inputs from the locus coeruleus
(LC) and raphe nucleus respectively, have been implicated in HPA regulation
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following haemorrhage (Gand D.S., 1977). However both the LC and the raphe
provide fairly limited direct innervation to the PVN (Sawchenko et al, 1983;
Cunningham & Sawchenko, 1988), thus their effects may be mediated via indirect
pathways. The brainstem NTS provides a major noradrenergic input to the PVN
(Herman & Cullinan, 1997; Sawchenko et al , 2000) and this drive is important in
promoting HPA axis activity in response to various stressors including immune
challenge and haemorrhage (Plotsky et al, 1989; Melik Parsadaniantz et al, 1995; Li
et al, 1996; Day & Akil, 1996).
1.6.4. Forebrain Pathways
Several forebrain structures have been reported to influence the activity of the HPA
axis, including the prefrontal cortex, hippocampus, amygdala and septum
(Sawchenko et al , 1996; Herman et al, 1996; Herman & Cullman, 1997). These
brain structures are of particular interest because they are all thought to play some
role in emotionality, and may therefore be involved in evaluating or perceiving the
stressful nature of a given situation. The amygdala is a limbic brain structure that has
been implicated in activation of the HPA axis in response to stress. Stimulation of the
amygdaloid complex elicits corticosterone secretion (Dunn & Whitener, 1986) and
furthermore large increases in c-fos expression have been reported in this brain area
in response to restraint and swim stress (Cullinan et al, 1995). Consistent with these
studies implicating a role for the amygdala in HPA activation, are lesion studies
where destruction of the medial or central amygdaloid nuclei, markedly inhibit HPA
responses to noise or photic stress (Feldman et al, 1994) and similarly lesions to the
central amygdala (CeA) significantly reduce the ACTH and corticosterone secretory
responses to restraint and fear conditioning (Van De Kar et al, 1991). Nevertheless
neither medial nor central amygdaloid lesions affect the HPA response to ether
exposure (Feldman et al , 1994) providing further evidence for stressor-specific
pathways.
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The bed nucleus of the stria terminalis (BNST) is a limbic structure which links the
amygdala and the hippocampus with the hypothalamic and brainstem regions
involved in controlling stress responses (Weller & Smith, 1982; Moga et al, 1989;
Cullinan et al, 1993). Stimulation of the BNST evokes corticosterone secretion
(Dunn, 1987) whereas, ablation of this region results in attenuated CRH mRNA
expression in the PVN and corticosterone secretion, normally induced by conditioned
fear (Gray et al, 1993; Herman et al, 1994).
1.6.5. Hypothalamic Pathways
Most hypothalamic areas have been reported to contribute afferents to parvocellular
PVN neurones (Cullinan et al, 1996), with the exception of a few nuclei, namely the
medial and lateral mammillary nuclei and the supraoptic nuclei. The principal
hypothalamic areas providing numerous afferents to the parvocellular PVN include
several preoptic areas, the anterior and posterior hypothalamic area, the dorsomedial
and ventromedial nuclei and the supramammillary nucleus. Little is known about the
precise functions of these nuclei in stress, though they may integrate stimuli
perceived by an organism and convey this integrated information to the PVN
(Swanson & Sawchenko, 1983).
1.7.1. Stressors
Stressors can be defined either as those that arise suddenly over a relatively short
duration: acute stressors, or those which develop over a longer duration and are
constantly recurring: chronic stressors.
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1.7.2. Acute Stress
A huge range of acute stressors have been used to evoke HPA axis activity including
cold, ether, footshock, i.p. hypertonic saline, restraint, forced swimming and surgical
stress. All of these challenges lead to an increase in ACTH secretion from the
anterior pituitary and increased corticosterone secretion from the adrenal gland. At
the level of the hypothalamus acute stress triggers a rapid, but transient increase in
immunoreactive CRH in the median eminence, lasting approximately 2-4 minutes
(Murakami et al, 1989). The time course involved is too rapid to reflect increased
CRH synthesis, and instead probably reflects increased transport and/or mobilisation
of CRH. Median eminence CRH content begins to decline around 15-30 minutes
following the onset of acute stress (Moldow et al, 1987), presumably reflecting an
increase in release of CRH into the hypophysial portal blood. A second peak in CRH
release occurs 60-80 minutes after the onset of the stress (Moldow et al, 1987) and it
is likely that this represents increased CRH synthesis and transport.
AVP is co-secreted with CRH into the hypophysial portal blood where it stimulates
pituitary corticotrope activity (Antoni, 1993). CRH and AVP mRNA expression in
the pPVN begin to increase two hours after exposure to an acute stress and peak
expression is generally observed at 4 hours after the stressor (Ma & Lightman, 1998).
Prior to changes in mRNA expression following stress, CRH and AVP heteronuclear
RNA (hnRNA) transcripts in the PVN increase, reflecting rapid gene transcription.
Proopiomelanocortin (POMC) is the ACTH precursor and expression of POMC
mRNA in the anterior pituitary has been shown to increase in response to acute
stressors such as hypertonic saline, forced swimming and restraint (Harbuz &
Lightman, 1989).
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The importance of the release of CRH and AVP in stimulating ACTH secretion
during stress has been demonstrated by immunoneutralisation studies. For example,
anti-CRH antiserum substantially reduces the ACTH response to restraint stress,
while anti-AVP antiserum is not as effective. However, a combination of both
antisera results in a greater reduction in ACTH secretion than either antisera alone
(Linton et al, 1985).
In summary, acute stress generally results in a rapid release of CRH and AVP from
stores in the median eminence and rapid stimulation of gene transcription for these
peptides in the pPVN, reflecting increased synthesis. CRH and AVP evoke release of
ACTH from the anterior pituitary, which results in a subsequent rise in corticosterone
secretion from the adrenal gland.
1.7.3. Chronic Stress
In chronically stressed animals the response of the HPA axis to a homotypic stressor
is reduced with each exposure until eventually there is no longer a response (Gomez
et al, 1996; Akana & Dallman, 1997). The desensitisation of HPA responsiveness to
a repeated stress may in part be associated with the desensitisation of the pituitary
ACTH response and down-regulation of anterior pituitary CRH receptors, though
changes in sensitivity to glucocorticoid feedback may also be involved. Previous
studies have shown that although PVN neurones fail to respond (by inducing CRH
gene transcription) to a single episode of restraint stress in repeatedly restrained rats,
neurones are recruited to produce AVP and there are increased AVP stores in the
median eminence (Ma et al, 1997a). Habituation (the gradual disappearance of
responsiveness to a stressor the animal has become accustomed to) seen in response
to repeated stress appears to be stressor specific. Although in chronically stressed rats
there is no longer a CRH response to the homotypic stressor the HPA axis remains
capable of producing a response to novel acute stressors (Kant et al, 1985).
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1.8. Corticotropin-Releasing Hormone
1.8.1. Historical Overview
The functional link between the hypothalamus and the adenohypophysis (anterior
pituitary) was first proposed by Harris in 1948 (Harris, 1948). The findings of two
main studies led to this hypothesis. The first demonstrated activation of the adrenal
cortex following electrical stimulation of the hypothalamus and the second showed
that lesions to the median eminence disrupted the activity of the adenohypophysis.
These observations led him to postulate that factors of hypothalamic origin were
released into the hypophysial portal blood and were responsible for controlling the
release of anterior pituitary hormones. Direct evidence for the existence and
necessity of a hypothalamic "releasing factor" for activation of pituitary corticotrope
cells and control of ACTH release was subsequently provided by Guillemin and
Rosenburg (Guillemin & Rosenberg, 1955) from experiments performed using in
vitro pituitary cultures. Since then, the role of the hypothalamus in the regulation of
ACTH secretion has been supported by in vivo experiments showing that electrical
stimulation of the hypothalamus elevates ACTH and corticosterone levels (Dunn &
Critchlow, 1973a) and that lesions to the medial basal hypothalamus reduces
pituitary-adrenal function (Dunn & Critchlow, 1973b). Over the next 25 years
various groups attempted to isolate and characterise the hypothalamic ACTH
releasing factor.
Early suggestions that AVP may be the physiological corticotropin-releasing factor
were refuted by studies using Brattleboro rats, which do not synthesis AVP, but have
essentially normal patterns of ACTH secretion (Arimura et al, 1967). Furthermore,
other studies demonstrated that hypothalamic fragments have far greater effects on
ACTH secretion than vasopressin (Yasuda et al, 1976). Besides AVP, several other
substances have been reported to stimulate ACTH secretion, including oxytocin,
noradrenaline, adrenaline, a-melanocyte stimulating hormone (a-MSH) and p*
lipotropin (P-LPH) (Vale & Rivier, 1976). However, for various reasons (Vale et al,
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1977) none of these known peptides met the criteria expected of the principal
hypothalamic corticotropic-releasing factor (CRF), and it became clear that in order
to understand the regulation of ACTH secretion, characterisation of the putative CRF
was required.
In 1981, Vale and colleagues (Vale et al, 1981) finally purified and characterised a
41 amino acid corticotropin-releasing factor (CRH-41) from ovine hypothalamic
fragments, and later sequenced rat CRH (Spiess et al, 1981). The most definitive
evidence for the role of endogenous CRH in controlling ACTH secretion was
provided by passive immunisation experiments. Antiserum against CRH was shown
to dramatically attenuate plasma ACTH levels in adrenalectomised rats and cause a
significant reduction in the ACTH response to stress (Rivier et al, 1982). These
findings allowed future studies to focus on interactions of factors known to influence
ACTH secretion with CRH.
1.8.2. CRH Gene Responses to Stress
Stressful stimuli activate pPVN neurones to stimulate CRH release into the portal
bloodstream, which in turn triggers the release of ACTH from the anterior pituitary.
CRH neurones respond to acute and chronic stress in different ways.
Acute stress
Exposure to a variety of acute stressors, including restraint, interperitoneal (i.p.)
hypertonic saline and forced swimming (Harbuz & Lightman, 1989) has been
reported to increase CRH mRNA expression in the parvocellular division of the PVN
(pPVN). Generally, a significant increase in CRH mRNA expression is observed 3-4
hours after the onset of stress, for example CRH mRNA is significantly increased 4
hours after the onset of a 60 minute period of restraint (Ma et al, 1997b). Measuring
levels of CRH heteronuclear RNA (hnRNA; represents primary transcripts and
includes precursors of mRNAs from which introns are spliced out) expression better
reflects rapid changes in gene transcription. Under basal conditions CRH hnRNA
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transcripts are virtually undetectable, however rats killed immediately after a 60
minute period of restraint show significantly elevated levels of CRH hnRNA in the
pPVN neurones (Ma et al , 1997b). Imaki and colleagues have also demonstrated
rapid increases in CRH hnRNA expression in response to restraint increasing within
5 min and a peak in expression at 30 minutes (Imaki et al, 1995; Imaki et al, 1996b).
The cascade of events that mediate the effects of extracellular signals on gene
transcription in the PVN is not fully known.
Restraint stress results in rapid induction of immediate early genes (IEGs), including
c-fos,jun B and nerve growth factor induced gene -B (NGFI-B) in the parvocellular
division of the PVN (Imaki et al, 1996b), all of which are undetectable before stress.
Although c-jun and jun-D mRNA are constitutively expressed in the PVN, small but
significant increases in c-jun and jun-D transcripts are observed 30 min after the
onset of restraint stress (Imaki et al, 1996b). The time course for induction of these
IEG's in response to stress indicates that their products are unlikely to regulate CRH
gene transcription, since CRH hnRNA is increased before their transcription.
Nevertheless, it is likely that IEGs may participate in the activation of CRH gene
transcription. Indeed, the presence of an NGFI-B response element (NBRE) in the
promoter region of the rat CRH gene has been reported (Wilson et al, 1991).
Chronic Stress
Lightman's group have demonstrated that levels of CRH mRNA in the PVN fail to
respond to restraint stress after repeated exposure to daily restraint for 12 days
(Lightman & Harbuz, 1993) and actually decline during chronic inflammatory stress
(Harbuz et al, 1992a). Chronic osmotic stimulation has also been shown to cause a
decrease in CRH mRNA in the PVN (Aguilera et al, 1993). In chronically restrained
rats, exogenous CRH has no effect on plasma ACTH (Hashimoto et al, 1988) and
pituitary CRH receptors decline (Hauger et al, 1990). In repeatedly restrained rats,
inhibition of CRH transcription is selective for the homotypic stressor (the same type
of stressor) and CRH responsiveness to a heterotypic stress (a different type of
stressor, such as i.p. hypertonic saline in this case) is preserved (Ma et al, 1999).
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Furthermore, exposure of a chronically stressed rat to a novel acute stress elicits a
normal (or sometimes enhanced) ACTH response despite the reduction in
corticotrope responsiveness due to a reduction in pituitary CRH receptors. Thus
repeated stress induces a desensitisation of CRH transcription responses, however
rats that have adapted to a chronic homotypical stress retain their ability to respond
to a novel heterotypic stressor.
1.8.3. Regulation of CRH gene expression in response to stress
Rapid induction of CRH hnRNA expression (within 5 min) has been reported
following exposure to ether stress (Kovacs & Sawchenko, 1996b). This rapid
response is incompatible with a primary involvement of any mechanism dependent
upon de novo protein synthesis. A response element for the immediate early gene,
NGFI-B has been identified in the 5' promoter region of the CRH gene (Kovacs &
Sawchenko, 1996b), however the rapid induction of CRH hnRNA within 5 min (at
least for ether stress) precedes the activation of the NGFI-B gene (which occurs at 30
min) (Kovacs & Sawchenko, 1996a; Kovacs & Sawchenko, 1996b) suggesting that
NGFI-B is not involved, at least in response to ether stress, in regulating CRH gene
transcription. CRH gene transcription could be mediated by modification of a
resident moiety to a transcriptionally active form, such as CREB phosphorylation.
CREB is a ubiquitously expressed nuclear protein that mediates transcription by
binding to cAMP response elements (CRE) of responsive genes. CREB is
phosphorylated (to pCREB) by protein kinase A (Armstrong & Montminy, 1993) or
Ca2+/calmodulin-dependent kinases (Hagiwara et al, 1993). A CRE has been
localised on the CRH promoter (Seasholtz AF, 1988). pCREB induction occurs in
the pPVN with a time-course parallel to that of CRH hnRNA expression (following
exposure to ether) supporting a role for pCREB in regulating CRH gene
transcription.
20
General Introduction Chapter I
1.8.4. Central Distribution of Corticotropin-Releasing Hormone
CRH-41 as discovered by Vale and colleagues is the major factor responsible for
triggering ACTH release. CRH has been detected by radioimmunoassay in the
external zone of the median eminence (Bloom et al, 1982) and in the portal blood of
rats (Gibbs & Vale, 1982), two areas involved in the transport of hypothalamic
factors to the pituitary gland. To determine the source of this CRH,
immunohistochemical studies have focussed on the central distribution of CRH.
Using antiserum directed against ovine CRH (oCRH), much research has shown
CRH is abundantly expressed and widely distributed throughout the rat brain
(Olschowka et al, 1982; Merchenthaler et al, 1982; Bloom et al, 1982; Cummings et
al, 1983; Swanson et al, 1983). Further studies using rat CRH antiserum demonstrate
similar findings (Rivier et al, 1983).
The principal source of CRH involved in control of ACTH secretion can be found in
a prominent cluster of approximately 2000 CRH immunoreactive (CRHir) cells in
the hypothalamic PVN on each side of the brain (Sawchenko & Swanson, 1985) (see
figure 1.5.) Although CRH-stained neurones can be found in each of the subdivisions
of the PVN (Swanson & Kuypers, 1980); (for details of PVN subdivisions see
section 1.4.) they are most abundant in regions of the parvocellular division (dorso-
medial), and these neurones have been shown by retrograde labelling studies to
project to the median eminence (Wiegand & Price, 1980a). The localisation of the
PVN as the site of CRH cell bodies regulating the anterior pituitary, is consistent
with studies of Dunn and Critchlow (Dunn & Critchlow, 1973a) and Palkovitz
(Palkovits, 1977) that have emphasised the importance of this hypothalamic area for
the regulation of ACTH secretion.
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In addition to the cell group that projects to the median eminence, a smaller group of
CRH-positive neurones are present in a subset of oxytocin neurosecretory neurones
(that project to the posterior pituitary) in the magnocellular division of the PVN and
in the supraoptic nucleus (SON) (Burlet et al, 1983; Sawchenko et al, 1984b).
However there is no evidence for co-localisation of CRH with AVP in magnocellular
PVN neurones (Roth et al, 1983). There are also neurones in the dorsal, medial-
ventral and lateral parvocellular subdivisions that express CRH and project to the
brainstem and spinal cord. The function of these neurones appears to be in regulating
the sympatho-adrenal system (Swanson & Kuypers, 1980). Besides the PVN and
SON, other hypothalamic nuclei, including the suprachiasmatic, preoptic and arcuate
nuclei (Daikoku et al, 1984) also stain positively for CRH peptide.
A number of cell groups in the forebrain and brainstem that are known to be involved
in regulation of the autonomic nervous system contain populations of CRHir
neurones. Among these are the bed nucleus of the stria terminalis (BNST), central
nucleus of the amygdala (CeA), parabrachial nucleus (PB), latero-dorsal tegmental
nucleus (LDT) and various brainstem catecholamine cell groups (Swanson et al ,
1983). CRH stained projections are also present in the two major fibre tracts that
inter-connect these areas: the medial forebrain and the periventricular system. This
system is a complex one, with the two fibre tracts containing CRH positive
ascending and descending projections. While the functional significance remains
unclear it is thought that CRH positive cells in these areas may be involved with the
central control of autonomic function, and that perhaps these cells mediate the
autonomic responses that are complementary to the neuroendocrine actions of CRH.
Brain CRH systems play a role in mediating behavioural responses to stress. The
behavioural effects of centrally administered CRH include increased locomotor
activity, rearing and grooming (when tested in a familiar environment) (Sutton et al,
1982; Dunn & Berridge, 1990b), decreased food intake (Arase et al, 1988),
decreased sexual behaviour (Sirinathsinghji et al, 1983; Sirinathsinghji, 1986) and
increased defensive burying (Diamant et al, 1992) and decreased exploration in an
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open-field (Sutton et al , 1982) or elevated plus maze (Baldwin et al, 1991). The
locus coeruleus, PVN, BNST and CeA are the brain sites predominantly implicated
in the behavioural actions of CRH. CRH injected directly into the BNST enhances
the acoustic startle response and neurotoxin lesions of the BNST or microinfusion of
a CRH receptor antagonist blocks the effects of centrally administered CRH on the
startle response (Lee & Davis, 1997). Further, CRH injected i.e.v. potentiates the
acoustic startle response (Liang et al, 1992) and lesions of the CeA, but not the PVN,
block the CRH potentiation of the acoustic startle response (Valentino & Foote,
1987). Micro-injection of a CRH receptor antagonist into the CeA reverses social
stess-induced suppression of exploratory behaviour in the elevated plus maze
(Heinrichs et al, 1992). The PVN may be involved in suppression of food intake.
CRH micro-injected into the PVN is effective in decreasing food intake and the CRH
receptor antagonist, a-helical CRH, when injected i.e.v. or into the PVN reverses
stress-induced suppression of feeding (Rrahn et al, 1988).
CRH itself could also be involved in the stimulation of transduction pathways within
PVN CRH cells to trigger the transcription of the peptide in response to stress. Ono
and colleagues first postulated the existence of ultra-short loop positive feedback
control of CRH during "alarm states" (Ono et al, 1985). Since then, a combined
immunocytochemical retrograde tract tracing study in the rat has elegantly
demonstrated that the axons of a few CRH neurones in the dorsomedial PVN (which
typically display 1-3 dendrites) give rise to terminal boutons around the lateral
margin of the PVN (Swanson et al, 1987). Thus, CRH-CRH synapses in the PVN,
arising from either local connections within the PVN or terminals from other brain
areas, could in theory represent CRH auto-regulation in the PVN.
1.9.1. CRH Receptors
The actions of CRH on ACTH secretion are mediated via specific receptors on the
plasma membrane of pituitary corticotrope cells. Receptors for CRH have been
identified and characterised from rat pituitary glands (Wynn et al, 1983).
Autoradiographic analysis of the binding of radiolabelled (12:T)-CRH in the rodent
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pituitary has shown specific receptors to be localised in the anterior and intermediate
lobes, with no evidence of binding sites in the posterior pituitary (Aguilera et al,
1987). In the rat pituitary, CRH binding is evident as dense clusters in the anterior
lobe, corresponding to the distribution of corticotrophs, whereas binding in the
intermediate lobe is more uniform, consistent with the homogenously distributed
cells known to synthesise proopiomelanocortin (POMC) derived products in this
area.
In the brain of both rats and monkeys (Wynn et al, 1984; Millan et al, 1986),
autoradiographic mapping of CRH binding sites has demonstrated localisation in two
functionally distinct regions: the neocortex and the limbic system. The highest
concentration of CRH binding sites has been localised to regions associated with
cognitive function (cerebral cortex), limbic areas associated with emotionality and
stress (amygdala, hippocampus and nucleus accumbens) in brainstem regions
involved in regulating autonomic function (locus coeruleus and NTS) and in the
olfactory bulb, the dorsal horn of the spinal cord and in the cerebellar cortex (De
Souza, 1987; Aguilera et al , 1987). The presence of CRH receptors in the locus
coeruleus (LC) and its multiple connections (to the hypothalamus, hippocampus,
cerebral cortex, olfactory bulb, cerebellum and spinal cord, demonstrated by
retrograde labelling) suggests that the LC plays an important role in integrating
endocrine, autonomic and behavioural aspects of the CNS response to stress.
Electrical stimulation of the amygdala has been shown to cause arousal, attention,
fear and rage, reactions associated with sympathetic activation (Kaada, 1972).
Similar reactions are observed during stress and after intracerebroventricular (i.e.v.)
administration of CRH (Vale et al, 1983). Since the amygdala contains CRH and
CRH receptors, and furthermore the areas that send afferent projections to and
receive efferent projections from the amygdala have all been found to contain CRH
receptors, it would seem that CRH may be involved in the generation of the above
responses.
26
General Introduction Chapter I
In addition, CRH receptors are also found in two hypothalamic areas involved in the
control of gonadotropin secretion: the preoptic area and the arcuate nucleus, in both
the rat and monkey. Studies demonstrating a reduction in release of luteinising
hormone (Rivier & Vale, 1984) and inhibition of sexual behaviour in female rats
(Sirinathsinghji et al, 1983) after CRH administration into arcuate-ventromedial
hypothalamic regions support a role for CRH in regulating sexual function.
1.9.2. CRH Receptor Subtypes
CRH receptors belong to the seven transmembrane G-protein linked receptor
superfamily and upon activation stimulate the adenylate cyclase/cAMP signal
transduction pathway (Grigoriadis et al, 1996). Two major subtypes of CRH receptor
(CRH-R) have been identified as the products of distinct genes. The first CRH-R
subtype is referred to as the type 1 CRH receptor (CRH-Ri) and the second as the
type 2 CRH receptor (CRH-R2). These receptors share -70% sequence homology.
The CRH-Ri has been cloned from several species including humans (Chen et al,
1993), mouse (Vita et al, 1993) and rat (Perrin et al, 1993). In each of these species
the CRH-Ri mRNAs encode proteins of 415 amino acids that share 98% homology.
While CRH-Ri generally exists as a single functional form, CRH-R2 is expressed in
three splice variant forms: CRH-R2a, CRH-R2p and CRH-R2y, that differ in their
terminal amino termini. Both the CRH-R2a and CRH-R2p have been cloned in rats
(Vita et al, 1993), whereas the CRH-R2y is exclusively found in humans (DeSouza &
Kuhar, 1986).
1.9.3. CRH Receptor Distribution
The two different CRH receptors exhibit different distribution in the CNS and
pituitary gland. In situ hybridisation studies indicate CRH-Ri mRNA is highly
expressed in the pituitary and specific brain regions including several areas of the
cerebral cortex, amygdala, cerebellum, hippocampus, brainstem and olfactory bulbs
(for reviews see (Grigoriadis et al , 1996; Dautzenberg et al, 2001)), with very low
levels of expression in the hypothalamus of both primates and rodents. In the
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periphery, CRH-Ri mRNA has been found in the adrenal medulla (Palchaudhuri et
al, 1998) as well as in the testes and ovaries (Vita et al , 1993; Nappi & Rivest,
1995). The human placenta has been shown to express CRH-Ri (Clifton et al, 1995;
Karteris et al, 1998). These binding sites are likely to be involved in regulation of
placental CRH (placental CRH is discussed in section 1.19, of this chapter).
The expression patterns of CRH-R2a and CRH-R2p in rats are clearly separated
between the brain and periphery ((Lovenberg et al, 1995). CRf^a mRNA is found in
the hypothalamus, lateral septum, BNST, dorsal raphe nucleus (DRN), amygdala and
hippocampus, whereas CRHHGp expression in the brain is limited to non-neuronal
areas such as the choroid plexus and cerebral arterioles (Dautzenberg et al , 2001).
CRH-R2P is found predominantly in the periphery particularly in the heart, lung,
skeletal muscle and the gastrointestinal tract (Dautzenberg et al, 2001).
The heterogeneous distribution of CRH-Ri and CRH-R2 receptor mRNA suggests
distinctive functional roles for each receptor. Within the pituitary, CRH-Ri
expression predominates over CRH-R2 in both the anterior and intermediate lobes,
indicating that type 1 CRH receptors are primarily responsible for CRH-induced
changes in ACTH release. Within the lateral septum, very high levels of CRH-R2
mRNA (Grigoriadis et al , 1996) are expressed. This brain region has reciprocal
connections with areas throughout the brain associated with learning, memory and
autonomic regulation (DeFrance, 1976). Furthermore the septum is involved in the
limbic circuitry associated with emotionality such as fear and aggression. The
absence of type 1 receptors here suggests a role for CRH-R2 in regulating limbic
circuitry at the level of the septum. In the hypothalamus, CRH-R2a mRNA is highly
expressed in the ventromedial nucleus (VMH), supraoptic nucleus (SON) and the
medial area of the PVN, SCN and median preoptic area (mPOA) (Grigoriadis et al,
1996). Interestingly, within the PVN, CRH-R2a mRNA expression coincides with
CRH mRNA expression, which suggests CRH-R2a may act as an autoreceptor in this
nucleus. The distribution of CRH receptors in cortical and limbic brain areas
correlates nicely with the immunocytochemical localisation of CRH cell bodies and
pathways (discussed in section 1.8.4.). Although the mechanisms are not fully
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understood the presence of functional CRH receptors in discrete structures of the
brain suggests that CRH is involved in regulating CNS function during stress
responses.
1.9.4. Regulation of the CRH Receptor
Exposure of the pituitary corticotroph to changes in levels of glucocorticoids, CRH
and AVP is thought to play a key role in regulating pituitary CRH receptors
(identified as CRH-Ri) during stress. Changes in receptors often parallel
responsiveness of the target cell to the hormone ligand. Removal of glucocorticoid
feedback by adrenalectomy (ADX) causes increases in hypothalamic CRH and AVP
and elevated levels of plasma ACTH (Wynn et al, 1985), which results in a marked
reduction (-80%) in CRH binding (Aguilera et al, 1987) and CRH-R mRNA levels
in the rat anterior pituitary (Sakai et al, 1996). This is due to a decrease in receptor
concentration with no change in binding affinity (Aguilera et al , 1987). This
receptor desensitisation is an adaptive response to prolonged hormone exposure and
has been described in a variety of endocrine systems (Catt et al, 1979).
The mechanism responsible for the decrease in pituitary CRH receptor mRNA
expression observed after ADX may reflect loss of glucocorticoid actions on the
pituitary and/or an increase in hypothalamic secretion of CRH and/or AVP (Plotsky
& Sawchenko, 1987; RabadanDiehl et al, 1997). Experiments using Brattleboro rats
(which lack endogenous AVP), demonstrate that ADX triggers only a small
reduction in CRH receptors, compared with an 80% loss in Sprague Dawley and
Long Evans rats (Holmes et al, 1987), suggesting AVP facilitates the down-
regulation of pituitary CRH receptors after ADX.
However, other studies have also demonstrated that corticosterone treatment leads to
a reduction in CRH binding, both in vivo (Hauger et al, 1987) and in vitro (Childs &
Unabia, 1990) and decreases CRH-R mRNA in vivo (Makino et al, 1995), although
the mechanisms of action are unclear. Administration of corticosterone causes a
dose-dependent decrease in the number of CRH receptors and hence CRH binding,
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both in vivo and in vitro (Schwartz et al, 1986; Childs et al, 1986; Hauger et ctl ,
1987) in parallel with a reduction in ACTH secretion (Aguilera et al , 1987). This
effect of glucocorticoids on CRH receptor down-regulation in the anterior pituitary
could be of physiological relevance during acute stress and may participate in the
general inhibitory actions of glucocorticoids on ACTH release. However it can only
partially account for the inhibitory effects of glucocorticoids on ACTH release since
as well as inhibiting CRH stimulated ACTH release glucocorticoids also inhibit the
ACTH releasing effects of AVP.
Levels of pituitary CRH receptor mRNA undergo marked alterations during stress,
although the changes are dependent upon the stress paradigm used. Using in situ
hybridisation, receptor binding autoradiography and northern blot analysis,
Aguilera's group have demonstrated that following acute hypertonic saline or
lipopolysaccharide (LPS) injection there is prolonged decrease in both CRH-Ri
mRNA expression and CRH binding in the pituitary (Rabadan-Diehl et al, 1995;
Aguilera et al, 2001). Whereas acute immobilisation stress (1 hour) results in
biphasic changes in pituitary CRH-R| mRNA, an initial decrease is followed by
recovery and an increase in expression at 4 hours after the onset of the stress, with a
concomitant increase in CRH binding (Rabadan-Diehl et al, 1995). The mechanism
and physiological significance of these responses are not clear, however they may
represent differential regulation of pituitary CRH-R in response to emotional and
physical stressors.
Several possible mechanisms responsible for down-regulation of CRH receptors have
been proposed. One theory is internalisation of receptors following binding to their
specific ligands. This hypothesis was supported when radiolabelled CRH was found
to be internalised into corticotrophs (Dohanics et al, 1991)). Reports of discrepancies
in CRH-R numbers and CRH-R mRNA levels suggest post-transcriptional regulation
of CRH receptors. A reduction in the binding capacity of CRH-Rs due to uncoupling
of the receptor from adenylate cyclase has also been hypothesised (Reisine, 1984).
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In contrast to the marked reduction in anterior pituitary CRH receptors, several
studies have demonstrated that CRH receptors in the brain are not affected by
adrenalectomy (Wynn et al , 1984), stress (Aguilera, 1998) or glucocorticoid
administration (Hauger et al , 1987). However, conflicting evidence was reported
more recently. Imaki et al demonstrated that both i.e.v. CRH and restraint increase
both CRH-Ri and CRH mRNA expression in the PVN (Imaki et al, 1991b; Imaki et
al, 1996a), suggesting CRH up-regulates CRH-R, mRNA in the PVN. This may act
to facilitate the positive feedback effects of CRH on its own expression (discussed
earlier). Further experiments are required, nevertheless there appear to be differential
mechanisms regulating pituitary and brain receptors.
Thus changes in CRH-R expression in the pituitary and/or PVN may affect the
responsiveness of the HPA axis.
1.10. Vasopressin
Arginine vasopressin (AVP) is a nonapeptide hormone which was first characterised
by du Vigneaud almost 50 years ago (duVigneaud et al, 1953). The primary role of
AVP is to maintain body fluid homeostasis by regulating blood volume, blood
pressure and extracellular fluid levels (Cunningham Jr & Sawchenko, 1991). The
source of circulating AVP responsible for these functions is magnocellular neurones
in the supraoptic and paraventricular nuclei (SON and PVN, respectively) of the
hypothalamus. Axons of these magnocellular neurones project to and terminate in the
posterior pituitary, and upon activation release AVP from nerve terminals into the
general circulation.
In addition to AVP of magnocellular origin, AVP is also synthesised by parvocellular
neurones of the PVN (pPVN). Unlike the magnocellular AVP producing neurones,
the parvocellular neurones project to the external zone of the median eminence
where they secrete AVP into the pituitary portal circulation. While CRH is potent in
stimulating ACTH secretion, AVP alone is a weak ACTH secretagogue (McCann &
Brobeck, 1954), however it does play an important role in modulating HPA activity
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through its interaction with CRH (Gillies et al, 1982). Although magnocellular AVP
has been shown under some experimental conditions to gain access to the portal
circulation and facilitate pituitary ACTH secretion (Holmes et al, 1986a), it is not
thought to play a major role in corticotroph regulation.
However, studies have shown that during physiological states involving activation of
the HPA axis, such as stress, there is increased expression and secretion of AVP
from pPVN neurones (Whitnall, 1989). Under basal conditions, AVP is coexpressed
in approximately 50% of parvocellular CRH positive neurones (Whitnall et al, 1985)
and during exposure to acute or chronic stress this proportion increases substantially
(De Goeij et al, 1991). CRH and AVP act synergistically to evoke ACTH release
both in vitro (Gillies et al , 1982) and in vivo (Rivier & Vale, 1983a). Rivier and
Vale reported that pre-treatment of rats with an AVP antagonist attenuates the
plasma ACTH response to ether stress and furthermore administration of the same
AVP antagonist in conjunction with anti-CRH antiserum completely abolishes ether-
stress induced ACTH release (Rivier & Vale, 1983b).
1.10.1. AVP Responses to Acute Stress
In contrast to magnocellular neurones that constitutively express AVP peptide,
mRNA and heteronuclear RNA (hnRNA) (Uhl et al, 1985), perikarya of the
parvocellular neurosecretory neurones do not contain detectable amounts of AVP
immunoreactivity, mRNA or hnRNA under basal conditions (Bartanusz et al, 1993;
Ma et al , 1997b). AVP gene transcription is up-regulated by various acute and
repeated stressors (Bartanusz et al , 1993). For example, a 60 minute period of
restraint rapidly induces AVP hnRNA expression in pPVN neurones and is
significantly elevated from control levels at 1 and 2 hours after the onset of the
stress, whereas AVP mRNA expression is not significantly increased until 4 hours
after the onset of the stress (Ma et al , 1997b). Similar time courses in AVP gene
activation in these cells have been reported after exposure to other stressors, such as
ether (Kovacs & Sawchenko, 1996a; Kovacs & Sawchenko, 1996b) and open-field
challenge (Priou et al, 1993). As well as up-regulated AVP gene expression,
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activation of the pPVN neurones stimulates AVP release into the pituitary portal
blood system. Upon binding to specific receptors on the pituitary corticotrope cells
(see section 1.10.), AVP activates the inositol phospholipid signal transduction
pathway and protein kinase C, which results in the mobilisation of Ca2+ from
intracellular stores and the release of ACTH. AVP does not stimulate POMC
transcription like CRH does; however it does accelerate the processing of POMC
hnRNA (Antoni, 1993).
1.10.2. Regulation of AVP Gene Expression during Stress
Compared to the time course of stress induced CRH hnRNA levels, which peak
within 5 min after an acute challenge (Imaki et al , 1995), AVP gene transcription
shows a delayed up-regulation in pPVN neurones, suggesting that different
mechanisms are involved in regulating the responses of these genes to the same
stressors. Regulation of AVP gene expression by glucocorticoids is discussed in
section 1.13.3.
The 5'-regulatory region of the AVP gene contains several DNA binding sites or
'response elements' to which transcriptional factors can bind including an NGFI-B
response element (NBRE), a CRE and a AP-1 site (Kovacs, 1998). Although the
promoter region of the AVP gene possesses a CRE, the onset of AVP gene
transcription after stress is delayed by ~ 2h compared to that of CRH and pCREB
induction. Other potential candidates for inducing AVP gene transcription during an
acute challenge are proteins encoded by immediate early genes (lEG's), such as c-fos
and nerve growth factor induced gene-B (NGFI-B). Both of these IEG's are induced
in parvocellular PVN neurones in response to various stressors (Chan et al, 1993a)
and as mentioned above response elements (binding sites) for both can be found
within the regulatory region of the AVP gene (Chan et al , 1993a). Maximal AVP
hnRNA expression in pPVN neurones occurs immediately after the peak of
expression of transcription factors encoded by IEGs such as Fos and NGFI-B
(Kovacs & Sawchenko, 1996b). Further evidence supporting the involvement of IEG
encoded transcription factors in stress-induced regulation of AVP gene expression
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was provided by Kovacs et al (Kovacs et al, 1998). They reported that protein
synthesis inhibitors (which completely prevent the stress-induced synthesis of IEG
encoded transcription factors) significantly attenuated, but did not prevent, AVP
hnRNA responses to acute stress. Conversely, protein synthesis blockade did not
affect CRH hnRNA levels or phosphorylation of CREB, in response to acute
challenge. The c-fos promoter itself contains a CRE which binds pCREB (Sassone-
Corsi et al, 1988). Thus, the mechanisms that regulate AVP gene expression in
response to acute stress stimuli may involve both cle novo synthesis of transcription
factors and phosphorylation of CREB.
1.10.3. Chronic Stress and AVP Facilitation
AVP appears to play an important role under chronic stress conditions. Studies have
shown that repeated restraint results in increased AVP stores and increased
colocalisation of AVP with CRH in pPVN neurones (Bartanusz et al, 1993). Plasma
corticosterone, and pPVN CRH mRNA and hnRNA levels increase significantly in
response to acute restraint stress in rats. These increases become progressively
smaller with increasing frequency of exposure to the same stressor, until finally the
response to restraint disappears after the rats have been restrained daily for 14 days
(Ma et al, 1997a; Ma & Lightman, 1998). However, AVP mRNA expression in the
pPVN progressively increases as the frequency of exposure to repeated restraint
increases (Ma & Lightman, 1998). AVP secretion from nerve terminals in the
median eminence has also been shown to increase in response to repeated or chronic
stress (De Goeij et al, 1992), with enhanced AVP receptor binding in the anterior
pituitary (Rabadan-Diehl et al , 1995). Furthermore, in repeatedly restrained rats,
plasma corticosterone and ACTH levels significantly increase in response to
exogenously administered AVP, but do not respond to exogenous CRH (Hashimoto
et al, 1988).
Schmidt and colleagues have shown that single exposure to a stressor can result in
long-lasting changes in AVP stores in the median eminence, and suggested that this
may serve as a "stress memory" in adapting responses in the event that the stress is
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repeated (Schmidt et al, 1995; Schmidt et al, 1996). These data suggest that AVP
synthesised in the pPVN may play an important role in maintaining HPA axis
activity under conditions of chronic stress. As mentioned earlier (in this section), rats
which have adapted to repeated stress maintain normal or increased ACTH responses
to a heterotypic stressor, and AVP may be an important mediator in maintaining this
responsiveness. Since AVP, but not CRH gene responses to repeated stress are
preserved, it suggests that the control mechanisms regulating gene transcription and
translation are different for AVP and CRH in parvocellular PVN neurones. Thus
instead of being considered as a simple potentiator of CRH actions, AVP can also be
thought of as an important factor in maintaining HPA responsiveness and in forming
"stress memories".
1.10.4. AVP Receptors and AVP Receptor Regulation
AVP secreted by parvocellular neurones of the hypothalamic PVN modulates
pituitary ACTH secretion by acting upon AVP receptors on the pituitary
corticotrophs. AVP receptors belong to the G-protein linked superfamily. Three
major receptor subtypes encoded by different genes have been identified and cloned:
(i) V^ receptors, found in smooth muscle and liver are coupled to phospholipase C
(PLC) (Morel et al, 1992); (ii) V]b (V3) receptors, expressed in the pituitary and also
linked to PLC (Sumimoto et al, 1994) and (iii) receptors, present in the kidney
which are coupled to adenylate cyclase (Lolait et al, 1992). Regulation of the Vib
receptors contributes to the adaptation of the HPA axis to stress.
The cDNA encoding the V]b receptor has been isolated and characterised for human
(Sumimoto et al, 1994), rat (Lolait et al, 1994) and mouse (Ventura et al, 1999). The
Vib receptor shares only 37-50% identity with the V)a and V2 type receptors (Lolait
et al, 1994; Sumimoto et al, 1994). The levels of expression of the Vib receptor are
highest in the anterior pituitary, however low levels of expression have also been
reported in some brain areas and in the periphery (Lolait et al , 1994; Saito et al,
1995). Northern blot analysis of rat pituitary mRNA reveals two Vjb transcripts with
molecular sizes of 3.7 and 3.2kb (Lolait et al, 1994). The 3.7kb transcript encodes a
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biologically active Vib receptor, while the 3.2kb transcript has not been
characterised, but appears to be a result of differential splicing or alternative
promoter utilisation.
In contrast to pituitary CRH type 1 receptors, a positive correlation exists between
pituitary AVP receptor numbers and pituitary ACTH responsiveness. For example,
during stress paradigms in which ACTH responses are reduced e.g. chronic osmotic
challenge, a down regulation of pituitary AVP receptors is observed, whereas chronic
stress protocols which are associated with increases in ACTH responses to novel
stressors are associated with up-regulation of AVP receptors (Aguilera, 1994).
Glucocorticoids are elevated during stress (Dallman et al, 1987) and thus are likely
candidates for regulation of Vib receptor mRNA and AVP binding during activation
of the HPA axis. In intact rats, glucocorticoid (dexamethasone) administration
decreases AVP binding (Rabadan-Diehl & Aguilera, 1998), despite an upregulation
of Vib receptor mRNA levels. This suggests that while glucocorticoids increase Vib
receptor mRNA expression by stimulating gene transcription, dexamethasone
reduces the number of receptors at the translational and/or post-translational levels. It
is difficult to unravel the causes of these changes since the direct effects of
glucocorticoid withdrawal on the pituitary are compounded by increased AVP and
CRH secretion into the portal blood as a consequence of removing glucocorticoid
feedback (Plotsky, 1991). The sustained down-regulation of AVP binding following
ADX can be prevented if AVP output is blocked by hypothalamic lesions (Antoni et
al, 1985); therefore it is feasible that the reduction in AVP binding following ADX is
due to an increase in receptor occupancy by AVP. However, administration of
corticosterone to rats with hypothalamic deafferentation fully prevents the pituitary
AVP receptor loss normally observed (Lutz-Bucher et al, 1986), suggesting that
glucocorticoids themselves can directly regulate the number of pituitary AVP
binding sites. The differential control of AVP receptor number and V^ receptor
mRNA may represent a mechanism by which AVP maintains corticotroph
responsiveness during stress. Thus changes in Vib receptor expression (for example
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as a result of changes in circulating glucocorticoids) will affect the way in which the
pituitary (and hence the adrenal gland) responds to stress.
1.11. Oxytocin
Oxytocin is a nonapeptide hormone that differs from AVP by two amino acid
residues. It is synthesised by magnocellular neurones in the supraoptic and
paraventricular nuclei (SON and PVN, respectively) of the hypothalamus. The axons
of these neurones project to the posterior pituitary gland, where oxytocin is stored in
vesicles within the nerve endings. Activation of the cell bodies in the hypothalamus
results in secretion of oxytocin into the peripheral circulation. The classical
physiological functions of oxytocin are associated with female reproductive
processes. Oxytocin in the bloodstream participates as a hormone in the control of
uterine contractions during parturition and in the milk ejection reflex during lactation
(for review see (Leng G, 2000)). Oxytocin, via neuronal projections, also acts on
various targets within the brain and modulates maternal, sexual and social
behaviours.
In addition to these well-established roles, oxytocin also appears to be a so-called
"stress hormone". In 1983 Lang and colleagues showed that in both male and female
rats, plasma oxytocin increased 2-3 fold following a 1 minute period of forced
swimming and 5-10 fold after a 1 minute period of immobilisation (Lang et al,
1983). Since then other studies have reported similar results in response to a range of
other acute stressors, including restraint, footshock and ether (for review see (Gibbs,
1986c). A study in 1993 provided evidence for the importance of the hypothalamic
PVN for oxytocin release during stress. Denervation of the PVN via anterolateral
cuts around the mediobasal hypothalamus (which leaves SON-neurohypophysial
connections intact) attenuates oxytocin and ACTH responses to immobilisation
stress. Furthermore, surgical lesions that isolate the PVN from autonomic brainstem
centres and the SON, abolish the increase in plasma oxytocin and ACTH normally
produced by the same stressor (Jezova et al, 1993).
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The functional relevance of oxytocin release into the peripheral circulation in
response to stress is unclear. However, as well as increased circulating oxytocin, high
concentrations of oxytocin have also been detected in hypophysial portal blood
(Gibbs, 1984) following stress and oxytocin containing nerve terminals have been
identified in the external zone of the median eminence (Kawata et al, 1983). High
concentrations of oxytocin probably reach the anterior pituitary from the median
eminence via the portal blood, however some collaterals of the axons of
magnocellular neurones may release oxytocin from axon swellings at the median
eminence. In the rat, oxytocin has been shown to potentiate the ACTH response to
CRH, both in vitro (Antoni et al, 1884) and in vivo (Rivier & Vale, 1985; Gibbs,
1986b). In vivo, the stimulatory effect of oxytocin on ACTH secretion has been
shown to require the presence of endogenous CRH (Rivier & Vale, 1985). Gibbs
reported that immunoneutralisation of oxytocin attenuated the ACTH response to tail
hanging stress (Gibbs, 1985). Furthermore he also demonstrated that
immunoneutralisation of oxytocin affects ACTH only during stresses associated with
increased oxytocin secretion, suggesting that basal levels of oxytocin have no direct
or permissive effect on ACTH secretion, and that it is not until oxytocin levels rise in
response to stress that the potentiating effects of oxytocin are expressed (Gibbs,
1986a). A more recent study using microdialysis, has demonstrated that oxytocin
levels within the PVN increase 7-fold in response to acute stress (Nishioka et al,
1998) raising the possibility that local release of oxytocin into the PVN may also
play a role in the neuroendocrine stress cascade. Oxytocin does not promote ACTH
release through oxytocin receptor receptors in the anterior pituitary, instead it acts via
the vasopressin Vib receptor (Schlosser et al, 1994).
1.12. ACTH and POMC
Proopiomelanocortin (POMC) is a large polypeptide which contains several
bioactive peptide sequences. In the rat, the highest densities of POMC derived
peptides are found in the anterior and intermediate lobes of the pituitary gland
(DeWied, 1993). POMC is cleaved to form seven peptides: ACTH, a-MSH, (3-MSH,
y-MSH, corticotropin-like intermediate lobe peptide (CLIP), y-lipotropin and (3-
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endorphin (an endogenous opioid) (Brown, 1998). The conversion of POMC into
these active peptides occurs in two stages as shown in figure 1.6. The first cleavage
occurs in both the anterior and intermediate lobes, resulting in the production of
ACTH and P-lipotropin. In the corticotroph cells of the anterior pituitary the major
end product is ACTH. In the melanotroph cells of the intennediate lobe ACTH is
further cleaved to produce its final secretory products a-MSH and CLIP, while p-
lipotropin is converted to P-endorphin and y-lipotropin.
In the brain, POMC-containing cell bodies are mainly localised in the arcuate
nucleus of the hypothalamus (Emeson & Eipper, 1986). POMC perikarya are also
present in the brainstem, in the NTS. In this area a-MSH, CLIP and P-endorphin
predominate (Joseph et al, 1983). Specialised cells of the anterior piutitary, termed
corticotrophs secrete ACTH when signalled by corticotropin-releasing factors (e.g.
CRH and AVP). ACTH is a 39 amino acid peptide (Li et al, 1943), which binds with
melanocortin receptors in the adrenal gland to stimulate secretion of glucocorticoids.
These ACTH receptors are part of the G-protein coupled receptor superfamily and
once activated increase the production of cAMP via adenylate cyclase (Haynes &
Berthet, 1957). Since ACTH is derived from POMC, the processing and availability
of POMC in the anterior pituitary corticotrophs determines ACTH output and thus
any changes in POMC expression can influence ACTH secretion in response to
stress (Young & Akil, 1985).
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Figure: 1.6. The proopiomelanocortin (POMC) molecule and its conversion
to active hormones in the anterior and intermediate lobes of the pituitary
gland. MSH, melanocyte stimulating hormone; ACTH, adrenocorticotropic
hormone; CLIP, corticotropin-like intermediate factor. Reproduced from Brown,
et al 1998.
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1.12.1. Regulation of ACTH release and POMC gene transcription
The stimulatory actions of CRH and AVP on ACTH have been well established (for
review see (Herman et al, 1996). Release of CRH and AVP at the median eminence
in response to stress stimulates ACTH relese from the anterior pituitary gland. ACTH
secretion is also under the inhibitory influence of corticosterone (discussed in section
1.13.3). In addition to acting as a potent ACTH secretagogue CRH has also been
shown to be the major factor stimulating POMC gene tanscription in the anterior
pituitary (Roberts et al, ). The exact mechanisms involved in regulating POMC gene
expression are not fully understood. In vitro studies have shown that CRH
stimulation of mouse AtT-20 tumour cells leads to rapid and transient induction of
the immediate early gene c-fos, accompanied by increased nuclear DNA binding
activity of transcription factor, AP-1 (Autelitano, 1994). Furthermore at least part of
the mechanism by which CRH stimulates POMC gene transcription in corticotrophs
is via a c-fos dependent activation of an AP-1 site in the promoter region of the
POMC gene (Boutillier et al, 1995). In vivo studies have also demonstrated that
exposure to acute restraint stress induces a rapid increase in c-fos and nuclear AP-1
binding activity in the anterior pituitary in parallel with an increase in pituitary
POMC gene expression (Autelitano, 1998). These data suggest a role for the
immediate early gene, c-fos in contributing to increased activity of AP-1 which may
be involved in regulating POMC gene transcription in response to stress.
1.13. The Adrenal Cortex and Glucocorticoids
The adrenal glands are located on the proximal poles of the kidneys and consist of
two distinct types of tissue: three layers of adrenal cortex surrounding the adrenal
medulla. The adrenal cortex is a true endocrine gland which secretes three categories
of steroid hormones: mineralocorticoids, glucocorticoids and sex steroids. The
adrenal medulla secretes adrenaline and noradrenaline, under the control of the
sympathetic branch of the autonomic nervous system. Aldosterone is the primary
mineralocorticoid produced by the adrenal cortex. Aldosterone is synthesised in the
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zona glomerulosa cells of the adrenal cortex and when released it acts to promote
renal reabsorption of sodium. The zona reticularis layer of the adrenal cortex
produces small amounts of gonadal steroids, which influence sexual differentiation at
puberty.
Glucocorticoids (Cortisol in humans, sheep and non-human primates, corticosterone
in rodents) are synthesised in the zona fasiculata cells of the cortex of the adrenal
gland via a series of enzymatic reactions that utilise cholesterol as the precursor
(Campeau et al , 1998). ACTH stimulates their synthesis and release during stress.
Glucocorticoids play a key role in maintaining homeostasis during stress, they
modulate carbohydrate metabolism to free energy supplies and also have anti¬
inflammatory and immunosuppressive actions. Corticosterone released from the
adrenal cortex in response to ACTH completes the negative feedback loop acting at
the level of the anterior pituitary, the hypothalamus and other higher brain centres.
1.13.1. Corticosteroid Receptors
The actions of glucocorticoids are mediated via intracellular receptors which belong
to the nuclear hormone receptor superfamily. The resulting activated hormone-
receptor complex binds to DNA (glucocorticoid response element, GRE) in the cell
nucleus and initiates gene transcription and protein synthesis (Munck et al, 1990).
Some reports have indicated that glucocorticoid receptors occur in the cytoplasm as
well as the nucleus (LaFond et al, 1988). Two types of receptor for adrenal steroids
have been identified (Arriza et al, 1987; De Kloet & Reul, 1987; De Kloet et al,
1987), Type I (mineralocorticoid, MR) receptors and type II (glucocorticoid, GR)
receptors. The two receptors differ in their affinity for ligands (Arriza et al, 1988).
Type I receptors bind aldosterone, corticosterone, Cortisol and deoxycorticosterone
equally in vitro. MRs may also bind some synthetic glucocorticoids (e.g.
dexamethasone) although with lower affinity (Luttge et al, 1989). Type II receptors
demonstrate high affinity for synthetic glucocorticoids (e.g. dexamethasone and
RU28362) and lower affinity for physiological glucocorticoids (e.g. Cortisol and
corticosterone) (Reul & De Kloet, 1985). GRs preferentially bind dexamethasone >
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Cortisol > corticosterone > deoxycorticosterone > aldosterone. MRs have
approximately 10-fold higher affinity for physiological glucocorticoids than GRs and
in the brain are thought to be involved in controlling basal expression of CRH and
AVP at the nadir (Dallman et al , 1987) and the peak of diurnal ACTH secretion
(Dallman et al, 1989). Whereas GRs have a far lower affinity for glucocorticoids and
are only activated by high levels of glucocorticoids secreted during stress, and thus
are considered to be involved in the control of stress-induced ACTH secretion (Reul
& De Kloet, 1985). They provide a mechanism by which negative feedback can
terminate stress-activated neural and endocrine (HPA) activation and regulate
behavioural responses to stress (McEwen et al, 1986). In the periphery, MRs are
located primarily in the kidney, whilst GRs occur in liver, muscle and fat cells.
However, both MRs and GRs also occur in the brain (Reul & De Kloet, 1985; Reul
& De Kloet, 1986).
Apart from regulating gene expression, glucocorticoids can act at the membrane
through specific receptors (which have yet to be cloned) to exert multiple rapid
effects on various tissues and cells, including nongenomic-mediated feedback
inhbition of CRH and ACTH secretion (for review see (Borski, 2000)). Actions at
these receptors are rapid since they occur independently of the genome and are
transduced by the same biochemical effector pathways resposible for mediating rapid
responses to neurotransmitters.
1.13.2. Distribution of Corticosteroid Receptors
Type I receptors have a restricted distribution in the brain, with highest expression
confined to the hippocampus, lateral septum, dentate gyrus and brainstem (Reul &
De Kloet, 1985; Reul & De Kloet, 1986). The hypothalamus and pituitary gland are
relatively devoid of MRs. In contrast, GRs are widely distributed throughout the
brain, however they are concentrated in the hippocampus, septum, amygdala, PVN,
cortex, brainstem and also in the corticotrope cells of the anterior pituitary. The
reason for having two different types of receptors that can bind the same
glucocorticoids in the brain is not clear. Evans & Arriza '89 (Evans & Arriza, 1989)
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have suggested that a single receptor system cannot respond to the wide range of
glucocorticoid levels (from 0.5-100nM), whereas two receptors with different
sensitivities could accommodate this range. Thus at low concentrations MRs regulate
circadian rhythmicity, while at high concentrations (for example, during stress) GRs
regulate stress responses.
Neuronal GR and MR proteins mediate the transcriptional effects of circulating
glucocorticoids. These receptors bind to the same DNA response element, yet
mediate different cellular functions (Paskitti et al, 2000). Corticosteroids enter target
cells by passive diffusion where they bind to either GR or MRs. After intranuclear
translocation, MR and GR homodimers or corticosteroid receptor heterodimers are
formed (Trapp et al, 1994), depending upon the relative concentrations of both
receptors. The different corticosteroid receptor dimers bind to glucocorticoid
response elements (GREs) in the flanking regions of target genes (CRH (Malkoski &
Dorin, 1999), AVP (Kim et al, 2001) and POMC (Drouin et al, 1987) all contain
GREs in their promoter regions) where they can regulate gene transcription.
1.13.3. Glucocorticoid Feedback Regulation of the HPA axis
The HPA axis is sensitive to feedback inhibition by corticosterone, under basal and
stress conditions. Many studies investigating glucocorticoid feedback have employed
adrenalectomy (ADX). Complete removal of glucocorticoid feedback by bilateral
ADX produces a rapid increase in ACTH secretion, within 20 minutes (Dallman et
al, 1972). At the PVN, CRH and AVP mRNA expression increases in parvocellular
neurones (Wolfson et al, 1985; Jingami et al, 1985), as does CRH and AVP peptide
expression (Swanson et al , 1983; Sawchenko et al, 1984a). The AVP-CRH ratio
also increases (Holmes et al, 1986b), suggesting that the signal to the pituitary for
ACTH release is enhanced. At the pituitary, POMC mRNA expression increases 4
hours after ADX (Eberwine & Roberts, 1984) and during the first 24 hours after
ADX, pituitary ACTH content and pituitary corticotrope cell numbers double
(Rappay & Makara, 1981). Within several days the rate of ACTH synthesis is
significantly increased, as are ACTH stores (Birnberg et al, 1983). All of these
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adaptations induced by ADX can be reversed by glucocorticoid treatment, indicating
that they are a consequence of disrupting the negative feedback loop.
The negative feedback effects exerted by glucocorticoids have been shown in vivo
and in vitro to occur over at least three distinct time domains: rapid (seconds to
minutes), intermediate (minutes to hours) and slow (hours to days) (for review see
(Keller-Wood & Dallman, 1984)).
1.13.3.1. Rapid Glucocorticoid Feedback
Rapid (or fast, rate-sensitive) feedback was first postulated by Dallman & Yates
(Dallman & Yates, 1969). Administration of corticosteroids to rats inhibits the
corticosterone response to histamine administration when the injection precedes
histamine by 15 seconds or 5 minutes, however not if the corticosterone is
administered 15 minutes before or 2 minutes after the administration of histamine
(Dallman & Yates, 1969). The authors suggested that this rapid feedback occurs
when plasma corticosterone levels are rising and suggested that this feedback is rate
sensitive. Later, Kaneko and Hiroshige (Kaneko & Hiroshige, 1978) demonstrated
that the rate of rapid corticosterone feedback was dependent upon the rate of
association of corticosterone with its receptor. Rapid glucocorticoid feedback
inhibition has been demonstrated to have rapid effects on both stimulated CRH
(Vermes et al, 1977) and ACTH secretion (Buckingham & Hodges, 1977; Vale &
Rivier, 1977). However, this rapid inhibition is not affected by pretreatment with
cycloheximide (a protein synthesis inhibitor) (Widmaier & Dallman, 1983a),
indicating that the rapid feedback action of corticosterone does not require protein
synthesis. Furthermore, fast corticosterone feedback does not affect ACTH content in
pituitaries (Widmaier & Dallman, 1983b) or CRH content in the hypothalamus,
indicating that the secretory process, but not the synthetic process is inhibited by
corticosteroids (Jones & Hillhouse, 1976; Jones et al, 1977).
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1.13.3.2. Delayed Glucocorticoid Feedback: Intermediate and Slow
Many studies have demonstrated delayed feedback by corticosteroids on stress-
induced activity of the HPA axis (Sayers & Sayers, 1947; Smelik, 1963; Hodges &
Sadow, 1967; Dallman & Yates, 1969). Infusions of corticosterone beginning 120
minutes before histamine administration inhibit the endogenous corticosterone
response to histamine, however, infusions beginning between 10-45 minutes before
the histamine administration have no effect on the response (Dallman & Yates,
1969). The authors hypothesised that this represents a delayed feedback effect of
corticosterone levels at the time of stress, which requires between 45-120 minutes to
develop. The effectiveness of corticosteroid administration appears to be dependent
upon the levels of steroid achieved (Sayers & Sayers, 1947; Dallman & Yates, 1969).
Takebe and colleagues demonstrated that the extent and duration of corticosterone
inhibition depends on the dose administered (Takebe et al, 1971). A range of studies
have demonstrated that the maximal inhibition of the adrenocortical responses occur
between 2-4 hours after administration of a single dose of corticosterone (Smelik,
1963; Takebe et al, 1971; Jones et al, 1974). The inhibitory effect is attenuated 6-12
hours after administration of corticosterone, however extremely high doses of
corticosterone prolong the duration of inhibition (Jones et al, 1974), as does repeated
corticosterone administration. Others have reported that as well as the dose, the
duration of corticosterone exposure also determines the period of inhibition of the
adrenocortical axis (Abe & Critchlow, 1980). Sustained elevation of glucocorticoids
for one or more days abolishes the capacity of the HPA axis to respond to various
stimuli (Buckingham & Hodges, 1974; Engeland et al, 1975). Thus an important
factor in delayed feedback appears to be the duration of exposure to enhanced levels
of corticosterone. Incubation of AtT-20 cells (a murine pituitary tumour cell line)
with dexamethasone (a synthetic glucocorticoid) for 5-25 hours causes a significant
reduction in ACTH release, however following 2-3 days of dexamethasone exposure,
as well as a reduction in ACTH secretion, ACTH content is also significantly
attenuated. Moreover, glucocorticoid administration for 3 days not only decreases
pituitary ACTH content (Keller-Wood & Dallman, 1984) but also the number of
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pituitary corticotrophs (Keller-Wood & Dallman, 1984). Together these data indicate
that prolonged exposure to corticosterone severely inhibits synthesis and secretion of
ACTH (Keller-Wood & Dallman, 1984). These findings led to the theory that
delayed feedback regulation by glucocorticoids exert distinct effects over time.
Subsequently delayed feedback inhibition was designated either "intermediate" for
corticosteroid feedback that results from 2-10 hours of prior corticosterone exposure
and lasts for relatively short durations; or "slow" for feedback inhibition that results
from constant corticosterone exposure for 12 or more hours and persists for relatively
longer durations. Furthermore, intermediate corticosterone feedback inhibits ACTH
release, but not synthesis, whereas slow feedback inhibits both. Nevertheless,
intermediate feedback requires DNA-dependent RNA synthesis, since the inhibitory
actions of corticosterone on ACTH secretion can be prevented by pre-incubation of
pituitaries with the RNA polymerase inhibitor, actinomycin D (Portanova & Sayers,
1974). In addition, intermediate feedback also influences CRH synthesis and release.
CRH bioactivity in the hypothalamus, and basal and stimulated CRH release are all
increased in ADX rats, an effect which can be reversed by corticosterone
replacement (Vernikos-Danellis, 1965; Sato et al, 1975; Hillhouse & Jones, 1976;
Buckingham, 1979). Since CRH content is not affected (Jones & Hillhouse, 1976), it
would seem that CRH synthesis is inhibited as well as CRH release.
Slow corticosterone feedback (exposure to glucocorticoids for 24 hours or more)
inhibits ACTH release (Engeland et al , 1975), ACTH synthesis (Keller-Wood &
Dallman, 1984) and reduces POMC mRNA expression (Schachter et al, 1982). In
summary, intermediate feedback appears after relatively short durations of
corticosterone exposure, whereas slow feedback becomes evident following
prolonged periods of high circulating plasma corticosteroids. Hence rapid and
intermediate feedback would be expected under conditions where increases in
plasma corticosterone occur in response to stress, whereas slow feedback would be
expected when elevated plasma levels of corticosterone persist for days.
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1.13.3.3. Sites of Glucocorticoid Feedback
There is evidence for glucocorticoid feedback at the level of the anterior pituitary,
hypothalamus and other higher areas in the brain. Injection of corticosterone or
dexamethasone directly into the pituitary decreases the corticosterone response to
stress (Russell et al, 1969). Administration of corticosterone or dexamethasone to
animals with median eminence or hypothalamic lesions (Jones et al , 1977) also
results in attenuated corticosterone responses. Further evidence for feedback at the
level of the pituitary has been provided by in vitro studies: corticosterone inhibits
stimulated ACTH release from various pituitary preparations, including monolayer
cultures (Fleischer & Rawls, 1970), isolated pituitary cells (Portanova & Sayers,
1974), perfused pituitaries (Widmaier & Dallman, 1983b; Widmaier & Dallman,
1984) and cultured AtT-20 cells (Herbert et al, 1978). The hypothalamus has been
implicated as a site of corticosteroid feedback since local administration or implants
of corticosterone in the median eminence or antero-medial hypothalamus effectively
inhibits pituitary-adrenal activity (for review see (Keller-Wood & Dallman, 1984)),
however this evidence is not definitive as implanted corticosterone may enter the
portal blood and exert its actions at the anterior pituitary. Nevertheless, both basal
and stress-induced CRH bioactivities within the hypothalamus are inhibited by
dexamethasone or corticosterone administration (Takebe et al, 1971; Buckingham &
Hodges, 1977; Kaneko & Hiroshige, 1978) and CRH release into the portal blood
system in response to haemorrhage is inhibited by dexamethasone pretreatment
(Plotsky & Vale, 1984) supporting the hypothalamus as a site for glucocorticoid
feedback regulation of the HPA axis. Corticosterone feedback has also been reported
at extra-hypothalamic sites in the brain, particularly at limbic brain structures.
Injection of corticosterone into the septum or hippocampus suppresses the adrenal
response to various stimuli (Keller-Wood & Dallman, 1984).
Several researchers have attempted to identify the receptors involved in
glucocorticoid feedback. Reul & deKloet reported that type I (high affinity) receptors
are 90% occupied during the normal circadian trough, when basal levels of
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corticosterone are low; whereas type II (low-affinity) receptors are less than 5%
occupied at this time and approximately 50% occupied at the circadian peak or
following stress in the morning when corticosterone levels are elevated (Reul & De
Kloet, 1985). Since type I receptors are restricted primarily to the lateral septum and
hippocampus and because they are essentially fully occupied by corticosterone
(Dallman et al, 1994), their role may be permissive. In contrast, the type II receptors
have a wider distribution, with high expression in the lateral septum, dentate gyrus,
NTS, CeA and PVN, and furthermore are only 50% maximally occupied at the
circadian peak and after stress during the trough phase. Thus the characteristics of
type II receptors indicate they are more suited to feedback regulation of the stress-
induced increases in ACTH secretion
1.13.4. Corticosterone Binding Globulin
Corticosterone binding globulin (CBG) is synthesised in the liver of most mammals
including rodents and humans (Hammond et al, 1987). CBG is a carrier protein
found in plasma which (as its name suggests) binds corticosterone. Between 90-95%
of circulating corticosterone becomes bound to CBG under normal conditions
(Hammond, 1990). Since corticosterone is active only in its free form (Mendel,
1989), there is normally only a small fraction of total corticosterone available for
bioactivity. Therefore, any variations in CBG levels can strongly influence the
glucocorticoid signal. Glucocorticoids are known to influence plasma CBG levels as
does stress. Removal of endogenous glucocorticoids by ADX increases circulating
levels of CBG (Weidenfeld & Feldman, 2000), whilst chronic corticosterone
administration causes plasma CBG levels to decline (Weidenfeld & Feldman, 2000).
Similarly, increases in plasma corticosterone following exposure to acute stress also
significantly reduce plasma CBG levels (Fleshner et al, 1995; Spencer et al, 1996).
Thus circulating CBG provides a mechanism by which the availability of
biologically active glucocorticoids may be regulated without necessarily altering
total levels. 1 ip-hydroxysteroid dehydrogenase (lip-HSD) may represent another
important factor in the control of corticosteroid feedback and is discussed in section
1.21.
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1.14. Circadian Rhythm of HPA Activity
Under normal conditions, many mammals including rats and humans display a
diurnal pattern of ACTH and corticosterone secretion (Krieger, 1977). The peak and
nadir of hormone secretion coincides with the initiation and termination of the
animal's active period, respectively. Rats are nocturnal animals, therefore plasma
levels of ACTH and corticosterone peak in the evening and are lowest in the morning
(Dallman et al, 1978). Plasma ACTH and corticosterone levels rise throughout the
afternoon, however the peak in ACTH secretion precedes the peak in corticosterone
secretion. In rats (entrained to a 12 hour light-dark cycle, lights on at 06:00h)
corticosterone levels are very low during the early morning (06:00-09:00h) and they
increase slightly between 11:00 and 13:00h. Corticosterone levels begin to rise
dramatically in the late afternoon, and peak at around two hours after the onset of the
dark phase (~20:00h). Plasma corticosterone then gradually declines reaching near
basal levels at 03:00h (Kwak et al, 1992). Rats also exhibit low plasma ACTH levels
in the morning. ACTH levels increase between 13:00-15:00h and peak just before the
dark phase at 17:00h (Kwak et al, 1992). ACTH levels decline rapidly ~ 1 hour after
the peak in corticosterone secretion and return to near basal levels at ~03:00h.
CRH is the principal regulator of ACTH secretion and its presence is necessary for a
normal circadian rhythm of ACTH. Immunoneutralisation of CRH abolishes the
evening rise in plasma ACTH and corticosterone levels (Bagdy et al, 1991). CRH
mRNA content in the hypothalamus also exhibits diurnal variations. Generally, CRH
mRNA content is low in the morning, begins to rise in the afternoon and peaks at the
onset of the dark phase (Kwak et al, 1992). Following this peak in the evening there
is a sharp decline in CRH mRNA content, which coincides with the peak of
corticosterone secretion, and then a second drop occurs early in the morning, when
CRH mRNA expression is minimal (Kwak et al, 1992).
The suprachiasmatic nucleus (SCN) of the hypothalamus is thought to play an
important role in generating the HPA diumal rhythm, as bilateral lesions to the SCN
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significantly attenuate (Abe et al, 1979) or completely abolish (Moore & Eichler,
1972) the peaks in ACTH and corticosterone secretion. Furthermore, the
serotoninergic innervation of the SCN neurones seems to be important in facilitating
the ACTH rhythm. Lesioning of the median and dorsal raphe nuclei (the site of
serotonin producing neurones) causes a marked depression (-40-50% reduction) in
the amplitude of ACTH secretion (Szafarczyk et al, 1980). It is not clear how the
SCN controls the circadian rhythm of adrenocortical function, however anterograde
tracing techniques have shown that some SCN neurones innervate the dorsomedial
parvocellular PVN cells (Stephan et al, 1981). Other lesioning studies have
demonstrated that the SCN stimulates CRH secretion at night (Cascio et al, 1987),
supporting the idea that the SCN-PVN pathway is important in regulating the
circadian rhythm of ACTH secretion.
As well as the input from the SCN, CRH neurones in the PVN also receive
catecholaminergic innervation from the locus coeruleus and the Al and A2 cell
groups in the brainstem. These brainstem projections have been implicated in
modulating the diurnal HPA rhythm (Kaneko et al, 1980), since destruction of the
ventral noradrenergic ascending bundle obliterates the circadian pattern of ACTH
and corticosterone.
The expression of so-called "pacemeaker" or "clock" genes in the SCN, including the
genes per (period) and tim (timeless) are fundamental in generating 24h rhythmicity.
The protein products of these genes act through a negative feedback loop to repress
their own transcription. This time-keeping mechanism relies on two factors: lag
between transcriptional induction ofper and tim and the nuclear translocation of the
repressor proteins they encode. The interaction of these genes with transcriptional
activators are thought to play a crucial role in the molecular machinery that drives
physiological and behavioural rhythmicity (for review see Wager-Smith & Kay,
2000).
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1.15. Opioids and the HPA axis
Endogenous opioids and their receptors are widely distributed throughout the CNS.
Their distribution is consistent with their involvement in a broad range of functions
and behaviours, including regulation of pain, reinforcement and reward, release of
neurotransmitters, autonomic and neuroendocrine modulation (Akil et al, 1984;
Olson et al, 1995). Three families of endogenous opioid have been identified: the
enkephalins, dynorphins and endorphins, each derived from different precursors:
proenkephalin (pENK), prodynorphin (pDYN) and proopiomelanocortin (POMC),
respectively (Drolet et al, 2001). Related to the opioid family is the recently
discovered peptide orphanin FQ (OFQ)/ nociceptin (Reinscheid et al, 1995; Meunier
et al, 1995).There are three main types of opioid receptor, all belonging to the G-
protein linked receptor superfamily, referred to as mu (p.), delta (5) and kappa (k)
(Mansour et al, 1994). Enkephalins bind to p- and 8-receptors, dynorphins to k-
receptors and endorphins to p- and k- receptors (Russell & Douglas, 2000). Opioid
synthesising neurones are present in stress related regions of the brain and brainstem,
including the cerebral and piriform cortex, central and medial amygdala, lateral
septum, BNST, preoptic area, hypothalamus (including the PVN), parabrachial
nucleus, NTS and VLM (Khachaturian et al, 1983; Harlan et al, 1987). Opioid
receptors are present in the median eminence and there are opioidergic inputs to the
PVN (Drolet et al, 2001). p-endorphin cells in the arcuate nucleus send projections
which traverse the median eminence and terminate in the PVN. These P-endorphin
nerve terminals impinge upon CRH neurones in the PVN and therefore may be
involved in controlling CRH release. Furthermore, enkephalins and dynorphins are
co-synthesised by noradrenergic neurones in the NTS which are known to project to
the PVN (for review see (Russell & Douglas, 2000)). Activation of these NTS
neurones which may co-express opioid peptides (pENK-A and pDYN mRNA)
occurs following exposure to stress (Russell & Douglas, 2000).
Immunocytochemical studies have revealed the coexistence of enkephalin and CRH
in pPVN cells (Hokfelt et al, 1983) and of enkephalin, CRH and AVP in granules in
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the median eminence (Hisano et al, 1987), suggesting a role for opioids in HPA axis
regulation, perhaps by a pre-terminal action in the median eminence. Expression of
pENK-A mRNA is increased in the PVN after exposure to various stressors, such as
i.p. hypertonic saline (Lightman & Young, 1987; Harbuz & Lightman, 1989), ether
(Watts, 1991), morphine withdrawal (Harbuz et al, 1991) or restraint (Ceccatelli &
Orazzo, 1993). However, the stress-induced increase in pENK-A mRNA in the PVN
is blocked by i.e.v. administration of a GR antagonist (Garcia-Garcia et al, 1998)
indicating that the increase may be a result of stress-induced glucocorticoid action
on these neurones (or their inputs). Thus opioids may influence HPA activity by their
actions at the level of the brainstem, PVN or the median eminence.
Various studies have indicated that opioid peptides play both stimulatory and
inhibitory roles in regulating HPA activity. Acute administration of morphine causes
a rise followed by a fall in hypothalamic CRH content and increases concentrations
of ACTH in plasma and in the anterior pituitary in vivo (Buckingham, 1982).
Furthermore, stress-induced increases in hypothalamic CRH and pituitary and
plasma ACTH levels are potentiated in rats pretreated with morphine (Buckingham,
1982). Incubation of isolated hypothalami with either morphine, met-enkephalin or
leu-enkephalin all stimulate CRH secretion, effects which can be inhibited by
naloxone (Buckingham, 1982); however, none of these opioids has any effect on
ACTH secretion from pituitary segments in vitro (Buckingham, 1982). These data
suggest that morphine and the enkephalins evoke HPA activity by stimulating
specific receptors in the hypothalamus. In contrast, hypothalami of morphine tolerant
rats fail to secrete CRH when stimulated with either morphine or met-enkephalin
(Buckingham & Cooper, 1984) both in vivo and in vitro. Morphine also inhibits
stress-induced ACTH secretion when given acutely to rats anaesthetised with sodium
pentobarbitone (Buckingham, 1982). P-endorphin has been shown to stimulate and
inhibit CRH secretion(Buckingham, 1986). At low concentrations, P-endorphin
causes dose-related increases in CRH release from rat hypothalami in vitro, whereas
at high concentrations, P-endorphin inhibits CRH release (Buckingham, 1986). The
stimulatory response is inhibited by naloxone, whereas the inhibitory response is not
readily reversed (Buckingham, 1986), indicating that each response is mediated by
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different receptors. The opposing actions of endogenous opioids in regulating HPA
function are thought to be mediated by specific opioid receptor subtypes in the
hypothalamus.
In rodents the ACTH response to acutely administered morphine can be mimicked by
selective p-receptor agonists and inhibited by naloxone, naltrexone and the selective
p-receptor antagonist, P-funaltrexamine (Pfeiffer et al, 1985; Hayes & Stewart, 1985;
Pechnick et al, 1985a; Pechnick et al, 1985b; Buckingham & Cooper, 1986).
Blockade of p-receptors has no effect on basal ACTH or corticosterone levels,
however the secretion of these hormones normally observed in response to surgical
stress is abolished (Cover & Buckingham, 1989), suggesting that these receptors may
facilitate the secretion of CRH that occurs in response to certain stressors. 8-
receptors do not appear to be involved in the regulation of the HPA axis, since
autoradiographic studies indicate the hypothalamus is almost completely devoid of 8-
binding sites (Mansour et al, 1987) and the 8-receptor antagonist has no effect on
ACTH and corticosterone responses to stress (Cover & Buckingham, 1989).
Blockade of k-receptors evokes a rapid hypersecretion of basal ACTH and
corticosterone and causes a pronounced exaggeration and prolongation of the stress
response (Cover & Buckingham, 1989). Furthermore, the hypothalamus is rich in k-
binding sites (Mansour et al, 1987) and k-agonists have been shown to depress the
secretion of immunoreactive CRH in vivo and in vitro (Yajima et al, 1986; Plotsky et
al, 1987), indicating a role for k-receptors in tonic inhibition of the HPA axis.
In the rat, stress stimulates oxytocin secretion. Endogenous opioids play an important
role in the control of oxytocin release (Clarke et al, 1979) and in the rat, have been
shown to exert an inhibitory influence. Oxytocin neurones of the SON and PVN co-
express enkephalins and dynorphins and upon activation, opioids are co-released
with oxytocin (for review see (Brown et al, 2000)). k- and p-receptors are expressed
on oxytocin cell bodies in the magnocellular region of the PVN and in the SON,
however only k-opioids have been identified on nerve terminals in the posterior
pituitary (Russell & Douglas, 2000). Since no evidence has demonstrated the
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presence of S-receptors in the hypothalamo-neurohypophysial system (HNS), it is
thought that opioids acting upon 5-receptors are not of primary importance in
regulating oxytocin secretion in response to stress. The oxytocin secretory response
to various stressors (such as forced swimming and restraint) is increased by naloxone
and inhibited by k- and p-opioids. In the rat, endogenous opioids to inhibit secretion
by acting on oxytocin axon terminals in the posterior pituitary (Douglas et al, 1993),
however, exogenous opioids can act directly on oxytocin cell bodies to inhibit their
activity via k- or p-receptors (Douglas et al, 1995).
A sexual dimorphism in the oxytocin response to stress exists (Carter et al, 1986).
Immobilisation stress causes a significant increase in plasma oxytocin concentration
in both intact male and female rats and in castrated males, however this response is
significantly potentiated by naloxone only in female and castrated male rats (Carter
et al , 1986). These results indicate that an inhibitory opioid mechanism exerts a
more profound influence on oxytocin secretion in female than in male rats and
suggests that gonadal hormones may modulate the opioid system regulating
neurohypophysial oxytocin secretion. Thus, endogenous opioids play important
modulatory roles in regulating both HPA and HNS activity in response to stress.
1.16. Interactions of the Neuroendocrine and Immune Systems
The importance of the immune and neuroendocrine systems for successful recovery
from infection or inflammation is well established. The immune system recognises
and eliminates foreign antigens, regulates inflammatory processes and plays a key
role in tissue repair. The neuroendocrine system ensures that the altered metabolic
demands of the host are adequately met. These two systems do not function
independently. The immune and neuroendocrine systems interact to maintain
homeostasis. Until recently most interactions between the immune and
neuroendocrine system were attributed to the immunosuppressive action of
glucocorticoids, however it is now well recognised that the immune-neuroendocrine
interactions are bidirectional. In addition to the effects of hormones on the immune
system, immune signals profoundly affect neuroendocrine functions.
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1.16.1. Neuroendocrine Effects on the Immune System
The anti-inflammatory effects of glucocorticoids were discovered in the early 1950's
(Hench & Kendall, 1950). The ultimate effect of adrenal glucocorticoids is to
suppress immune/inflammatory responses. They suppress lymphocyte traffic and
function, the secretion of cytokines and other inflammatory mediators and inhibit the
effects of several of these mediators on their target tissues (Blalock, 1989), so as to
prevent compromising homeostasis. Under normal conditions glucocorticoids exert a
tonic inhibitory influence on the immune system, however they are not present in
large enough quantities to prevent the organism mounting an immune response to a
challenge. As the hypersecretion of corticosterone is dependent upon the immune
challenge it occurs after activation of the immune response. This means the organism
is capable of mounting an immune response that can then be restrained by
glucocorticoids to prevent the immune system over-responding and posing a threat to
the organism. Indeed, removal of these steroids by ADX often has fatal results in
response to immune stimulation with cytokines (Blalock, 1989).
The role of the HPA axis in regulating the immune system has been demonstrated in
animal models of inflammatory disease. Lewis rats are susceptible to inflammatory
disease, such as arthritis and this is associated with HPA axis hyporesponsiveness,
whereas Fischer rats are resistant to inflammatory disease and demonstrate HPA axis
hyperresponsiveness (Sternberg et al, 1989a; Sternberg et al, 1989b). Treatment of
Fischer rats with the GR antagonist, RU486 renders them susceptible to
inflammatory disease, while treatment of Lewis rats with low dose dexamethasone
significantly diminishes symptoms of inflammatory disease (Sternberg et al, 1989a),
suggesting a role for glucocorticoids in regulating the immune system. Cells of the
immune system are now known also to produce peptide hormones such as CRH,
ACTH, TSH, prolactin, LH and GH (for review see (Blalock, 1989)) classically
thought of as being exclusive to neuroendocrine systems. The quantity of hormones
secreted by leucocytes is small and their action is probably paracrine or autocrine.
Glucocorticoids were the first hormones to be recognised as having
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immunosuppressive activity, however the other HPA hormones, CRH and ACTH
may also act directly on the immune system (Tomaszewska & Przekop, 1997).
Immune cells such as phagocytes and macrophages contain both CRH peptide and
CRH receptors (Tomaszewska & Przekop, 1997). I.e.v. or i.v. CRH suppresses
natural killer cell activity and decreases T cell proliferation (Tomaszewska &
Przekop, 1997); furthermore ACTH receptors have been described on lymphocytes
and administration of ACTH restrains several immune functions, including antibody
formation and inflammation (Tomaszewska & Przekop, 1997).
1.16.2. Effects of Immune Signals on the HPA Axis
Immune signals have a stimulatory effect on the HPA axis. This action is important
so that the appropriate metabolic, behavioural and endocrine changes can be made
for restoration of homeostasis following infection and inflammation.
1.16.2.1. Cytokines
Following immune system activation, macrophages increase production of cytokines
that regulate immunity and inflammation. Cytokines are a large family of
polypeptide mediators that act as intercellular messengers within the immune system
by modulating the activity of closely adjacent cells (Balkwill & Burke, 1989).
Cytokines interact with specific high affinity receptors to regulate the inflammatory
response (Gillis, 1991). These major proinflammatory cytokines include interleukins
(IL-la, IL-1 p and IL-6) and tumour necrosis factor alpha (TNF-a). Many studies
have provided evidence that cytokines are responsible for informing the brain that an
immune response is occurring and stimulating the HPA axis, resulting in increased
secretion of ACTH and corticosterone.
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1.16.2.2. Cytokine Receptors
There are three major families of cytokine receptors (Foxwell et al, 1992): the
haematopoietic growth factor receptor family (including the IL-6 receptor), the
tumour necrosis receptor family (including two TNF receptors; TNF-R55 and TNF-
R75) and the immunoglobulin supergene family (including two interleukin-1
receptors, types I and II). The majority of work has focussed on the IL-1 receptor.
The type II IL-1 receptor is a receptor decoy that does not elicit a cellular signal
(Colotta et al, 1993), which can make interpretation of IL-1 binding studies
complicated. Nevertheless, studies have demonstrated that in the rat brain, binding of
both radiolabelled IL-1 a (Farrar et al, 1987) and IL-ip (Katsuura et al, 1988) is
fairly widespread, with a significant signal in the hypothalamus. In agreement with
these findings are in situ hybridisation studies which have reported the presence of
IL-receptor (type I) mRNA in neurones of the hypothalamus (ventro-medial
hypothalamus and arcuate nucleus) as well as in the organum vasculosum of the
lamina terminalis (OVLT) (Yabuuchi et al, 1994). In addition to the expression in
neurones, IL-lRi mRNA is also expressed on the vascular walls and the epithelial
cells of the choroid plexus and the ventricles (Yabuuchi et al , 1994). IL-1, type I
receptors are also present in the external layer of the median eminence (the site of
CRH and AVP parvocellular nerve terminals) (Farrar et al , 1987) and the anterior
pituitary (Grigoriadis & De Souza, 1989), but not in the adrenal gland (Cunningham
Jr et al, 1992).
Fewer studies have investigated IL-6 and TNF-a receptor expression in the
neuroendocrine system. In the rat, IL-6 receptor mRNA is present in the preoptic,
dorso-medial and ventro-medial areas of the hypothalamus, the olfactory bulb,
hippocampus (Schobitz et al, 1992) and the pituitary gland (Ohmichi et al, 1992).
TNF-a receptor mRNA is expressed in the pituitary of rats but is not apparent in the
brain (Wolvers et al, 1993).
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1.16.2.3. Effects of Cytokines on the HPA Axis
Given the abundance of cytokine receptors in tissues associated with the HPA axis, it
is hardly surprising that cytokines have a profound effect on the HPA activity. A
plethora of studies have provided unequivocal evidence that peripheral (i.v. or i.p.)
administration of either IL-1 agonists (IL-la or IL-ip), IL-6 and TNF-a increase
plasma ACTH and corticosterone levels in laboratory rats (Sapolsky et al, 1987;
Berkenbosch et al, 1987; Rivier et al, 1989; Harbuz et al, 1992b) and passive
immunisation of rodents against IL-1 attenuates the HPA response to the endotoxin
lipopolysaccharide (LPS, a macrophage activator which stimulates release of
cytokines (Besedovsky & Del Rey, 1992). The mechanisms by which cytokines
released in response to immune challenge activate the HPA axis are not fully
understood, but appear complex and involve both centrally mediated responses and
actions at the level of the pituitary and adrenal and the vagus nerve. A variety of in
vivo and in vitro studies indicate that the marked increases in circulating ACTH and
corticosterone initiated by cytokines are triggered by increased hypothalamic drive to
the pituitary corticotrophs. Thus, in the rat, peripheral administration of IL-1 (3
increases secretion of CRH into the portal circulation and this is accompanied by
decreased immunoreactive CRH content in the median eminence and consequently
increases in plasma ACTH and corticosterone (Sapolsky et al, 1987), for review see
(Turnbull & Rivier, 1995; Buckingham et al, 1996). It appears that CRH is necessary
for this effect of IL-1 (3 since immunoneutralisation of endogenous CRH
(Berkenbosch et al , 1987; Sapolsky et al , 1987), or PVN lesion (Rivest & Rivier,
1991) inhibits activation of the HPA axis by peripheral injection of IL-1 p. In
addition, i.v. IL-lp stimulates CRH mRNA expression in the PVN (Suda et al,
1990).
There is conflicting evidence for a concomitant rise in AVP release with CRH
following cytokine administration. Earlier studies suggested that cytokines stimulate
the CRH neurones in the PVN which are deficient in AVP (Berkenbosch et al ,
1987), however more recent in vivo push-pull perfusion experiments show significant
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AVP release at the median eminence (presumably of parvocellular origin), following
local hypothalamic administration of IL-1 (3 (Watanobe & Takebe, 1993).
Furthermore, central (but not systemic) IL-ip administration increases AVP mRNA
expression in the pPVN and triggers increases in ACTH secretion, which are
attenuated by administration of AVP antisera (Turnbull & Rivier, 1995).
These data provide convincing evidence that cytokine-induced ACTH secretion is
mediated by CRH, however they do not provide definitive evidence for a direct
action of cytokines on the hypothalamic PVN neurones. It was therefore necessary to
establish whether cytokines activate nerve terminals in the median eminence or
whether they stimulate CRH perikarya in the PVN. Studies providing evidence for a
dose-dependent increase in ACTH secretion following central administration of IL-1
(a or (3) and IL-6 in rats (Katsuura et al , 1988; Rivier et al , 1989) raised the
possibility of different mechanisms of cytokine-induced HPA activation depending
on the route of administration. For some time it was thought likely that centrally
administered IL-1 acted upon cell bodies of hypophysiotropic neurones within the
PVN and systemic IL-1 acted at the level of the nerve terminals of these neurones in
the median eminence. Indeed IL-1 injected directly into the median eminence rapidly
stimulates ACTH secretion in the rat (Matta et al, 1990). This argument was fuelled
by the fact that cytokines are large polypeptides (17-26 kDa) and therefore unlikely
to cross the blood-brain-barrier (BBB) freely and gain access to targets in the CNS.
However, in vitro studies have demonstrated the ability of cytokines (IL-la, IL-1 p,
IL-6 and TNF-a) to initiate release of CRH from isolated hypothalami (without
median eminence) (Navarra et al, 1991; Loxley et al, 1993) and that IL-6 has fails to
evoke CRH release from the isolated median eminence incubated in vitro under the
same conditions (Navarra et al , 1991). Furthermore IL-1 does not stimulate ACTH
release from rat anterior pituitary cell cultures (Dunn, 1992), suggesting a direct
action of cytokines on CRH secreting cells in the hypothalamus. Moreover, i.e.v.
injection of an IL-1 receptor antagonist effectively blocks the HPA response to
systemic IL-1 (3 (Fukata et al, 1989).
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Effects ofCytokines on the Pituitary
The majority of the literature concerning the effects of cytokines on pituitary ACTH
secretion argues against a direct role for cytokines in regulating pituitary ACTH
release. However, some studies have shown that incubation with IL-1 (a or P), IL-6
or TNF-a (Fukata et al, 1989; Ray & Melmed, 1997; Katahira et al, 1998) increases
ACTH secretion from the mouse corticotrope tumour cell line, AtT-20. Nevertheless,
whether this cell line accurately reflects the response of normal pituitary cells to
cytokines has been disputed, as inconsistent effects have been reported. Furthermore,
long incubation periods (2-8 hours vs 20 min for CRH release) are required if these
cytokines are to stimulate ACTH secretion from pituitary cells. Furthermore, IL-ip
(Tsagarakis et al, 1989a), IL-6 (Navarra et al , 1991) and TNF-a (Bernardini et al,
1990) have all been shown to evoke CRH release from in vitro hypothalamic
preparations at concentrations of much lower magnitude than those necessary to
elicit ACTH secretion from cultured pituitary cells. Therefore, it seems that rapid
elevations of ACTH secretion in vivo in response to low doses of cytokines are
mediated by increased CRH release and perhaps during conditions of prolonged
exposure, cytokines may influence pituitary secretion directly.
Effects of Cytokines on the Adrenal Gland
Despite unsuccessful attempts to detect receptors for IL-1 within the adrenal gland,
direct actions of IL-1 on glucocorticoid secretion have been reported. In vivo studies
have demonstrated a stimulatory effect of IL-1 (given peripherally) on corticosterone
secretion when administered to anaesthetised rats with isolated adrenals perfused in
situ (Roh et al, 1987). Similarly, in vitro experiments have shown IL-1 (a and P)
increases glucocorticoid secretion from quartered rat adrenals (Gwosdow et al,
1992), rat adrenal slices (Andreis et al, 1991) and from isolated rat (Gwosdow et al,
1992) and human (Whitcomb et al, 1988) adrenal cells. Similarly IL-6 and TNF-a
(Darling et al, 1989; Tominaga et al, 1991) appear to evoke corticosterone release
from adrenal cell cultures, although only receptors for IL-6, and not IL-1 or TNF-a,
have been reported in the adrenal gland (Ehrhart-Bornstein et al, 1998). However,
once again the effects of cytokines on adrenal corticosterone require extremely high
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doses and long incubation periods, suggesting that the direct influence of cytokines
on adrenal glucocorticoid secretion occurs only after prolonged exposure and
therefore may serve to prolong glucocorticoid responses to immune challenge.
1.16.3. How do Cytokines Gain Access to the Brain?
So far the evidence strongly implicates the brain as the primary site at which
cytokines exert their effect on the HPA axis. However this poses a problem: how do
cytokines gain access to the brain? As mentioned earlier, cytokines are large
molecules and therefore are not thought to be able to freely cross the BBB,
nevertheless several hypotheses of how cytokines may penetrate the brain have been
suggested.
(1) Cytokines may enter the brain at circumventricular organs e.g. organum
vasculosum of the lamina terminalis (OVLT) and median eminence (ME).
(2) Active transport of circulating cytokines across the BBB or perhaps cytokines can
cross the choroid plexus.
(3) During inflammation the BBB may become more penetrable by cytokines.
(4) An increase in peripheral cytokines may stimulate synthesis and release of central
cytokines.
(5) Secondary messengers (released in response to increased circulating cytokines)
may activate CRH neurones or excitatory neurones impinging upon them.
While all of these mechanisms may be involved in permitting cytokines access to the
brain a growing body of evidence suggests that activation of pPVN neurones need
not depend on cytokines entering the brain, but instead their effects are largely
mediated by soluble mediators released in response to the actions of cytokines on
brain blood vessels. It is thought that once released, these mediators may target the
pPVN directly and/or drive the HPA axis by activating neuronal inputs to the PVN.
Another possibility is that cytokines activate brain pathways via an action on the
vagus nerve (see section 1.16.5.2.).
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1.16.4. Eicosanoids
Eicosanoids are lipid mediators derived from arachidonic acid, which are known to
contribute to the hypothalamic mechanisms controlling ACTH release (Cowell &
Buckingham, 1989; Buckingham et al , 1996). Prostaglandins (PGs) are a class of
eicosanoids, and their production is stimulated in the presence of elevated circulating
interleukins (Dinarello, 1988). A strong body of evidence suggests that IL-1 acts on
the endothelium of blood vessels to activate the release of PGs. Indeed brain
microvessels express the IL-1 type I receptor (Ericsson et al, 1995). PGE2 action has
been implicated during immune challenge (Rivest et al, 2000). IL-1 increases release
of PGE2 from rat hypothalamic explants in vitro (Navarra et al, 1992) as well as from
the mPOA, OVLT, PVN and dorsal hippocampus in vivo (Komaki et al, 1992).
Moreover, local injection of PGE2 into the third ventricle, PVN, OVLT, ME or POA
causes a significant increase in HPA activity, reflected by increases in CRH mRNA
expression in the PVN and increased ACTH secretion (Katsuura et al, 1990; Lacroix
et al, 1996). Furthermore, both PGE2 and PGF2a stimulate CRH release from isolated
hypothalami (Mulla & Buckingham, 1999). The ACTH response to centrally
administered PGE2 in vivo is attenuated by pretreatment with CRH antisera (Cowell
& Buckingham, 1989), indicating that CRH is necessary for PGE2-induced HPA
activation. The findings above led to the concept that PGs may be important
mediators of the hypothalamic response to immune challenge. Several experimental
approaches have been taken to investigate this theory. In vitro experiments have
shown that indomethacin, a non-selective cyclo-oxygenase (COX; the enzyme
complex that forms the common precursor substrate for PG synthesis) inhibitor
blocks CRH release by isolated hypothalamic fragments in response to interleukins
(Navarra et al , 1991). Similarly the importance of eicosanoid pathways has also
been reported in vivo. Acute treatment with indomethacin (i.v. or i.e.v.) or i.v.
ibuprofen (another COX inhibitor) virtually abolishes the effect of IL on ACTH
secretion (Katsuura et al, 1988; Watanabe et al, 1990; Morimoto et al, 1991; Rivier,
1993). These COX inhibitors have also been reported to inhibit c-fos expression in
pPVN neurones induced by i.c.v. and i.p. IL-1 (3, i.v. IL-6 and endotoxin (Niimi et al,
1996; Niimi et al, 1997), and to block CRH and AVP release evoked by IL-1 P, IL-6
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and TNF-a in vitro (Navarra et al , 1991). Comparable results have been
demonstrated employing antibodies against PGEi, PGE2 and PGF2a- These
antibodies prevent IL-l(3-induced ACTH secretion (Watanobe et al, 1995). Further
evidence for a role for PGs in mediating the effects of interleukins on the HPA axis,
came from studies showing that the time course of eicosanoid generation in the
hypothalamus complements the activation of the pPVN neurones. For example, IL-
1(3 and IL-6 increase the release of PGE2 from rat hypothalami in vitro and in vivo
along a time course that closely parallels the release of CRH/AVP (Navarra et al ,
1992).
The site of PG synthesis appears to be within vascular regions of the brain, as
indicated by the robust increase in expression of COX-2 mRNA within microvessels
in response to systemic inflammation (Cao et al, 1996; Cao et al, 1998; Lacroix &
Rivest, 1998). Moreover, administration of i.v. IL-1 (3 causes a significant rise in
COX-2 mRNA expression within endothelial cells of the CNS blood vessels (Lacroix
et al, 1996).
The actions of PGE2 are mediated by their specific seven transmembrane receptors,
of which there are four subtypes: EPi, EP2, EP3 and EP4. Three isoforms of EP3
receptors have been identified, EP3a, EP3p and EP3y (Rivest et al , 2000). In situ
hybridisation studies have shown EP3 receptor mRNA and binding sites in neurones
of numerous regions of the rat brain, including the ventral septal area (VSA), NTS,
VLM and numerous other hypothalamic nuclei (Matsumura et al, 1990; Matsumura
et al, 1992). The EP2 receptor has been detected in the BNST, lateral septum,
subfornical organ (SFO), ventro-medial hypothalamic nucleus, CeA, locus coeruleus
and the anterior pituitary; whereas EP4 receptor mRNA is present in the ventral
septum, POA, PVN (magnocellular division), SON, PBN, LC, NTS and VLM
(Zhang & Rivest, 1999). The EP4 receptor seems to play an important role in
mediating the HPA response to immune challenge, since administration of LPS, IL-
1(3 (i.v.) or turpentine (i.m.) up-regulates EP4 mRNA within CRH neurones of the
pPVN (within 3h of LPS and IL-1 p injection and 6h of the turpentine injection).
Activation of the EP4 containing CRH neurones by these stimuli is reflected by
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induction of Fos protein in these cells. The EP4 transcript is also present in activated
catecholaminergic neurones of the NTS, VLM and LC (Zhang & Rivest, 1999)
following immune challenge. Together these data support the view that the effects of
cytokines on HPA axis activation are mediated via eicosanoids which interact with
specific receptors on brain blood vessels to stimulate the release of soluble PGs
which can subsequently trigger HPA activation.
1.16.5. Cytokine Signalling
1.16.5.1.Catecholamine Pathways
Central catecholaminergic modulation of the secretion of CRH and ACTH has been
well documented (Rivier & Vale, 1983b; Tilders et al, 1985; Szafarczyk et al, 1985;
Guillaume et al, 1987) and several lines of investigation have indicated a role for
catecholaminergic pathways in driving HPA responses to immune challenge.
Systemic IL-1 administration stimulates central and peripheral release of
catecholamines, concomitant with an increase in ACTH and corticosterone secretion.
Immunocytochemical and in situ hybridisation studies have shown induction of c-fos
mRNA and Fos expression in brain areas such as the NTS and VLM (Day & Akil,
1996), which represent sources of afferent catecholaminergic projections to the PVN,
following systemic administration of IL-1 p. Several studies have focussed on the
effects of interrupting catecholaminergic innervation from the brainstem to the
hypothalamus. When such lesions are performed bilaterally, they result in a
significant attenuation of the ACTH secretory response and block increases in PVN
CRH mRNA expression, following i.v. and i.e.v. IL-ip (Melik Parsadaniantz et al ,
1995). Moreover, unilateral lesions prevent the induction of CRH mRNA by IL-ip
only in the ipsilateral PVN and not the contralateral PVN (Li et al, 1996). However,
bilateral lesions of ascending catecholaminergic tracts fail to have any effect on
ACTH secretion when IL-ip is infused directly into the PVN (Ericsson et al, 1994).
Administration of adrenoreceptor antagonists also attenuates ACTH secretion and
prevents increases in expression of Fos protein in the PVN induced by systemic IL-
ip (Givalois et al, 1995). The evidence indicates that the actions of IL-1 on HPA
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axis activation may in part be mediated by catecholaminergic inputs to the PVN. The
mechanisms of how IL-1 activates medullary catecholaminergic neurones are not
clear. It is unlikely that IL-1 acts directly on brainstem catecholamine neurones,
since there are few IL receptors in this region (Rivest et al , 2000). Two alternative
mechanisms have been proposed: IL-1P may act on local perivascular cells to trigger
the release of PGs, as discussed above or interleukins may act via the vagus nerve
(see below). The EP-3 receptor is expressed in the NTS and VLM (Rivest et al ,
2000) and injection of PGE2 into the VLM induces patterns of Fos protein expression
in the pPVN, similar to those induced by i.v. injection of IL-1 (3 (Ericsson et al,
1997). Furthermore, treatment with indomethacin (PG synthesis inhibitor) inhibits
the rise in hypothalamic noradrenaline turnover and Fos expression in the pPVN and
brainstem (Ericsson et al , 1997; Buller et al, 1998) normally observed following
peripheral IL-1P administration.
1.16.5.2. Vagal Inputs
Cytokines such as interleukins may exert effects within the periphery that influence
HPA activity. Several studies have indicated a role for vagal afferents in effecting
HPA responses to i.p. endotoxin, IL-1J3 and TNF-a (Gaykema et al, 1995; Fleshner
et al, 1997; Hansen et al, 1998). Vagal lesions inhibit ACTH responses to these
cytokines and also block the increases in c-fos mRNA expression in the pPVN and
NTS, noradrenaline release in the PVN and IL-1 (3 mRNA in the hypothalamus and
hippocampus, normally evoked in response to i.p. injection of IL-1 p or endotoxin.
However, vagotomy does not affect neuroendocrine responses to cytokines
administered by other routes, for example, i.v. administration of IL-1P causes
increases in CRH mRNA in the pPVN and Fos expression in the pPVN and
brainstem, none of which are unaffected by sub-diaphragmatic vagotomy (Ericsson
et al , 1997). Again, the mechanism by which i.p. cytokines activate the vagal
afferents is unclear. These neurones do not seem to express IL-1 receptors (Turnbull
& Rivier, 1995), however ganglionic cells which synapse onto vagal afferents are
reported to express IL-1 receptors (Mulla & Buckingham, 1999), thus this action
may be important. On the other hand, PGs released by macrophages in the
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peritoneum may be of primary importance in activation of the vagus (Mulla &
Buckingham, 1999). It appears from the data that vagal afferents may provide an
important communication link between the immune system and the brain following
cytokine administration via the i.p. route.
1.16.6. Cytokine Production
It is known that the brain, pituitary and adrenal gland are all capable of synthesising
and secreting various cytokines upon endotoxin stimulation (Turnbull & Rivier,
1995), which suggests cytokines produced in such tissues may regulate HPA activity
in a paracrine fashion.
(i) Cytokine Synthesis in the Brain
Expression of IL-ip mRNA (Ban et al, 1992) and protein (Hagan et al, 1993) have
been reported to increase in rat brain (including in the hypothalamus) following
systemic administration of endotoxin. Furthermore increased hypothalamic
expression of IL-la, IL-ip, IL-6 and TNF-a mRNA has also been reported
following i.p. or i.v. administration of endotoxin in mice (Pitossi F, 1997). The extent
to which brain-derived cytokines contribute to hypothalamic responses to immune
challenge is not clear. I.e.v. administered IL-1 receptor antagonist significantly
suppresses the ACTH response to i.e.v. endotoxin and i.e.v. IL-1 p, but does not
affect ACTH secretion induced by either i.v. IL-1 (3 or endotoxin (Habu et al, 1998).
However Kakucska et al observed that i.e.v. administration of IL-1 receptor
antagonist prevented the rise in plasma ACTH and CRH mRNA expression in the
PVN normally observed in rats treated with i.p. endotoxin (Kakucska et al, 1993).
Hence, endogenous brain cytokines may play a role in mediating HPA activation
under certain circumstances and may act to synergise with noradrenaline (released in
the hypothalamus following activation of brainstem catecholamine cell groups) to
amplify the hypothalamic response to immune insults.
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(ii) Cytokine Synthesis in the Pituitary
The pituitary gland is also able to synthesise cytokines. Messenger RNAs for IL-1(3
(Koenig et al, 1990), IL-6 (Muramami et al, 1993) and TNFa (Gatti & Bartfai,
1993) have all been demonstrated in the anterior pituitary following peripheral
administration of endotoxin.
(Hi) Cytokine Synthesis in the Adrenal Gland
Within the adrenal gland, IL-1(3 immunoreactivity is present in chromaffin cells
(Schultzberg et al, 1989) and a resident macrophage population (at the cortico-
medullary junction) synthesises IL-1, IL-6 and TNF-a. This evidence has suggested
a role for these cytokines in stimulating corticosterone secretion following immune
challenge (Ehrhart-Bornstein et al , 1998). The expression of mRNAs for these
cytokines is increased in the adrenal gland within 2 hours of endotoxin
administration (i.p. or i.v.) (Ehrhart-Bornstein et al, 1998). However, once again the
effects of cytokines on adrenal corticosterone secretion require extremely high doses
and long incubation periods, suggesting that the direct influence of cytokines on
adrenal glucocorticoid secretion occurs only after prolonged exposure and therefore
may serve to prolong glucocorticoid responses to immune challenge.
The functional significance of pituitary and adrenal cytokine generation is not well
defined. It is possible that cytokines synthesised in the pituitary and adrenal
following immune challenge act via local receptors in a paracrine manner to
influence ACTH and corticosterone secretion, respectively.
(iv) Cytokine Generation in Response to Non-Immunological Stimuli
In all the cases discussed so far cytokine production has been associated with
activation of the immune system, yet it is now generally accepted that other stressors
are capable of provoking cytokine production. In the rat, exposure to open-field
(LeMay et al, 1990), electric footshock (Turnbull & Rivier, 1995) or physical
restraint (Zhou et al, 1993) results in significantly elevated plasma levels of IL-6, and
immobilisation stress stimulates increases in hypothalamic IL-ip mRNA (Minami et
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al, 1991) and bioactive IL-1 (Shintani et al, 1995). Hence, the brain is capable of
synthesising interleukins in response to non-inflammatory/infectious stimuli.
In summary, cytokines are released by macrophage cells in response to immune
challenge. Cytokines activate the HPA axis, resulting in increased circulating
corticosterone. Corticosterone has suppressive actions on the immune response, an
effect necessary for maintenance of homeostasis. The brain seems to be the primary
site via which cytokines activate hypothalamic CRH/AVP neurones, however due to
their large molecular size several mechanisms by which their effects are mediated
have been suggested, including via prostaglandins. Prostaglandins may act on
receptors to activate brainstem catecholaminergic neurones that project directly to
the PVN. Alternatively prostaglandins may act directly on pPVN neurones.
Following i.p. cytokine administration, vagal afferents to the brainstem may be
important in mediating the influence of cytokines on the HPA axis. The brain,
pituitary and adrenal are all well known to be capable of synthesising cytokines.
Brain cytokines may have synergistic actions in activating hypothalamic pPVN
neurones. Cytokines may also act within the brain, pituitary or adrenal in a paracrine
fashion. Finally, evidence suggests that cytokines may be involved in HPA axis
regulation in response to non-infectious/non-inflammatory stressors.
1.17. Neuroendocrine Adaptations to Stress in Pregnancy
Virgin animals display complex neuroendocrine responses to stress including
activation of the HPA axis and the hypothalamo-neurohypophysial system (HNS)
which result in increased circulating ACTH, corticosterone, oxytocin, prolactin,
adrenaline and noradrenaline. It is well established that during lactation these
neuroendocrine responses to stressful stimuli are altered considerably. The stress-
related activation of the HPA axis and HNS system is markedly attenuated, thus less
ACTH and corticosterone are secreted by the anterior pituitary and adrenal gland,
respectively and less oxytocin is released by the posterior pituitary (Lightman &
Young, 1989; Windle et al, 1997). More recently, studies have indicated that the
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alterations in HPA reactivity to stress, evident in lactation, are established during late
pregnancy (Douglas et al, 1996; Neumann et al, 1998) (da Costa et al, 1996).
1.17.1. Basal Activity of the HPA axis in Pregnancy
(i) PVN: CRH and A VP Expression
A recent in situ hybridisation study has demonstrated that CRH mRNA expression
in the medial parvocellular region of the PVN is significantly reduced (by -30%) on
day 21 of pregnancy (Johnstone et al, 2000a). Although the values did not reach
statistical significance, AVP mRNA is also apparently decreased since the ratio of
AVP mRNA to CRH mRNA content does not change in pregnancy. These data
suggest that in late pregnancy, pPVN neurones are synthesising less CRH peptide,
however AVP peptide production is not increased to compensate. Compared with
CRH, AVP is a less effective secretagogue in triggering ACTH secretion, thus in
pregnancy it seems that the factors released by pPVN neurones provide less drive to
the anterior pituitary. The reduction in CRH biosynthesis in pregnancy (reflected by
reduced CRH mRNA content in the PVN) may be a result of attenuated stimulatory
inputs to the PVN neurones, for example from brainstem catecholaminergic afferents
(Pacak et al, 1996), or as a consequence of increased inhibitory inputs to the PVN,
perhaps by GABA neurones (Herman et al , 1996), or be a result of enhanced
negative feedback by glucocorticoids (Dallman et al, 1972).
(ii) ACTH and Corticosterone
In the rat, the circadian variation in ACTH secretion is evident early in pregnancy,
but diminishes after mid-gestation (Atkinson & Waddell, 1995). This appears to be
due to a reduction in evening peak levels (46 ± 5 pg/ml in diestrus, compared with 25
± 2 pg/ml on day 22 of pregnancy) (Atkinson & Waddell, 1995). The circadian
variation in corticosterone is maintained throughout rat pregnancy, however the
absolute levels of plasma corticosterone change. The daily mean (or mesor) declines
in early pregnancy, reaching a minimum by day 10 of gestation, but then increases
progressively to term (Atkinson & Waddell, 1995). The increases in corticosterone
secretion in the second half of pregnancy appears to be as a result of increases in
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trough levels with no changes in peak levels and occur without any changes in
ACTH. Several factors have been suggested to contribute to the change in the plasma
ACTH-corticosterone relationship in pregnancy, including reduced metabolic
clearance of corticosterone, foetal corticosterone entering the mother's circulation
(indeed surgical adrenalectomy does not abolish maternal circulating corticosterone)
or an increased sensitivity of the maternal adrenal gland to ACTH.
A reduction in metabolic clearance of corticosterone can be ruled out since Waddell
and Atkinson have shown that corticosterone clearance is maintained at pre¬
pregnancy levels throughout gestation (Waddell & Atkinson, 1994). However, it is
possible that the amount of free corticosterone declines in pregnancy, consistent with
an increase in circulating corticosterone binding globulin (CBG) in pregnancy
(Lohrenz et al, 1967). It seems unlikely that contribution to the maternal pool of
corticosterone by the foetal adrenals is the only factor involved in the increases in
corticosterone secretion in the second half of pregnancy, since the foetal adrenal only
develops the capacity for corticosterone synthesis from day 17 of pregnancy
(Milkovic et al, 1973), whereas maternal corticosterone levels are increased by day
14. Furthermore, placental 1 ip-hydroxy-steroid dehydrogenase (lip-HSD; see
section 1.20.) should limit the transfer of corticosterone from the foetal to the
maternal circulation (Burton & Waddell, 1994). On the other hand, increased
responsiveness of the maternal adrenal to ACTH could certainly account for the
changes observed in the ACTH-corticosterone relationship in pregnancy. Oestrogen
is known to increase the sensitivity of the adrenal to ACTH (Carr et al, 1981)
perhaps by increasing ACTH receptors, and secretion of oestrogen from the ovary
increases during the second half of pregnancy in the rat (Schulte et al, 1990; Waddell
& Atkinson, 1994).
1.17.2. HPA Axis Responses to Stress in Pregnancy
The responsiveness of the HPA axis to both emotional (elevated plus maze) and a
combined emotional-physical stressor (forced swimming) is significantly attenuated
in pregnancy, reflected by reduced stress-induced ACTH and corticosterone
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secretion (Neumann et al, 1998). The hyporesponsiveness of the HPA axis to stress
is evident from day 15 (Neumann et al , 1998) of gestation and persists through
pregnancy and lactation, until weaning (Windle et al , 1997). The attenuated
responsiveness of the HPA axis in pregnancy is likely to involve adaptations at the
level of the anterior pituitary. In vivo experiments have demonstrated attenuated
ACTH secretory responses (a 4.4-fold increase in virgin rats compared with a 1.5-
fold increase in day 21 pregnant rats) to intravenously administered CRH (Neumann
et al , 1998), indicating reduced reactivity of pituitary corticotrophs to CRH.
Similarly, CRH is less effective in stimulating cAMP production from pituitary
segments isolated from late pregnant rats (day 17 and day 22) compared with those
of virgin animals (Neumann et al, 1998). Furthermore, receptor autoradiography has
revealed a significant reduction in radio-labelled CRH binding site density in the
anterior pituitaries of pregnant rats (on day 11, day 17 and day 22) (Neumann et al,
1998).
A more recent study has reported increased 11 P-HSD-1 activity in the anterior
pituitary in late pregnancy (Johnstone et al , 2000a). Since 11 p-HSD-1
predominantly acts as a reductase, reactivating glucocorticoids from their inert
forms, its increased activity in pregnancy would presumably enhance local
glucocorticoid levels, thereby increasing the negative feedback action of
corticosterone on anterior pituitary corticotrope cells. In the same study, 11P-HSD
activity in the PVN was found to have doubled by day 16 and trebled by day 21 of
pregnancy (Johnstone et al , 2000a), suggesting a role for enhanced glucocorticoid
feedback mechanisms on pPVN CRH neurones as well as anterior pituitary
corticotrope cells. Moreover GR mRNA expression in the dentate gyrus was also
increased at the end of pregnancy (Johnstone et al , 2000a). However, i.e.v.
administration of the 11 P-HSD inhibitor, glycyrrhetinic acid (GA) was not effective
in increasing the ACTH secretory response to forced swimming in the pregnant
group (Johnstone et al, 2000a). Furthermore, removal of endogenous corticosterone
by pharmacological ADX (phADX), results in a comparable elevation of plasma
ACTH levels in both virgin and pregnant rats, indicating that endogenous
glucocorticoids restrain ACTH secretion similarly in both groups (Johnstone et al ,
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2000a). Pregnant rats also appear to be less sensitive to rapid glucocorticoid feedback
as demonstrated by ACTH responses in phADX rats to s.c. corticosterone
administration, but are similarly sensitive to delayed corticosterone feedback
(Johnstone et al , 2000a). These data suggest that reduced neural drive to PVN
CRH/AVP neurones may account for the hyporesponsiveness of the HPA axis to
stress in pregnancy, rather than enhanced negative feedback by glucocorticoids.
Supporting this theory is a study demonstrating that c-fos mRNA expression in the
pPVN of late pregnant rats (day 19-21) is significantly reduced following 30 minutes
of restraint, compared with the respective virgin group (da Costa et al, 1996).
1.17.3. Oxytocin Secretory Responses to Stress in Pregnancy
As mentioned earlier (see section 1.11), exposure to stressors stimulates oxytocin
secretion in the rat. While oxytocin may act to stimulate corticosterone secretion
from the adrenal gland, its functional significance in coping with stress is not clear.
In lactating rats, the oxytocin secretory response to stress is markedly attenuated
(Lightman & Young, 1989). This may be a consequence of depleted
neurohypophysial oxytocin stores due to the frequent pulses of oxytocin release
required for the milk-ejection reflex (Higuchi et al, 1991). During pregnancy, in
preparation for parturition, the oxytocin content of the rat posterior pituitary
increases progressively (Douglas et al , 1993; Douglas et al , 1995) and the
accumulated store is secreted during parturition to stimulate uterine contractions and
foetal expulsion. The build up of oxytocin stores occurs as a result of active restraint
of oxytocin secretion by endogenous opioids (Douglas et al , 1993; Douglas et al ,
1995). However, in contrast to lactation, pregnant and virgin rats demonstrate similar
oxytocin secretory responses to forced swimming (Douglas et al, 1998). Moreover,
oxytocin secretory responses to forced swimming in pregnancy are strongly
enhanced by naloxone (an opioid antagonist), which indicates that endogenous
opioids actually mask an exaggerated response after exposure to stress. Previous
studies have shown that endogenous p-opioids strongly inhibit oxytocin neuronal
activity and secretion in late pregnancy, at the level of oxytocin cell bodies and their
inputs (Douglas et al , 1995). The opioid restraint on oxytocin secretion following
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stress in pregnancy may involve a similar mechanism, though action on the inputs to
oxytocin neurones is more probable since endogenous opioids do not appear to be
responsible for attenuated oxytocin secretory responses to hyperosmotic stimulation
(Bull & Russell, 1992) or electrical stimulation of the OVLT (Bull et al, 1994) in
pregnancy.
1.17.4. Opioids and the HPA Axis in Pregnancy
Opioids are known to play an important modulatory role in regulating both HPA
activity and oxytocin secretion in response to stress (see section 1.16). Since in late
pregnancy (from day 16 onwards) endogenous opioids exert inhibitory tone on
oxytocin neurones (Douglas et al , 1993; Douglas et al , 1995), it would seem
plausible that a similar central inhibitory opioid mechanism may be involved in the
attenuated HPA responses to stress stimuli in pregnancy. Pretreatment with naloxone
significantly attenuates the rise in ACTH secretion in virgins exposed to forced
swimming, while pregnant rats demonstrate a modest increase in ACTH secretion
(Douglas et al, 1998). It would seem that pregnant rats no longer display the opioid
enhancing effects on ACTH secretion observed in virgins, and instead endogenous
opioids have a net inhibitory action over HPA activity in pregnancy. The site at
which endogenous opioids may act to restrain HPA responses to stress in pregnancy
and their source is unclear, however it is possible that arcuate nucleus POMC
neurones which project to the PVN may play a role, as may co-produced opioids in
brainstem neurones projecting to the PVN (see Chapter 4).
1.17.5. Sex Steroids and Neuroendocrine Responses to Stress in Preenancy
A clear sex difference in stress-induced secretion of pituitary hormones exists.
Naloxone significantly potentiates the oxytocin secretory response to immobilsation
stress in female rats, but not in males (Carter et al , 1986) and this is partly
determined by gonadal hormones, since testosterone acting in the preoptic area has
inhibitory actions.
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Since there is greatly increased production of the sex steroids, oestrogen and
progesterone in pregnancy, it would seem likely that they may be involved in the
physiological adaptations of the neuroendocrine system which occur at this time. In
the rat, oestrogen and progesterone levels peak in mid-gestation, around the time
when these neuroendocrine adaptations are first observed; followed by progesterone
withdrawal 1-2 days before parturition (on day 22) (Bridges, 1984). Treatment of
virgin rats with s.c. oestradiol and progesterone capsules for 17 days strongly
enhances the oxytocin secretory response to forced swimming in the presence of
naloxone (Douglas et al, 2000). This indicates that oestrogen and progesterone
treatment not only up-regulates the oxytocin secretory response to forced swimming,
but also induces strong opioid inhibition of this response. Thus sex steroids appear to
be partly responsible for enhanced oxytocin neurone responsiveness and induction of
endogenous opioid restraint of oxytocin secretion in pregnancy. Thus it seems that
sex steroids are important in pregnancy for inducing opioid restraint over oxytocin
secretion and enhanced oxytocin neurone responsiveness.
There is little evidence to support a role for sex steroids in the hyporesponsiveness of
the HPA axis in pregnancy. Indeed virgin rats implanted subcutaneously with 17(3-
oestradiol and progesterone capsules (for 17 days) to mimic pregnancy levels of
circulating sex steroids do not demonstrate attenuated ACTH or corticosterone
secretory responses to forced swim stress (Douglas et al, 2000).
The significance of a hyporesponsive HPA system in pregnancy may be that it
provides a protective mechanism for the foetuses. Restraining the maternal HPA axis
may avoid overwhelming the placental mechanism which limits the passage of
corticosterone across the placenta (see section 1.20.3.), thus protecting the offspring
from the detrimental consequences of exposure to excessive levels of corticosterone
in utero (see section 1.21.). There may also be metabolic advantages to the pregnant
mother (see Chapters 5 and 8)
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1.18. Placental CRH and POMC
The presence of CRH in human placental extracts (closely related to CRH of
hypothalamic origin) was reported by Shibasaki and colleagues in 1982 (Shibasaki et
al, 1982). In humans, CRH of placental origin is the main source of circulating CRH
in pregnancy. Placental CRH output dramatically increases as pregnancy progresses
in humans and is accompanied by increased CRH gene expression in the placenta
(McLean & Smith, 1999). Production of placental CRH appears to be species-
specific, since although CRH activity has also been detected in the sheep (Jones et al,
1989), neither CRH protein nor mRNA has been detected in rat or guinea pig
placentae (Robinson et al, 1989).
In sheep and humans maturation of the fetal HPA axis is important for the stimulus
of the onset of parturition (for review see Riley & Challis, 1991). Although
glucocorticoids exert negative feedback on PVN CRH neurones, they have a positive
effect on CRH release from amnion, chorion and decidual placental cells. Local CRH
effects on human and sheep placenta, decidua and myometrium include stimulatory
roles on local production of oxytocin and prostaglandins, blood vessel dilation and
uterine contractility (Reis et al, 1999). CRH released from the foetal membranes and
placenta provides further stimulation to the fetal HPA (and possibly the maternal
HPA) axis, thus establishing a feedforward loop, the outcome of which is parturition.
The presence of POMC mRNA in rat placenta has been reported, however
expression is very low and does not change throughout the duration of pregnancy
(Chen et al, 1986). Since placental CRH is undetectable and POMC expression is
constitutively low throughout pregnancy in the rat, it is unlikely that they are
involved in regulation of parturition in this species. However this also means that the
rat is a good model in which to study the adaptations of the HPA axis in pregnancy,
since there are no unnecessary complications with respect to the impact of placental
CRH and/or POMC on maternal HPA function.
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1.19. CRH-Binding Protein
In humans, the liver secretes CRH binding protein (CRH-BP) which protects the
corticotrophs in the anterior pituitary from domination by placental CRH. The
existence of a binding protein for CRH was first reported by Linton et al in 1986
(Linton & Lowry, 1986) who demonstrated its presence in human plasma. Although
CRH concentrations in the peripheral circulation are normally low, they increase
throughout pregnancy in humans (Suda et al, 1985; Linton et al, 1987), and in the
third trimester reach levels which when present in hypophyseal portal plasma elicit
ACTH release (Plotsky & Sawchenko, 1987). Nevertheless, maternal plasma ACTH
concentrations remain within non-pregnant limits throughout gestation (Rees et al,
1975).
CRH binding protein is a 37-kDa protein capable of binding CRH with high affinity
(Linton & Lowry, 1986) and negating its biological activity, thereby preventing
inappropriate pituitary-adrenal stimulation in pregnancy. CRH-BP has been partially
sequenced and cloned (Potter et al, 1991; Behan et al, 1993) from both human liver
and rat brain libraries. The structures of the human and rat CRH-BPs are highly
conserved, showing 85% identity in amino acid sequence, however the pattern of
tissue distribution of CRH-BP transcripts in the two species is distinct. In humans the
CRH-BP gene is expressed in liver, placenta and brain, whereas in the rat CRH-BP
mRNA has only been detected in the brain (Potter et al , 1991; Baigen & Lowry,
2000). This may reflect differences in placental CRH production. In primates the
placenta also produces CRH, whereas the rodent placenta does not produce
significant amounts of CRH and therefore peripheral CRH-BP is not required to
antagonise the biological activity of placental CRH and prevent inappropriate effects
on the pituitary.
Combined immunohistochemical and in situ hybridisation studies have revealed
CRH-BP mRNA and protein is expressed throughout the rat CNS, in the cerebral
cortex, the amygdaloid complex and the BNST (Potter et al, 1992). In the brainstem,
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sensory relays associated principally with the auditory, olfactory, trigeminal and
vestibular systems and several raphe nuclei of the midbrain and pons, express CRH-
BP hybridised and immunoreactive neurones (Potter et al, 1992). Instances of CRH-
BP and CRH peptide colocalisation have been demonstrated in the BNST, median
preoptic area (mPOA), CeA, mesencephalic central gray, interpeduncular nucleus,
lateral dorsal tegmental nucleus, inferior colliculus, lateral reticular nucleus and
olfactory bulb. Interestingly, evidence suggests potential CRH-CRH-BP interactions.
Dense CRH-BP stained nerve terminal fields have been shown to coincide with cell
groups rich in CRH immunoreactive perikarya in the BNST, CeA and SCN (Potter et
al , 1992). Furthermore CRH-BP immunoreactivity and mRNA are expressed
extensively and almost exclusively over ACTH-positive cells in the anterior pituitary
(Potter et al , 1992), and CRH-BP is capable of inhibiting CRH-induced ACTH
release from pituitary cultures (Potter et al, 1991). Taken together these data imply
that CRH-BP, an endogenous modulator of the biological activity of CRH in the
periphery, could interact with CRH and/or its receptor to modulate the synaptic and
hormonal actions of CRH at select sites in the CNS and pituitary.
1.20. llB-Hydroxysteroid Dehydrogenase
It is well established that as well as CBG and type II corticosteroid receptors, control
of glucocorticoid action is also regulated by pre-receptor enzyme-mediated
metabolism. 11 P-hydroxysteroid dehydrogenase (lip-HSD) plays an important role
in determining the access of glucocorticoids to both MR and GR in peripheral tissues
(Seckl & Brown, 1994). llp-HSD catalyses the interconversion of corticosterone
(Cortisol in humans) and 11-dehydro-corticosterone (see figure 1.7.). The latter has
little intrinsic affinity for MR or GR and is considered inert. There are two distinct
isoforms of 11P-HSD. The first, 1 lp-HSD-1, is a NADP(H)-dependent enzyme with
a relatively low affinity for corticosterone (Lakshmi & Monder, 1988; Agarwal et al,
1989) which catalyses predominantly the reductase reaction to regenerate active
corticosterone (Low et al, 1994; Rajan et al, 1996). The second, lip-HSD-2, is a
NAD-dependent, exclusive dehydrogenase, which inactivates corticosterone, for
which it has very high affinity (Brown et al, 1993; Albiston et al, 1994). 11P-HSD-1
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has fairly widespread distribution with high levels found in the liver, while 11(3-
HSD-2 is most abundantly expressed in the placenta (Waddell et al, 1998). In the
placenta lip-HSD-2 provides a barrier to protect the foetus from maternal
glucocorticoid concentrations (Seckl, 1994), which can have damaging effects on the
foetus (see section 1.22.).
NAD NADH
Figure 1.7. Interconversion of corticosterone and 11-dehydrocorticosterone by
lip-HSD. The lip-HSD type 1 enzyme acts as a reductase to convert 11-
dehydrocorticosterone into active corticosterone, whereas the lip-HSD type 2
enzyme acts as a dehydrogenase and inactivates corticosterone.
More recently immunocytochemical and in situ hybridisation studies have shown
that 1 ip-HSD-1 protein and mRNA expression is fairly widespread in the brain. 1 lp-
HSD has been detected in the cerebellum, brainstem, hippocampus (including the
dentate gyrus), the neocortex, some hypothalamic nuclei (including the PVN) and
most anterior pituitary cells (Moisan et al, 1990a; Moisan et al, 1990b). Reverse
transcriptase-PCR studies have demonstrated lip-HSD-2 transcripts are present in
most brain subregions, including the hippocampus, cerebellum, cortex, brainstem,
hypothalamus and pituitary (Seckl, 1997). However in situ studies are discordant,
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lip-HSD-2 mRNA expression has been reported to have a restricted distribution in
the commissural NTS (cNTS) subcommissural organ (SCO), VMH and medial
vestibular nucleus (Seckl, 1997). Thus further studies are necessary to confirm the
distribution of 11 [3-HSD in the brain.
1.20.1. Effects of 113-HSD on the HPA Axis
lip-HSD-1 mRNA and protein are expressed in many magnocellular and
parvocellular PVN neurones (Sakai et al, 1990). It has been suggested that in the
PVN, lip-HSD-1 is colocalised with MRs and GRs (Sakai et al , 1990).
Glycyrrhetinic acid (GA) an active component of liquorice, inhibits lip-HSD
activity both in vitro (Moisan et al , 1990a) and in vivo (Monder et al, 1989).
Treatment of rats with GA causes CRH levels in hypophysial portal blood to fall to
-50% of control values (Seckl et al, 1993) suggesting that lip-HSD regulates the
effective corticosterone feedback signal to pPVN CRH neurones. This effect is
abolished in ADX rats, suggesting dependence on adrenal products (Seckl et al ,
1993). In contrast, GA treatment induces two- to threefold increases in arginine
vasopressin and oxytocin release into portal blood, effects also dependent upon intact
adrenal glands (Seckl et al , 1993). These data suggest that lip-HSD in the PVN,
and possibly other sites, may represent an important control point of corticosteroid
feedback on CRH release in vivo.
1.20.2. Placental 11B-HSD
Glucocorticoids are for the most part prevented from entering the foetal compartment
by placental lip-HSD-2 (Seckl, 1994; Benediktsson et al, 1995). However the
efficiency of placental exclusion of corticosterone varies considerably in rats and
humans (Benediktsson et al, 1993a; Benediktsson et al , 1995). Nonetheless the
presence of this enzyme in placental tissue is of vital importance in regulating foetal
environment and may help protect the foetus from adverse programming by
corticosterone (see section 1.21.).
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1.21. Foetal Programming
Stress is a risk factor for a range of diseases, from auto-immune disorders to mental
illness. As mentioned earlier, the typical response to stress involves activation of the
HPA axis, resulting in increased secretion of glucocorticoids from the adrenal cortex.
The adrenal medulla releases catecholamines, such as adrenaline and noradrenaline
in response to stress. These adrenal compounds act together triggering a switch in
metabolism, which favours glucose production. Circulating catecholamines activate
glycogenolysis and rapidly augment free fatty acid supply to the heart and muscles.
Glucocorticoids facilitate this lipolysis and also provide amino acid substrate for
gluconeogenesis. Together these hormones shift glucose utilisation towards the CNS
and away from peripheral tissues and raise blood pressure and cardiac output, so as
to improve delivery of substrates to tissues that are critical to the immediate defence
of the organism. Hence the availability of energy is increased to enable the organism
to cope with the stress. Obviously prolonged activation of the "stress response"
outlined above poses a risk to the health of an individual. Studies have indicated that
prolonged or exaggerated stress responses increase susceptibility to steroid-induced
diabetes, atherosclerosis and hypertension (Brindley & Rolland, 1989), conditions
that are associated with an increased risk of heart disease (Seeman et al, 1997). In
addition, chronic activation of the HPA axis can affect cognitive function and
increase vulnerability to states of anxiety and depression (Arborelius et al, 1999). So,
a problem arises: the "stress responses" necessary for coping with and surviving
stressful events can, if not kept in check, ultimately lead to disease. Substantial
evidence indicates that early life events, both pre- and post-natal, can influence the
development of the HPA axis and have long tenn effects on its responsivity to stress.
The concept that non-genetic factors act early in life to imprint physiological systems
is referred to as "programming".
The majority of studies on the effects of prenatal stress (preNS) have been performed
in rodents. Pregnant dams have been exposed to various stressors, e.g. restraint
(Deminiere et al, 1992), immobilisation (Ward & Weisz, 1984), noise (Fride &
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Weinstock, 1984) and electric tail shocks (Takahashi & Kalin, 1991), usually on an
unpredictable basis throughout or during a specific period in pregnancy. These
studies have provided evidence that maternal stress has permanent and often
profound effects on the offspring. Prenatally stressed rats display altered, usually
exaggerated neuroendocrine and behavioural responses to stress (Dunn & Berridge,
1990a).
1.21.1. Effects of Prenatal Stress on Behaviour, Anxiety and Cognition
In adulthood prenatally stressed (preNS) rats tend to display a higher degree of
anxiety related behaviours (Fisher & Brown, 1991). Studies in rats and monkeys
have demonstrated that preNS animals display behavioural abnormalities, including a
reduced propensity to play (Takahashi et al, 1992) and disturbed social interactions
(Schneider, 1992; Schneider & Coe, 1993; Clarke & Schneider, 1993). When preNS
rats are exposed to 'emotionality' tests, such as the open field, they typically show
reduced locomotion and exploration and increased defecation (Wakshlak &
Weinstock, 1990; Poltyrev et al, 1996) and they also spend less time on the open
arms of the elevated plus maze (EPM) (Poltyrev et al , 1996; Vallee et al, 1997).
Anxiolytic drugs such as benzodiazepines significantly increase the number of
entries rats make onto the open arms of the EPM (Pellow & File, 1986) confirming
that preNS rats are more anxious. Chronic stress exposure or i.e.v. administration of
CRH to rats, induces these behaviours seen in preNS rats, including decreased social
interaction (Dunn & File, 1987), suppression of locomotion in the open-field (Britton
et al, 1982) and aversion to the open arms of the EPM (Dunn & Berridge, 1990a).
Together these data show that prenatal stress programmes the brain, leading to
increased anxiety-related behaviour in adulthood, an effect possibly mediated via
enhanced CRH release.
Retrospective studies on human behaviour have shown that children of mothers who
experienced psychological stress during pregnancy (e.g. marital problems, death of
spouse, war) exhibit behavioural abnormalities, including excessive clinging, crying,
hyperactivity, unsociable and inconsiderate behaviour (Stott, 1973). Another study
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has demonstrated that children born to mothers whose spouse died during their
pregnancy were more likely to experience psychiatric disorders at adolescence
including schizophrenic episodes, minor depressive symptoms, alcoholism and
asocial or criminal behaviours (Huttunen & Niskanen, 1978). In the early 1990s a
link between prenatal stress and hyperactivity-attentional deficit disorder was
suggested (Clements, 1992). The evidence from human studies is in accord with the
animal data, supporting the concept that stress during pregnancy can programme for
behavioural abnormalities later in life.
Adult cognition is also clearly affected by prenatal stress. PreNS rats spend more
time looking for the platform in a watermaze (Szuran et al, 1994; Hayashi et al,
1998). This may be due to the reduced levels of hippocampal corticosterone
receptors (Weinstock et al, 1992; Henry et al, 1994) since water-maze performance
is a hippocampus-associated function, influenced by occupation of corticosterone
receptors (Morris et al, 1982; Oitzl & De Kloet, 1992; Oitzl et al, 1997; Sandi,
1998). Thus exposure to elevated corticosterone levels in preNS rats may lead to
hippocampal damage (as observed in aged rats) and explain poorer performance in
tests of cognitive function.
1.21.2. Effects of Prenatal Stress on the HPA Axis and its Regulation
In prenatally stressed rats, increased basal HPA activity has been reported. The
effects of preNS on circulating ACTH and corticosterone levels are more marked in
females (McCormick et al, ; Weinstock et al , 1992). Some studies have
demonstrated elevated corticosterone levels during the pre-weaning period in male
rats (Takahashi & Kalin, 1991), whereas others have reported no effect of preNS on
basal corticosterone and ACTH secretion in males at this time (Fride et al, 1986;
Takahashi et al, 1990; Henry et al , 1994), these differences may reflect the type of
stressor used and the period of gestation in which the stress was administered.
Nevertheless, stress-induced increases in ACTH and corticosterone are consistently
higher in preNS animals (McCormick et al , ; Peters, 1982; Fride et al , 1986;
Takahashi & Kalin, 1991; Weinstock et al , 1992) and post-stress corticosterone
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levels show prolonged elevation compared with controls (Takahashi & Kalin, 1991;
Henry et al , 1994). Furthermore preNS rats fail to adapt to repeated homotypic
stressors and continue to release high amounts of corticosterone (Fride et al , 1986).
The mechanisms underlying the impaired feedback regulation of the HPA axis in
preNS animals are not completely understood. On reaching adulthood, preNS rats
demonstrate higher circulating corticosterone levels, concomitant with reduced levels
of hippocampal MR and GR receptors (Henry et al , 1994). This evidence implies
abnormal negative feedback control of CRH release in preNS rats. On postnatal day
3, preNS rats have higher levels of plasma corticosterone than control pups, but
similar numbers of hippocampal MRs and GRs (Henry et al, 1994). The reduction in
MRs and GRs is not observed until weaning (~ postnatal day 21), but persists into
adulthood (Henry et al, 1994). Thus increased corticosterone levels precede changes
in MR and GR binding and hence elevated HPA activity in neonatal life may be
responsible for altered development of hippocampal MR and GR expression.
PreNS offspring have higher levels of CRH in the amygdala (Cratty et al, 1995).
This may be a consequence of increased levels of plasma corticosterone, since
glucocorticoid administration has been shown to increase CRH mRNA in the CeA
(Makino et al, 1994). It is tempting to speculate that increased amygdala CRH
content in preNS rats may underlie their anxiety related behaviour (discussed earlier)
especially since CRH micro-injection into the amygdala (Davis, 1992) induces
similar 'anxiety' behaviours. PreNS rats also have less brain opioid receptors than
controls (Insel et al, 1990) and a decrease in POMC mRNA in the hypothalamus
(Weinstock et al, 1992). |3-endorphin has been shown to have an inhibitory action on
CRH release (Buckingham, 1986), and blockade of opioid receptors by naloxone
(Siegel et al, 1982; Odio & Brodish, 1990) increases plasma corticosterone (in
control rats), thus a decrease in inhibitory tone by opioids could explain the higher
corticosterone levels in preNS rats. However, it is unlikely that reduced opioid
mediated inhibition is the sole mechanism responsible for elevated corticosterone
levels in preNS rats, since these rats show larger increases in corticosterone levels
following treatment with naloxone than control rats do (Weinstock et al, 1996).
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1.21.3. Effects of Prenatal Stress on Brain Amines
Under basal conditions, preNS rats demonstrate significantly higher noradrenaline
turnover in the cerebral cortex and locus coeruleus with similar effects observed
following electric foot-shock treatment (Takahashi et al, 1992). Furthermore,
increases in noradrenaline release in the amygdala and hippocampus may lead to a
reduction in corticosterone feedback inhibition of CRH by decreasing the number of
glucocorticoid receptors (Maccari et al, 1992). States of conditioned fear and anxiety
are characterised by increased dopamine turnover in the prefrontal cortex and
decreased dopamine turnover in the striatum and nucleus accumbens (Claustre et al,
1986). In accord with their augmented anxiety in stressful situations, preNS rats have
higher dopamine turnover in the prefrontal cortex and lower turnover in the striatum
and nucleus accumbens (Fride & Weinstock, 1988). Changes in dopamine turnover
in preNS rats explain the reduction in exploratory activity in behavioural tests of
anxiety.
1.21.4. Effects of Prenatal Administration of Glucocorticoids
It seems likely that maternal glucocorticoids play a role in the effects of preNS on the
foetus (Barbazanges et al, 1996) and many studies have investigated the effects of
glucocorticoid administration to pregnant rats on behavioural and HPA function of
the offspring. Dexamethasone is a synthetic glucocorticoid and a potent GR (but not
MR) agonist, which can readily cross from mother to foetus via the placenta. Prenatal
dexamethasone exposure throughout gestation or in the last week only has been
shown to induce anxiety-related behaviour in adult rats in the open-field test
(Welberg et al, 2001; Welberg & Seckl, 2001). These behavioural changes may be
associated with amygdalar adaptations, since prenatal dexamethasone treatment
(either throughout or in the last trimester) increases CeA expression of CRH mRNA
(Welberg et al , 2001; Welberg & Seckl, 2001). Dexamethasone administration to
rats on days 15-20 of gestation results in reduced pup birth weights (which is
strongly associated with hypertension in adulthood). In adulthood, the offspring
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display elevated blood pressure (Lindsay et al, 1992; Benediktsson et al, 1992;
Edwards et al, 1993; Benediktsson et al, 1993b; Levitt et al, 1996) and increased
basal levels of plasma corticosterone (Levitt et al , 1996). Moreover, hippocampal
GR and MR mRNA expression are significantly and permanently attenuated (Levitt
et al, 1996) compared to controls. This may underlie reduced feedback inhibition by
glucocorticoids and explain elevated corticosterone levels in preNS rats.
If glucocorticoids are in fact involved in mediating the effects of preNS on the
foetus, then 11P-HSD2 may play an important role in modulating the programming
effects of prenatal exposure to endogenous glucocorticoids. Although 11-HSD2 in
the placenta acts as a barrier to maternal glucocorticoids, this barrier is leaky and it
can become saturated (Shibasaki et al , 1982). Endogenous inhibitors of 11 (3-HSD
activity have been described (Buhler et al, 1994) which may also be involved in
regulating foetal exposure to maternal corticosterone. Inhibition of feto-placental
11P-HSD2 with carbenoxolone (CBX) during pregnancy decreases birth weight of
the offspring and programmes permanent hypertension and hyperglycaemia in
adulthood (Edwards et al, 1993; Lindsay et al, 1996a; Lindsay et al, 1996b; Welberg
et al, 2000). These effects are abolished if the mother is adrenalectomised (Lindsay
et al , 1996a; Lindsay et al , 1996b), indicating that inhibition of 11P-HSD2 allows
increased levels of maternal corticosterone to access foetal GR, hence programming
the offspring. CBX treatment also affects HPA activity of the offspring, causing
increased basal and stress-induced corticosterone levels and CRH mRNA in the PVN
(Welberg et al , 2000). GR mRNA expression is reduced in the PVN of prenatally
treated CBX rats, suggesting that attenuated corticosterone feedback may be
involved in the HPA adaptations. Furthermore anxiety-like behaviours similar to
those observed in preNS rats are displayed in adult prenatally CBX treated rats. Thus
exposure to elevated glucocorticoids during pregnancy as a result of prenatal stress
or feto-placental 11P-HSD dysfunction can permanently programme the behaviour
and neuroendocrine responses of the offspring.
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1.21.5. Effects of the Post-Natal Environment on the Offsprin2
The post-natal environment can also influence the activity of the HPA axis and
anxiety behaviour (for reviews see (Meaney et al, 1994; Ladd et al, 2000;
Champagne & Meaney, 2001)). Maternal behaviour plays an important role in the
development of the HPA axis. In rats, high licking and grooming behaviour directed
towards the pups by the mother and arched back nursing have been found to correlate
with reduced PVN CRH mRNA expression, enhanced glucocorticoid negative
feedback and lower stress responses (ACTH and corticosterone) in adulthood
(Champagne & Meaney, 2001). Furthermore, early maternal separation results in
exaggerated HPA responses to stress (restraint or novelty) later in life, an effect that
can be abolished if the pups are handled and stroked during maternal deprivation
(Meaney et al, 1994). The mechanisms responsible for this are not known, however
they are likely to involve altered glucocorticoid feedback sensitivity (Plotsky & Vale,
1984; Plotsky et al, 1986; Sawchenko, 1987; Plotsky & Sawchenko, 1987; Owens et
al, 1990; Imaki et al, 1991a). Since the HPA axis continues to develop after birth in
the rat, the possibility that the adverse programming effects of exposure to prenatal
stress can be reversed or modulated by the postnatal environment and maternal
behaviour is an exciting area which requires more research and may in the future
have important implications for humans.
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What are the important questions that arise?
Taking into account the literature reviewed above several key questions arise. The
ACTH and corticosterone secretory responses to two stressors (namely the elevated
plus maze and forced swimming) are markedly attenuated in pregnancy, however
what causes these changes are not known.
♦ Is this a consequence of reduced activation of the pPVN CRH/AVP neurones by
stress in pregnancy?
♦ Does the HPA axis respond less to other emotional stressors in pregnancy,
including those that are perhaps more physiologically relevant i.e. responses to
social stress?
♦ Is the HPA axis also less responsive to immune challenge in pregnancy?
♦ Metabolic signals are known to activate the HPA axis, and clearly metabolism is
altered in pregnancy, however no study has investigated the effects these signals
have on the HPA axis in pregnancy.
♦ Are the changes in HPA axis responsiveness in pregnancy a result of the
CRH/AVP neurones themselves being less responsive to all excitatory stimuli?
♦ If so, is this a result of increased inhibitory influences in the pPVN (e.g. by
endogenous opioids)?
♦ Is glucocorticoid feedback inhibition of HPA activity altered in pregnancy to
restrain the axis?
♦ What about other species? Are the changes in HPA axis responsiveness to stress
in pregnancy in the rat species-specific or do pregnant mice display similarly
reduced responses to stress?
Why is it important to understand the mechanisms involved in reduced HPA
axis responses to stress in pregnancy?
Pregnancy is associated with a series of adaptive changes necessary for the
development and maintenance of the foetus. These changes are necessary in order
that the maternal physiology meets both her demands and those of the foetus. One of
88
General Introduction Chapter I
the major adaptations that occurs during pregnancy is the change in responsiveness
of the HPA axis. The aim of this thesis is to investigate the brain mechanisms (with
particular focus on the hypothalamus) that occur in pregnancy and permit reduced
neuroendocrine responses to stress, and will maximise the chances of a successful
outcome. The plasticity of the HPA axis in pregnancy is in itself an interesting focus
of study, however the need to understand the mechanisms involved relates also to the
long term well-being of the foetus and the mental health of the mother. Exposure to
prenatal stress has programming effects on the foetus that can have life-long
consequences on the neuroendocrine and immune systems as well as on behaviour
and cognition. Furthermore, given the well established involvement of CRH in
depressive illness (Gutman et al, 2001), a rebound in HPA activity from a dampened
state in pregnancy may be involved in the manifestation of post-natal depression.
Thus understanding the mechanisms underlying reduced stress responses in




The experiments in this thesis were designed to investigate changes in the central
mechanisms underlying attenuated HPA axis responses to stress in late pregnant rats.
Several approaches were taken and the specific aims were:
• to investigate whether the HPA axis is less responsive to several 'emotional'
stressors in pregnancy, namely restraint and maternal aggression.
• to establish whether attenuated HPA axis responses to emotional stress in
pregnancy is a consequence of reduced activation of the CRH and/or AVP
neurones in the parvocellular region of the PVN.
• to determine whether pregnant rats demonstrate altered HPA axis and oxytocin
secretory responses to the 'physical' stressor, immune challenge and to investigate
the mechanisms involved, specifically the role of endogenous opioids.
• to determine whether CRH neurones are non-responsive in pregnancy to other
excitatory stimuli, specifically those involved in regulating metabolism and
arousal.
• to investigate roles for enhanced slow and rapid glucocorticoid negative feedback
in attenuated HPA axis responses to stress in pregnancy.
• to establish whether the HPA axis is less responsive to stress during late
pregnancy in mice, as it is in rats.
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2.1. Animals
All animals were maintained on a 12 hour light- 12 hour dark photoperiod (lights on
at 07:00h for rats and 19:00h for mice) under standard conditions of temperature
(ambient temperature of 20-22°C) and humidity in the Medical Faculty animal
facility at Edinburgh University, unless otherwise stated. Food and water was
available to all animals ad libitum. Animals were given at least 1-2 weeks of
acclimatisation to animal quarters prior to any experimental procedures or mating.
For pregnant groups virgin females were mated overnight with a sexually
experienced stud male. The presence of a vaginal plug of semen in the mating cages
the following morning was designated day 1 of pregnancy. All procedures performed
on animals were approved by the Home Office under the Animals (Scientific
Procedures) Act 1986.
2.1.1. Rats
Female Sprague-Dawley rats (Bantin & Kingman) were used throughout these
experiments, unless otherwise specified. On arrival at the animal unit rats weighed
between 230-260g. Rats were initially housed in groups of 5-6 until surgery, after
which they were caged individually.
2.1.2. Mice
For the mouse experiment female BK-white mice (Bantin & Kingman) were used.
On arrival to the animal unit mice weighed approximately 30g. From the day of
arrival mice were maintained in groups of 6-8 under a reverse 12h light-dark cycle
(lights on at 19:00h). Mice were given at least two weeks to acclimatise to this
switch in light-dark cycle before mating, and were then maintained with reverse
lighting until the end of the experiment. Mice were caged individually from day
14/15 of pregnancy.
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2.2. Anaesthesia
For recovery experiments, rats were anaesthetised in a perspex chamber by
inhalation of halothane (3% halothane in 600ml/min each of oxygen and nitrous
oxide), and anaesthesia maintained throughout by inhalation.
2.3. Surgery
For recovery experiments surgery was performed under sterile conditions using
autoclaved instruments; fur was shaved over surgical incision sites.
2.3.1. Cannulation of the jugular vein
The rat was laid on its back and a small skin incision was made between the angle of
the mandible and the clavicle (rostro-lateral to the right thoracic nipple). The
subcutaneous fat was displaced until the right external jugular vein was located. The
connective tissue was gently teased away and once a length of vein had been freed
two ligatures (EP1 suture silk) were placed loosely around the vein. The cranial
ligature was tightened to prevent venous return from the head. A small 'v-shaped'
incision was made in the vein into which a silastic cannula (bore= 0.5mm; wall=
0.25mm: Altec), 12cm in length and filled with heparinised saline (50 units/ml) was
inserted. The cannula was guided approximately 3cm into the length of the vein (at
which point its tip should meet the atrium of the heart) until blood could be freely
withdrawn with a 1ml syringe. The second ligature was tightened to secure the
cannula in place and prevent blood loss, then a third ligature was used to secure the
cannula tightly to the vein. Once secured, the cannula was exteriorised through a
small incision just behind the ears on the back of the neck. The cannula was closed
off with a blocked stainless steel connector and the exposed portion was secured
with adhesive tape sutured to the skin. Both wounds were closed with sutures (EP3).
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23.2. Implantation of intracerebroventricular (i.c.v.) cannulae
Rats were implanted with an i.e.v. cannula for drug administration 5-6 days before
the experiment. The rat was positioned in a stereotaxic frame and a midline incision
was made through the scalp. The scalp and connective tissue were retracted to
expose the dorsal surface of the skull and bregma. The i.e.v. guide cannula was
aimed at the right lateral ventricle through a hole drilled in the skull (stereotaxic co¬
ordinates: 1.6mm lateral and 0.6mm posterior to bregma. The guide cannula was a
22-gauge, stainless steel tube (Plastics One) which was inserted to a depth of 4mm
from the surface of the skull. The cannula was secured in place with dental acrylic
keyed onto the surface of the skull with two jewellers screws. Finally, a dummy
cannula (Plastics One) was inserted into the guide cannula and the skin was sutured.
After the surgery the rats were handled, dummy caps rinsed in 0.9% saline and
loosened and tightened each day to familiarise them with the procedure prior to the
day of the experiment and thus reduce non-specific stress responses.
2.4. In situ Hybridisation
Since its conception in 1969 (Pardue & Gall, 1969; Gall & Pardue, 1969), in situ
hybridisation (ISH) has been comprehensively applied to the detection and
localisation of specific nucleic acid sequences within a wide range of tissue
preparations. This approach offers obvious advantages over other molecular biology
techniques since it provides precise information about the site of gene expression at
the single-cell level, and can be quantified. The principle behind ISH is the specific
annealing of a labelled (a radioisotope or hapten label) nucleic acid probe to
complementary sequences of cellular DNA or mRNA in fixed tissue to form a stable
hybrid, followed by visualisation of the probe. A critical requirement of this
technique is that the nucleic acid is retained in situ, since degradation results in a
diminished signal. Deoxyribo- and ribo- nucleases (DNase and RNase, respectively)
are the most common source of contamination (for DNA and RNA hybridisation,
respectively) therefore all equipment and consumables must be autoclaved and
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solutions are prepared using sterile double distilled, diethylpyrocarbonate (DEPC)
treated water (wherever possible).
Both types of nucleic acid sequences (DNA or RNA) can be employed as probes for
hybridisation to localise specific DNA or mRNA. The advantages and disadvantages
of using different probes are summarised in table 2.1.
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Type ofProbe Advantages Disadvantages
(i) Hybridises to both strands (i) DNA-DNA hybrids are the
of chromosomal DNA. least stable.
Double-stranded (ii) Specific sequences may be (ii) Requires denaturation of
DNA probes amplified probe prior to use.
(iii) Can self-anneal in
hybridisation buffer.
(iv) Low yield of labelled
probe.
(i) Re-annealing of probe (i) DNA-DNA hybrids are the
Single-stranded cannot occur. least stable.
cDNA probes (ii) Specific sequences may be (ii) Probe must be purified
amplified. from template mixture.
(i) Higher specific activity than (i) Incorporation of label per
cloned DNA probes. molecule of probe is low.
(ii) Good penetration (ii) The shorter the probe the
properties. lower the stability of the
Synthetic (iii) Available commercially hybrids formed.
oligonucleotide and relatively inexpensive.
probes (iv) Specific sequences can be
(~20-50 bases) used to identify different
members of the same gene
family.
(v) "Oligo-cocktail" can be
used to amplify signal.
(i) High specific activity. (i) Strict RNase free working
Single-stranded (ii) High stability of RNA- conditions vital.
RNA probes RNA hybrids.
(iii) Negative control (sense)
probe also produced.
TABLE 2.1. Advantages and disadvantages of DNA and RNA probes.
Adapted from Beesley, 2001.
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2.4.1. Materials
(i) Microscope Slides
Slides (super premium twin-frost; BDH, Merck House, Poole, Dorset BH15 1TD,
UK) were washed overnight in chromic acid and the next day rinsed in cold running
water for 2-3 hours. The slides were then passed through a series of rinses: 3 x
autoclaved double distilled water (ddH20), 1 x DEPC treated water and 1 x 80%
alcohol.
(ii) Glassware and Plasticware
All glassware and metal slide racks were wrapped in foil and then baked in an oven
overnight at 200°C. Plasticware (eppendorf tubes etc) was autoclaved for 20 minutes
at 121°C and 1.7 bar. Items unsuitable for autoclaving were washed thoroughly in
dilute Teepol (BDH).
(Hi) General Solutions
Solutions were made using DEPC treated double distilled water (ddH20) and
autoclaved wherever possible. High purity or molecular biology grade reagents were
used.
Chrome alum gelatine subbing solution
2.25g gelatine
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DEPC-treated water
0.1 % diethyl pyrocarbonate (v/v) [Sigma]
1000ml ddH20
4% Paraformaldehyde in 0.1 M PBS; pH 7.2-7.4
4% (w/v) paraformaldehyde [Sigma]
0.1MPBS
0.1M Phosphate buffered saline (PBS); pH7.2-7.4
11.5g di-sodium hydrogen orthophosphate (Na2HP04)
2.96g sodium dihydrogen orthophosphate 2-hydrate (Na2HP04.2H20)
8.5g sodium chloride
1000ml DEPC ddH20




To make 1 x SSC we used 50ml of stock + 950ml ddH20
Triethanolamine (TEA)/acetic anhydride solution
2.98ml triethanolamine
0.50ml acetic anhydride
840pl concentrated hydrochloric acid OR 1.8g NaCl
200ml sterile ddH20.
(iv) Hybridisation Buffer
Hybridisation buffer was prepared from twelve components, for which details are















lg bovine serum albumin [Sigma]
50ml DEPC ddH20
Then passed through a 0.2pm acrodisk filter.
1M Dithiothreitol (DTT)
154 mg dithiothreitol [Sigma]
lml DEPC ddHzO
After 30 min DTT was filtered through an acrodisk.
N.B. DTT was not added to the hybridisation buffer until the day of use.
Ethylenediaminetetraacetic acid (EDTA) 250mM
23.26g EDTA [Sigma]
250ml sterile ddH20
The pH was adjusted to 8.0 using NaOH.
Formamide (50%)
We used 25ml of 100% stock per 50ml hybridisation buffer. [Sigma]
Poly (A)
15mg poly (A) [Sigma]
lml DEPC ddH20
Salmon testes DNA
50mg salmon testes DNA [Sigma]
5ml sterile ddH20
After dissolving the salmon testes DNA it was agitated for 2 hours and then sheared
by passing through a sterile 19-gauge needle eight times. The tube was placed into a
beaker ofboiling water for 5 min and then cooled to room temperature.
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5M Sodium Chloride (NaCl)






2.98g Trizma base [Sigma]
20ml sterile ddH20
The pH was adjusted to 7.6.
Yeast tRNA
1 OOmg yeast tRNA [Sigma]
4ml DEPC ddH20
Yeast total RNA
60mg yeast total RNA [Sigma]
3ml DEPC ddH20
A 250(a.l aliquot was boiled for 10 min before adding it to the hybridisation buffer.
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Reagents Concentration ofstock Volume ofstock added
to hybridisation buffer
Denhardt's Solution 1ml
Dextran Sulphate 500mg/ml 5ml
Diothiothreitol* 154mg/ml 550pl
EDTA 250mM 93mg/ml 400pl
Formamide 100% 25ml
Poly (A) 15mg/ml 330pl
Salmon testes DNA 1 Omg/ml 1ml
NaCl 5M 292mg/ml 12ml
5% NaPPI 5 Omg/ml 500pl
Tris pH7.6 149mg/ml 1ml
Yeast tRNA 25mg/ml 200pl
Yeast total RNA 20mg/ml 250pl
TABLE 2.2. Preparation of 50ml of hybridisation buffer.
The appropriate amounts of each of the components of the hybridisation buffer were
added to a sterile tube and made up to 50ml using sterile ddH20. *DTT was added
immediately prior to use.
(v) Probes
Synthetic oligonucleotide probes purified by a high performance salt free (HPSF)
process (MWG-Biotech UK Ltd.) were employed throughout. Oligonucleotides are
particularly attractive for use in ISH since they are commercially available and can
be produced in large quantities with a high level of purity. Since they are relatively
small they are readily accessible to the target and have good penetration properties, a
factor which is considered to be important for successful ISH (see table 2.1. for
summary).
(vi) Probe specificity
Oligonucleotide probes for ISH were generally selected by consulting the literature
to find a previously validated probe sequence for the RNA of interest. Where a probe
sequence for the RNA of interest had not already been published the sequence of the
gene of interest was found using a web-based search program
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(www.ncbi.nlm.nih.gov/Entrez/). A sequence (approximately 36-45 bases long)
complementary to a region within the exon (when mRNA was to be detected) or the
intron (when hnRNA was to be detected) with a GC content > 60% was selected and
the specificity checked (see below).
In both cases the specificity of the probe to be used was checked by performing a
web-based "BLAST search" (www.ncbi.nlm.nih.gov/BLAST). BLAST® (Basic
Local Alignment Search Tool) is a set of similarity search programs designed to
explore all of the available sequence databases (including the rat, mouse and human
genome) regardless of whether the query is protein or DNA. The BLAST search
results show all the sequences in which there is an overlap with the sequence of
interest and provide information about the species, which gene(s) the sequence
corresponds to and the percentage match, details of the exact location of the
sequence on the gene and whether the sequence is complementary to (plus/minus) or
identical (plus/plus) to the gene.
2.4.2. Methodology
To prevent any contamination gloves were worn throughout the ISH procedure.
(i) Tissue Collection and Sectioning
At the end of each experiment animals were killed by decapitation. The brains were
rapidly removed, placed on aluminium foil on dry ice and covered with powdered
dry ice. Once completely frozen the brains were stored in pre-labelled plastic bags at
-70°C. Coronal brain sections (15pm) containing regions of interest (usually PVN)
were cut using a cryostat at -16°C (Bright Instrument Co. Ltd). Whilst cutting, the
location of all areas of interest was confirmed with sections (1 in 6) stained with
toluidine blue in consultation with a stereotaxic rat brain atlas (Konig & Klippel
1963; Paxinos & Watson, 1996). Sections were thaw-mounted (2-3 sections/slide)
directly from the knife onto chrome alum subbed microscope slides and stored at -
70°C until use for specific ISH analysis.
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(ii) 3' end labelling ofoligonucleotide probes
35 35 tIn each experiment probes were labelled using a radioactive isotope. [ S] (as [ S]-
dATP) was used since this has been found to give good resolution within a fairly
short exposure time.
Terminal deoxynucleotidyl transferase (TdT; an enzyme which catalyses a template
independent addition of deoxyribonucleoside triphosphates to the 3'-OH ends of
double or single stranded DNA) was used to label the 3' end of the probe with
radiolabelled nucleotides (poly-A tail).
Labelling Reaction:
27pl sterile ddH20
lOpl 5x TdT Tailing Buffer
5pi 25mM Cobalt chloride
5 pi 35S dATP
2pl Probe (lOpmol/pl)
lpl TdT enzyme (25 units/pl)
The reaction was incubated in a sterile eppendorf tube at
Cooling the eppendorf tube on ice stopped the reaction.
(Hi) Purification of labelled probe.
QIAquick (Qiagen) spin columns were used to separate labelled probe from the free
label and remove DNA fragments (< 10 bases), enzymes, salts and incorporated
nucleotides. The reaction mixture (50pl) was added to a spin column together with
500pl of PN (binding buffer) buffer (from kit), the column was centrifuged for 1 min
at 6,000 rpm and the radioactive flow-through discarded. Next, 500pl of PE (ethanol
wash buffer) buffer (from kit) was added to the column, which was then centrifuged
for an additional minute at 13,000 rpm. To elute the labelled probe 50pl of elution






37°C for 1 hour.
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completely covered the resin filter and allowed to stand for 1 minute. The column
was then centrifuged for 1 minute at 13,000 rpm and the eluted solution was
collected into a sterile Eppendorf tube. A lpl sample of the eluted solution
(containing the labelled probe) was added to a scintillation vial containing 3.5 ml
Ultima Gold scintillation fluid (Packard Bioscience) and then counted for 1 minute in
a (3-scintillation counter. Incorporation of 35S-dATP was acceptable if the
radioactivity was greater than 300,000cpm. The labelled probe was stored at -20°C
until hybridisation.
(iv) Tissue Fixation and Prehybridisation
The sectioned tissue has to be pre-treated to optimise the efficiency of hybridisation
(McCabe & Pfaff, 1989). Slides for ISH were selected with the aid of marker slides
and then transferred to a separate box (inside the freezer) and sealed with tape. On
the day of hybridisation the slides were removed from the -70°C freezer and allowed
to warm for ~2 hours until they reached room temperature.
Slides were placed in racks and fixed in 4% (w/v) paraformaldehyde in 0.1M PBS
(pH 7.2-7.4) for 10 mins, (paraformaldehyde is a cross-linking fixative and generally
preferred for optimum retention of cellular RNA, (McCabe & Pfaff, 1989)). Next,
the sections were washed twice in 0.1M PBS (5 mins each time), followed by
acetylation in triethanolamine/acetic anhydride solution for 10 mins to increase tissue
permeability and reduce non-specific probe binding to positively charged amino
groups. The sections were then dehydrated through 70%, 95% and 100% ethanol
(3min each), delipidated in chloroform for 3 mins, dehydrated in 100% ethanol and
partially rehydrated in 95% ethanol (3mins). Slides were then air dried thoroughly.
(v) Hybridisation
The hybridisation procedure performed was adapted from a previously described
protocol (da Costa et al, 1997). After air drying the slides were arranged on glass
platforms in a humidified chamber containing filter paper soaked in ddH20. The
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labelled probe was diluted in hybridisation buffer, so that a 45pi aliquot of buffer
diluted probe would contain 200,000 cpm of activity (if a slide had more than two
brain sections the dilution was adjusted so that the hybridisation buffer contained
100,000 cpm/section). Dithiothreitol (DTT) was added (lpl per 90pl of
hybridisation buffer) to reduce background, by protecting the sulphur from oxidation.
45pl of hybridisation buffer (containing radiolabeled probe) was pipetted onto each
pair of sections/slide. A parafilm "coverslip" was positioned over the sections to
ensure the mixture was evenly distributed across the tissue. Chambers were then
sealed and incubated at 37°C overnight (approximately 16-18 hours).
In each ISH run positive and negative control slides were included. Positive controls
were used to indicate the success of the ISH and were brain sections (containing the
region of interest) from rats treated with 1 ml 1.5M NaCl i.p. and killed by
decapitation at the appropriate time after the injection for the transcript of interest
(i.e. 4h for CRH mRNA and 30 min for NGFI-B mRNA). To confirm that
hybridisation of the labelled probe was specific, negative control sections were either
hybridised in the same way as above with sense oligonucleotide probes or unlabelled
antisense probes (no 35S was included in the labelling reaction).
(vi) Post Hybridisation
After the hybridisation process, slides were individually rinsed in 1 x SSC to remove
the Nescofilm "coverslips". Slides were then briefly washed three times in 1 x SSC at
room temperature to remove excess buffer and unhybridised probe. Next the slides
were placed in metal slide racks and washed for 4 x 15min washes in 1 x SSC at 50-
70°C (the temperature of these washes is usually 20-25°C below that of the melting
temperature of the probe) followed by a further 2 x 30 min wash at room
temperature. Slides were rinsed in ddH20 and air-dried.
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(vii) Hybrid detection
The final step of ISH is the detection of the labelled probe in the tissue. Once dry the
slides were placed in autoradiographic cassettes and exposed to Hyperfilm-p-max
autoradiography film (Amersham) together with 14C standard microscales
(Amersham) for 2-4 weeks (dependent on the probe) at room temperature. Exposed
film was developed in D19 developer (Kodak) for 5 mins, rinsed in tap water and
then fixed (Ilford Hypam rapid fixer) 2x5 mins.
Once the slides had been exposed to film they were dipped in liquid autoradiographic
emulsion for the cellular localisation of the RNA of interest. The emulsion (Kodak,
type NTB-3) was warmed in a waterbath to 43°C until molten and then under safe
light conditions slides were dipped into the emulsion and air dried for 2 hours. Once
the slides were dry they were transferred to light tight boxes containing desiccant.
The slide boxes were sealed with black electrical tape and wrapped in foil and stored
at 4°C for up to 10 weeks (again depending on the probe). Once exposed for the
required time slides were developed and fixed in a similar manner to the film.
Sections were then counterstained using haematoxylin and eosin, dehydrated in a
graded ethanol series, cleared in xylene and coverslipped using DPX mountant.
(viii) Quantitative Analysis
In each case the negative control sections showed no signs of hybridisation,
indicating the specificity of the oligo-probe used. The relative amount of RNA in a
brain area was assessed using a light microscope (Wang 6000 series microscope)
connected to a CCD video camera and the NIH image analysis system (version 1.62)
on an Apple Macintosh computer. For autoradiographic films exposed to the brain
tissue, a frame was drawn around the nucleus of interest and grain areas were
measured (for pPVN measurements the area was divided as shown in figure 2.1.).
Background grain area measurements (6 per section) were made over areas adjacent
to the region of interest. The areas used for background analysis were not different
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between sections hybridised with the antisense probe and the control sections (i.e.
those hybridised with the sense or unlabelled probe). The value of grain area per
mm was obtained by subtracting the mean background grain area from each specific
nucleus measurement, then dividing the resulting figure by the area of the counting
frame. The films were viewed under x 2.5 or x 4 objective depending on the area
being measured. For each experiment measurements were taken from at least 3-6
sections (ie. 6-12 PVN profiles).
Emulsion dipped sections were also used for cellular analysis of RNA. This method
of analysis involved counting the total number of positive expressing cells in the
PVN (of known area). Ten cells adjacent to the nucleus of interest were selected for
background measurements and the number of silver grains over these cells counted.
A positive cell was defined as one which expressed more silver grains than the mean
background + 3 standard deviations. The measurements were then converted to
number of positive cells/mm2.
107
General Methods Chapter 2
dpPVN
3V
Figure 2.1. Diagram to indicate the subdivisions of the paraventricular
nucleus (PVN)
Cells and grain density measurements were made in the parvocellular region of
the PVN (pPVN). 3V, third ventricle; pvPVN, periventricular PVN; mgPVN,
magnocelluar division of PVN; dpPVN, dorsal parvocellular PVN; mpPVN,
medial parvocellular PVN.
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2.5. Immunocytochemistry
Immunocytochemistry is a widely used technique first described by Coons et al
(Coons et al, 1941) which enables the detection of specific antigens in a biological
sample. It exploits the specific binding of an antibody to its antigen. The reaction is
localised in the tissue by attaching a microscopic marker such as an enzyme (e.g.
peroxidase) or alkaline phosphatase to the antigen-antibody complex. Many
macromolecules (e.g. proteins, carbohydrates, nucleic acids and lipids) can act
as successful antigens for raising antibodies. Both polyclonal and monoclonal
antibodies can be used for immunocytochemistry. Polyclonal sera contain a mixture
of high affinity antibodies, each active against different epitopes on the antigen,
whereas monoclonal antibodies are specific to a single epitope on the antigen. There
are numerous immunocytochemical techniques that may be used to localise antigens.
Here the 'two step indirect method' has been employed. This is where an unlabelled
primary antibody reacts with the antigen and is visualised by a labelled secondary
antibody targeted against the immunoglobulin of the animal in which the primary
antibody has been raised (figure 2.2.). The indirect method is more sensitive than the
direct method (where a labelled primary antibody reacts directly with the antigen in
the tissue preparation), since several secondary antibodies are capable of reacting
with distinct antigenic sites on the primary antibody, therefore more labelled
secondary antibody binds to the primary antibody thus amplifying the signal
(Beesley, 2001).
2.5.1 Fos Immunocytochemistry
Fos is the protein product of the immediate early gene (IEG) c-fos and can be
detected by immunocytochemistry using either the indirect method (described
in(Johnstone et al, 2000)) or the avidin-biotin complex (ABC) (described in
(Srisawat et al, 2000)) method. Here Fos immunoreactivity was localised using a
rabbit affinity purified polyclonal antibody: c-fos (Ab-2; Oncogene research
products). The antibody was raised against the peptide corresponding to residues 4 to
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17 of human Fos. The Fos immunoreactivity was visualised using a labelled
secondary antibody: goat anti-rabbit IgG peroxidase (Vector Laboratories).
Diaminobenzidine (DAB) was used as the substrate for the enzyme reaction, which
converts a colourless chromagen into coloured end products, enhanced by nickel-
glucose.
Figure 2.2. Two step indirect immunolabelling method.
Adapted from (Beesley, 2001).
2.5.1.1. Materials
(i) Microscope Slides
Microscope slides were purchased from BDH and coated using a chrome alum
gelatine solution (as before except using distilled water instead ofDEPC water).
(ii) General Solutions
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4% Paraformaldehyde
4g Paraformaldehyde
1.15g disodium hydrogen orthophosphate (Na2HP04)
[Sigma]
[BDH]
0.296g Sodium dihydrogen orthophosphate-2-hydrate (NaH2P04.2H20) [BDH]
0.85g Sodium Chloride (NaCl) [BDH]
100ml dH20
pH to 7.2-7.4
1M Phosphate Buffer (PB)
1000ml dH20
On the day of use this was diluted 1 in 10 with dH20 to give 0.1M PB and adjusted
to pH 7.2-7.4.
0.1 M Phosphate Buffer-Triton X (PB-T)
0.3% (v/v) Triton [BDH]
0.1MPB
Hydrogen Peroxide Solution (to inactivate endogenous peroxidase)
20% (v/v) Methanol [BDH]
0.2% (v/v) Triton-X [BDH]
1.5% (v/v) Hydrogen peroxide [BDH]
50% (v/v) 0.2M PB
Make up with dH20.
Preincubation Buffer
1 % (v/v) normal sheep serum [Sapu]
PB-T
115g disodium hydrogen orthophophate (Na2HPC>4.2H20)
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Primary Antibody Buffer
0.3% (v/v) Triton-X
1 % (v/v) normal sheep serum






The primary antibody; rabbit polyclonal anti-Fos (c-fos Ab-2) [Ongogene] was
diluted 1 pl/ml in preincubation buffer.
Secondary Antibody Solution
The secondary antibody; goat anti-rabbit IgG-peroxidase [Vector Laboratories] was
diluted 2pl/ml in preincubation buffer.
0.2M Acetate Buffer




5g Nickel ammonium sulphate [BDH]
400mg Glucose [Sigma]
80mg Ammonium chloride [Sigma]
50mg Diaminobenzidine (DAB) [Sigma]
3mg Glucose oxidase [Sigma]
100ml Acetate buffer
100ml dH20
To make 200ml of the nickel-DAB solution, the nickel ammonium sulphate was first
dissolved in 100ml acetate buffer. To this the glucose was added, followed by the
ammonium chloride. 1ml of DAB (50mg/ml) was added to 100ml of dH20 and then
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filtered (in the dark, since it is photosensitive). This was then added to the nickel
solution and mixed well. The glucose oxidase was added immediately before use.
Stop Solution
The reaction was stopped in a 50:50 solution of 0.2M acetate buffer and dH20.
2.5.1.2 Method
Tissue collection and preparation was performed as previously described in section
2.4.2. In brief, rats were killed by decapitation and brains/brainstems were rapidly
removed and frozen on dry ice. Brains/brainstems were cut into 15pm coronal
sections through the region of interest using a cryostat. Sections were thaw-mounted
onto gelatine coated slides and stored at -70°C until immunocytochemical
processing.
As with ISH, positive and negative control sections were included for
immunocytochemistry (ICC). Positive controls were used to indicate the success of
the ICC and were brain sections (containing the region of interest) from rats treated
with 1 ml 1.5M NaCl i.p. and killed by decapitation at the appropriate time after the
injection (i.e. 90 min for Fos protein). To confirm the specificity of the labelling,
negative control sections were included. These were treated in the same way as the
experimental sections however the primary antibody step was omitted from the
procedure.
Day 1
Slides were removed from the freezer and allowed to reach room temperature. They
were then transferred to glass staining dishes and fixed in 4% paraformaldehyde for
30 min at room temperature, followed by 3 x 5 min washes in 0.1M PB. The
immunocytochemistry process was performed with gentle agitation on a rotational
shaker throughout. Endogenous peroxidase was deactivated with the hydrogen
peroxide solution for 15 min and then the sections were washed in PB-T. To prevent
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non-specific labelling the sections were incubated in preincubation buffer. After 1 h
the slides were transferred to flat slide trays containing filter paper soaked in 0.1M
PB. A hydrophobic border was drawn around the sections using a PAP pen (Bayer
Diagnostics). The sections were then liberally covered (750pl/slide) with the primary
antibody solution containing rabbit anti-Fos (Ab-2) diluted 1:1000 (lpl/ml) in
primary antibody buffer. The slide tray were then covered and incubated at 4°C for
48 h.
Day 2
Additional primary antibody solution was applied if necessary to prevent the sections
from drying out, and then the slide trays were returned to the refrigerator (4°C) until
day 3.
Day 3
The primary antibody solution was drained from the slides, which were then
transferred back to the glass staining dishes. The sections were then washed
extensively in PB-T (3 x 15min) and returned to the slide trays. The sections were
then incubated in an excess (750pl/slide) of secondary antibody solution that
contained the goat anti-rabbit peroxidase complex diluted 1:500 (2pl/ml) in
preincubation buffer. The trays were covered and stored at 4°C for 24 h.
Day 4
Excess secondary antibody solution was drained from the slides, which were then
transferred to the glass staining dishes. The sections were washed 3x15 min in 0.1 M
PB, followed by a 10 min rinse in acetate buffer. Sections were then incubated in the
nickel-DAB solution for approximately 10 min. The reaction was monitored by
viewing sections under a light microscope and once the Fos nuclei were visualised
the reaction was terminated with a 5 min wash in stop solution. The sections were
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rinsed in dH20, dehydrated in an ascending alcohol series (70%, 90%, 95%, 100%,
100%), cleared in xylene and finally coverslipped using DPX mountant.
Fos positive cells were viewed using a light microscope and manually counted in the
region of interest. The area of the region of interest was measured using the NIH
image computer program. Data is presented as number of Fos positive cells /mm . In
each experiment no Fos immunoreactivity was detected in the negative control
sections.
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2.6. Treatment of Blood Samples
Blood was collected into sterile 1ml syringes containing either EDTA or heparinised
saline, depending on intended hormone assay. Blood samples collected for eventual
oxytocin radioimmunoassay were collected in syringes containing 80pl heparinised
saline (50units/ml) per 1ml of blood. Blood samples collected for eventual ACTH or
corticosterone radioimmunoassay were collected into syringes containing 50pl
EDTA (5%) per 1ml of blood. All blood samples were stored in eppendorf tubes on
ice until centrifugation. Blood was centrifuged at 13,000 rpm for 2-3 minutes.
Plasma was separated and stored at -20°C until radioimmunoasssay. In each
experiment, blood withdrawn during sampling was replaced with an equal volume of
sterile 0.9% saline.
2.6. Radioimmunoassays
Quantitative determination of plasma hormone concentrations was made by
radioimmunoassay for oxytocin and corticosterone and an immunoradiometric assay
for ACTH (see section 2.7.). The essential principle of radioimmunoassay is based
on the ability of a limited concentration of primary antibody to bind a fixed amount
of radiolabeled ligand. Increasing amounts of unlabelled antigen in the test sample
to be assayed progressively inhibit the binding of labelled antigen to the primary
antibody, since they must compete for specific binding sites on the antibody.
Therefore, the percentage of bound radiolabeled antigen decreases as a function of
the increasing concentration of unlabelled antigen in the sample, thus the amount of
bound labelled ligand is inversely proportional to the amount of hormone in the
sample. Separation of the bound and free radiolabeled antigen is necessary in order
to determine the quantity of unlabeled antigen. This is accomplished by the addition
of a second antibody directed against the primary antibody. The concentration of
hormone in the unknown sample is then determined by comparing the radioactivity
of the precipitate (after centrifugation and aspiration) with the standard curve created
by measuring radioactivity in samples of known hormone concentration.
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(i) Intra-assay coefficient ofvariation
To assess variation between samples within an assay, stock solutions of known
hormone concentration were prepared and measured in duplicate at the beginning
and the end of the assay. Intra-assay coefficients of variation are expressed as
percentages and were calculated using the following equation:
Intra-assay variation = S.D.
X
x 100
Where 'X' is the mean of the hormone concentration from all intra-assay tubes of a
specific standard and 'S.D.' is the standard deviation around that mean.
ii) Inter-assay coefficient ofvariation
To assess variation between assays containing samples from comparable
experiments, stock solutions prepared to calculate intra-assay variation were frozen
at -20°C and incorporated in the next assay. The inter-assay coefficient of variation




Where 'X' is the mean hormone concentration from inter-assay tubes of a specific
standard from all assays and 'S.D.' is the standard deviation around that mean
(standards were chosen that best represented the range as samples in the assay).
(Hi) Assay Sensitivity
In order to calculate the sensitivity of an assay it is first necessary to calculate the
amount of radioactivity bound (B) by each standard as a percentage of the maximum
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binding in the assay (Bmax) or %B/Bmax. This is calculated using the following
equation:
%B/Bmax mean cpm of standard - mean cpm of NSB
mean cpm of Bmax-mean of NSB
x 100
Where NSB is the average number of counts for the non-specific binding tubes.
A graph is then created of %B/Bmax against the log concentration of the standards
(for example see figure 2.3). Assay sensitivity, expressed as % of total binding, is
then calculated using the following equation:
Sensitivity = [Bmax - (2 x S.D. Bmax)l - NSB
Bmax - NSB
The graph can then be used to convert the sensitivity of the assay from percentage of
total binding to a hormone concentration.
2.6.1. Corticosterone Radioimmunoassay
Plasma corticosterone concentrations were quantified using a commercially available
125
radioimmunoassay kit (IDS Ltd.). The corticosterone assay utilises I-labelled
corticosterone and a specific anti-corticosterone antiserum to determine the levels of
hormone in a plasma sample by the double antibody technique. The cross-reactivity
of the assay was evaluated by measuring samples containing various other hormones
and steroids. The manufacturers evaluated the cross-reactivity of the assay and found
it to specifically measure only corticosterone.
2.6.1.1. Materials
A Gamma-B i25I-Corticosterone RIA Kit containing:
(i) Assay Buffer: phosphate buffered saline
(ii) Corticosterone antiserum: rabbit anti-corticosterone
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(iii) [125I]-corticosterone
(iv) Second antibody: goat anti-rabbit antiserum
(v) Corticosterone standard: lOOOng/ml corticosterone
2.6.1.2. Method
(1) Eleven serial dilutions of the corticosterone standard were made to give a
range of concentrations from 0.5-1000 ng/ml. Three other standards were also
prepared: total counts (TC), non-specific binding (NSB) and maximum
binding (Bmax).
TC: contained an aliquot of 125I-corticosterone only, to determine the total
count of the radioactivity added.
NSB: contained 125I-corticosterone and second antibody but no first antibody
or unlabelled corticosterone, to determine non-specific binding.
Bmax: contained 125I-corticosterone, first and second antibody but no
unlabelled corticosterone, to determine the maximum % binding of
radioactivity.
(2) lOOpl of each standard and sample (containing an unknown concentration of
corticosterone) was added to duplicate tubes (except TC).
(3) lOOp.1 of [125I] corticosterone was added to all tubes.
(4) lOOpl of corticosterone antiserum was added to all tubes except TC and NSB.
The tubes were vortex mixed and incubated for 1 hour at room temperature.
(5) 1ml of saline was added to all tubes except TC, and then the tubes were
centrifuged at 1500-1600g for 15 minutes at 2-8°C.
(6) The supernatant of each tube (except TC) was aspirated.
(7) The radioactivity of the pellet in each tube was counted for 1 minute in a
gamma counter (LKB Wallac 1272 Clinigammma).
The Wallac Ultroterm 2 software automatically generates a standard curve by
plotting the average radioactivity (cpm) for each tube against the known
concentration of the corticosterone standards and calculates the unknown values in
the plasma samples. An example standard curve from the corticosterone assay is
shown in figure 2.3.
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log corticosterone concentration (ng/ml)
Figure 2.3. An example standard curve from a corticosterone
radioimmunoassay. Counts per minute (cpm) are plotted against the known
corticosterone concentrations of the standards.
In order to calculate the sensitivity of the assay it is first necessary to construct a
graph of %B/Bmax against concentration of the corticosterone standards (as
previously described, 2.6.(iii)). An example is given in figure 2.4.
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log corticosterone concentration (ng/ml)
Figure 2.4. Example of binding curve from a corticosterone radioimmunoassay.
Percentage of total binding of the standards is plotted against the concentration of
corticosterone in each of the standards.
Using the equation detailed in section 2.6. the sensitivity of this assay was calculated
to be 83%. From the graph above (figure 2.4.) this is converted into a corticosterone
concentration. Thus the sensitivity of the example assay was 0.85ng/ml.
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2.6.2. Oxytocin Radioimmunoassay
Plasma oxytocin concentrations were determined using an in-house oxytocin
radioimmunoassay. The method employed is adapted from that of Higuchi et al
(Higuchi et al, 1985). They injected a synthetic oxytocin-BSA conjugate into rabbits
and raised and purified antibodies against oxytocin. The specificity of the anti-
oxytocin serum was determined by comparing the inhibition of binding of 125I
labelled oxytocin with that of various other plasma hormones, namely, arginine
vasopressin (AVP), arginine vasotocin (AVT), melanocyte-stimulating hormone
release inhibiting factor (MIF), luteinising hormone (LHRH), thyrotrophin-releasing
hormone (TRH), angiotensin II, rat luteinising hormone, rat follicle stimulating
hormone and rat prolactin. The antibody was found not to cross-react with any of the
peptides examined. When known amounts of unlabelled oxytocin (range 6.3-400
pmol/1) from male and pregnant female rats were added to serum and measured by
this assay recovery was found to be between 94-107%.
A limited concentration of rabbit anti-oxytocin antibody was added to duplicate
aliquots of plasma samples (containing unknown concentrations of oxytocin) and to
tubes containing the standards (known oxytocin concentration). After 24h incubation,
a fixed amount of radio-iodinated oxytocin was added to all the tubes. The tubes
were mixed and again incubated (this time for 48h) after which time the amount of
1 2 5
I-oxytocin bound to the rabbit antibody was inversely proportional to the
concentration of oxytocin in the sample. In order to measure the radioactivity of the
rabbit anti-oxytocin- I-oxytocin complex it was separated by precipitation using a
secondary antibody technique. Donkey anti-rabbit gammaglobulin was added which
binds with the primary antibody; the resulting aggregate was precipitated out of
solution with pansorbin cells. Radioactivity of the precipitate was measured with a
gamma counter and unknown oxytocin concentrations read directly from the
standard curve (created by measuring radioactivity in samples of known hormone
concentration) automatically produced by the Ultraterm 2 software package.
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2.6.2.1. Materials
(i) Assay (phosphate) buffer
The assay buffer used was prepared in ddH20 and contained the following:
125mg Sodium dihydrogen orthophosphate (NaH2P04.2H20) [BDH]
595mg di-sodium hydrogen orthophosphate (Na2HP04)
500mg Sodium azide (NaN2)





Standard oxytocin (4th International Standard) was obtained from the National
Institute for Biological Standards and Control as a freeze-dried aliquot containing
21pg of oxytocin. This was resuspended in assay buffer to give a 50ng/ml solution
and re-frozen as lrnl aliquots.
(Hi) First Antibody Buffer
Normal rabbit serum (Sapu) was used in assay buffer at a 1:400 dilution to aid the
binding of the secondary antibody.
(iv) First Antibody
The rabbit anti-OXT antibody THF-3 was kindly donated by Dr T. Higuchi. It was
stored diluted 1:200 in assay buffer at -20°C. On the day of use, the first antibody
solution was used at a final dilution of 1:200,000 in antibody buffer.
(v) Second antibody
The second antibody was donkey anti-rabbit gammaglobulin (IDS Ltd.) It was stored
at 4°C and used at a dilution of 1:25 in assay buffer.
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(vi) ['251]-Oxytocin
125
[ I]-OXT (NEN Life Science Products) arrived in a lyophilised form. It was
resuspended in assay buffer, aliquoted into 0.5ml eppendorf tubes and stored at -
20°C. We used the [125I]-OXT at a concentration calculated to contain between 7-
10,000cpm/50pl This was verified by counting a 50p.l aliquot in the P-scintillation
counter for 1 minute.
(vii) Standard Pansorbin Cells
Pansorbin cells were supplied by Novabiochem Ltd. as a 10% (w/v) solution in
phosphate buffered saline containing 0.1% (w/v) sodium azide. This solution was
used at a 1:25 dilution with assay buffer.
2.5.2 Methods
On day 1 of the assay 50pl of rabbit anti-OXT antibody was added to duplicate
aliquots of the experimental rat plasma samples (containing unknown concentrations
of OXT) and to triplicate tubes containing standard OXT (of known concentration) in
assay buffer. The tubes were vortex mixed, covered in foil and stored at 4°C for 24
hours; after which time we added a 50pl aliquot of l25I-OXT (which contained
approximately 8-9000 cpm) to all of the tubes. The mixture was left for 48h or over
the weekend after which time the amount of 125I-OXT bound to the rabbit antibody
was inversely proportional to the concentration of OXT in the plasma
sample/standard. Before the radioactivity of the rabbit anti-OXT-l25I-OXT complex
could be measured it had to be precipitated out of solution. This was achieved by
adding 50pl of the secondary antibody; donkey anti-rabbit. The tubes were incubated
overnight at 4°C and the folowing morning the precipitate was separated by
centrifugation (3000rpm, at 4°C for 30 mins) with white pansorbin cells, which aid
visualisation of the precipitate. The resulting supernatant was aspirated and the
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radioactivity of each precipitate was then measured for 1 min using a gamma counter
(Wallac).
To quantify the unknown OXT concentrations in the plasma samples it was
necessary to construct a standard curve of precipitate radioactivity versus standard
OXT concentrations (Ultroterm 2 software). On day one of the assay serial dilutions
of stock OXT (50ng/ml) were made which created eleven standard concentrations
ranging from 2.4-2500pg/ml. In order to determine the sensitivity and binding of the
assay three other standards were prepared as below:
Total Count (TC): 125I-OXT only
Non-specific binding (NSB): 125I-OXT + 2nd Antibody
Maximum % binding (Bmax): 125I-OXT + 1st antibody + 2nd antibody
To measure intra-assay variation duplicate tubes containing either 10, 50, 100, 250 or
500 pg/ml OXT were incorporated at the beginning and at the end of the assay. The
remainder was stored at -20°C until the next assay in order to assess inter-assay
variation.
An example standard curve generated from an oxytocin assay is shown in figure 2.5.
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Fieure 2.5. Example of a standard curve from an oxytocin radioimmunoassay.
order to calculate the sensitivity of the assay it is first necessary to construct a
iph of %B/Bmax against concentration of the oxytocin standards
scribed in 2.6.(iii)). An example is given in figure 2.6.
(as previously
Using the equation detailed in section 2.6. the sensitivity of this assay was calculated
to be 96%. From the graph below (figure 2.6.) this is converted into an oxytocin
concentration. The sensitivity of the example assay was found to be lower than the
first standard of 2.4 pg/ml.
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Figure 2.6. Example of binding curve from an oxytocin radioimmunoassay.
Percentage of total binding of the standards is plotted against the concentration of
oxytocin in each of the standards.
2.7. Adrenocorticotropic hormone immunoradiometric assay
Adrenocorticotropic hormone (ACTH) is a single chain polypeptide consisting of 39
amino acids. The first 24 A-terminal amino acids are essential for the hormone's
biological activity. Here a commercially available two-site solid phase
immunoradiometric (IRMA) kit was employed for the quantitative determination of
intact ACTH in plasma (Hodgkinson et al, 1984).
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Two polyclonal antibodies, recognising different binding sites on the ACTH (rat and
1
mouse) molecule were used in excess. One antibody is a [ I]-labelled sheep
immunoglobulin that recognises the amino terminal region of ACTH. The second
antibody is immobilised and coupled to the sheep anti-rabbit coated reaction tubes.
This antibody reacts with the C-terminal of the ACTH molecule. Following
overnight incubation a "sandwich-type" complex was formed and bound to the tube
wall (see figure 2.7.). The excess [l25I]-sheep-anti-ACTH was removed by
aspiration. Following two washes the radioactivity in the tubes was measured using
a gamma counter (Wallac) and at this time was directly proportional to the
concentration of the ACTH in the sample. Recovery was determined by adding
known amounts of ACTH to plasma samples and measuring the concentration using
this kit. The recovery was found to be between 99-104%. Cross reactivities were
determined by the manufacturer by measuring plasma samples containing a-
melanocyte stimulating hormone (a-MSH), (3-MSH and P-endorphin. The ACTH








Figure 2.7. Schematic representation of the coated tube ACTH assay.
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2.7.1 Materials
An ACTH IRMA kit (IDS Ltd.) containing:
(i) Seven standard ACTH solutions ranging from 0 pg/ml-1250 pg/ml
(ii) Two reference controls containing ~30 pg/ml and ~300 pg/ml ACTH
(iii) [125I]-ACTH antibody (rabbit-anti-ACTH)
(iv) Coated Tubes: C-terminal anti-ACTH coupled to sheep-anti-rabbit coated tubes
(v) Wash Buffer
2.7.2 Method
(1) 200pl of each standard, reference control and plasma sample (containing an
unknown concentration of ACTH) were added to duplicate tubes (except total
count; TC).
(2) Next, 200pl of [123I] ACTH antibody solution was added to each tube and
vortex mixed.
(3) The tubes were incubated overnight at room temperature.
(4) The following day all tubes (except TC) were washed twice with wash buffer.
(5) The excess [125I] ACTH antibody was aspirated.
(6) The radioactivity of each tube was counted for 1 min in a gamma counter
(LKB Wallac 1272 Clinigammma).
Wallac Ultroterm 2 software automatically generates a standard curve by plotting the
average radioactivity (cpm) for each tube against the known concentration of the
ACTH standards and calculates the unknown values in the plasma samples (figure
2.8).
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Figure 2.8. Example of ACTH standard curve.
cpm vs ACTH concentration.
The sensitivity of this assay defined as plus 2 standard deviations (i.e. 95%
confidence limit) from the zero calibrator is l.Opg/ml. Intra- and inter- assay
variation were assessed as previously described (see section 2.6).
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CHAPTER 3




Emotional Stress and HPA axis Chapter 3
3.1. Introduction
It is well established that lactation is associated with attenuated neuroendocrine
responses to stress, including reduced ACTH, corticosterone (Windle et al, 1997),
oxytocin (Higuchi et al, 1988) and prolactin (Higuchi et al, 1989) secretion. Less is
known about the physiological adaptations that occur in response to stress in
pregnancy. Recently Neumann and colleagues (Neumann et al, 1998) reported that
the reduced responsiveness of the HPA axis to stress observed in lactation manifests
in late pregnancy. Pituitary ACTH secretion and corticosterone release from the
adrenal gland are attenuated in pregnant rats following 5 minutes exposure to an
emotional stressor, the elevated plus maze. This seems to involve adaptations at the
level of the anterior pituitary, since in vivo the pituitary corticotrophs are less
sensitive to stimulation by exogenously administered CRH in pregnancy and CRH is
less effective in evoking cAMP production (Neumann et al , 1998) from isolated
pituitary segments from late pregnant rats; a reduction in pituitary CRH binding sites
is likely to be involved (Neumann et al, 1998).
The changes that occur at the level of the anterior pituitary may account for the
attenuated HPA axis responses in pregnancy, however it is likely that changes at the
level of the hypothalamus may also contribute to the hyporesponsiveness of the HPA
axis to stress at this time. CRH mRNA content in the parvocellular PVN is
significantly reduced by day 21 of pregnancy and the CRH mRNA: AVP mRNA
ratio is unaltered indicating decreased basal production of both CRH and AVP in
pregnancy (Johnstone et al, 2000a). It is not known if stress-induced CRH and/or
AVP gene transcription are differentially regulated in pregnant rats. It seems
plausible that if the pPVN neurones themselves, or the inputs impinging upon them
are less responsive to stress in pregnant animals then this may explain the attenuated
responsiveness of the HPA axis in pregnancy. Thus the aim of the present set of
experiments was to investigate whether the reduced responsiveness of the HPA axis
to stress in pregnancy was a consequence of reduced activation of hypothalamic
pPVN neurones.
132
Emotional Stress and HPA axis Chapter 3
Restraint Stress
In experiments 1 and 2 the stress paradigm used was exposure to 30 minutes restraint
in a perspex tube, since this is a well characterised 'emotional' or 'psychological'
stressor which acts as a potent activator of the HPA axis (Ma et al, 1997). In non¬
pregnant rats, acute exposure to restraint stress evokes ACTH and corticosterone
secretion and increases CRH and AVP mRNA expression in the pPVN (Harbuz et al,
1994; Ma et al , 1997). Increases in CRH and AVP mRNA expression indicate that
stress activates gene transcription in the parvocellular PVN neurones.
Immediate early genes (IEGs) are characterised by their rapid and transient induction
in many cell types and their responses are independent of protein synthesis. NGFI-B
(nerve growth factor induced gene B) is classified as an immediate early gene and is
induced rapidly in neurones by a variety of stimuli, including stress (Chan et al,
1993); (Imaki et al, 1996) and i.e.v. administration of CRH (da Costa et al, 1997).
Its rapid transcription means that NGFI-B is a good indicator of neuronal activation.
NGFI-B was first identified in the rat phaeochromocytoma cell line PC 12, as a gene
induced by nerve growth factor (Maruyama et al, 1998). NGFI-B belongs to an
orphan (so called since specific ligands for these receptors have yet to be identified)
subclass of the nuclear steroid receptor superfamily. These receptors are ligand-
activated transcription factors which regulate the expression of target genes via
binding to specific sequences (known as hormone response elements), in their
promoter regions.
C-fos is another IEG that has been extensively studied and like NGFI-B has been
identified as a marker of neuronal activation at various levels within the brain,
including cells in the parvocellular region of the rat PVN (Wisden et al, 1990). Its
protein product, Fos, forms a dimer with proteins encoded by c-jun. This
heterodimer is known to interact with a specific sequence, the AP-1 site to regulate
transcription of target genes (Chan et al, 1993). Several studies have shown that Fos
is induced in the PVN in response to stress, however the CRH gene promoter does
not appear to have a functional AP-1 binding site, suggesting that Fos is not directly
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involved in stress induced changes in CRH expression. However, a potential NGFI-
B response element has been found in the 5' promoter region of the rat CRH gene
(Wilson et al, 1991) and similar sequences have been found in the promoter regions
of the oxytocin (Ivell & Richter, 1984) and arginine vasopressin (Mohr & Richter,
1990) genes. It is yet to be elucidated whether NGFI-B is capable of binding to the
potential NGFI-B response elements (NBRE) identified (in any of the genes
mentioned above) and initiating transcriptional activation, however NGFI-B could be
a link between neuronal depolarisation and activation of the CRH gene.
In experiment 1 to determine whether attenuated HPA axis responses in pregnancy
are a consequence of reduced activation of pPVN neurones, in situ hybridisation for
NGFI-B mRNA was employed to indicate rapid neuronal activation in hypothalamic
pPVN neurones following exposure to restraint stress. NGFI-B mRNA expression
was also measured in the hippocampus, since this structure is important in regulating
the activity of pPVN CRH and AVP neurones (Herman & Cullinan, 1997). In
experiment 2, rats were also exposed to restraint, however this time, brains were
processed by in situ hybridisation for AVP heteronuclear RNA (hnRNA).
Heteronuclear RNA (hnRNA) represents the primary transcripts of RNA polymerase
II and includes precursors of mRNAs from which introns are spliced out. Therefore,
measurement of hnRNA expression should reflect the rate of gene transcription more
directly than the measurement of stable pools of mRNAs (Ma et al , 1997).
Heteronuclear RNAs are rapidly processed to mature mRNA in the nucleus and have
a high turnover rate meaning they are usually detectable in the cytoplasm at
approximately 15-30 minutes after transcriptional activation. Since changes in levels
of cytoplasmic mRNA occur over a relatively slow time course, changes in total
levels of cytoplasmic mRNA may not correlate well with changes in gene
transcription. Therefore when looking at rapid changes in gene transcription
following physiological challenge, measuring changes in IEG and heteronuclear
RNA expression are perhaps more suitable methods to use.
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The aims of experiments 1 and 2 was to establish whether the ACTH secretory
response to acute restraint stress (30 min) is attenuated in late pregnancy, and if so, to
establish whether this is a result of reduced activation of the CRH/AVP pPVN
neurones.
Maternal Defence Test
In most studies investigating HPA activity a variety of stressors have been employed,
such as forced swimming (Neumann et al, 1998), restraint (Harbuz et al, 1994; Ma
et al , 1997), elevated plus maze (Neumann et al , 1998) and noise (Windle et al ,
1997). Although these stressors are relevant models in that they activate the HPA
axis, concerns have arisen that these type of stressors may not be of primary
significance to a rat during the later stages of pregnancy. In male rats social defeat
has been used as an emotional stressor to activate the HPA axis (Haller et al, 1995;
Wotjak et al, 1996). Social defeat is an emotionally challenging situation that
consists of placing the experimental animal (intruder) in the home cage of an adult
male rat (resident). The resident is housed with a female prior to the experiment, so
as to stimulate territorial aggression (Flannelly & Lore, 1977). Female rats tend to be
relatively docile animals and are only territorial and aggressive during lactation,
therefore the maternal defence test was devised as a relevant emotional stressor for
female rats (Neumann et al, 2001). The test relies upon female aggression directed
against an intruder that approaches the nest. The aggressive behaviour displayed by
the lactating mother is related to the protection and defence of her young and is part
of the complex behavioural pattern described as maternal behaviour (Rosenblatt et
al, 1994).
Therefore the aim of experiment 3 was to establish whether pregnant rats
demonstrate attenuated HPA axis responses to a physiologically relevant stressor,
namely the maternal defence test. In situ hybridisation for NGFI-B mRNA was again
employed to study rapid changes in gene transcription in pPVN neurones.
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3.2. Materials and Methods
3.2.1. Animals
Female Sprague Dawley rats were used in experiments 1 and 3 and were maintained
in the animal facility within the Faculty of Medicine, University of Edinburgh.
Experiment 2 was performed in the Max Planck Institute for Psychiatry in Munich
(in collaboration with Drs. Alexander Wigger, Inga Neumann and Alison Douglas)
and female Wistar rats were used (animal procedures were performed in accordance
with the guide for the care and use of laboratory animals issued by the government of
Bavaria). In all cases rats were maintained under standard conditions described in
chapter 2. For the pregnant groups, rats were mated overnight with a sexually
experienced male. The presence of a vaginal plug of semen in the breeding cage the
following morning was designated day 1 of pregnancy.
3.2.2. Stress Paradigms
All experiments were performed in the morning between 08:30-1 1:30h.
Experiment 1: Rats were individually caged at least five days before the start of the
experiment. Virgin females and rats on day 10 and day 21 of pregnancy were used.
Virgin and pregnant rats were either restrained for 30 minutes in Perpsex restraining
tubes (diameter= 70mm, the length of the tubes were adjusted to prevent the animal
from turning around) or left undisturbed in their home cages and then killed
immediately by decapitation (rats were conscious and no anaesthesia was used). This
time point, i.e. 30 min after the onset of stress was chosen since it has been shown to
correspond with the peak in NGFI-B mRNA, c-fos mRNA and CRH hnRNA
(Parkes et al, 1993; Imaki et al , 1996; Mansi et al, 1998) expression in the pPVN.
Brains were rapidly removed and frozen on pieces of aluminium foil on dry ice. To
aid freezing they were covered with powdered dry ice. Once frozen the brains were
stored at -70°C. Trunk blood was collected into chilled plastic tubes contained 5%
EDTA (150pl per 1ml of blood). Blood samples were kept on ice until they were
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centrifuged (3 min at 13000 rpm) and plasma separated. Plasma samples were then
stored at -20°C until assayed.
Experiment 2: Female virgin and day 21 pregnant Wistar rats were used. Rats were
caged in pairs of the same reproductive state, 5 days prior to the start of the
experiment. From each pair one rat was exposed to 30 minutes restraint stress in a
plexiglass tube (diameter 80mm). After the period of restraint, rats were returned to
their home cage and left undisturbed for a further 60 minutes, after which time they
were killed by decapitation (i.e. 90 minutes after the onset of stress). The control
animal from each pair was killed by decapitation immediately prior to or
immediately after its 'stressed' partner. Brains were rapidly removed, snap-frozen in
methylbutane on dry ice, then stored at -70°C.
Experiment 3: Female virgin and day 21 pregnant Sprague Dawley rats were used.
Maternal defence test: 2-3 days before expected parturition (day 22) seven pregnant
rats were transferred into individual cages. After parturition these rats were kept with
their litters. This group of rats was used in the experiment to provide the stress
stimulus and referred to as the 'lactating residents'. The experiments were performed
when the resident mothers were between days 4-6 of lactation (the day after
parturition was designated day 1 of lactation). On the morning of the experiment the
virgin or pregnant (day 21) intruder was taken from its home cage and placed into the
cage of the lactating resident. The intruder rats were exposed to the 'maternal defence
test' for 30 minutes, during which time the number of attacks launched upon the
intruder rat by the lactating resident was recorded. Each lactating resident was used
twice, so each was exposed to intruders of both reproductive states. Thus, if on day 1
the lactating resident was exposed to a virgin intruder, then on day two a pregnant
intruder was used, and vice versa. After 30 minutes exposure to the 'maternal defence
test' the virgin and pregnant intruder rats were immediately killed by decapitation.
Virgin and pregnant control rats were undisturbed, then killed by decapitation. Trunk
blood was collected into chilled plastic tubes containing 5% EDTA (150pl per 1ml
blood), plasma was separated by centrifugation (as above) and stored at -20°C until
radioimmunoassay.
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3.2.3. In situ hybridisation
Brains were sectioned at 15 pm and mounted on slides as previously described in the
General Methods Chapter. To detect NGFI-B mRNA expression a 45-mer
oligonucleotide probe was used [MWG-Biotech], complementary to nucleotides
spanning amino acids 1-15 (see below) (Wisden et al, 1990).
5'- GGT GGC AGG TGC GGT GGG CGC CGT CTC GGG GCT GGC CAG
GTC CAT -3'
To detect AVP hnRNA expression a 39-mer oligonucleotide probe [MWG-Biotech],
complementary to the first 39 bases of intron 1 of the rat AVP gene was employed
(see below).
5'- ACG GCA CTG TCA GCA GCC CTG AAC GGA CCA CAG TGG TAC -3'
Both probes were labelled with [35S] as previously described in the General Methods
Chapter. Hybridisation and post-hybridisation washes were performed as before. The
melting temperature of the NGFI-B mRNA oligo-probe is 85°C and for the AVP
hnRNA oligo-probe is 78°C, therefore the heated SSC washes were performed at
65°C and 58°C, respectively. Once dry, the sections were exposed to
autoradiographic film in autoradiographic cassettes at room temperature. The
exposure time was 21 days for NGFI-B mRNA and 25 days for AVP hnRNA. The
relative amount of NGFI-B mRNA or AVP hnRNA in the pPVN was assessed by
measuring silver grain density from the autoradiographic film using a computer
based image analysis system as described in the General Methods Chapter.
3.2.4. Radioimmunoassays
Plasma ACTH and corticosterone concentrations were determined using
commercially available kits (see sections 2.6.1. and 2.7.). For both experiments 1 and
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3, the sensitivity of the ACTH assay was 1 pg/ml. The intra-assay variation was <
8% for experiment 1 and <4% for experiment 3. The sensitivity of the corticosterone
assay was 0.5ng/ml and the intra-assay variation was <3%.
3.2.5. Statistical Analysis
Two way analysis of variance (2-way RM ANOVA), followed by Student-Newman-
Keuls multiple comparison test was used to analyse the data. P values less than 0.05
were considered statistically significant.
3.3. Results
Experiment 1
3.3.1. Effects of restraint on plasma ACTH
Basal plasma concentrations of ACTH did not differ between any of the groups.
Following exposure to 30 min restraint a significant increase in plasma ACTH
concentration was observed in all 3 groups (see figure 3.1). Further analysis revealed
that plasma ACTH concentration in the d21 pregnant group (20.2 ± 2.8 pg/ml) was
significantly attenuated (p<0.001; Two-way ANOVA) when compared to the levels
in the virgin and dlO pregnant groups (36.9 ± 3.9 and 40.65 ± 7.1 pg/ml,
respectively). No significant difference was found between the virgin and the dlO
pregnant animals following restraint.
3.3.2. Effects of restraint on NGFI-B mRNA expression in the pPVN
Levels of NGFI-B mRNA expression in the pPVN of control animals were not
significantly different between any of the groups (figure 3.2.). Exposure to 30 min
restraint evoked a marked increase in the expression of NGFI-B mRNA in the
parvocellular region of the PVN in virgin (3-fold increase in grain area) and dlO
pregnant rats (4.9-fold increase in grain area).
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Figure 3.1. The effect of 30 minutes restraint on plasma ACTH concentrations
in virgin and pregnant rats.
Trunk blood was collected immediately after the 30 minute period of restraint.
Control rats were removed from their home cages and killed immediately. Values are
plotted as group means ± SEM. Group numbers: virgin/control, n = 8; day 10
pregnant/control, n = 5; day 21 pregnant/control, n=8; virgin/restraint, n = 10; day 10
pregnant/restraint, n = 6; day 21 pregnant restraint. Two-way ANOVA followed by
Student Newman-Keuls multiple comparison test was used for statistical analysis of
the data: *p < 0.001 vs basal values in the same group; #p < 0.001 vs virgin/restraint.
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In contrast, only a small non-significant increase was observed in the day 21
pregnant group (1.3-fold increase in grain area; see figure 3.2). A two-way ANOVA
revealed a significant effect of restraint stress in both the virgin and dlO pregnant
group on NGFI-B mRNA expression, however the increase in expression observed in
the d21 pregnant group proved not to be significantly different from basal levels.
Statistical analysis across the groups demonstrated that following 30 minutes of
restraint, levels of NGFI-B mRNA in the PVN of virgin animals was significantly
greater than those seen in animals on day 21 of pregnancy. The levels of expression
found for dlO pregnant rats appeared to be intermediate with no significant
difference in levels compared with either virgin or d21 pregnant rats.
3.3.3. Effects of restraint on NGFI-B mRNA expression in the hippocampus
Basal expression of NGFI-B mRNA in the hippocampal sub fields of control animals
were not significantly different between any of the groups (figure 3.3). Following 30
min exposure to restraint, NGFI-B gene transcription showed a tendency to increase
only in the virgin group, however this was not significant. Nevertheless, after
restraint, the NGFI-B mRNA signal was found to be significantly less in the CA2,
CA3 subfields and dentate gyrus in the day 21 pregnant rats compared with the
virgin rats.
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Figure 3.2.(a) The effect of 30 minutes restraint on NGFI-B mRNA expression
in the pPVN of virgin and pregnant rats: Quantification of autoradiographs.
Rats were killed immediately after exposure to a 30 minute period of restraint.
Coronal brain sections were hybridised with 35S-labelled oligonucleotide probe for
NGFI-B mRNA. Autoradiographs were quantified by computer based image
analysis. Values plotted are group means ± SEM for grain area (mm2/mm2). Group
numbers, as in figure 3.1. Two-way ANOVA followed by Student Newman-Keuls
multiple comparison test was used for statistical analysis of the data: *p < 0.001 vs
respective control group; #p < 0.02 vs virgin/restraint.
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Figure 3.2.(b) The effect of 30 minutes restraint on NGFI-B mRNA expression
in the pPVN of virgin and pregnant rats: Photomicrographs.
Coronal brain sections were hybridised with a l5S-labelled oligonucleotide probe
complementary to NGFI-B mRNA from A, virgin/control; B, virgin/restraint; C, day
10 pregnant/control; D, day 10 pregnant/restraint; E, day 21 pregnant/control; F, day
21 pregnant/restraint. PVN, paraventricular nucleus; CA1, CA2, CA3, hippocampal
subfields; DG, dentate gyrus. Scale bar: 1mm.
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Experiment 2
3.3.4. Effects of restraint on AVP hnRNA expression in the pPVN
Analysis of film autoradiographs revealed AVP hnRNA expression in the pPVN was
significantly less in the undisturbed pregnant rats than in the virgin group (two-way
ANOVA, p<0.02; figure 3.4.). Restraint increased AVP hnRNA expression in the
pPVN in the virgin but not in the day 21 pregnant rats (figure 3.4.). Levels of AVP
hnRNA expression in the virgin restrained group were 600% of the virgin control
group, whereas the pregnant restrained group level was 40% of that of the virgin
control group.
Experiment 3
3.3.5. The effect of 30 minutes exposure to maternal defence on plasma ACTH
and corticosterone levels in the intruders
Plasma concentrations of ACTH and corticosterone in the virgin and pregnant
control rats did not differ (two-way ANOVA; figure 3.5.). Exposure to the maternal
defence test caused a significant increase in plasma ACTH concentration in the
virgin group but not in the pregnant group (figure 3.5). Thus the ACTH response in
the virgin intruders (2.3-fold increase, p < 0.001) was significantly greater than in the
pregnant intruders (1.4-fold increase, not significant). Similarly, the maternal defence
test induced a significant increase in corticosterone secretion only in the virgin group
and had no effect in the pregnant rats (figure 3.6.). In the virgin group plasma
corticosterone was significantly elevated (36% increase) compared with the pregnant
group (1.7% increase).
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Figure 3.4.(a) The effect of 30 minutes restraint on AVP hnRNA expression in
the pPVN of virgin and pregnant rats: Quantification of autoradiographs.
Rats were killed 90 minutes after the onset of exposure to a 30 minute period of
restraint. Control rats were undisturbed prior to killing. Coronal brain sections were
hybridised with 35S-labelled oligonucleotide probe for AVP hnRNA.
Autoradiographs were quantified by computer based image analysis. Values plotted
are group means ± SEM for grain area (mmW). Group numbers: virgin/control,
n=9; day 21 pregnant/control, n=7; virgin/restraint, n=6; day 21 pregnant/restraint,
n=7. Two-way ANOVA followed by Student Newman-Keuls multiple comparison
test was used for statistical analysis of the data: +p < 0.02 vs virgin/control; *p <
0.001 vs all other groups.
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Figure 3.4.(b) The effect of 30 minutes restraint on AVP hnRNA expression in
the pPVN of virgin and pregnant rats: Photomicrographs.
Brightfield photomicrographs of coronal sections through the paraventricular nucleus
(PVN) hybridised with a '5S-labelled oligo-probe complementary to arginine
vasopressin heteronuclear RNA (AVP hnRNA) from A, virgin/control; B,
virgin/restraint; C, day 21 pregnant/control; D=day 21 pregnant/restraint. pPVN,
parvocellular division of paraventricular nucleus; mgPVN, magnocellular division of
PVN; 3V, third ventricle. Scale bar: 100pm.
<~svr-'
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Figure 3.5. The effect of 30 minutes exposure to the maternal defence test on
plasma ACTH concentrations in virgin and pregnant rats.
Trunk blood was collected immediately after exposure to the maternal defence (MD)
test for 30 minutes. Control rats were undisturbed before being removed from their
home cages and killed. Values are plotted as group means ± SEM. Group numbers:
virgin/control, n = 5; pregnant/control, n=6; virgin/maternal defence, n = 8;
pregnant/maternal defence, n = 5. Two-way ANOVA followed by Student Newman-
Keuls multiple comparison test was used for statistical analysis of the data: *p <
0.001 vs virgin/control group; #p < 0.001 vs virgin/maternal defence group.
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Figure 3.6. The effect of 30 minutes exposure to the maternal defence test on
plasma corticosterone concentrations in virgin and pregnant rats.
Trunk blood was collected immediately after exposure to the maternal defence (MD)
test for 30 minutes. Control rats were undisturbed before being removed from their
home cages and killed. Values are plotted as group means ± SEM. Group numbers as
before (see figure 3.5.). Two-way repeated measures ANOVA followed by Student
Newman-Keuls multiple comparison test was used for statistical analysis of the data:
*p < 0.01 vs virgin/control group; #p < 0.03 vs virgin/maternal defence group.
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3.3.6. Behaviour of Lactating Resident
Aggressive behaviour displayed by the lactating resident was not significantly
affected by the reproductive status of the intruder rat (table 3.1). Latency to attack a
virgin (5.2 ± 3.0 minutes; t-test) or a pregnant intruder (3.5 ±1.0 minutes; t-test) was
not significantly different, nor was the number of attacks launched by the lactating






Virgin 5.2 ±3.0 4.0 ±0.7
Pregnant 3.5 ± 1.0 5.6 ± 1.0
Table 3.1. Aggressive behaviour displayed by the lactating resident against
intruder rats. Aggressive behaviour displayed by the lactating resident was recorded
throughout the 30 min maternal defence test. Specifically, latency to attack and the
number of attacks launched were measured. Data is presented as group means ±
SEM. Group numbers as before (see figure 3.5.). No significant differences were
detected between any of the groups (Student's t-test; p> 0.05).
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3.4. Discussion
Experiments 1 & 2 : Restraint Stress
The present data demonstrate that in rats the ACTH secretory response to restraint
stress is attenuated in late pregnancy (day 21). This confirms previous studies
employing other stressors (eg. elevated plus maze and forced swimming) in late
pregnancy (Neumann et al , 1998). Following exposure to restraint stress, plasma
ACTH concentration in the day 10 pregnant rats was not different from that of the
virgin rats, however in late pregnant rats the ACTH response was significantly
reduced. This suggests that the attenuated ACTH response to stress is manifested in
mid-gestation, at sometime after day 10 of pregnancy. These results are consistent
with previous studies using other stressors (Neumann et al, 1998).
Restraint induced an increase in pPVN NGFI-B mRNA expression in all of the
groups, however the level of expression in the day 21 pregnant group was
significantly attenuated when compared with the virgin and day 10 pregnant group.
The decreased NGFI-B mRNA response to restraint in the pPVN of the late pregnant
rats indicates that the parvocellular neurones in the PVN are stimulated less strongly
by the stressor. The blunted ACTH response observed in the day 21 pregnant group
is likely to be a result of reduced neuronal activation in the pPVN, indicated by the
attenuated NGFI-B response. Since NGFI-B is a putative regulator of CRH gene
transcription (Wilson et al, 1991), the results suggest that restraint is less effective in
activating CRH gene transcription in late pregnant rats. In the hippocampus,
stimulation of NGFI-B mRNA expression by restraint stress was also reduced in the
day 21 pregnant group indicating reduced activation of stressor processing circuits in
pregnancy (Herman & Cullinan, 1997). These results are consistent with those
reported by Da Costa and colleagues, who demonstrated reduced c-fos mRNA
expression in the hippocampal subfields following central administration of CRH in
lactating rats compared with virgin rats (da Costa et al, 1997).
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Restraint is a good example of an emotional (or neurogenic) stressor. Emotional
stressors often rely upon somatosensory pathways for their transduction and involve
a distinct cognitive and/or affective component. These stressors have common
features, they require processing and integration from sensory modalities and they do
not involve an immediate threat, but rather constitute stimuli that become stressful
only by comparison with previous experiences. HPA axis responses to restraint stress
involve processing by the limbic system (Sawchenko et al, 2000). As well as in the
PVN, restraint stress induces Fos expression in the prefrontal cortex, central (CeA)
and medial amygdaloid (MeA) nuclei, bed nucleus of the stria terminalis (BNST),
lateral septum, hippocampus, median preoptic area (MPOA), dorso-medial
hypothalamus, locus coeruleus (LC) and in brainstem noradrenergic (Al and A2) and
adrenergic (CI and C2) nuclei (Melia et al, 1994; Herman & Cullinan, 1997;
Chowdhury et al, 2000; Sawchenko et al, 2000; Dayas et al, 2001). Lesions to the
prefrontal cortex, hippocampus, septum or amygdala result in a reduced HPA axis
response to restraint (Herman & Cullinan, 1997). In particular, the MeA appears to
play an important role in activation of the HPA axis in response to restraint stress.
Some of the MeA neurones activated following restraint have been shown to project
directly to the PVN and ibotenic lesions of the MeA, but not the CeA greatly reduce
restraint-induced activation of the pPVN neurones (Dayas et al, 1999). In pregnancy,
processing of stress stimuli through the MeA (or any of the other aforementioned
brain regions) may be disrupted thus explaining reduced activation of the pPVN
neurones and hence the HPA axis.
Generally the hippocampus is thought of as having an inhibitory effect on the HPA
axis (Herman et al, 1989; Herman et al, 1992). However, hippocampal regulation of
the HPA axis is complex and lesions can result in an increase or a decrease in
glucocorticoid secretion and electrical stimulation of the hippocampus can stimulate
or inhibit corticosterone secretion (Dunn & Orr, 1984). It is not clear from these
experiments whether the hippocampal neurones are exerting an overall negative or
positive effect on HPA activity. If these neurones are exerting an excitatory influence
over the HPA axis then it follows that reduced activation of the hippocampal
subfields in response to restraint in the late pregnant rats would correlate with
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reduced HPA axis activation. If on the other hand these neurones are exerting a net
inhibitory influence over HPA activity then it is possible that in pregnancy the pPVN
CRH neurones overcome this reduced inhibitory drive from the hippocampus and
remain less responsive. This may also explain the more prolonged ACTH secretory
response to stress (although still markedly less than in virgins) frequently observed in
pregnancy (Douglas et al, 1998; Neumann et al , 1998) associated with a loss of
glucocorticoid feedback inhibition of the HPA axis.
Basal expression of AVP hnRNA in the pPVN was significantly less in the day 21
pregnant group compared with the virgin group. This is consistent with findings
indicating reduced CRH and AVP mRNA expression at the end of pregnancy
(Johnstone et al , 2000a). Exposure to restraint stress significantly increased AVP
hnRNA expression in the pPVN of virgin rats, which is in agreement with previous
studies using this and other stressors (Kovacs & Sawchenko, 1996; Ma et al, 1997).
The absence of an increase in AVP hnRNA expression in the pPVN in late pregnant
rats further suggests reduced activation of CRH/AVP pPVN neurones by restraint
stress in pregnancy. The promoter region of the AVP gene contains two functional
cAMP and a putative NGFI-B response element, as well as an AP-1 binding site
(Kovacs & Sawchenko, 1996). Either of these may play a role in translating stress-
related input into AVP gene transcription. Thus reduced expression of NGFI-B
mRNA in the pPVN of pregnant rats following exposure to restraint (as reported in
experiment 1) may lead to reduced activation of the AVP gene in response to
restraint in pregnancy (as described in experiment 2). Alternatively, changes in AVP
gene transcription in response to stress in pregnancy may be the result of changes in
CREB phosphorylation (Kovacs & Sawchenko, 1996).
Together these data suggest that reduced stimulation of ACTH (and thus
corticosterone) secretion by an emotional stressor (restraint) in pregnancy is a
consequence of reduced stimulation of CRH/AVP neurones in the parvocellular
region of the PVN. The hippocampus may be involved in the circuitry regulating
these neurones, and stress-induced activation of the neurones here is also less in the
day 21 pregnant rats compared with the virgin rats. The causes of these changes are
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unclear. The CRH/AVP neurones themselves may be less responsive to stressful
stimuli in late pregnancy or it may be that the neurones impinging upon the pPVN
neurones are less activated by stressors and thus the central drive to these neurones is
reduced in pregnancy. Thus, the adaptations that occur at the level of the anterior
pituitary in pregnancy (Neumann et al , 1998) are likely to be a consequence of
reduced drive from the CRH/AVP neurones, rather than the primary cause of the
attenuated responsiveness of the HPA axis in pregnancy.
Experiment 3: Maternal Defence Test
To meet the concerns regarding the 'physiological relevance' of restraint stress to a
late pregnant rat, exposure to the maternal defence test was used in experiment three.
Exposure to a maternally aggressive lactating resident for 30 minutes (which
involves olfactory, visual and auditory cues) significantly activated the HPA axis in
the virgin intruders; this is reflected by increased levels of plasma ACTH and
corticosterone concentration in the trunk blood. Comparison of the hormonal
responses of the virgin and pregnant intruders revealed that the maternal defence test
failed to evoke a significant ACTH or corticosterone response in the day 21 pregnant
group, confirming previous results demonstrating blunted ACTH and corticosterone
to the elevated plus maze and forced swimming (Neumann et al, 1998). Furthermore
these results are consistent with the attenuated ACTH response to restraint in late
pregnant rats, described in experiment 1 of this chapter. The differences in the ACTH
and corticosterone secretory responses following the maternal defence test are not a
consequence of differential behaviour displayed by the resident dependent on the
reproductive status of the intruder, since a similar number of attacks were launched
by the resident whether the intruder was a virgin or pregnant. The brain pathways
involved in processing stimuli to effect an HPA response to maternal aggression are
not known though probably involve limbic forebrain pathways, as is the case with
other emotional stressors (Herman & Cullinan, 1997). Fos expression is induced in
the lateral septum, bed nucleus of stria terminalis, lateral preoptic area, lateral
hypothalamic area, paraventricular nucleus, medial and central amygdala as well as
in the autonomic and monoaminergic nuclei of the brainstem in male rats following
social defeat (Martinez et al, 1998). It is likely that the pathways involved in female
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rats are similar to those in males. Thus any interruption in the processing of these
stimuli by the various forebrain and brainstem structures in pregnancy may result in
reduced activation of the HPA axis.
In conclusion, as with forced swimming and the elevated plus maze (Douglas et al ,
1998; Neumann et al, 1998), late pregnant rats display reduced HPA axis responses
to the emotional stressors, restraint and maternal aggression. In the case of restraint
this appears to be a result of reduced drive by CRH and/or AVP, as indicated by
reduced activation of the pPVN neurones.
To date no study has investigated whether pregnant rats display attenuated HPA axis
responses to physical stressors. In the next chapter the effects of immune challenge
on HPA axis activation are investigated in late pregnancy.
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4.1. Introduction
Following immune activation an organism elicits a physiological response during
which information is conveyed to the brain to enable the organism to make the
appropriate endocrine and behavioural adaptations necessary to restore physiological
balance. As mentioned in Chapter 1, an important interaction occurs between the
neuroendocrine and immune axes and it is now widely accepted that activation of the
HPA axis plays a vital role in restoring homeostasis following immune challenge
(Turnbull & Rivier, 1995).
In Chapter 3, the responsiveness of the HPA axis to emotional (or psychological)
stressors was shown to be markedly reduced in pregnancy. To determine whether a
mechanism is in place in late pregnancy to restrain the responsiveness of the HPA
axis to all stressors, it was important to investigate HPA responses to a 'purely'
physical stressor. To date, no previous studies have investigated the effects of
immune challenge (a physical stressor) on HPA activity in late pregnancy.
4.1.1. Effects of endotoxin LPS and cytokines on the HPA axis
In non-pregnant animals various models have been used to investigate the HPA
response to infection, inflammation and tissue damage. Peripheral administration of
endotoxin lipopolysaccharide (LPS) is one such model. LPS is a component of the
cell wall of gram-negative bacteria such as Escherichia coli (Aubry et al, 1997).
Acute administration of LPS acts as a potent stimulator of the HPA axis (Takemura
et al, 1997; Turnbull et al, 1998). Systemic LPS injection increases ACTH and
corticosterone secretion (Turnbull et al , 1998), CRH release (Givalois et al, 1995)
and CRH mRNA expression in the PVN (Kakucska et al, 1993) and is associated
with an increase in the circulating levels of cytokines (Andersson et al, ), such as
tumour necrosis factor-a (TNF-a), interleukin-ip (IL-ip) and interleukin-6 (IL-6)
released from activated macrophage cells. The mechanism(s) by which LPS activates
the HPA axis is not clear but cytokine mediated interactions with the hypothalamus
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(Lenczowski et al, 1997) and activation of vagal inputs to the CNS (Gaykema et al,
1995b; Kapas et al, 1998) are thought to be important. Cytokines such as TNF-a, IL-
1 and IL-6 have all previously been shown to activate the HPA axis after systemic
administration and antisera to these cytokines significantly attenuate the HPA
responses to LPS endotoxin (Besedovsky & Del Rey, 1992). Furthermore passive
immunisation of IL-1 significantly attenuates the response of the HPA axis to LPS in
rodents (Besedovsky & Del Rey, 1992).
LPS evokes secretion of cytokines from circulating monocytes/neutrophils. In order
to do this, the endotoxin must reach the bloodstream where it binds with LPS-
binding protein (LBP). This complex then binds to the membrane CD 14 receptor
located on the cell surface of phagocytes and triggers the release of cytokines
(Wright et al, 1990). Recently it has been reported that LPS induced the expression
of CD 14 mRNA in circumventricular organs (Lacroix et al, 1998) (brain structures
which lack an effective blood-brain-barrier) suggesting that LPS can possibly have a
direct action on the brain, rather than being dependent upon the production of
cytokines in the periphery.
Systemic administration of IL-1 p is a potent CRH secretagogue (Harbuz et al, 1992;
Besedovsky & Del Rey, 1992), leading to increased ACTH secretion from the
anterior pituitary and consequently elevated plasma concentrations of corticosterone.
CRH plays an important role in mediating IL-ip-induced ACTH release. It has been
shown that immuno-neutralisation of endogenous CRH inhibits IL-ip-induced
ACTH secretion (Sapolsky et al, 1987; Berkenbosch et al, 1987) and PVN lesions
attenuate the ACTH secretory response to IL-1 P administration (Rivest & Rivier,
1991).
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4.1.2. How do cytokines activate the HPA axis?
As discussed in the General Introduction Chapter, the precise mechanisms and sites
of action through which cytokines interact with the HPA axis are unclear, however a
strong body of evidence supports the theory that IL-1 acts on the endothelium of
brain blood vessels to activate the release of intermediate mediators, such as
prostaglandins (see section 1.17. of Chapter 1). Indeed brain microvessels express
the IL-1 type 1 receptor (Ericsson et al, 1995). The synthesis of prostaglandins (PG)
is initiated by the action of cyclooxygenase (COX). Intravenous administration of
LPS and IL-1 p induces COX-2 mRNA and protein along blood vessels of the entire
brain microvasculature, choroid plexus and meninges. Furthermore, administration of
COX inhibitors (e.g. ibuprofen and indomethacin) almost completely abolishes the
HPA axis response to IL-ip administration (Katsuura et al, 1988; Watanabe et al,
1990; Morimoto et al, 1991; Rivier, 1993; Niimi et al, 1997).
It is generally held that brainstem catecholamine cell groups in the nucleus of the
solitary tract (NTS) and ventro-lateral medulla (VLM), (in particular the VLM Al
and NTS A2 noradrenergic neurones) are likely to be important sites for receiving
and integrating peripheral immune signals and conveying this information to the
CRH neurones in the PVN (see figure 4.1.). It has previously been shown that
brainstem catecholamine cells activated by IL-ip project to the PVN (Ericsson et al,
1994). Furthermore transection of ascending catecholamine projections from the
brainstem to the hypothalamus (Ericsson et al , 1994), destruction of PVN
catecholaminergic terminals (Weidenfeld et al, 1989) and lesions to the NTS and
VLM (Buller et al, 2001) all result in attenuated IL-1 P-induced HPA axis responses.
The PG receptor, EP3 is expressed in the NTS and VLM neurones, which may
represent a mechanism by which peripheral immune signals activate these brainstem
neurones.
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Thus brainstem catecholamine neurones seem to play an important role in generating
HPA responses to systemic administration of IL-ip. However, in addition to the
direct projections from the brainstem to the pPVN, indirect pathways via forebrain
structures may also be involved in mediating activation of the CRH neurones in
response to systemic IL-lp. In particular the central nucleus of the amygdala (CeA)
is a possible site important in regulating HPA axis responses to systemic IL-ip. The
concept that the CeA is involved in modulating HPA activity was realised some time
ago. Electrical stimulation of the CeA causes an increase in ACTH release, whilst
lesions of the CeA attenuate HPA axis responses to a wide variety of stimuli
(Beaulieu et al, 1986; Beaulieu et al, 1987; Feldman et al, 1994). Ericsson and
colleagues (Ericsson et al , 1994) first demonstrated that neurones in the CeA are
robustly activated in response to systemic IL-ip (Ericsson et al , 1994; Buller et al,
1998; Xu et al, 1999). However more recently it has been shown that bilateral
ibotenic acid lesions of the CeA causes a significant reduction in the number of PVN
CRH cells activated and a significant attenuation of the ACTH secretory response to
i.v. IL-lp (Xu etal, 1999).
The number of direct neural projections from the CeA to the pPVN is restricted to
only a small population of cells and it has been reported that CeA neurones activated
(as demonstrated by Fos expression) by IL-ip are distinct from those found to
project directly to the PVN (Ericsson et al, 1994). Thus it seems likely that the CeA
influences CRH neurone activity via indirect neural pathways. A potential 'relay
centre' is the bed nucleus of the stria terminalis (BNST). Anatomical studies have
demonstrated a direct connection between the CeA and BNST (Sun et al, 1991). C-
fos mRNA expression in the BNST is increased following systemic IL-ip
administration (Ericsson et al , 1994; Buller et al , 1998) and CeA lesions
significantly reduce the levels of IL-lp-induced c-fos expression in the BNST (Xu et
al, 1999). Noradrenergic neurones in the VLM (Al) and NTS (A2) have been shown
to project to the CeA (Jia et al, 1992; Roder & Ciriello, 1993; Roder & Ciriello,
1994; Zardetto-Smith & Gray, 1995). It has been reported that NTS (but not VLM)
ibotenic acid lesions significantly reduce the number of CeA cells activated in
response to IL-P (Buller et al , 2001), thus indicating the importance of these
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brainstem populations in conveying information to the CeA following immune insult
via IL-lp.
The mechanism by which LPS/cytokines activate the HPA axis seems dependent
upon the route of administration. Vagal afferents play an important role in effecting
HPA responses to immune challenge (LPS and IL-ip) following administration via
the intra-peritoneal route (Fleshner et al, 1995). Vagal lesions block ACTH
responses to i.p. LPS and IL-lp and inhibit c-fos mRNA expression in the pPVN and
NTS and inhibit NA release in the PVN (Gaykema et al, 1995a; Fleshner et al, 1997;
Hansen et al, 1998), normally evoked following immune challenge. However,
vagotomy does not significantly affect these responses when LPS and IL-lp are
administered by other routes, e.g. intravenously. Activation of vagal afferents by i.p.
LPS and IL-ip appears to be at least partly dependent upon the production of PGs at
the vagal somata (Ek et al, 1998). Therefore it seems that the participation of vagal
sensory mechanisms in mediating the HPA response to immune challenge is limited
to i.p. delivery of LPS/cytokine or local peritoneal inflammation.
In summary, peripherally administered IL-ip acts on type 1 IL-1 receptors located on
or closely associated with blood vessels at circumventricular organs (one possibility
is the area postrema). This results in the local production of prostaglandins (via COX
pathways), which are soluble and may diffuse through brain parenchyma to activate
brainstem catecholaminergic neurones (see figure 4.1.). These activate PVN CRH
neurones via direct and/or indirect projections (via the CeA and the BNST).
The aim of the present experiments was to determine whether pregnant rats
demonstrate reduced HPA axis responses to immune challenge, and if so to
investigate some of the underlying mechanisms. Immune challenge with i.v.
administration of either LPS or IL-1 P was employed as a physical stressor. There are
several advantages to using immune challenge, firstly LPS/IL-lp can be
administered i.v. via a previously implanted cannula, thus minimising disturbance to
the animal and preventing the introduction of non-specific emotional stressors
through handling and removing the rat from its home cage. Secondly, activation of
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the HPA axis by immune challenge does not rely on the rat's cognitive function or
perception of the stressor, and finally IL-ip acts, at least in part, via a well-defined
monosynaptic pathway.
Noradrenergic inputs to the PVN appear to be important in mediating HPA responses
to immune challenge. In experiment 2, Fos activation was measured in the A2 cell
group (including noradrenaline cells) of the NTS in the brainstem, to establish if
changes here may explain the hyporesponsive nature of the HPA axis to IL-ip in
pregnancy.
Oxytocin is a so-called 'stress hormone' in the rat (Lang et al, 1983). Previous
studies have shown that oxytocin secretion following exposure to forced swimming
is modestly attenuated in late pregnancy. This seems to be a result of enhanced
opioid inhibition of oxytocin neurones (Douglas et al, 1998), as treatment with the
opioid receptor antagonist naloxone, prior to forced swimming, reveals a greatly
enhanced oxytocin secretory response (compared to the virgin group). In the present
experiments plasma oxytocin was measured to establish whether this is affected by
systemic IL-ip. Since endogenous opioids have been shown to restrain oxytocin
secretion in response to stress in late pregnancy, it seemed plausible that they may
also be involved in restraining HPA activity. Previously Douglas et al (Douglas et al
, 1998) have shown that treatment with naloxone reduces the ACTH secretory
response to forced swimming in female virgin rats, whilst causing a modest increase
in ACTH secretion and restoring a corticosterone secretory response in pregnant rats.
Thus the effects of removing opioid inhibition on the HPA axis and the
neurohypophysial oxytocin system in response to immune challenge were measured.
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The aims of this set of experiments were:
(0 to establish whether the HPA axis and oxytocin system was less responsive to
stimulation with LPS and IL-ip in late pregnancy, and if so
(ii) to establish whether this is a consequence of differential activation of the
brainstem NTS neurones in response to IL-ip in pregnancy.
(iii) and investigate a role for endogenous opioids in restraining HPA axis and
oxytocin secretory responses to immune challenge in pregnancy.
4.2. Materials and Methods
4.2.1, Animals
Female Sprague Dawley rats were used throughout this set of experiments and were
maintained under conditions detailed in chapter 2. After surgery all rats were caged
individually.
4.2.2 Surgery
Five days prior to the day of the experiment, virgin and pregnant rats (day 16 of
pregnancy) were fitted with a jugular vein cannula under inhalation of halothane
anaesthesia, as described previously (see section 2.3. of chapter 2).
4.2.3. Experimental Procedure
Blood Sampling
For blood sampling experiments rats had the jugular vein cannula connected to PVC
extension tubing (wall = 1mm, internal diameter = 0.5mm) filled with heparinised
saline (1ml heparin; 5000 units/ml in 100ml 0.9% saline) and attached to a 1ml
syringe, on the morning of the experiment (between 07:30-09:00h). Rats were then
left undisturbed for at least one hour prior to the start of blood sampling.
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The volume of blood withdrawn was dependent upon the eventual assay. For analysis
of oxytocin, 0.3 ml samples were taken, for ACTH, 0.5 ml and for ACTH and
corticosterone 0.6 ml samples were taken. Blood samples taken for analysis of
ACTH or corticosterone were collected into 1 ml syringes containing 5% EDTA and
those taken for oxytocin analysis were collected in syringes containing heparinised
saline (see general methods; chapter 2). In each case blood was stored in eppendorfs
on ice until centrifugation (see general methods). The blood sampling protocol used
was different for each experiment due to different action times of LPS and IL-1J3 on
the HPA axis and hypothalamo-neurohypophysial system. Details of the precise
protocol used are given below.
Experiment 1:
Two basal blood samples (for ACTH) were taken 60 min apart. Following the second
basal sample, rats were administered either lpg/kg lipopolysaccharide (LPS)
endotoxin (2 pg/ml) or 0.9% saline i.v. Four more blood samples were then taken 60,
120, 180 and 240 min after the injection.
Experiment 2:
Two basal blood samples were taken 30 min apart. Following the second basal blood
sample, rats were treated i.v. with either 500 ng/kg human recombinant (rh) IL-1P (1
pg/ml) or the appropriate volume of vehicle (0.2 % bovine serum albumin in
phosphate buffered saline; 0.2% BSA in PBS). Sequential blood samples were
withdrawn 15, 30, 60, 90 and 120 min after the injection. Rats were killed by
conscious decapitation 4h after administration of the IL-ip/vehicle. Trunk blood was
collected into universal tubes containing chilled 5% EDTA solution. After
centrifugation (see General Methods chapter), plasma was separated and stored at -
20°C until radioimmunoassay for ACTH, corticosterone and oxytocin. Brains and
brainstems were rapidly removed and frozen on dry ice for CRH mRNA in situ
hybridisation and Fos immunocytochemistry, respectively.
166
Physical Stressors and the HPA Axis Chapter 4
A separate group of rats was fitted with jugular cannulae as before. On the day of the
experiment, jugular vein cannulae were connected to extension tubing and animals
were left undisturbed for one hour. Each rat was then treated i.v. with either 500
ng/kg rh IL-1 (3 (1 pg/ml) or vehicle (0.2% BSA in PBS). Ninety minutes after the
injection (the optimum time for Fos protein expression) rats were killed by
decapitation. Brainstems were rapidly removed and frozen on dry ice, as before.
Brainstems were then transferred to a -70°C freezer until sectioning and Fos
immunocytochemistry.
Experiment 3:
One basal blood sample was taken (for ACTH). Immediately after the first blood
sample, rats were treated with either 5 mg/kg naloxone (10 mg/ml) or an equivalent
volume of 0.9 % saline, intravenously. One post-naloxone/vehicle blood sample was
withdrawn 15 minutes after the injection. All rats were then treatedadministered i.v.
with 500 ng/kg rh IL-1P (1 pg/ml). Further blood samples (all for ACTH) were taken
15, 30, 60 and 90 min after administration of IL-1 p.
Experiment 4:
One basal blood sample was taken (for oxytocin). Immediately after the first blood
sample, rats were treated with either 5 mg/kg naloxone (10 mg/ml) or vehicle (0.95
saline) i.v. Two post-naloxone/vehicle blood samples were withdrawn 5 and 15 min
after the injection. All rats were then treated with 500 ng/kg rh IL-1 (3 (1 pg/ml) i.v.
Further blood samples (all for oxytocin) were then taken 5, 15, 30 and 60 min after
administration of IL-lp. Rats were killed by decapitation 4 hours after the IL-1P
injection. Brains were rapidly removed (for CRH mRNA in situ hybridisation) and
frozen on dry ice, as before.
4.2.4. In situ hybridisation
Brains for in situ hybridisation were sectioned coronally at 15pm and mounted on
gelatinised slides as previously described in the General Methods chapter. To detect
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CRH mRNA expression a 42-mer oligonucleotide probe was used [MWG-Biotech],
The sequence of the CRH mRNA oligo-probe used is given below. It is
complementary to bases 496-537 which encode amino acids 22-35 of the rat CRH
peptide (Jingami et al, 1985).
5'- CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC-3'
Probe labelling and hybridisation were performed as described in the General
Methods chapter. The post-hybridisation washes were performed in the usual way.
The melting temperature of the CRH mRNA oligo-probe is 78°C, therefore the
heated SSC washes were performed at 58°C. Once dry, the sections were exposed to
autoradiographic film for 21 days at room temperature. CRH mRNA expression in
the PVN was quantified from autoradiographs using a computer based image
analysis system as described in the General Methods Chapter.
4.2.5. Fos Immunocytochemistrv
Brainstem sections (15pm) were cut through the A2 cell region of the nucleus of the
solitary tract (at the level of the area postrema) on a cryostat and mounted on
gelatinised slides. Fos immunocytochemistry was performed using the method
described in section 2.5.1. of the General Methods chapter. Fos positive stained cells
were counted in the NTS in 8-10 sections from each rat. The area of the NTS was
measured using an AppleMac computer and NIH Image software.
4.2.6. Radioimmunoassays
All samples from a particular experiment were always assayed together. Plasma
ACTH and corticosterone concentrations were determined using commercially
available kits (see sections 2.6.1. and 2.7.). The sensitivity was 1 pg/ml and 0.4
ng/ml, respectively and the intra-assay variation was <11% and <6%, for the ACTH
and corticosterone assays respectively. Plasma oxytocin concentration was
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determined using an in-house assay based on a method described by Higuchi et al
(Higuchi et al, 1985). The sensitivity of the assay was 4.4 pg/ml and the intra-assay
variation <12%.
4.2.7. Statistical Analysis
Two way repeated measures analysis of variance (2-way RM ANOVA), followed by
Student-Newman-Keuls multiple comparison test was used to analyse plasma
ACTH, corticosterone and oxytocin data. CRH mRNA and Fos data were analysed




4.3.1. Effects of i.v. LPS on plasma ACTH concentration
Basal plasma concentrations of ACTH were not different between any of the groups.
Administration of isotonic saline had no significant effect on plasma ACTH in either
the virgin or the pregnant group (figure 4.2.). Intravenous LPS induced a significant
increase in plasma ACTH concentration in the virgin group (p<0.001; 2-way RM
ANOVA), which was significantly higher than basal levels within 60 min (70-fold
increase) of the injection, peaked 120 min (85-fold increase) after the injection, and
was still significantly elevated 240 min after LPS administration. However, LPS
evoked only a small increase in plasma ACTH concentration in the pregnant group,
with levels not significantly changed from basal levels (figure 4.2). ACTH secretion
peaked 120 min after the LPS injection and was 137.8 ± 6.9 pg/ml in the virgin
group and 28 ± 8.9 pg/ml in the pregnant group.
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Figure 4.2. The effect of i.v. lipopolysaccharide on plasma ACTH concentrations
in virgin and pregnant rats.
Two basal blood samples were collected 30 minutes apart, prior to i.v. administration
of either 0.9% saline or 1 pg/kg LPS. Further blood samples were withdrawn 60,
120, 180 and 240 minutes post-injection. Values are plotted as group means ± SEM.
Group numbers: virgin/vehicle, n = 10; pregnant/vehicle, n = 7; virgin/LPS, n = 11;
pregnant/LPS, n = 10. Two-way ANOVA for repeated measures followed by Student
Newman-Keuls multiple comparison test was used for statistical analysis of the data:
*p < 0.001 vs basal values in the same group; #p < 0.001 vs all other groups at the
same time point.
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Experiment 2
4.3.2. Effects of i.v. IL-1B on plasma ACTH concentration
Basal plasma ACTH concentrations were not significantly different between any of
the groups (figure 4.3.). Administration of vehicle (0.5 ml/kg) did not affect plasma
ACTH concentrations in either the virgin or the pregnant group. Intravenous
administration of IL-ip caused a rapid increase (3.3-fold) in ACTH secretion within
15 min in the virgin group (p<0.001; 2-way RM ANOVA; figure 4.3.).
Plasma ACTH concentration remained significantly higher than basal levels for 120
min after IL-ip in the virgin group, and although still elevated at 240 min, levels
were not significantly different compared with basal levels. Whereas in the pregnant
group, IL-ip induced only a small increase (1.7-fold) in plasma ACTH
concentration, 30 min after the injection, however this increase was not significant
(figure 4.3.).
4.3.3. Effects of i.v. IL-1B on plasma corticosterone concentration
Basal plasma corticosterone was slightly higher in the pregnant groups, however this
was not significant (figure 4.4.). Vehicle administration had no significant effect on
corticosterone secretion in either the virgin or the pregnant group. Following IL-ip
administration, plasma corticosterone concentration increased significantly within 30
min in the virgin group and was still significantly higher than pre-injection levels at
240 min (p< 0.001; 2-way RM ANOVA). Consistent with the ACTH data, i.v. IL-ip
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Figure 4.4. The effect of i.v. interleukin-1 (3 on plasma corticosterone
concentrations in virgin and pregnant rats.
One basal blood sample was collected prior to i.v. administration of either 0.2% BSA
in PBS or 500 ng/kg rh IL-ip. Plasma from blood samples withdrawn 30 and 90
minutes post-injection and from trunk blood collected 240 min post-injection were
assayed for corticosterone. Values are plotted as group means ± SEM. Group
numbers: virgin/vehicle, n = 9; pregnant/vehicle, n = 6; virgin/IL-1 p, n = 8;
pregnant/IL-lp, n = 7. Two-way ANOVA for repeated measures followed by Student
Newman-Keuls multiple comparison test was used for statistical analysis of the data:
*p < 0.001 vs basal values in the same group; +p < 0.001 and #p < 0.01 vs all other
groups at the same time point.
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4.3.4. Effects of i.v. IL-lfl on plasma oxytocin concentration
Plasma oxytocin concentration was not significantly different under basal conditions
between any of the groups (figure 4.5.). Vehicle administration had no effect on
plasma oxytocin in any of the groups. Following IL-1 (3 administration, plasma
oxytocin concentration was significantly increased in the virgin group, however not
in the pregnant group, although there was a slight increase (34.1 ± 6.3 pg/ml in the
virgin/IL-lp group vs 14.5 ± 8.1 pg/ml in the pregnant group, 15 min after the
injection; figure 4.5.).
4.3.5. Effects of i.v. IL-113 on CRH mRNA expression in the pPVN
In the control groups, CRH mRNA expression in the PVN tended to be less in the
pregnant animals than in the virgins, though this was not significant (figure
4.5.(a,b)). Four hours after IL-lp administration, CRH mRNA expression (measured
by grain area) in the parvocellular region of the PVN was significantly increased in
the virgin group (p<0.001; 2-way ANOVA), however no change in CRH mRNA
expression was observed in the pregnant group (figure 4.6.(a)). Similarly the number
of cells within the pPVN expressing CRH mRNA significantly increased following
IL-ip administration only in the virgin group (figure 4.6.(b, c)).
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Figure 4.5. The effect of i.v. interleukin-ip on plasma oxytocin concentrations in
virgin and pregnant rats.
One basal blood sample was collected prior to i.v. administration of either 0.2% BSA
in PBS or 500 ng/kg rh IL-1 p. Plasma from blood samples withdrawn 15 and 30
minutes post-injection was assayed for oxytocin. Values are plotted as group means
± SEM. Group numbers: virgin/vehicle, n = 9; pregnant/vehicle, n = 6; virgin/IL-ip,
n = 6; pregnant/IL-ip, n = 6. Two-way ANOVA for repeated measures followed by
Student Newman-Keuls multiple comparison test was used for statistical analysis of
the data: *p < 0.001 vs basal values in the same group; #p < 0.001 vs all other groups
at the same time point.
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Figure 4.6.(a) The effect of i.v. interleukin-ip on CRH mRNA expression in the
parvocellular region of the PVN in virgin and pregnant rats.
Rats were treated i.v. with either 0.2% BSA in PBS or 500 ng/kg rh IL-ip. Four
hours after the injection rats were killed by decapitation. Measurements of grain area
were made from film autoradiographs over the pPVN. Values are plotted as group
means ± SEM. Group numbers: virgin/vehicle, n = 10; pregnant/vehicle, n = 11;
virgin/IL-ip, n = 8; pregnant/IL-ip, n = 7. Two-way ANOVA followed by Student
Newman-Keuls multiple comparison test was used for statistical analysis of the data:
*p < 0.001 vs all other groups.
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Figure 4.6.(b) The effect of i.v. interleukin-ip on the number of cells expressing
CRH mRNA in the parvocellular region of the PVN in virgin and pregnant rats.
Rats were treated i.v. with either 0.2% BSA in PBS or 500 ng/kg rh IL-ip. Four
hours after the injection rats were killed by decapitation. Cells positive for CRH
mRNA expression (defined as a cell with more overlying silver grains than the mean
background + 3 standard deviations) were counted in the PVN and the area of the
PVN was measured (using NIH Image 1.62 computer software). The data were
converted to number of CRH mRNA positive cells per mm2 and values are plotted as
group means ± SEM. Group numbers: virgin/vehicle, n = 10; pregnant/vehicle, n =
11; virgin/IL-ip, n - 8; pregnant/IL-ip, n = 7. Two-way ANOVA followed by
Student Newman-Keuls multiple comparison test was used for statistical analysis of
the data: *p <0.001 vs all other groups.
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Figure 4.6.(c) The effect of i.v. interleukin-lp on CRH mRNA expression in the
parvocellular region of the PVN in virgin and pregnant rats: Photomicrographs.
Darkfield autoradiographs of coronal sections through the paraventricular nucleus
hybridised with a S-labelled oligonucleotide probe complementary to CRH mRNA
from: A, virgin/vehicle; B, vigin/IL-iP; C, pregnant/vehicle; D, pregnant/IL-1 p. 3V,
third ventricle; mgPVN, magnocellular division; pPVN, parvocellular division of
PVN. Scale bar: 100pm.
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4.3.6. Effects of i.v. IL-1B on Fos expression in the A2 cell region of the NTS
In the vehicle-treated groups, the number of cells expressing Fos in the A2 cell
region of the NTS was similar in virgin and pregnant rats. IL-ip administration
induced a significant increase in Fos expression in the NTS of both virgin and
pregnant rats killed 90 min after the injection (figure 4.7.(a, c)). There was no
significant difference in the level of Fos expression in the NTS between the virgin
(188.2 ± 25.5 Fos positive nuclei/mm2) and pregnant (176.7 ± 28.7 Fos positive
nuclei/mm2) IL-l(3-treated groups. Similarly, rats killed 4h after IL-1 (3 administration
demonstrated increased levels of Fos expression in the NTS, which was not different
between virgin and pregnant rats (figure 4.7. (b)).
Experiment 3
4.3.7. Effects of pretreatment with naloxone on plasma ACTH responses to i.v.
administration of IL-1 B
Basal levels of plasma ACTH were not significantly different between any of the
groups. Treatment with either 0.9 % saline or naloxone did not significantly affect
basal plasma ACTH concentration in any of the groups (figure 4.8.). IL-ip
administration evoked a rapid increase in plasma ACTH concentration in the vehicle
treated virgin group which peaked within 15 min (63.5 ± 2.8 pg/ml) and this
response was significantly attenuated in the vehicle treated pregnant group (17.9 ±
3.5 pg/ml). Pretreatment with naloxone had no significant effect on the ACTH
secretory response to systemic IL-lp in the virgin group (figure 4.8.), however in the
pregnant group, naloxone significantly enhanced ACTH secretion in response to IL-
ip Cp < 0.001; two-way RM ANOVA). Plasma ACTH concentration in the naloxone
treated pregnant group did not reach the levels observed in the virgin groups
following IL-ip administration (figure 4.8.).
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Figure 4.7.(a) The effect of i.v. interleukin-ip on Fos expression (at 90 min) in
the A2 cell region of the NTS in virgin and pregnant rats.
Rats were treated i.v. with either 0.2% BSA in PBS or 500 ng/kg rh IL-ip. 90 min
after the injection rats were killed by decapitation. Brainstem sections were cut on a
cryostat and processed for Fos immunocytochemistry. Fos positive cells were
counted in the A2 cell region of the NTS (at the level of the area postrema, ~ 13.5-
14.0 mm caudal to Bregma) and the area of the NTS was measured using NIH Image
1.62 software. The data were then converted to Fos positive cells per mm2. Values
are plotted as group means ± SEM. Group numbers: virgin/vehicle, n = 6;
pregnant/vehicle, n = 7; virgin/IL-l(3, n = 6; pregnant/IL-1 p, n = 8. Two-way
ANOVA followed by Student Newman-Keuls multiple comparison test was used for





































Figure 4.7.(b) The effect of i.v. interleukin-ip on Fos expression (at 4h) in the
A2 cell region of the NTS in virgin and pregnant rats.
Rats were treated i.v. with either 0.2% BSA in PBS or 500 ng/kg rh IL-ip. Four
hours after the injection rats were killed by decapitation. Brainstem sections were cut
on a cryostat and processed for Fos immunocytochemistry. Fos positive cells were
counted and data is expressed as before (see figure 4.7.(a) legend). Values are plotted
as group means ± SEM. Group numbers: virgin/vehicle, n = 10; pregnant/vehicle, n =
11; virgin/IL-ip, n = 7; pregnant/IL-ip, n = 7. Two-way ANOVA followed by
Student Newman-Keuls multiple comparison test was used for statistical analysis of
the data: *p < 0.001 vs vehicle.
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Figure 4.7.(c) The effect of i.v. interleukin-ip on Fos expression (at 90 min) in
the A2 cell region of the NTS in virgin and pregnant rats: Photograph.
Coronal sections through rat brainstem showing Fos immunoreactivity in the nucleus
of the tractus solitarius (NTS) from: A, virgin/vehicle; B, virgin/lL-1 P; C,
pregnant/vehicle; D, pregnant/IL-ip. AP, area postrema, CC, central canal; 10,
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Experiment 4
4.3.8. Effects of pretreatment with naloxone on plasma oxytocin responses to i.v.
administration of IL-1B
Basal plasma oxytocin concentration did not differ between any of the groups.
Vehicle administration had no effect on oxytocin secretion in either the virgin or the
pregnant groups (figure 4.9.). Naloxone treatment induced a small increase in plasma
oxytocin concentration in both groups, however this increase was not significant. As
before (see section 4.3.4.) administration of IL-lp evoked a significant increase (5.4-
fold) in oxytocin secretion within 15 min of the injection in the virgin vehicle treated
group but had no effect in the pregnant vehicle treated group (figure 4.9.). Naloxone
pretreatment seemed to further enhance the oxytocin secretory response to IL-ip in
virgin rats, although this was not significant, whereas in the pregnant group,
naloxone significantly increased (8.4-fold and 12.4-fold increase at 15 and 30 min
post-IL-ip injection, respectively) the oxytocin secretory response to IL-ip, which
was greater than in both virgin groups (figure 4.9.).
4.3.9. Effects of naloxone pretreatment on CRH eene responses in the pPVN to
i.v. IL-1B
CRH mRNA expression in the pPVN 4 hours after IL-ip administration was 7.4-fold
greater in the virgin vehicle treated rats compared with the pregnant vehicle treated
rats (figure 4.10.(a)). Naloxone treatment significantly increased CRH mRNA
expression in response to IL-ip in the pregnant group (447% of vehicle treated
pregnant group) and significantly reduced CRH mRNA expression in response to IL-
ip in the virgin group (66% of vehicle treated virgin group).
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Figure 4.9. The effect of pretreatment with naloxone on plasma oxytocin
responses to i.v. interleukin-1 (3 in virgin and pregnant rats.
One basal blood sample was collected, prior to i.v. administration of either 0.9%
saline or 5 mg/kg naloxone (10 mg/ml). Further blood samples were withdrawn 5
and 15 min after the naloxone/vehicle injection, which was immediately followed by
i.v. administration of 500 ng/kg rh IL-ip (lpg/ml). Sequential blood samples were
taken 5, 15, 30 and 60 min after IL-ip administration. Values are plotted as group
means ± SEM. Group numbers: virgin/vehicle, n = 6; pregnant/vehicle, n = 6;
virgin/naloxone, n = 6; pregnant/naloxone, n = 6. Two-way ANOVA for repeated
measures followed by Student Newman-Keuls multiple comparison test was used for
statistical analysis of the data: *p < 0.05 vs basal values in the same group; #p < 0.05
vs all other groups at the same time point.
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Figure 4.10.(a) The effect of naloxone pretreatment on CRH mRNA expression
in the parvocellular region of the PVN following i.v. interleukin-ip in virgin and
pregnant rats.
Rats were treated with either 0.9% saline or 5 mg/kg naloxone (10 mg/ml) i.v.
followed 15 min later by an i.v. injection of 500 ng/kg rh IL-ip (lpg/ml) in all rats.
Four hours after the IL-ip injection the rats were killed by decapitation.
Measurements of grain area were made from film autoradiographs over the pPVN
using the NIH Image 1.62 software package. Values are plotted as group means ±
SEM. Group numbers: virgin/vehicle, n = 6; pregnant/vehicle, n = 6;
virgin/naloxone, n = 6; pregnant/naloxone, n = 7. Two-way ANOVA followed by
Student Newman-Keuls multiple comparison test was used for statistical analysis of
the data: *p < 0.001 vs virgin/vehicle group; #p < 0.001 vs all other groups.
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Figure 4.10.(b) The effect of naloxone pretreatment on CRH mRNA expression
in the parvocellular region of the PVN following i.v. interleukin-ip in virgin and
pregnant rats: Photomicrographs.
Brightfield photographs of autoradiographic film exposed for 21 days to coronal
brain sections hybridised with a 35S-labelled oligo-probe complementary to CRH
mRNA from: A, virgin/vehicle; B, virgin/naloxone; C, pregnant/vehicle; D,
pregnant/naloxone. 3V, third ventricle; mgPVN, magnocellular division of PVN;
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4.4. Discussion
The aim of the present set of experiments was to test whether the responsiveness of
the HPA axis to a specific physical stressor is attenuated in pregnancy as it is to
emotional stressors. The data clearly demonstrate that the HPA axis is less
responsive to systemic immune signals in pregnancy, consistent with the results
observed following exposure to emotional stressors in pregnancy (see chapter 3).
Activation ofthe HPA axis following immune challenge
The results from experiment 1 demonstrate that the HPA axis is activated (reflected
by ACTH secretion) following immune challenge with i.v. LPS in non-pregnant
female rats. These data are consistent with previous studies in male rats (Takemura et
al, 1997; Turnbull et al, 1998). However during late pregnancy (day 21) the ACTH
secretory response to peripheral administration of LPS was strongly and significantly
attenuated. This attenuated HPA axis response to endotoxin induced immune
challenge does not occur as a result of changes in cytokine generation in pregnancy,
since the ACTH and corticosterone secretory responses were also markedly reduced
following stimulation with the cytokine, IL-1 (3 (experiment 2). These changes in
pregnancy are comparable to the attenuation of HPA axis responses previously
discussed following exposure to emotional stressors (restraint and maternal defence)
in chapter 3.
These results are unlikely to reflect an enhanced metabolic clearance of
corticosterone during pregnancy, since the clearance rate of corticosterone is reported
not to differ between virgin and pregnant rats (Waddell & Atkinson, 1994). It is more
likely that the attenuated pituitary and adrenal gland responses to immune challenge
are a consequence of reduced CRH drive. Indeed, CRH mRNA expression in the
pPVN was not stimulated by i.v. IL-1P administration in the pregnant group as it was
in the virgin rats. If it is assumed that CRH gene activation (reflected by increased
CRH mRNA expression) reflects stimulation of the CRH cell bodies which
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simultaneously causes release of pre-formed CRJH from the nerve terminals, it is
likely that less CRH is released from the nerve terminals at the median eminence in
response to IL-ip in the pregnant rats, thus explaining the attenuated ACTH and
corticosterone responses.
Reduced activation of CRH mRNA expression in the pregnant rats following IL-1 (3
could be a consequence of altered neural input. CRH expression is under tonic
stimulatory influence from ascending noradrenergic and adrenergic pathways (Kiss
et al, 1996). Thus if these stimulatory pathways are tonically inhibited or opposed by
an inhibitory input (e.g. GABAergic projections) this could explain why the CRH
neurones are non-responsive in pregnancy. NAergic projections from the NTS to the
PVN have been shown to be important in relaying information from the periphery to
the PVN neurones following activation of the immune system. To test whether these
inputs were activated less by peripheral administration of IL-ip in pregnant rats, Fos
(an immediate-early gene which is rapidly up-regulated when a neurone is activated,
therefore it provides a good indicator of neuronal activation) expression was
evaluated in the A2 cell region (where NA cells are located) of the NTS in the
brainstem, l.v. IL-ip induced similar levels of Fos expression in the A2 cell region of
the NTS in the virgin and pregnant groups, indicating that the NTS neurones were
not differently activated by IL-ip during pregnancy. These results demonstrate that
IL-lp signalling to the noradrenergic NTS neurones is intact in the pregnant rats.
Thus it seems unlikely that signalling mechanisms from blood vessels in response to
systemic IL-ip (involving generation of prostaglandins via COX pathways) are
affected in pregnancy and instead the "breakdown in communication" which prevents
the CRH neurones from responding to systemic IL-1 p occurs somewhere on a
pathway between the NTS neurones and the PVN CRH neurones. Whether the
neurones in the NTS that are activated by IL-1P are noradrenergic neurones needs to
be verified with immunocytochemical double-labelling techniques. There are several
possibilities as to what is happening. When the ascending noradrenergic projections
from the brainstem to the hypothalamus are lesioned bilaterally (by intracerebral
injection of 6-hydroxydopamine), there is a significant reduction in ACTH secretion
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and increases in PVN CRH mRNA expression in response to i.v. IL-ip are virtually
abolished (Melik Parsadaniantz et al, 1995). Thus, brainstem neurones projecting
rostrally, including those projecting to the pPVN, are essential in mediating HPA
axis responses to IL-lp. Here activation of the brainstem NTS neurones was similar
in the virgin and pregnant rats, however it is not known whether these neurones were
noradrenergic, and if so, whether NA release from the nerve terminals was similar in
the two groups. Since NA has been shown to have an excitatory effect on CRH
neurones, differences in NA release may explain the differences in CRH neurone
activation in response to IL-ip. To establish if this is the case it would be necessary
to measure NA release in the PVN by microdialysis following administration of IL-
lp. It is not clear whether changes in NA release in pregnancy would be mediated
through pre- (e.g. inhibition of NA release) or post-synaptic (such as antagonism at
NA receptors or inhibition of the signalling pathways activated by NA binding its
receptor) actions.
In addition to the direct input pathway from the NTS neurones to the PVN, it has
been proposed that brainstem catecholamine cells in the NTS and VLM may also
mediate HPA axis responses to systemic IL-lp indirectly via the CeA and the BNST
(Buller et al, 2001). Therefore if signalling from the NTS to the PVN via these
forebrain structures were somehow disrupted in pregnancy, this could also account
for the reduced responsiveness of the HPA axis to IL-1 p.
Activation ofthe oxytocin system following immune challenge
The oxytocin secretory response to immune challenge with systemic IL-ip was
markedly less in the pregnant group compared with the virgin group. It is likely that
hypothalamic oxytocin neurones are activated following systemic IL-ip by a similar
brainstem input as the CRH neurones. The A2 cell group in the NTS provides a
direct excitatory input to oxytocin neurones in the SON and PVN (Onaka et al, 1995)
and combined retrograde tracing and immunocytochemical studies have shown that a
high proportion of these neuronal inputs are catecholaminergic (Meddle et al, 2000).
Stimulation of this pathway with intravenous cholecystokinin (CCK; which acts via
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the vagus nerve (Smith et al, 1981) to activate brainstem NTS neurones (Luckman,
1992)) activates oxytocin cell bodies in the SON (Verbalis et al, 1991), resulting in
increased firing rate of oxytocin neurones, increased oxytocin secretion and
increased Fos expression in the SON (Onaka et al, 1995). A large body of evidence
indicates that activation of the SON oxytocin neurones by CCK stimulation is
mediated by noradrenaline. Indeed, i.v. CCK induces Fos expression in a
noradrenergic population of cells in the NTS (Luckman, 1992), increases NA release
in the SON and PVN (Kendrick et al, 1991) and destruction of the noradrenergic
innervation to the SON (by selective neurotoxins) blocks Fos expression in the SON
ipsi-lateral to the lesion, but not in the contra-lateral SON or in the NTS (Onaka et al
, 1995). Furthermore, recent evidence suggests that activation of the oxytocin
neurones in the SON at parturition involve a noradrenergic brainstem pathway
(Meddle et al , 2000; Douglas et al, 2001). Thus in the present experiments it is
possible that oxytocin secretion in the virgin rats following systemic administration
of IL-lp is a consequence of activation of a noradrenergic pathway from the NTS. If
this is the case then it is likely that, noradrenergic signalling is interrupted between
the NTS and the magnocellular oxytocin neurones in late pregnancy, since the NTS
neurones were activated similarly by IL-ip in virgin and pregnant rats.
Effect ofopioids on HPA axis responses to immune challenge
Endogenous opioids have previously been shown to actively inhibit oxytocin
secretion following stress in late pregnancy (Douglas et al, 1993; Douglas et al,
1995). More recently it has been shown that blocking the actions of endogenous
opioids with naloxone, causes a reduction in the ACTH secretory response to forced
swimming in virgin female rats and evokes a moderate (though not significant)
increase in ACTH secretion in late pregnant rats exposed to forced swimming
(Douglas et al, 1998). Thus it seemed plausible that opioids may act to restrain HPA
axis responses to IL-ip in pregnancy. Here pretreatment with naloxone did indeed
reinstate an ACTH response to IL-ip administration in the pregnant group, although
ACTH secretion in the pregnant rats did not reach the levels observed in the virgin
group. These data strongly suggest a role for endogenous opioids in the attenuated
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ACTH secretory response to peripheral administration of IL-ip. It is likely that some
other factor contributes to the attenuated HPA axis responses to IL-1 p in pregnancy
since naloxone treatment only partially restored an ACTH response in the pregnant
rats. However the ACTH secretory response to IL-ip in the pregnant rats may not be
maximal due to reduced stimulation of pituitary corticotropes by AVP as a result of
reduced drive to the pPVN AVP neurones in late pregnancy (reflected by decreased
AVP hnRNA expression, see Chapter 3).
Naloxone pretreatment also restored a response to IL-1 p at the level of the CRH
neurones in the pregnant group, as indicated by increased CRH mRNA expression.
In contrast to the lack of effect of naloxone on the ACTH response in virgin rats,
naloxone resulted in an attenuated PVN CRH mRNA response to IL-ip in the virgin
group. A similar effect of naloxone has previously been reported on ACTH secretion
in virgin rats (Douglas et al , 1998). The apparent discrepancy between the ACTH
and CRH mRNA results in the virgin-naloxone treated group may reflect that the
relationship between CRH neurone activation and the ACTH secretory response was
at the top end of the CRH-ACTH dose-response curve. The CRH mRNA data
indicate that the effects of endogenous opioids switch from being excitatory in non¬
pregnant rats to being inhibitory in pregnant rats. Indeed, pretreatment with morphine
has been shown to potentiate stress-induced increases in hypothalamic CRH and
plasma ACTH levels in vivo (Buckingham, 1982) in male rats. Furthermore,
incubation of isolated hypothalami (from male rats) with either morphine, met-
enkephalin or leu-enkephalin induces CRH secretion, effects which can be blocked
by treatment with naloxone (Buckingham, 1982). Here, administration of naloxone
prior to stimulation with IL-1 p has revealed an inhibitory action of opioids on HPA
activity in the pregnant rats. A similar effect has been reported following forced
swimming (Douglas et al , 1998), where blocking the actions of opioids with
naloxone resulted in an attenuated ACTH secretory response to forced swimming in
virgin rats, but caused a modest increase in ACTH secretion in the pregnant rats
exposed to swim stress. Together these data further support a role for differential
actions of opioids in virgin and pregnant rats.
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The opioid receptor type involved in mediating these effects on HPA activity cannot
be established from these experiments, however it is possible that the opposing
actions of opioids observed in virgin and pregnant rats is mediated through different
opioid receptor subtypes. At the dose used, naloxone will be able to act on all opiate
receptors and specific receptor antagonists are necessary to ascertain the receptors
involved. Previous studies have indicated that the hypothalamus is almost completely
devoid of 5-binding sites (Mansour et al, 1987) suggesting that these receptors are
unlikely candidates in HPA axis regulation. Blockade of p-receptors with specific
antagonists abolishes the ACTH response to surgical stress in male rats (Cover &
Buckingham, 1989) suggesting that opioids acting on these receptors mediate an
excitatory effect on HPA activity. Thess data together with the present findings
suggest that in the virgin rats naloxone may be blocking p-receptors, thus causing an
attenuated CRH mRNA response to systemic IL-ip administration. In contrast,
blockade of K-receptors results in exaggeration and prolongation of the stress
response (Cover & Buckingham, 1989). In the pregnant group naloxone may be
acting by blocking opioid binding to K-receptors, thus removing a tonic inhibitory
effect on HPA activity. This could explain the restoration of a HPA response to IL-
ip in the pregnant group pretreated with naloxone. On the other hand, pregnancy
may involve activation of an inhibitory p-opioid mechanism that functions to restrain
HPA activity, as is the case for endogenous opioid restraint of oxytocin neurones at
this time (Douglas et al, 1995).
The origin of the endogenous opioids responsible for restraining HPA activity in the
pregnant group is not known. One likely region however is the arcuate nucleus. P~
endorphin cells in the arcuate nucleus are known to project to the PVN where the
former have been shown to terminate on CRH neurones (Drolet et al, 2001). In late
pregnancy (by day 21) there is an increase in the number of arcuate neurones
expressing POMC and its protein product P-endorphin (personal communication
with A.J. Douglas). Therefore these opioid neurones in the arcuate nucleus may play
an important role in modulating CRH release in response to stress. Enkephalin is co-
expressed with CRH in pPVN cells, however since very few of these neurones are
activated in pregnant rats following stress it seems unlikely that opioids from this
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source are acting to restrain CRH secretion. Opioids (such as enkephalins and
dynorphins) are synthesised by neurones in the NTS (Bronstein et al, 1992;
Ceccatelli et al, 1992) and retrograde labelling has shown that noradrenergic
neurones project to the PVN (Ericsson et al , 1994). It is therefore conceivable that
opioids may be co-expressed in the brainstem NTS noradrenergic neurones that
innervate the PVN. If this is indeed the case, these neurones may be the same NTS
neurones found here to be activated by IL-ip administration. Moreover, if these
opioids are co-released with NA in response to immune challenge then it is plausible
that in pregnancy the amount of opioids being released is increased, which may then
act on the NA neurones themselves to limit NA release or on CRH neurones to
inhibit their responses. Indeed pro-enkephalin (pENK) and p-opioid receptor mRNA
expression in brainstem NTS neurones has recently been shown to be significantly
elevated in late pregnancy (Meddle et al, 2001).
Effect ofopioids on oxytocin secretory responses to immune challenge
Endogenous opioids actively restrain oxytocin secretion during late pregnancy, and
this may enable the posterior pituitary to accumulate oxytocin stores in preparation
for parturition when large amounts of oxytocin are required for uterine contraction
(reviewed in (Russell & Leng, 1998)). To test whether endogenous opioids were
actively restraining oxytocin secretion in response to i.v. IL-ip, rats were pretreated
with the opioid receptor antagonist, naloxone. Administration of naloxone evoked a
modest, though insignificant increase in basal plasma oxytocin concentration in both
the virgin and the pregnant rats. However naloxone pretreatment revealed a hyper¬
secretion of oxytocin in response to IL-ip in the pregnant rats. These data indicate
that in pregnancy the oxytocin secretory response to immune challenge is restrained
by endogenous opioids. A similar response has been observed in pregnant rats
following exposure to forced swimming (Douglas et al, 1998; Neumann et al, 1998).
Thus when opioid inhibition is blocked by naloxone an exaggerated oxytocin
response is unmasked in the pregnant group. This hypersecretion of oxytocin in
response to IL-1(3 may, in part reflect expanded neurohypophysial stores of oxytocin,
however it may also be a consequence of increased drive to the oxytocin neurones
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and/or enhanced opioid tone on either the oxytocin cells themselves or their
excitatory inputs (e.g. noradrenergic nerve terminals). Indeed, evidence reported by
Douglas et al would support this theory. They demonstrated that treatment with
naloxone potentiates the increase in firing rate of oxytocin neurones in the SON
induced by CCK in day 21 pregnant rats (but not in 16 day pregnant or virgin rats)
(Douglas et al, 1995), indicating that increased activation of oxytocin cell bodies in
response to excitatory stimuli is masked by enhanced opioid inhibition in late
pregnancy. The functional significance of oxytocin release in response to IL-1 (3, as
observed in the virgin group is not clear. Elevated levels of oxytocin following stress
(but not basal oxytocin) have been reported to potentiate the ACTH response to
exogenously administered CRH in vivo (Rivier & Vale, 1985), therefore oxytocin
may be involved in modulating activity of the HPA axis in response to stress.
However, the effects of oxytocin in the periphery, with regard to facilitating adaptive
responses to stress are not clear. Oxytocin has been reported to increase both heart
rate and blood pressure (Ishizuka et al, 1993) which may help to facilitate "fight-
flight" responses. Oxytocin can also act on the thymus gland to enhance T cell
growth (Geenen et al, 1989), which clearly may be important in response to immune
challenge.
Summary and Conclusions
Thus in pregnancy the responsiveness of the HPA axis to immune challenge with
LPS and IL-1(3 (physical stressors) is markedly attenuated, as it is following
exposure to the emotional stressors described in Chapter 3. The reduction in ACTH
and corticosterone secretion following IL-1 p administration is probably a
consequence of reduced drive by CRH neurones. The failure of the CRH neurones to
respond to IL-1P in the pregnant rats is not a consequence of interrupted cytokine
signalling to brainstem neurones in pregnancy, since the Fos study indicated that the
NTS neurones were similarly activated by IL-1 p in the virgin and pregnant groups.
Thus the mechanisms that limit activation of the pPVN CRH neurones in response to
immune challenge in pregnancy lie somewhere between the brainstem NTS neurones
and the PVN. These mechanisms are likely to involve endogenous opioids, since
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removing opioid inhibition in pregnancy reinstated an ACTH response and CRH
mRNA response to IL-1 (3. Other mechanisms, not yet studied may involve changes
in signalling from the NTS to the PVN via forebrain structures such as the CeA and
the BNST (Buller et al, 2001).
Similarly the oxytocin secretory response to IL-1 p is also significantly attenuated in
pregnancy, however in this case pretreatment with naloxone, does not only reinstate
an oxytocin response, instead it "unmasks" an exaggerated oxytocin response to IL-
ip. The functional relevance of this strong opioid restraint over oxytocin secretion to
stress in pregnancy, is probably concerned with expanding posterior pituitary stores
for when they are required at parturition.
A distinctive pattern is beginning to emerge from the data presented in this and the
previous chapter; this is that the HPA axis seems to be less responsive to both
emotional and physical stressors in late pregnancy. Could it be that the HPA axis is
less responsive to all stimuli in pregnancy? To address this question, the
responsiveness of the HPA axis to metabolic signals is investigated in the next
chapter.
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5.1. Introduction
The hypothalamus plays a major role in maintaining energy homeostasis by
controlling food intake and body weight. Two main brain areas involved have been
identified as the ventromedial hypothalamus (VMH), also termed the "satiety centre"
and the lateral hypothalamus (LHA) or "hunger centre" (for review see (Bray et al,
1990)). Electrical stimulation of the VMH suppresses food intake, whereas
stimulation of the LHA induces food intake. Bilateral lesioning of the VMH induces
hyperphagia and obesity whereas lesioning of the LHA results in reduced food intake
leading to anorexia.
5.1.1. Orexins
Three years ago, two novel hypothalamic peptides were identified and characterised.
These neuropeptides were named orexin-A and orexin-B (from the Greek word for
appetite, orexis) (Sakurai et al, 1998). Both orexin-A and orexin-B (also known as
hypocretins 1 and 2) (De Lecea et al, 1998) have been shown to stimulate food
intake (De Lecea et al , 1998; Sakurai et al , 1998), but they also have arousing
actions.
Orexin-A is a 33-residue peptide and orexin-B is a 28-residue peptide. Both orexins
are produced by the same 130 amino acid precursor protein, pre-pro-orexin, and
share 46% amino acid homology. There are two types of orexin receptors, the orexin-
1 (OXi) receptor and orexin-2 (OX2) receptor, which belong to the G-protein coupled
receptor superfamily and share 64% sequence homology (Muhtashan et al, 2000).
Orexin-A has highest affinity for the OXi receptor, while the OX2 receptor binds
both orexin subtypes, the affinity for orexin-B is 10-fold higher than for orexin-A
(Muhtashan et al, 2000).
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5.1.2. Distribution of Orexin and Orexin Receptors
In the rat brain, pre-pro-orexin mRNA and immunoreactive orexin-A expression is
restricted to neurones within the lateral hypothalamus (LHA), a region classically
implicated in the central regulation of feeding behaviour and energy homeostasis
(Bernardis & Bellinger, 1993; Bernardis & Bellinger, 1996) and perifornical
hypothalamus (Date et al, 1999), whereas orexin neuronal fibres are widely
distributed throughout the brain, with widespread projections to the olfactory bulb,
cortex, thalamus, hypothalamus and brainstem. Orexin containing nerve fibres are
abundant in the paraventricular thalamic nucleus (PVT), dorsal raphe nucleus
(DRN), central gray, median raphe nucleus. Moderate numbers of orexin fibres are
also present in the PVN (excluding the lateral magnocellular division), locus
coeruleus (LC), olfactory bulb, amygdala, suprachiasmatic nucleus (SCN),
supramamillary nucleus, nucleus of the solitary tract (NTS) and the dorsal motor
nucleus of the vagus (Date et al, 1999).
Messenger RNA for both orexin receptors is widely distributed throughout the brain.
Within the hypothalamus OXi receptor mRNA is most abundant in the ventromedial
nucleus (VMH), whereas OX2 receptor mRNA is predominantly expressed in the
PVN. These sites may be important for receiving orexigenic inputs from the LHA
and the posterior hypothalamus since both the PVN and VMH have been implicated
in feeding behaviour (Kalra et al, 1991).
5.1.3. Functions of Orexins
The majority of studies investigating the function of orexins have focussed on their
physiological roles in feeding behaviour, energy homeostasis and the sleep/wake
cycle. I.c.v. administration of either orexin-A or orexin-B stimulates food intake in a
dose-dependent manner (Sakurai et al , 1998; Haynes et al, 1999; Edwards et al,
1999), while withdrawal of food for 48h hours causes up-regulation of hypothalamic
pre-pro-orexin mRNA expression in rats (Sakurai et al, 1998). The effects of orexin-
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A are longer lasting than those of orexin-B. Two hours after i.e.v. injection, orexin-B
has little effect on stimulation of food intake, whereas the effects of orexin-A persist
4 hours after the injection (Sakurai et al, 1998). However both are significantly less
potent in stimulating food intake when compared with neuropeptide Y (NPY; another
appetite stimulating peptide) (Edwards et al, 1999).
The site at which orexins exert this effect is not known, however centrally
administered orexin-A induces neuronal activation (indicated by c-fos mRNA
expression) in the PVN, arcuate nucleus and the VMH (Edwards et al , 1999). The
PVN has been reported to be an important area in regulation of food intake and is the
major site of action for many orexigenic agents, including NPY (Stanley &
Leibowitz, 1984) and galanin (Tempel et al, 1988), however little is known about the
output pathways from the PVN involved in regulating food intake. Furthermore, the
PVN and arcuate nucleus are the major sources of expression of endogenous NPY
(Chronwall et al, 1985) and lesioning studies have indicated the VMH is an
important area in regulating food intake (Bray, 1984). The presence of orexin
receptors in these brain areas further implicates them as participating in the actions
exerted by orexin on food intake. The wide distribution of orexin fibres suggests that
orexins play an important role in other physiological functions besides feeding,
indeed recently it has been demonstrated that orexins increase gastric acid secretion
(Takahashi et al, 1999) as well as increasing blood pressure and heart rate (Samson
et al, 1999). Other behaviours, besides feeding, have also been reported to increase
following central administration of orexins, including face washing, grooming,
burrowing and exploring (Ida et al, 1999). Furthermore, orexin has been reported to
be involved in regulating the sleep-wake cycle (Hagan et al, 1999).
Narcolepsy is a neurological disease that affects both humans and animals. It is
characterised by the sudden onset of sleep at times when it would not normally occur
(eg. during the daytime in humans), uncontrollable bouts of rapid eye movement
(REM) sleep and episodes of cataplexy (sudden and temporary paralysis) (Chemelli
et al, 1999). Recent breakthroughs in canine narcolepsy demonstrated that a mutation
in the orexin-2 receptor gene are the underlying cause behind the disease (Lin et al,
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1999), suggesting a possible connection between orexins and regulation of the sleep-
wake cycle. Orexin knockout mice also show symptoms of narcolepsy (Chemelli et
al , 1999) and in human narcolepsy, there is a reduction in the number of orexin
neurones in the brain (Thannickal et al, 2000). These findings that dysfunctional
orexin receptors and the removal of orexin pathways both lead to narcolepsy
emphasises that orexin pathways play an important role in arousal and sleep
regulation. Thus, in addition to their effects on feeding behaviour, orexins are also
believed to be involved in increasing arousal and locomotor activities.
5.1.3. Regulation of Appetite and Energy Homeostasis
The pancreatic hormone insulin, and leptin a hormone secreted by adipocytes, are the
two key signalling hormones involved in regulating energy homeostasis. Both
hormones circulate at levels proportional to body fat content (Bagdade et al, 1967;
Considine et al, 1996) and enter the CNS in levels proportionate to their
concentration in plasma (Baura et al, 1993; Schwartz et al, 1996b). Receptors for
both leptin and insulin are present in brain areas involved in appetite/energy
regulation (Baskin et al, 1988; Cheung et al, 1997; Baskin et al, 1999). Leptin and
insulin act on specific neurones in the hypothalamus to stimulate neural circuits that
inhibit food intake and increase energy expenditure and inhibit other neural circuits
that increase food intake and reduce energy expenditure.
Besides orexins, several other hypothalamic neuropeptides have been implicated in
controlling energy homeostasis (see table 5.1.).
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Stimulates Feeding Inhibits Feeding
Neuropeptide Y (NPY) Pro-opiomelanocortin (POMC)
Agouti Related Peptide (AGRP) a-Melanocyte Stimulating Hormone
(oc-MSH)
Orexins (A and B) Corticotropin Releasing Hormone (CRH)
Melanin Concentrating Hormone (MCH) Cocaine & Amphetamine Regulated
Transcript (CART)
Galanin Thyroid Releasing Hormone (TRH)
Interleukin-ip (IL-ip)
Table 5.1. Neuropeptides involved in control of energy homeostasis
Neuropeptide Y (NPY) and Agouti related peptide (AGRP) are colocalised in a set of
arcuate nucleus neurones (Hahn et al, 1998; Broberger et al, 1998). Pro¬
opiomelanocortin (POMC) and cocaine and amphetamine regulated transcript
(CART) are colocalised in another set of arcuate nucleus neurones (Elias et al, 1998).
These neurones are thought to provide an important pathway for leptin signalling to
the brain. Indeed most NPY/AGRP and POMC/CART neurones coexpress leptin
receptors (Cheung et al, 1997; Baskin et al, 1999) and are regulated by leptin in an
opposing manner. NPY/AGRP neurones are inhibited by leptin (Stephens et al, 1995;
Schwartz et al, 1996a; Hahn et al , 1998; Broberger et al , 1998), while
POMC/CART neurones are stimulated by leptin (Thornton et al, 1997; Schwartz et
al, 1997; Kristensen et al, 1998).
The PVN, PFA and LHA all receive rich innervation by axons from the arcuate
nucleus NPY/AGRP and POMC/CART neurones (Elmquist et al, 1999). Orexin
neurones are thought to be under the influence of these inputs: inhibited by the
POMC/CART input and stimulated by the NPY/AGRP input from the arcuate
nucleus.
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5.1.3. Effects of Orexins on the HPA Axis
The HPA axis is involved importantly in metabolic regulation via the action of
corticosterone on glucose mobilisation (Wahlestedt et al, 1987; Hanson & Dallman,
1995), and it is now clear that factors regulating appetite also affect HPA axis
activity. It has recently been reported that i.e.v. administration of orexin-A elevates
plasma ACTH and corticosterone in non-stressed rats (Jaszberenyi et al, 2000; Ida et
al, 2000). This pituitary-adrenal activation is associated with the induction of c-fos
mRNA in the parvocellular division of the PVN (pPVN) (Jaszberenyi et al , 2000),
suggesting the involvement of orexins on HPA axis activity. Moreover, pretreatment
of rats with the CRH antagonist, a-helical CRH has been shown to block the
behavioural effects of centrally administered orexin-A (Ida et al , 2000) and
completely abolish the corticosterone response evoked by orexin-A and orexin-B
(Jaszberenyi et al, 2000). These data suggest that orexin-A may be acting centrally
and that its effects are mediated via secretion of CRH. Al-Barazanji and colleagues
recently reported that in addition to the induction of c-fos in the pPVN following
i.c.v. injection of orexin-A, there is an increase in CRH and AVP mRNA expression
in this region (Al-Barazanji et al, 2001). This finding further supports a role for CRH
in mediating the action of orexin-A but also implicates a mediatory role for AVP.
In chapter three, it was suggested that the attenuated responsiveness of the HPA axis
during pregnancy is likely to be a consequence of the CRH neurones or the pathways
impinging upon them being less responsive to the stressors used. If indeed the CRH
neurones are less responsive, it follows that they should also respond less to other
stimuli. Since orexin-A has been shown to activate the HPA axis at a central level it
provides a convenient model in which to study this hypothesis. Thus, the aim of the
present study was to seek changes in the responsiveness of the HPA axis to centrally
administered orexin-A during pregnancy.
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5.2. Materials and Methods
5.2.1. Animals
Female Sprague Dawley rats were used throughout this set of experiments and were
maintained under conditions detailed in chapter 2. After surgery all rats were caged
individually.
5.2.2 Surgery
Five days prior to the day of the experiment, virgin and pregnant rats (day 16 of
pregnancy) were fitted with jugular vein and intracerebroventricular (i.c.v.) cannulae
under halothane anaesthesia, as described previously (see section 2.3. of chapter 2).
5.2.3. Experimental Procedure
On the morning of the experiment (between 07:30-09:00h), rats had the jugular vein
cannula connected to PVC extension tubing (wall = 1mm, internal diameter =
0.5mm) filled with heparinised saline (1ml heparin; 5000 units/ml in 100ml 0.9%
saline) and attached to a 1ml syringe. I.c.v. cannulae were prepared as follows. The
cannula was attached to polythene tubing (wall = 0.5mm, internal diameter = 0.5mm)
and then filled with ddH20. Using a Hamilton syringe, 2(0,1 of either orexin-A (0.5|og
or 140 pmoles orexin-A [Sigma]) or vehicle (artificial cerebrospinal fluid, aCSF) was
drawn into the tip of the cannula and separated from the ddH20 by a small air
bubble. The dummy i.c.v. cannulae were removed and i.c.v. injection cannulae
(containing either drug or vehicle) were inserted into the guide cannula. Rats were
then left undisturbed for two hours, prior to the start of blood sampling.
Blood Sampling
In each case, 0.5 ml blood samples were withdrawn into 1ml syringes containing 50
pi of chilled 5% EDTA. Blood was stored in eppendorfs on ice until centrifugation
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(see general methods). Two basal blood samples (0.5ml) were taken 30 minutes
apart. Following the second basal sample, rats were treated with either 2pl orexin-A
(0.5pg) or aCSF i.c.v., over a period of ~30 seconds. Sequential blood samples were
then taken 10, 20, 30, 60, 90 and 120 minutes after the i.c.v. infusion. The volume of
blood withdrawn was replaced with an equal volume of 0.9% sterile saline. Rats
were killed by decapitation 4 hours after the i.c.v. infusion. Brains and brainstems
were removed, frozen and stored as before (chapter 2).
5.2.4. In situ hybridisation
Brains were sectioned coronally at 15 pm and mounted on slides as previously
described in the general methods chapter. To detect CRH mRNA expression a 42-
mer oligonucleotide probe was used [MWG-Biotech]. The sequence of the CRH
mRNA oligo-probe used is given below. It is complementary to bases 496-537 which
encode amino acids 22-35 of the rat CRH peptide (Jingami et al, 1985).
5'- CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC-3'
Probe labelling and hybridisation were performed as previously described. The post-
hybridisation washes were performed in the usual way. The melting temperature of
the CRH mRNA oligo-probe is 78°C, therefore the heated SSC washes were
performed at 58°C. Once dry, the sections were exposed to autoradiographic film for
21 days at room temperature. CRH mRNA expression in the PVN was quantified
from autoradiographs using a computer based image analysis system as described in
the general methods chapter.
5.2.5. Radioimmunoassays
Plasma ACTH and corticosterone were determined using commercially available kits
(see sections 2.6.1. and 2.7.). The sensitivity was 1 pg/ml and 0.4 ng/ml, respectively
and the intra-assay variation <11% and <6%, for the ACTH and corticosterone
assays respectively.
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5.2.6. Behavioural Measurements
The number of 'grooming behaviour events' was recorded during the two hours
immediately following the i.e.v. injection. Face and head washing, body grooming,
genital licking and tail cleaning were all included as measures of grooming
behaviour for the purpose of this study.
5.2.7. Statistical Analysis
Two way repeated measures analysis of variance (2-way RM ANOVA), followed by
Student-Newman-Keuls multiple comparison test was used to analyse plasma ACTFI
and corticosterone data. CRT! mRNA was analysed using a two way ANOVA.
Behavioural data were analysed using a Student t-test. P values less than 0.05 were
considered statistically significant.
5.3. Results
5.3.1. Effects of i.c.v. orexin-A on plasma ACTH and corticosterone
Basal plasma concentrations of ACTH and corticosterone did not differ between any
of the groups. I.c.v. administered aCSF had no significant effect on plasma ACTH in
both the virgin and pregnant groups (figure 5.1.). However, the virgin rats treated
with aCSF tended to display slightly higher levels of ACTH than the pregnant group,
although this was not significant. I.c.v. infusion of orexin-A induced a rapid rise in
plasma ACTH concentration in the virgin group (p<0.001; 2-way RM ANOVA),
which was significantly higher than basal levels within 10 minutes of the infusion
(71.2 ± 14.3 vs 22.4 ± 2.9 pg/ml), and remained elevated for 90 minutes (figure 5.1.).
However, orexin-A failed to evoke any such effect on plasma ACTH in the pregnant
group, with levels unchanged from pre-infusion values (figure 5.1). At 20, 30, 60 and
90 minutes after orexin-A administration, plasma ACTH concentration was
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Figure 5.1. The effect of i.c.v. orexin-A on plasma ACTH concentrations in
virgin and pregnant rats.
Two basal blood samples were collected 30 minutes apart, prior to i.c.v.
administration of either aCSF or orexin-A (0.5pg). Further blood samples were
withdrawn 10, 20, 30, 60, 90 and 120 minutes post-infusion. Values are plotted as
group means ± SEM. Group numbers: virgin/vehicle, n = 5; pregnant/vehicle, n = 6;
virgin/orexin-A, n = 5; pregnant/orexin-A, n = 8. Two-way ANOVA for repeated
measures followed by student Newman-Keuls multiple comparison test was used for
statistical analysis of the data: *p < 0.001 vs basal values in the same group; #p <
0.002 vs all other groups at the same time point.
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significantly higher in the virgin group compared with the pregnant group. During
this time plasma ACTH concentration in the virgin/orexin-A group was on average
4.2-fold higher than in the pregnant/orexin-A group.
Infusion of vehicle had no significant effect on plasma concentrations of
corticosterone in either the virgin or the pregnant group (figure 5.2.). Administration
of orexin-A induced a significant increase in corticosterone secretion only in the
virgin group and had no effect in the pregnant rats (figure 5.2.). In the virgin group
plasma corticosterone was significantly elevated from basal levels within 20 minutes
of the orexin-A infusion (188.4 ± 46.3 vs 63.1 ± 9.7 ng/ml) and remained elevated at
120 minutes after the treatment.
5.3.2. Effects of i.c.v. orexin-A on CRH mRNA expression in the pPVN
Quantification of autoradiographs revealed that CRH mRNA expression in the pPVN
of pregnant rats treated with aCSF was significantly less (by 78%) compared with the
virgin group (p < 0.001; figure 5.3.). Orexin-A administered i.c.v. evoked a
significant increase in CRH mRNA expression in the virgin group, however this
response was absent in the pregnant group (0.408 ± 0.025 vs 0.095 ± 0.02,
respectively; arbitrary units; figure 5.3.). The level of CRH mRNA expression in the
PVN was 4.3-fold greater in the virgin/orexin-A group compared with the
pregnant/orexin-A group (figure 5.3.).
7.3.3. Effects of i.c.v. orexin-A on grooming behaviour
I.c.v administration of aCSF had no significant effect on grooming behaviour in
either of the groups (figure 5.4.). Administration of orexin-A into the lateral ventricle
significantly increased grooming behaviour to a similar extent in both the virgin and
the pregnant groups (4.5 ± 0.85 vs 3.5 ± 0.96 'grooming events'/ 60 min,
respectively; p< 0.03; see figure 5.4.).
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Figure 5.2. The effect of i.c.v. orexin-A on plasma corticosterone concentrations
in virgin and pregnant rats.
One basal blood sample was collected before i.c.v. administration of either aCSF or
orexin-A (0.5pg), followed by further blood samples 20, 60, 120 minutes post-
injection. Values are plotted as group means ± SEM. Group numbers as before (see
figure 5.1. legend). Two-way repeated measures ANOVA followed by Student
Newman-Keuls multiple comparison test was used for statistical analysis of the data:
*p < 0.001 vs basal values in the same group; fp < 0.03 vs all other groups at the

























Figure 5.3.(a) The effect of i.c.v. orexin-A on CRH mRNA expression in the
PVN of virgin and pregnant rats.
Rats were killed 4 hours after administration of either orexin-A (0.5pg) or aCSF.
Coronal brain sections were hybridised with 35S-labelled oligonucleotide probe for
CRH mRNA. Autoradiographs were quantified by computer based image analysis.
Values plotted are group means ± SEM for grain area (mm2/mm2). Group numbers:
virgin/vehicle, n = 5; pregnant/vehicle, n = 8; virgin/orexin-A, n = 8;
pregnant/orexin-A, n = 9. Two-way ANOVA followed by student Newman-Keuls
multiple comparison test was used for statistical analysis of the data: +p < 0.001 vs
virgin/vehicle group; *p < 0.001 vs all other groups; #p < 0.001 vs virgin/orexin-A
group.
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Figure 5.3.(b) The effect of i.c.v. orexin-A on CRH mRNA expression in the
PVN of virgin and pregnant rats: Photomicrographs.
Darkfield autoradiographs of coronal sections through the paraventricular nucleus
hybridised with a 3sS-labelled oligonucleotide probe complementary to corticotropin
releasing hormone from: A, virgin/vehicle; B, virgin/orexin-A; C, pregnant/vehicle;
D, pregnant/orexin-A. 3V, third ventricle; mgPVN, magnocellular division of PVN;
pPVN, parvocellular division of PVN. Scale bar: 100pm
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Figure 5.4. The effects of i.c.v. orexin-A on grooming behaviour in virgin and
pregnant rats.
Grooming behaviour was recorded after administration of either i.c.v. aCSF or
orexin-A. Values are plotted as group means ± SEM. Group numbers as before (see
figure 5.3. legend). Student's t-test was used to analyse the data: *p < 0.03 vs vehicle
treated group.
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5.4. Discussion
The present study has demonstrated that i.e.v. administration of orexin-A evokes
HPA axis activation in conscious virgin female rats, consistent with previous studies
in male rats (Jaszberenyi et al , 2000; Al-Barazanji et al , 2001). Here the marked
increase in plasma ACTH and corticosterone secretion following treatment with
orexin-A was associated with increased expression of CRH mRNA in the
parvocellular region of the PVN 4 hours after the injection. This is in agreement with
a study which demonstrated increased c-fos mRNA in this region (Kuru et al, 2000)
and another recent study which reported increased CRH and AVP mRNA expression
in the pPVN (Al-Barazanji et al, 2001). However in late pregnant rats, i.e.v. orexin-
A failed to evoke any such increase in plasma ACTH and induced only a non¬
significant rise in corticosterone secretion. Furthermore, orexin-A did not have any
significant effect on CRH mRNA expression in the PVN of pregnant rats. CRH
mRNA levels were significantly attenuated in pregnant rats treated with aCSF
compared with their virgin counterparts. It is possible that injecting fluid into the
brain (albeit vehicle) induces a small stress response, which is attenuated in
pregnancy or that these levels of CRH mRNA expression may reflect basal levels.
This would be consistent with findings reported by Johnstone et al (Johnstone et al,
2000a) which demonstrated attenuated levels of CRH mRNA expression under basal
conditions on day 21 of pregnancy. This may be a consequence of reduced neural
drive or enhanced inhibitory inputs to the CRH neurones at the end of pregnancy.
Orexin-A is considered to exert its effects on the HPA axis by acting centrally at the
level of CRH and/or AVP neurones in the PVN (Jaszberenyi et al , 2000; Al-
Barazanji et al, 2001), although the mechanisms of its actions are not clear (some of
the possibilities are shown in figure 5.5). The present data would support this, in that
the CRH neurones are clearly activated by orexin-A in non-pregnant rats. The PVN
is innervated by orexin-A immunoreactive projections which originate from orexin
cell bodies in the LHA and PFA (Cutler et al, 1999). OX2 receptor mRNA is
predominately expressed in the PVN region (Trivedi et al, 1998) suggesting that if
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the activation of the HPA axis by orexin-A as reported here in virgin females and by
others in male rats (Jaszberenyi et al , 2000; Al-Barazanji et al , 2001) is a
consequence of a direct action of orexin-A at the level of the PVN it is likely that the
orexin type 2 receptor mediates the response (although this cannot be confirmed until
co-localisation of CRH neurones with orexin type 2 receptors has been
demonstrated).
The effects of orexins on HPA axis hormone secretion in non-pregnant animals
strongly resemble those ofNPY (Tsagarakis et al, 1989b; Suda et al, 1993). A recent
study demonstrated that pretreatment with either a NPY antagonist or NPY antiserum
inhibits the corticosterone secretory response to orexin-A (Jaszberenyi et al, 2001).
These data strongly suggest that NPY mediates orexin-induced activation of the HPA
axis. Orexin-containing nerve terminals have previously been shown to synapse on
NPY neurones in the arcuate nucleus (Peyron et al, 1998; Horvath et al, 1999) and
NPY projections from the arcuate nucleus to the PVN are abundant (Liposits et al,
1988; Broberger et al, 1999; Horvath et al , 1999; Li et al, 2000). Thus it may be
hypothesised that under conditions of fasting, orexin neurones in the LHA are
activated, by signals from the periphery (as a result of decreased leptin and insulin).
Activation of these neurones triggers orexin release, which binds to orexin receptors
on NPY neurones in the arcuate nucleus. These activated neurones release NPY in
the PVN inducing activation of parvocellular CRH neurones and consequently the
HPA axis. Here orexin-A was administered i.e.v., meaning it may be acting
anywhere in the brain, so whether orexin is exerting its effects on the HPA axis via a
mediatory action of NPY, or acting directly via its actions on type 2 receptors in the
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Since it is unclear how orexin activates the HPA axis in non-pregnant rats, it is
difficult to predict what adaptations are occur in this signalling pathway in
pregnancy that prevent CRH neurones responding to orexin-A. To date, nothing is
known about orexin receptor expression in pregnancy, however if the orexin
receptors on the NPY neurones in the arcuate nucleus or orexin receptors in the
PVN itself were down-regulated in pregnancy or blocked by an endogenous
antagonist, then it would be expected that orexin would be incapable of activating
CRH neurones. Alternatively, NPY receptors on PVN CRH neurones may be
down-regulated in pregnancy preventing activation of CRH neurones mediated via
NPY.
The activity of CRH neurones projecting to the median eminence may provide
information about centrally projecting CRH neurones. The PVN CRH neurones that
project to the median eminence are non-responsive to stimulation by orexin-A in
pregnancy. Since centrally acting CRH is known to inhibit food intake (Schwartz et
al, 2000), it may be that CRH neurones that project to feeding centres in the brain
are also non-responsive in pregnancy. It would be beneficial to increase appetite in
pregnancy so as to help meet the demands of the fetuses while maintaining a
positive energy balance in the mother. However the behavioural data suggest that
this may not be the case. The experiment was performed in the morning during the
light phase, a time when rats are normally inactive. At the beginning of the
experiment most rats were sleeping/resting. Those given vehicle were found to
become active briefly before settling down again, whereas the rats injected with
orexin-A became more active. Orexin-A administration significantly increased the
incidence of grooming behaviour similarly in both virgin and pregnant rats, and
although not measured, orexin treated rats seemed to demonstrate increased 'oral
motor activity'. The fact that orexin-A induced grooming behaviour at a time when
rats are normally inactive, supports a role for orexin as an arousing peptide.
Grooming behaviour is thought to be induced by increased central release of CRH
(Dunn et al, 1988). So, if centrally projecting neurones were also less responsive to
stimulation by orexin-A in pregnancy, we may expect central administration of
orexin-A to have little effect on grooming behaviour in the pregnant group.
218
Orexin and the HPA Axis Chapter 5
However, no difference in grooming behaviour was observed between the orexin
treated virgin and pregnant rats. It may be that CRH is not the sole factor involved
in orexin-A induced grooming behaviour or that CRH pathways to feeding centres
are differentially regulated from those involved in eliciting grooming behaviour.
This study has clearly demonstrated that the responsiveness of the HPA axis (at all
levels) to the appetite stimulating/arousing peptide, orexin-A is attenuated in late
pregnancy. Taken together with the data from the experiments employing
'psychological' and 'physical' stressors in chapters 3 and 4 respectively, it seems that
in pregnancy an adaptation (or adaptations) occurs which results in a 'global'
attenuation in the responsiveness of the HPA axis to a variety of stimuli.
Collectively the data support the theory that it is indeed the CRH neurones
themselves that are less or even non-responsive. This adaptation seems to occur by
some unknown mechanism activated in late gestation and is evident irrespective of
the nature of the stressor applied. The possible mechanisms involved will be
explored later.
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CHAPTER 6
The role of glucocorticoid negative
feedback in attenuated
hypothalamo-pituitary-adrenal axis
responses to stress in pregnancy
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6.1. Introduction
There are several possible adaptations that may explain the hyporesponsiveness of
the HPA axis to stress in pregnancy. Changes at the level of the anterior pituitary are
likely to be involved, since ACTH secretion is less sensitive to systemically
administered CRH in late pregnancy and the number of CRH binding sites is
significantly reduced from mid-gestation onwards in the rat (Neumann et al, 1998).
Attenuated central drive to the axis may also explain the hyporesponsiveness.
Reduced c-fos mRNA expression has been demonstrated in the PVN and in afferent
processing areas such as the medial amygdala and lateral septum (da Costa et al,
1996) in response to acute restraint stress in late pregnancy, indicating diminished
activation of the neurones in response to stressors.
In chapters 3-5 the role(s) of attenuated forward drive to the PVN neurones and less-
responsive CRH neurones in explaining the hyporesponsiveness in late pregnancy
was discussed. As well as changes in afferent inputs to the PVN and reduced
sensitivity of CRH neurones to stress in pregnancy, changes in the glucocorticoid
feedback signal may also influence the responsiveness of the HPA axis to stressors.
As mentioned earlier (Chapter 1) the stress axis is sensitive to feedback inhibition by
corticosterone under basal and stress conditions, at the level of the anterior pituitary,
hypothalamus and other higher centres (see Chapter 1). Corticosterone exerts its
negative feedback effects through two different types of receptor in the CNS,
mineralocorticoid (MR) and glucocorticoid (GR) receptors. MR mRNA has limited
distribution, being restricted to the hippocampus and lateral septum (Reul & De
Kloet, 1985), whereas GR mRNA expression is more widespread and found in the
hippocampus, amygdala, hypothalamus and brainstem. MRs are -90% occupied
during the normal circadian nadir and are thought to be involved in controlling basal
expression of CRH and AVP (Dallman et al, 1987; Dallman et al, 1994).
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The finding that GRs become occupied in the presence of elevated corticosterone
levels (Reul & De Kloet, 1985) such as after exposure to stress, suggests that these
receptors play an important role in regulating stress induced ACTH secretion.
The effects of corticosterone negative feedback on the HPA axis have been well
described. Adrenalectomy results in a rapid hypersecretion of ACTH (Dallman et al,
1972) with a corresponding increase in POMC mRNA expression in the anterior
pituitary (Jingami et al, 1985a). In the parvocellular PVN, CRH and AVP mRNA
expression increases (Jingami et al , 1985a), as does CRH and AVP peptide
expression. The mechanisms by which glucocorticoids effect feedback on CRH and
AVP gene transcription are unclear, but are thought to involve either a direct
interaction between an occupied GR and a glucocorticoid response element (GRE) in
the promoter region of the AVP gene (Mohr & Richter, 1990; De Kloet et al, 1998)
or an indirect mechanism via transcription factors which switch off transcription
(Bamberger et al, 1996).
Changes in basal ACTH and corticosterone secretion are apparent during pregnancy.
The circadian rise in ACTH secretion diminishes after mid-gestation. Daily
corticosterone levels decline in early pregnancy, reaching their lowest levels by day
10 (Atkinson & Waddell, 1995), however in the second half of pregnancy (~ day 14)
corticosterone secretion increases progressively as term approaches, with no
concomitant rise in ACTH secretion (Atkinson & Waddell, 1995), which probably
reflects changes in the sensitivity of the adrenal gland to ACTH, possibly in response
to increasing levels of oestrogen. It is not clear whether this increase in
corticosterone secretion (the daily mean is 34% higher on day 22 of pregnancy than
in non-pregnant females) will necessarily increase the negative feedback signal, since
CBG levels have been shown to increase in pregnancy (Lohrenz et al, 1967), which
may limit the amount of free circulating corticosterone. Basal expression of CRH and
AVP mRNA in the pPVN is attenuated by day 21 of pregnancy (Johnstone et al,
2000), however whether this is a result of enhanced negative feedback or a
consequence of reduced central drive to these neurones has not been established.
Nevertheless, evidence for enhanced feedback mechanisms has been reported in
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pregnancy. Activity of 11J3-HSD-1 (which predominately acts as a reductase in intact
cells to reactivate corticosterone from inert 11-dehydrocorticosterone) has been
reported to increase in the PVN during the second half of pregnancy (Johnstone et al
, 2000), which would presumably increase local glucocorticoid levels. Furthermore,
levels of GR mRNA expression in the dentate gyrus have been shown to be
significantly higher on day 21 than on day 10 of pregnancy (Johnstone et al , 2000),
suggesting increased sensitivity to corticosterone negative feedback at this time.
However changes in GR expression and lip-HSD activity in pregnancy seem more
likely to represent a mechanism for enhanced 'slow' negative feedback. In fact
pregnant rats may be less sensitive to 'rapid' feedback since acute corticosterone
replacement is less effective in decreasing ACTH in phADX pregnant rats compared
with virgins (Johnstone et al, 2000). To date, the effects of rapid negative feedback
by corticosterone on stress-induced ACTH secretion has not been investigated in
pregnancy.
The present set of experiments was designed to investigate whether glucocorticoid
negative feedback is enhanced in late pregnancy. Two approaches were employed to
investigate this hypothesis. The first was to remove the glucocorticoid feedback
signal. It was not feasible to do this in the traditional way by surgically removing the
maternal adrenal glands, since the foetal adrenals are also known to secrete
corticosterone (from ~ day 18 of pregnancy) which can cross the placenta and enter
the maternal circulation (although this should be limited by placental lip-HSD
(Burton & Waddell, 1994)). Therefore synthesis of corticosterone was blocked
pharmacologically, by administration of a series of metyrapone (a 11 p-
dehydroxylase inhibitor which prevents the conversion of 11-deoxycorticosterone to
corticosterone) injections and a single injection of aminoglutethimide (an inhibitor of
20a-hydroxylase which prevents the conversion of cholesterol to pregnenolone)
using a previously described protocol (Plotsky et al, 1986; Plotsky & Sawchenko,
1987).
In experiment 1, virgin and pregnant rats were treated over a 48h period to induce
pharmacological adrenalectomy (phADX) and the effects of removing glucocorticoid
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feedback on basal HPA activity were investigated. In the second experiment, rats
were again treated to induced phADX and this time the effects of blocking
corticosterone negative feedback on stress-induced responses were investigated. In
the final experiment, rats were pretreated with corticosterone, prior to exposure to
forced swimming, and the effects of enhanced rapid corticosterone negative feedback
on stress responses were measured in virgin and pregnant rats.
The aims of each experiment were:
Experiment 1: to determine whether 'slow' glucocorticoid negative feedback control
over basal HPA activity was enhanced in late pregnancy.
Experiment 2: to determine whether glucocorticoid negative feedback control over
stress-induced HPA activity was enhanced in late pregnancy.
Experiment 3: to determine whether 'rapid' glucocorticoid feedback was more
effective in restraining stress-induced HPA activity in late pregnancy.
6.2. Materials and Methods
6.2.1. Animals
Female Sprague Dawley rats were used throughout this set of experiments (weighing
between 260-300g at the beginning) and were maintained under conditions detailed
in chapter 2. For experiment 1, rats were housed singly for at least 5 days prior to the
first experiment and for experiments 2 and 3, all rats were caged individually after
surgery.
6.2.2 Surgery
For experiments 2 and 3, virgin and pregnant rats (day 16 of pregnancy) were fitted
with a jugular vein cannula five days prior to the day of the experiment, under
halothane inhalation anaesthesia, as described previously (see section 2.3. of Chapter
2).
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6.2.3. Experimental Procedure
(i) Pharmacological Adrenalectomy
For experiments 1 and 2 it was necessary to block the synthesis of endogenous
glucocorticoids. This was achieved pharmacologically by administration of the 1 lp-
hydroxylase inhibitor, metyrapone [Sigma] and the 20a-hydroxylase inhibitor,
aminoglutethimide [Sigma], as previously described (Plotsky et al, 1986; Plotsky &
Sawchenko, 1987; Johnstone et al, 2000).
Experiment 1: Virgin and pregnant rats were treated with either 100 mg/kg
metyrapone (dissolved in 0.9% saline) or saline subcutaneously (s.c.) at 8 hour
intervals over a 48 hour period. Pharmacological adrenalectomy over 48h was
chosen since a previous study has shown that there is a pronounced increase in CRH
and AVP immunoreactivity in the PVN between 24-72 h of phADX treatment
(Plotsky & Sawchenko, 1987). All rats in experiment 1 were given a total of seven
metyrapone or saline injections, beginning at 08:00h on day 19 of pregnancy). The
final metyrapone injection (at 08:00h on day 21 of pregnancy) was followed 75 min
later by a subcutaneous injection of 200 mg/kg aminoglutethimide or vehicle
(dimethyl-sulfoxide; DMSO)[Sigma], One hour after the aminoglutethimide/DMSO
injection rats were killed by decapitation. Brains were rapidly removed and frozen on
dry ice for in situ hybridisation. Trunk blood was collected into chilled plastic tubes
containing 5% EDTA and plasma was separated by centrifugation, as before (see
general methods chapter) for determination of plasma hormone and glucose
concentrations. The number of fetuses in utero was recorded and the combined
weight of five pups (with placentae attached) was measured. Since glucocorticoids
influence the weight of the thymus and the weight of the adrenal glands is influenced
by ACTH, they were removed from the rats post-mortem and weighed to provide
indicators of the success of adrenalectomy.
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Experiment 2: Virgin and pregnant rats were treated as described in experiment 1, to
induce a state of pharmacological adrenalectomy (phADX), however this time rats
were given only 4 metyrapone/vehicle injections over a 24 hour period, beginning at
08:00h on day 20 of pregnancy. Here rats were treated to induce phADX over a 24h
period as this has previously been shown to be sufficient time to reduce
corticosterone secretion to minimal levels and hence induce increased ACTH
secretion. Immediately before the final metyrapone injection (at 08:00 h on day 21),
rats had extension tubing attached to a 1ml syringe (both filled with heparinised
saline) connected to the jugular vein cannula. 75 min after the final metyrapone
injection rats were administered either aminoglutethimide or DMSO as before.
(ii) Blood Sampling
Experiment 2: Jugular vein cannulae were connected at 07:00h on the day before the
experiment (day 20 of pregnancy) and a blood sample was withdrawn approximately
one hour later, prior to any treatment with metyrapone. After the blood sample was
taken the cannula was flushed with heparinised saline and disconnected until the
following morning. On the morning of the experiment (day 21 of pregnancy)
cannulae were connected for blood sampling as described above. Two basal blood
samples were withdrawn (30 min apart) 1 hour after the aminoglutethimide injection.
Immediately after the second basal sample, all rats were transferred from their home
cage into a Perspex restraining tube (diameter = 70 mm, the length of the tube was
adjusted to prevent the animal from turning around) for 30 minutes and then returned
to their home cage. Further blood samples were withdrawn 15, 30, 45, 60 and 90
minutes after the onset of the period of restraint. Rats were killed by an i.v. overdose
of pentobarbitone and the number of fetuses in utero was recorded.
Experiment 3: On the morning (between 07:30-09:00h) of the experiment (day 21 of
pregnancy) rats had the jugular vein cannula connected to PVC extension tubing
(wall = 1mm, internal diameter = 0.5mm) filled with heparinised saline (1ml heparin,
5000 units/ml in 100ml 0.9% saline) and attached to a 1ml syringe. Rats were then
left undisturbed for at least one hour prior to the start of blood sampling. Two basal
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blood samples were withdrawn, 30 min apart. After the second basal sample, rats
were administered either 2 mg/kg corticosterone-21-acetate [Sigma] s.c. (dissolved in
a 10% alcohol in 0.9% saline solution) or vehicle. One hour later a further blood
sample was withdrawn. Immediately after this blood sample was collected all the rats
were forced to swim for 90 seconds in a cylindrical container (dimensions = height,
38 cm; diameter, 33 cm) filled to a depth of ~ 30cm with tap water at 19°C. After
exposure to forced swimming, rats were gently towel-dried for 15-20 seconds and
then returned to their home cages. Further blood samples were withdrawn 5, 15, 50
and 80 min after the end of the swim stress. After the last blood sample rats were
killed by an i.v. overdose of pentobarbitone and the number of fetuses in utero was
recorded.
The volume of blood withdrawn in each of the experiments detailed above was
dependent upon the eventual assay. For analysis of ACTH only, 0.5 ml samples were
taken, for ACTH and corticosterone, 0.7 ml and for corticosterone only 0.3ml
samples were taken. All blood samples taken for analysis of ACTH and/or
corticosterone were collected into 1 ml syringes containing 5% EDTA (see General
Methods; Chapter 2). The volume of blood withdrawn was replaced immediately by
an equal volume of 0.9% sterile saline. In each case blood was stored in eppendorfs
on ice until centrifugation (see General Methods).
6.2.4. In situ hybridisation
Brains for in situ hybridisation were sectioned coronally at 15pm through the PVN
and thaw-mounted on gelatinised slides as previously described in the General
Methods (Chapter 2). To detect CRH mRNA expression a 42-mer oligonucleotide
probe was used [MWG-Biotech], The sequence of the CRH mRNA oligo-probe used
is given below. It is complementary to bases 496-537 which encode amino acids 22-
35 of the rat CRH peptide (Jingami et al, 1985b).
5'- CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC -3'
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To detect AVP mRNA expression a 45-mer oligonucleotide probe [MWG-Biotech],
complementary to the sequence encoding the last 15 amino acids of the AVP peptide
was used (Ma et al, 1997). The sequence is given below.
5'- GAC CCG GGG CTT GGC AGA ATC CAC GGA CTC TTG TGT CCC AGC
CAG -3'
Probe labelling and hybridisation were performed as described in the General
Methods (Chapter 2). The post-hybridisation washes were performed in the usual
way. The melting temperatures of the CRH and AVP mRNA oligo-probes were 78°C
and 81°C respectively, therefore the heated SSC washes were performed at 58°C and
61°C, respectively. Once dry, the sections were exposed to autoradiographic film: 21
days for CRH mRNA and 11 days for AVP mRNA (both at room temperature).
CRH and AVP mRNA expression in the parvocellular region of the PVN was
quantified from autoradiographs using a computer based image analysis system (NIH
Image 1.62) as described in the General Methods (Chapter 2).
6.2.5. Radioimmunoassays
All samples from a particular experiment were assayed together. Plasma ACTH and
corticosterone concentrations were determined using commercially available kits
(see sections 2.6.1. and 2.7.). The sensitivity was 1 pg/ml and 0.85 ng/ml,
respectively and the intra-assay variation <10% and <6%, for the ACTH and
corticosterone assays respectively.
6.2.6. Plasma Glucose Measurements
Since glucocorticoids play an important role in mobilising glucose stores,
adrenalectomy can have major metabolic consequences for the rat. To ascertain
whether the pharmacological adrenalectomy procedure was causing the rats to suffer
any metabolic stress, plasma glucose levels were measured.
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Plasma glucose concentrations were determined using test strips and a Reflolux®
blood glucose meter [both from Boehringer Mannheim], The principle of the test is
based upon the glucose-oxidase/peroxidase reaction and the manufacturers have
determined it is specific for glucose. The detection range of the test strips used was
0.5-27.7 mmol/1.
6.2.7. Statistical Analysis
Experiment 1: Levels of CRH and AVP gene expression and hormone levels in trunk
blood were all analysed using a two-way ANOVA followed by a Student Newman-
Keuls multiple comparison test. Plasma glucose concentrations were analysed using
a Kruskal-Wallis analysis followed by Dunn's post-hoc test. Comparisons of adrenal
and thymus gland weights were made using a two-way ANOVA. The effect of
phADX on foetal weight was analysed using a two-tailed unpaired t-test.
Experiment 2: Two way repeated measures analysis, followed by Student-Newman-
Keuls multiple comparison test was used to analyse plasma ACTH and
corticosterone data. Plasma glucose concentrations were analysed using a two-tailed
paired t-test.
Experiment 3: ACTH and corticosterone data from the blood sampling were analysed
using a two-way ANOVA for repeated measures.
In each case, p values less than 0.05 were considered statistically significant.
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6.3. Results
Experiment 1:Effect of 48h pharmacological adrenalectomy on basal
HPA activity
6.3.1. Effect of 48h pharmacological adrenalectomy on basal expression of CRH
mRNA in the pPVN
Quantification of film autoradiographs revealed that levels of CRH mRNA
expression in the pPVN in vehicle treated rats was not significantly different between
the virgin and the pregnant groups (figure 6.1.). Pharmacological adrenalectomy
(phADX) for 48h induced a significant increase in the level of CRH mRNA
expression in both the virgin and the pregnant groups (p<0.05; two-way ANOVA).
The increase in CRH gene expression induced by metyrapone/aminoglutethimide
treatment was significantly greater in the pregnant group (58 % increase from vehicle
injected rats) compared with the virgin group (47 % increase from vehicle injected
rats) (p<0.05; two-way ANOVA).
6.3.2. Effect of 48h pharmacological adrenalectomy on basal expression of AVP
mRNA in the pPVN
In the vehicle treated rats, levels of AVP mRNA expression in the pPVN tended to
be less in the pregnant group compared to the virgin group, however this difference
was not statistically significant (figure 6.2.). Treatment with metyrapone over 48h
and aminoglutethimide to induce phADX resulted in a significant (p< 0.05, two-way
ANOVA) increase in pPVN AVP mRNA expression in both the virgin and the
pregnant groups (figure 6.2.). The increase in AVP gene transcription evoked by 48 h
phADX was significantly greater in the pregnant/phADX group (122 % increase)
than in the virgin/phADX group (55 % increase) (p< 0.01; two-way ANOVA).
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Figure 6.1 .(a) Effect of 48h pharmacological adrenalectomy on basal levels of
CRH mRNA expression in the pPVN of virgin and pregnant rats.
Virgin and pregnant rats were treated with metyrapone (MET; 100 mg/kg s.c.) or
vehicle at 8-hourly intervals over a 48h period. The final MET injection was
followed 75 min later by an injection of aminoglutethimide (AG; 200 mg/kg s.c.).
One hour after the AG/vehicle injection (on day 21 of pregnancy) rats were killed by
decapitation. Coronal brain sections were hybridised with a 35S-labelled oligo-probe
complementary to CRH mRNA. Autoradiographs were quantified by computer based
image analysis. Values are plotted as group means ± SEM for grain area (mmW).
Group numbers: virgin/vehicle, n = 8; pregnant/vehicle, n = 6; virgin/phADX, n = 6;
pregnant/phADX, n = 5. Two-way ANOVA followed by Student Newman-Keuls
multiple comparison test as used for statistical analysis of the data: *p< 0.005 vs
vehicle treated groups; #p< 0.05 vs all other groups.
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Figure 6.1.(b) Effect of 48h pharmacological adrenalectomy on basal levels of
CRH mRNA expression in the pPVN of virgin and pregnant rats:
Photomicrographs.
Brightfield photomicrographs of coronal sections through the paraventricular nucleus
hybridised with a ,5S-labelled probe complementary to CRH mRNA from A,
virgin/vehicle; B, virgin/phADX; C, pregnant/vehicle; D, pregnant/phADX. 3V, third
ventricle. Scale Bar: 100pm.
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Ffeure 6.2.(a) Effect of 48h pharmacological adrenalectomy on basal levels of
AVP mRNA expression in the pPVN of virgin and pregnant rats.
Virgin and pregnant rats were treated with metyrapone and aminoglutethimide to
induce pharmacological adrenalectomy (phADX) as above (see figure 6.1(a) legend).
Coronal brain sections were hybridised with a 35S-labelled oligo-probe
complementary to AVP mRNA. Autoradiographs were quantified by computer based
image analysis. Values are plotted as group means ± SEM for grain area (mmW).
For group numbers see figure 6.1(a) legend. Two-way ANOVA followed by Student
Newman-Keuls multiple comparison test as used for statistical analysis of the data:
*p< 0.001 vs vehicle treated groups; #p< 0.01 vs all other groups.
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Figure 6.2.(b) Effect of 48h pharmacological adrenalectomy on basal levels of
AVP mRNA expression in the pPVN of virgin and pregnant rats:
Photomicrographs.
Brightfield photomicrographs of coronal sections through the paraventricular nucleus
hybridised with a S-labelled probe complementary to arginine vasopressin mRNA
from A, virgin/vehicle; B, virgin/phADX; C, pregnant/vehicle; D, pregnant/phADX.
3V, third ventricle; mgPVN, magnocellular division of PVN; pPVN, parvocellular
region of PVN. Scale Bar: 100pm.
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6.3.3. Effect of 48h pharmacological adrenalectomy on basal plasma ACTH
concentrations
Basal concentrations of plasma ACTH were not significantly different between the
virgin and pregnant control groups (figure 6.3.). Pharmacological adrenalectomy
(over 48 h) evoked a significant increase in plasma ACTH concentration in both the
virgin and the pregnant groups, however this increase was significantly greater in the
virgin-metyrapone treated group (8.5-fold increase) than in the pregnant metyrapone
treated group (4.2-fold increase) (p< 0.001; two-way ANOVA).
6.3.4. Effect of 48h pharmacological adrenalectomy on basal plasma
corticosterone concentrations
Basal plasma corticosterone concentration in the vehicle treated rats was
significantly greater in the pregnant group than in the virgin group (figure 6.4.a). As
expected treatment with metyrapone over 48h to induce a state of pharmacological
adrenalectomy, caused a significant suppression in corticosterone secretion in both
the virgin and the pregnant groups (p< 0.002; two-way ANOVA). Although the
reduction in plasma corticosterone in the phADX resulted in levels that were not
significantly different between the groups, the change in plasma corticosterone
concentration was significantly different (p< 0.01; Student t-test). There was a 42%
reduction in corticosterone secretion in the virgin phADX group compared with a
73% reduction in the pregnant phADX group (figure 6.4.(b)).
6.3.5. Effect of 48h pharmacological adrenalectomy on plasma glucose
concentrations
Plasma glucose concentration was significantly lower in the pregnant vehicle treated
rats compared with the virgin vehicle treated rats (figure 6.5.). Pharmacological
adrenalectomy did not have a significant effect on plasma glucose levels in the virgin
group, however phADX caused a significant reduction in plasma glucose
concentration in the pregnant group (p< 0.05; Kruskal-Wallis, followed by Dunn's
post-hoc test).
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Treatment with metyrapone or vehicle for 48h had no significant effect on body
weight in the virgin rats. As expected, there was a significant increase in body
weight (increase of 9.0 ± 2.7 g) in the vehicle treated pregnant rats (after 48h
treatment; Students t-test, p< 0.01; data not shown). Metyrapone treatment (over
48h), tended to cause a reduction in body weight in the pregnant rats, though this was
not significant. A comparison of body weight between the pregnant vehicle treated
rats and the pregnant metyrapone treated rats revealed body weight in the latter was
significantly reduced (Students t-test, p< 0.01; data not shown). This was a
consequence of an increase in body weight in the vehicle treated pregnant group and
a reduction in body weight in the metyrapone treated group.
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Figure 6.3. Effect of 48h pharmacological adrenalectomy on basal plasma
ACTH concentrations in virgin and pregnant rats.
Trunk blood was collected following 48h pharmacological adrenalectomy. Values
are plotted as group means ± SEM. For group numbers see figure 6.1(a) legend.
Two-way ANOVA followed by Student Newman-Keuls multiple comparison test
was used for statistical analysis of the data: *p< 0.001 vs vehicle treated groups; #p<
0.001 vs all other groups.
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Figure 6.4.(a) Effect of 48h pharmacological adrenalectomy on basal plasma
corticosterone concentrations in virgin and pregnant rats.
Trunk blood was collected following 48h pharmacological adrenalectomy. Values
are plotted as group means ± SEM. For group numbers see figure 6.1(a) legend.
Two-way ANOVA followed by Student Newman-Keuls multiple comparison test
was used for statistical analysis of the data: *p< 0.002 vs vehicle treated groups; #p<
0.001 vs all other groups.
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Fieure 6.4.(b) Change in plasma corticosterone concentration after 48h
pharmacological adrenalectomy in virgin and pregnant rats.
Trunk blood was collected following 48h pharmacological adrenalectomy. Values
plotted are change in plasma corticosterone concentration (from their vehicle
counterparts) after 48h phADX and are plotted as group means ± SEM. Group
numbers: virgin, n = 6; pregnant, n = 6. Students t-test was used for statistical
analysis of the data: *p< 0.01 vs virgin group.
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Figure 6.5. Effect of 48h pharmacological adrenalectomy on plasma glucose
concentrations in virgin and pregnant rats.
Trunk blood was collected following 48h pharmacological adrenalectomy (see figure
6.1.(a) legend). Values are plotted as group means ± SEM. For group numbers see
figure 6.1(a) legend. Kruskal-Wallis followed by Dunn's post-hoc test was used for
statistical analysis of the data: *p< 0.05 vs virgin/vehicle group; #p< 0.05 vs all other
groups.
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6.3.6. Effect of 48h pharmacological adrenalectomy on adrenal gland weight
Adrenal weight did not differ between virgin and pregnant control groups (but tended
to be lower in the pregnant rats; figure 6.6.)- In both groups, phADX caused a
significant increase in adrenal gland weight relative to the vehicle treated groups (p<
0.005; two-way ANOVA), however the increase in the weight of the adrenal glands
was greater in the pregnant/phADX (131% increase) group than in the virgin/phADX
(45% increase) group.
6.3.7. Effect of 48h pharmacological adrenalectomy on thymus gland weight
Thymus gland weight was significantly lower in the pregnant control rats compared
with the virgin control rats (figure 6.7.(a)). Removal of glucocorticoid feedback by
phADX did not significantly affect the weight of the thymus gland in the virgin
group, however phADX significantly increased thymus gland weight in the pregnant
group (p< 0.02; two-way ANOVA). Thymus weight was indirectly proportional to
plasma corticosterone concentration (figure 6.7.(b)). There was a negative correlation
between thymus weight and plasma corticosterone concentration in the pregnant
groups, but not in the virgin groups, when the data were analysed separately (figure
6-7.(c)).
6.3.8. Effect of 48h pharmacological adrenalectomy on foetal weight
The combined foetal and placental weight was significantly (p< 0.02; two-tailed
unpaired t-test) lower in the pregnant/phADX group compared with the pregnant
vehicle treated group (figure 6.8.). Further analysis revealed that this reduction was
due to a significant reduction in foetal weight (p< 0.04) with no significant change in
placental weight (data not shown).
The phADX treated rats were not alert and were non-responsive when handled. The
reasons for this are not known, but appear to be an unexpected result of phADX.
Despite this and the reduction in foetal weight, the foetuses were still alive in utero at
the end of the experiment. Pregnant rats with dead and/or under-developed foetuses
were excluded from the analysis.
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Figure 6.6. Effect of 48h pharmacological adrenalectomy on adrenal gland
weights in virgin and pregnant rats.
Rats were killed after 48h pharmacological adrenalectomy (see figure 6.1.(a) legend).
Both adrenal glands were dissected from the rat and adipose/connective tissue was
removed. The tissue was transferred to eppendorf tubes and weighed. Values are
plotted as group means ± SEM. For group numbers see figure 6.1(a) legend. Two-
way ANOVA followed by Student Newman-Keuls multiple comparison test was
used for statistical analysis of the data: *p< 0.005 vs vehicle treated groups; #p< 0.03
vs all other groups.
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Figure 6.7.(a) Effect of 48h pharmacological adrenalectomy on thymus gland
weights in virgin and pregnant rats.
Rats were killed after 48h pharmacological adrenalectomy (see figure 6.1.(a) legend).
The thymus gland was dissected from the rat and adipose/connective tissue was
removed. The tissue was transferred to eppendorf tubes and weighed. Values are
plotted as group means ± SEM. For group numbers see figure 6.1(a) legend. Two-
way ANOVA followed by Student Newman-Keuls multiple comparison test was
used for statistical analysis of the data: *p< 0.02 vs vehicle treated pregnant group;
#p< 0.002 vs virgin/vehicle group.
243























0 20 40 60 80 100 120 140 160 180
























0 20 40 60 80 100 120 140 160 180
Plasma Corticosterone Concentration (ng/ml)
Figure 6.7.(b, c): Relationship between thymus gland weight and plasma
corticosterone concentration.
Rats were killed after 48h pharmacological adrenalectomy (see figure 6.1.(a) legend).
Trunk blood was collected and subsequently assayed for corticosterone. The thymus
gland was dissected from the rat and adipose/connective tissue was removed. The
tissue was transferred to eppendorf tubes and weighed.
(b) Values from all rats are plotted as thymus gland weight against plasma
corticosterone concentration. There is a significant correlation between thymus gland
weight and plasma corticosterone concentration (p< 0.03; Pearson Product Moment
Correlation test; the correlation coefficient is -0.4347).
(c) Values from the virgin and the pregnant rats are plotted separately as thymus
weight against plasma corticosterone concentration. There is a significant correlation
between thymus gland weight and plasma corticosterone concentration in the
pregnant group (p< 0.04; Pearson Product Moment Correlation test; the correlation
coefficient is -0.6339), but not in the virgin group.
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Figure 6.8. Effect of 48h pharmacological adrenalectomy on foetal weights in
pregnant rats.
Rats were killed after 48h pharmacological adrenalectomy (see figure 6.1 .(a) legend).
Five pups (with placentae attached) were removed from the pregnant rat uteri and
weighed. Values plotted are group means ± SEM. Group numbers: pregnant/vehicle,
n = 6; pregnant/phADX, n = 5. Two-tailed unpaired t-test was used for statistical
analysis of the data: *p< 0.02 vs vehicle treated group.
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Experiment 2: Effect of 24h pharmacological adrenalectomy on stress-
induced HPA activity
6.3.9. Effect of 24h pharmacological adrenalectomy on stress-induced plasma
ACTH concentrations
Prior to any treatment, basal plasma concentrations of ACTH did not differ between
any of the groups (figure 6.9.)- Subcutaneous vehicle injections over a 24h period
had no significant effect on plasma ACTH concentrations in either the virgin or the
pregnant group (figure 6.9.). Metyrapone treatment (for 24h) resulted in a significant
increase in plasma ACTH levels in both groups (p< 0.002; two-way RM ANOVA).
As expected, exposure to 30 min of restraint stress evoked a significant increase in
ACTH secretion in the virgin vehicle treated group, which peaked between 15-30
min after the onset of the stress (figure 6.9.). There was also a significant increase in
plasma ACTH levels in the pregnant/vehicle group within 15 min of the onset of
restraint stress, however this response was significantly attenuated when compared
with the virgin/vehicle group (p< 0.001; two-way RM ANOVA). Surprisingly,
restraint had no effect on plasma ACTH concentration in either the virgin or pregnant
phADX groups with plasma ACTH levels not significantly different from basal
levels measured after 24 h metyrapone treatment (figure 6.9.). However the phADX
treated rats were markedly subdued and non-responsive when handled.
6.3.10. Effect of 24h pharmacological adrenalectomy on stress-induced plasma
corticosterone concentrations
Basal levels of corticosterone measured prior to metyrapone treatment were not
significantly different between any of the groups, although plasma corticosterone
concentration tended to be higher in the pregnant groups (figure 6.10). Following
24h of treatment with metyrapone and a single injection of aminoglutethimide basal
levels of corticosterone were measured.
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Pharmacological ADX over 24h resulted in a significant reduction in plasma
corticosterone levels in both virgin and pregnant rats compared with the vehicle
injected controls (p< 0.01; two-way RM ANOVA), with no difference between the
virgin and pregnant phADX groups (figure 6.10). Exposure to 30 min restraint stress
caused a significant increase in plasma corticosterone concentration in both the
virgin and pregnant vehicle treated rats (p< 0.002; two-way RM ANOVA), however
this failed to evoke any response in either the virgin or pregnant phADX groups
(figure 6.10.).
6.3.11. Effect of 24h pharmacological adrenalectomy on plasma glucose
concentrations
Plasma glucose concentrations were not significantly different in either the virgin or
pregnant group after 24h phADX compared with their respective controls (figure
6.11.). Plasma glucose levels were lower in both the pregnant groups (pre- and post-
treatment) when compared with the virgin/vehicle group (Student t-test; p< 0.02).
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Figure 6.11. The effect of 24h phADX on plasma glucose concentration in virgin
and pregnant rats.
Blood samples were withdrawn for measurement of plasma glucose levels before and
after treatment with metyrapone (MET; 4 x lOOmg/kg s.c.) and aminoglutethimide
(200 mg/kg s.c.). Values are plotted as group means ± SEM. For group numbers see
figure 6.9. legend. Two-way ANOVA for repeated measures followed by Student
Newman-Keuls multiple comparison test indicated no significant differences within
any of the groups after treatment with vehicle or metyrapone treatment for 24h (p>
0.05). * p< 0.02, significantly lower than virgin/vehicle treated groups (Student t-
test).
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Experiment 3: Effect of enhanced corticosterone negative feedback on
stress-induced HPA activity
6.3.12. Effect of corticosterone pre-treatment on stress-induced plasma ACTH
concentrations
Plasma ACTH concentrations were not significantly different between any of the
groups under basal conditions (figure 6.12.(a)). Neither corticosterone nor vehicle
treatment had any effect on plasma ACTH levels measured 60 min after the injection
in any of the groups. As expected, exposure to 90 seconds of forced swimming
resulted in a rapid increase (within 5 min) in ACTH secretion in the virgin control
group, with levels remaining significantly elevated 50 min after the stress (p< 0.001;
two-way RM ANOVA). Plasma ACTH concentration was also significantly
increased in the pregnant control group 15 min after forced swimming (figure
6.12.(b); p< 0.01, repeated measures ANOVA on ranks). Swim stress significantly
increased ACTH secretion from basal levels in the virgin group pre-treated with
corticosterone, however the magnitude of this increase was significantly lower than
that observed in the virgin control group (5.8-fold increase in the virgin control
group vs. 2.5-fold increase in the virgin corticosterone treated group). Pre-treatment
with corticosterone had no further effect on the ACTH secretory response to forced
swimming in the pregnant group, with plasma concentrations not significantly
different from the pregnant control group (figure 6.12.(a, b)).
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Figure 6.12.(b) Increase in plasma ACTH concentration after corticosterone
treatment and forced swimming.
The increase in plasma ACTH concentration at 5 min post-swim (sample 4 on
figure 6.12.(a)) from pre-swim levels (sample 3) was calculated and is plotted as
group mean ± SEM. Repeated measures ANOVA on ranks followed by Dunn's
post-hoc test was used to analyse the data: # indicates the increase in ACTH
secretion this group was greater than in any of the other groups (p< 0.01). Paired t-
test revealed significant increases in plasma ACTH concentration from pre-swim
levels (*p < 0.03; **p < 0.005).
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6.4. Discussion
Basal and stress induced activity of the HPA axis is dependent upon integration of
all the excitatory and all the inhibitory neural inputs to the pPVN neurones and
feedback inhibition mediated via glucocorticoids. In late pregnancy, the balance
between stimulation and inhibition shifts, resulting in reduced feed-forward
mechanisms (Neumann et al , 1998; Johnstone et al , 2000a). Here evidence was
sought for altered glucocorticoid feedback sensitivity during pregnancy.
Experiment I: The role ofglucocorticoid feedback on basal HPA axis
activity in late pregnancy
The present study demonstrated that removal of the glucocorticoid inhibitory
feedback signal by phADX resulted in an increase in both CRH and AVP mRNA
expression in the parvocellular region of the PVN of both virgin and pregnant rats.
These results support a role for tonic glucocorticoid inhibition in regulating CRH
and AVP gene expression, which has previously been described following surgical
adrenalectomy (Young et al, 1986). If it is assumed that the mRNA is translated
into protein, then by preventing the feedback actions of corticosterone it follows
that phADX increases production of CRH and AVP. In the pregnant group phADX
induced a significantly greater increase in PVN CRH and AVP mRNA expression
under basal conditions, suggesting that in late pregnancy the PVN neurones are
more sensitive to slow glucocorticoid negative feedback. Increased sensitivity to
the negative feedback actions of glucocorticoids in pregnancy has previously been
suggested from a study demonstrating increased GR mRNA expression in the
dentate gyrus in late pregnant rats and increased 11 p-HSD activity in the PVN
(Johnstone et al, 2000a). However this same study reported reduced levels of basal
CRH and AVP mRNA expression in the PVN, an effect not observed in the control
rats of the present experiment. This is likely to be a result of the stress associated
with handling and administration of the vehicle injections.
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Under basal conditions, Atkinson and Waddell have reported a decrease in levels of
plasma ACTH as pregnancy progresses (Atkinson & Waddell, 1995). Here, no
differences in plasma ACTH concentration were observed between the virgin and
pregnant control groups. This can be easily explained. The evidence presented by
Atkinson and Waddell to support reduced ACTH secretion in late pregnancy,
demonstrated reduced mean daily levels in plasma ACTH in pregnancy, however
this reduction in ACTH secretion was due to a loss of the evening rise in ACTH
levels with morning basal levels not significantly affected by pregnancy. Here
plasma ACTH was measured at one time point during the morning at a time when
ACTH secretion is at its lowest and there is little variation between virgin and
pregnant rats.
Pharmacological ADX evoked a significant increase in ACTH secretion in both the
virgin and the pregnant groups. This is consistent with the reported effects of
surgical ADX on plasma ACTH levels (Plotsky & Sawchenko, 1987). The increase
in ACTH secretion observed after phADX is likely to be a consequence of
increased drive to the pituitary corticotropes by CRH and/or AVP. Since
corticosterone also has negative feedback effects at the level of the anterior
pituitary, by blocking these actions it would be expected that ACTH release would
be increased. However, surprisingly the increase in ACTH levels following 48h
phADX was greater in the virgin (7-fold increase) than in the pregnant group (3-
fold increase). This result is difficult to interpret, especially as CRH and AVP
mRNA levels were greater in the pregnant group, though seems to suggest a change
in the sensitivity of the anterior pituitary to CRH and/or AVP in late pregnancy.
There are several possibilities: pituitary corticotropes may fail to up-regulate
receptor levels sufficiently, indeed it has previously been reported that CRH
binding sites decline in late pregnancy (Neumann et al , 1998), which may
contribute to the reduced ACTH response after phADX in the pregnant group.
Alternatively there may be a depletion of ACTH stores, resulting from reduced
production of ACTH from its precursor POMC. Lastly, increased CRH and AVP
mRNA expression in the pPVN does not necessarily mean that CRH and AVP
secretion (or indeed peptide production) are increased simultaneously. Thus,
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although removal of glucocorticoid inhibition increases CRH and AVP mRNA
expression, it may still be that reduced forward drive (see next experiment)
restrains CRH and/or AVP secretion (and hence ACTH secretion) more in pregnant
rats. Following this explanation, feedback restraint of ACTH secretion in late
pregnancy is less effective on ACTH secretion than in virgins.
Basal corticosterone levels were found to be significantly greater in the pregnant
control group compared with the virgin control group. Others have also reported an
increase in circulating corticosterone in late pregnancy (Atkinson & Waddell, 1995;
Neumann et al , 1998). Several hypotheses have been suggested to explain the
increase in corticosterone secretion at this time. As the foetal adrenal glands mature
they begin to secrete corticosterone, which is detectable from ~ day 17 of gestation
(Dupouy et al, 1975; Waddell, 1993), although placental lip-HSD should limit the
amount of corticosterone that crosses from the foetus to the maternal circulation.
Increased production of oestrogen in pregnancy is reported to increase the
sensitivity of the adrenal gland to ACTH (Carr et al, 1981; Burgess & Handa,
1992). Whether these elevated concentrations of plasma corticosterone enhance the
negative feedback system at the end of pregnancy is not clear as increased
circulating CBG (Waddell & Atkinson, 1994) is likely to limit the feedback effects
in late pregnancy.
Following 48h phADX, plasma corticosterone levels were significantly reduced to
similar levels in the virgin and pregnant groups, indicating that the treatment was
successful, however the reduction in corticosterone secretion was greater in the
pregnant group. Thus the different effects of phADX on basal ACTH secretion in
virgin and pregnant rats is not attributable to a lesser reduction in corticosterone
production in pregnant rats. However, the greater overall percentage decrease in
corticosterone secretion in the pregnant rats may explain the greater increase in
pPVN CRH and AVP mRNA expression. Other parameters were measured to
indicate the success of the phADX, namely thymus and adrenal gland weight. In
both virgin and pregnant rats, 48h phADX increased the weight of the adrenal
glands. These effects are probably a result of increased ACTH drive which leads to
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adrenal hypertrophy (Carr et al , 1981). The increase in adrenal gland weight was
significantly greater in the pregnant group than in the virgin group. Given that these
rats have decreased ACTH drive (compared with the virgin phADX group), the
greater increase in adrenal weight indicates that the sensitivity of the adrenal gland
to ACTH (or other POMC products) increases in pregnancy.
Glucocorticoids have immuno-suppressive actions and act on the thymus gland to
inhibit inappropriate responses (Brown, 1998). Thymus weights were significantly
lower in the pregnant control group compared with the virgin control group,
perhaps a consequence of the elevated corticosterone levels in pregnancy.
Pharmacological ADX had no significant effect on thymus weight in the virgin
group, however it significantly increased thymus weight in the pregnant group.
These data suggest that in pregnancy the thymus gland is more sensitive to the
effects of corticosterone.
A primary role of glucocorticoids is to mobilise glucose from glycogen stores. The
present results indicate increased metabolic demand during late pregnancy,
reflected by significantly lower plasma glucose levels in the control pregnant rats
than in the virgins. This may represent the increasing energy demand made by the
fetuses, despite increased maternal food intake (Johnstone & Higuchi, 2001).
Treatment with metyrapone did not have any significant effect on plasma glucose
concentrations in the virgin group, however phADX further decreased glucose
levels in the pregnant group. The decreased plasma glucose concentration in
phADX pregnant rats may have potentiated the effects of reduced corticosterone
secretion on CRH and AVP mRNA expression in the pPVN as glucose provides an
important signal in the regulation of the HPA axis (Bhatnagar et al, 2000; Bell et al,
2000; Laugero et al, 2001; Laugero, 2001). Glucocorticoids are essential in
pregnancy to cope with the increased demand for energy (Waddell & Atkinson,
1994). Indeed this study indicated that foetal weight was significantly lower when
mothers were treated over 48h to induced phADX, which is likely to be due to
reduced nutrient transfer, as indicated by maternal glucose levels or a lack of
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corticosterone actions (e.g. cellular uptake of amino acids and glucose and storage
of glycogen by the liver) in the foetuses.
Experiment 2: Effect of 24h pharmacological adrenalectomy on stress-
induced HPA activity
In the second experiment, restraint induced a significant increase in ACTH
secretion in both the virgin and pregnant vehicle treated groups and this response
was significantly attenuated in the pregnant group. These results are consistent with
those presented in Chapter 3 where plasma ACTH concentrations were measured in
trunk blood following 30 min restraint stress. If enhanced corticosterone negative
feedback is responsible for the reduced responsiveness of the HPA axis in
pregnancy, it would be expected that removing corticosterone negative feedback by
phADX would enhance the ACTH response to stress. However this was not the
case. Neither of the phADX groups mounted an ACTH response when exposed to
restraint stress, suggesting that the ability to generate a stress response was absent
in these rats, presumably as an unexpected result of the phADX process. There are
several possible explanations as to why the ACTH response was absent. Rats
treated to induce phADX (in both experiments 1 and 2) displayed were lethargic,
evidently unaware of their environment and non-responsive to handling. The
reasons behind this behaviour are not clear, although plasma glucose levels tended
to be lower in the pregnant groups, levels in neither the virgin nor pregnant groups
were significantly affected by phADX over 24 hours. Since these experiments were
performed, Bell and colleagues (Bell et at , 2000) have reported that a sucrose
supplement in addition to drinking water counteracts the metabolic deficits of
surgical adrenalectomy (provided the rats have previously learned to drink the
sucrose solution). Whether this treatment would have restored normal behaviour in
our phADX rats is not known, but should be kept in mind when interpreting the
results. In hindsight, it may have been more appropriate to use a different stressor
such as forced swimming, which would have required a response from the rats or to
have stimulated ACTH secretion by administration of IL-ip. It is possible that after
24h phADX, increased drive by CRH and/or AVP resulted in depletion of anterior
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pituitary ACTH stores, thus rendering the rats unable to respond to further
stimulation. This seems unlikely since plasma ACTH concentrations remained
significantly elevated after 48h phADX in experiment 1. It is possible that
following prolonged stimulation the ACTH stores become depleted within 24h and
that up-regulation of ACTH from POMC takes longer than this (but less than 48h).
The plasma corticosterone data showed that corticosterone production was
significantly decreased after 24h in the phADX groups. It is difficult to interpret the
corticosterone results after stress. Neither the virgin nor the pregnant group
responded to the restraint stress, however whether this was a result of phADX or a
result of a lack of ACTH drive is not clear.
Metyrapone blocks the final step in the pathway of corticosterone production,
which presumably will cause a build-up of precursors, many of which are sex
steroids; and because of increased ACTH secretion their production will be
stimulated. Due to their lipophilic nature, steroids can easily cross the blood brain
barrier. It is possible that these steroids are "neuroactive" (Rupprecht & Holsboer,
1999) and indeed may be affecting the brain and actively blocking a stress response
in these rats. It has previously been shown that neuroactive steroids involved in
biosynthesis of corticosterone from cholesterol are capable of binding to the
GABAa receptor subunit and modulating their activity (Truss & Beato, 1993). The
steroids, 3a, 5a- tetrahydraprogesterone and 3a, 5a- tetrahydrodeoxy-
corticosterone can bind to GABAa receptors, where they increase the CI " current as
well as the frequency and duration of openings of the chloride ion channel, thus
enhancing the inhibitory effects of GABA. Thus increased levels of neuroactive
steroids (as a result of blocking the final step in the biosynthetic pathway of
corticosterone) may be actively restraining the HPA axis response to stress
following phADX. To further investigate the HPA axis without these complications
it would be necessary to employ a specific antagonist to corticosterone. RU 486 is a
GR antagonist which has been used in the past to study feedback effects on the
HPA axis, however this compound also inhibits progesterone actions which would
compromise the pregnancy and thus would be an unsuitable option. A selective GR
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antagonist has recently become available and it would be interesting to study its
effects on HPA axis responses in pregnancy.
Experiment 3: Effect of enhanced corticosterone negative feedback on
stress-induced HPA activity
In the vehicle treated groups exposure to forced swim stress evoked a rapid increase
in ACTH secretion in virgin rats, an effect which was significantly attenuated in the
pregnant/vehicle treated group. These results are consistent with previous studies
employing the same stressor (Douglas et at, 1998; Neumann et al , 1998). Acute
corticosterone administration resulted in a dramatic reduction in stress-induced
ACTH secretion in the virgin group, whereas in the pregnant group pretreatment
with corticosterone had no significant effect. This insensitivity to acute feedback
can be interpreted in two ways. First, the results are consistent with loss of
corticosteroid feedback in this time-domain. A previous study on acute
corticosterone effects on ACTH secretion in phADX pregnant and virgin rats
showed reduced sensitivity in phADX pregnant rats (Johnstone et al , 2000a).
Although peak secretion of ACTH following stress in pregnant rats, is less than in
virgin rats, ACTH secretion frequently shows a more prolonged response in
pregnant rats compared with virgins (Douglas et al, 1998; Neumann et al, 1998).
This is not compatible with greater rapid feedback. Secondly, the present findings
superficially support a role for enhanced negative feedback in late pregnancy. By
enhancing the feedback signal with exogenous corticosterone, the ACTH response
to forced swimming was attenuated in virgin rats. However corticosterone
administration had no further effect on lowering the ACTH response to the same
stress in the pregnant group. It could be that in late pregnant rats, the HPA axis is
already under maximal corticosterone feedback inhibition, thus the animals
demonstrate insensitivity to enhanced rapid corticosterone feedback.
Although basal expression of CRH and AVP mRNA in the pPVN neurones
increased more in late pregnancy 48h after phADX than in virgin rats, this may
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have been a consequence of the greater decrease in corticosterone secretion in
pregnant rats, rather than increased sensitivity to slow feedback mechanisms.
In conclusion, it seems unlikely that enhanced rapid negative feedback is involved
in the reduced responsiveness of the HPA axis to acute stress in pregnancy and
instead, if corticosterone feedback is involved it is a consequence of more
prolonged exposure to elevated corticosterone levels associated with slow-
feedback mechanisms, reducing the capacity of CRH/AVP neurones to respond.
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CHAPTER 7
The responsiveness of the
hypothalamo-pituitary-adrenal axis
to stress during pregnancy in mice
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7.1. Introduction
Non pregnant mice, like rats, display robust activation of the HPA axis in response to
a range of emotional (e.g. restraint and immobilisation) (Chesnokova et al, 1998;
Dunn & Swiergiel, 1999) and physical (e.g. LPS and IL-1 (3 ) (Delrue-Perollet et al,
1995; Neveu & Liege, 2000) stressors. To date no study has investigated the
responsiveness of the HPA axis to stress during pregnancy in mice. Here a
comparative study was performed to determine whether the HPA axis is
hyporesponsive during pregnancy in other species as it is in rats. The model used to
test this was the mouse.
The use of transgenic animals as a tool to research the HPA axis has dramatically
increased over the last few years. Transgenic animals have been generated with
defined defects or 'knockout' of genes with roles in various components of the HPA
axis and autonomic nervous system (eg. CRH (Muglia et al, 1996; Dunn &
Swiergiel, 1999; Venihaki & Majzoub, 1999; Muglia et al, 2000), CRH-R (Smith et
al, 1998), lip-HSD (Holmes et al, 2001) and GR (Dijkstra et al, 1998) knock out
mice). Although these models provide valuable and novel insights into the
development, function, interactions and organisation of the stress system, they have
one major drawback, that is, that the vast majority of transgenic models have been
developed in mice. Physiology of the HPA axis in mice has been much less studied
than this system in the rat. Thus in order to take advantage of this 'new' tool to study
the HPA axis in pregnancy, it is important that first the responsiveness of the HPA
axis to stress in normal wildtype mice is evaluated in pregnancy.
In the present set of experiments virgin and pregnant mice were exposed to two
different stressors: confinement to a glass jar for 10 min (emotional stressor) or 10
min forced swimming at 17°C (combined emotional and physical stressor). Due to
the difficulties in cannulating a vein for blood sampling in mice (due to their size)
and the limited amount of blood that could be taken for radioimmunoassay, they
were killed by decapitation immediately after exposure to the stressor and trunk
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blood was collected to determine neuroendocrine stress responses (i.e. ACTH and
corticosterone concentrations). To investigate the effects of stress on the
hypothalamic pPVN neurones the brains were removed and in situ hybridisation was
performed for the immediate early gene product, nur77 mRNA.
Nur77 (also known as NGFI-B in rats) is a member of the steroid nuclear receptor
superfamily of transcription factors and it can bind as a monomer to the cA-acting
sequence, AAAGGTCA, to regulate gene expression, without a requirement for
ligand binding (Wilson et al, 1991; Davis et al, 1991). Nur77 expression is rapidly
induced by neuronal membrane depolarisation (Law et al, 1992), thus it provides a
good indicator of neuronal activation and it has previously been used to determine
the brain areas activated by exposure to stress. Nur77 mRNA is rapidly induced in
the PVN in response to stress (Chan et al, 1993; Honkaniemi et al, 1994) and central
administration of CRH significantly increases expression of nur77 within the PVN
(Parkes et al, 1993). Nur77 transcripts are also strongly induced in the anterior
pituitary (the site of POMC synthesis)(Saucedo-Cardenas & Conneely, 1996) and in
the adrenal cortex (Davis & Lau, 1994) by stress, as well as in Y1 adrenocortical
cells treated with ACTH or cAMP (Wilson et al, 1993b; Davis & Lau, 1994). The
induction of nur77 in the adrenal gland has been implicated in the transcriptional
regulation of the steroidogenic enzyme, steroid-21a-hydroxylase (Wilson et al ,
1993b), a rate-limiting enzyme in glucocorticoid synthesis.
Specific DNA-binding sites for nur77 (NBRE) have been identified in the promoter
regions of the CRH and POMC genes (Murphy et al, 1995; Murphy & Conneely,
1997), indicating that nur77 may play a role in regulation of these genes. Indeed
nur77 antagonises the negative feedback effect of glucocorticoids on the synthesis
and secretion of ACTH in pituitary corticotropes by binding to the negative
glucocorticoid response element in the promoter region of the POMC gene (Okabe et
al, 1998). Further, glucocorticoids can antagonise the stimulatory effects of nur77 on
CRH and POMC gene transcription (Philips et al, 1997; Drouin et al, 1998). Thus
the nur77 signalling pathway appears to be a point of convergence for stimulatory
signals and glucocorticoid feedback in the neuroendocrine stress system.
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The aim of the present experiment was to establish whether HPA axis responses to
stressors (confinement to a glass jar and forced swimming) are reduced in pregnancy,
and whether as in rats, this involves decreased activation of the pPVN neurones.
7.2. Materials and Methods
7.2.1. Animals
Female BK-white mice (Bantin & Kingman) were used for these experiments. On
arrival in the animal unit the mice weighed approximately 30g. From the day of
arrival mice were maintained in groups of 6-8 per cage under a reversed 12h light-
dark cycle (lights on at 19:00h; the light cycle was reversed to allow studies on
parturition (reported elsewhere), which predominantly occurs during the dark phase
in mice). Mice were given at least two weeks to acclimatise to this switch in light-
dark cycle before mating, and were then maintained with reversed lighting until the
end of the experiment. Mice were caged individually from day 14/15 of pregnancy.
7.2.2. Experimental Procedure
The experiment was performed when the pregnant mice were on day 17-18 of
pregnancy (the expected day of parturition was day 19) between 19:00-22:00h (i.e.
the first 3 hours of the light phase). Mice were exposed to either 10 min forced
swimming (in a container 150 mm in diameter; 175 mm in height) in water at 17°C
or confinement to an empty glass jar (diameter, 70 mm; height, 120 mm) for 10 min.
Immediately after exposure to the stress mice were killed by decapitation. Control
mice were left in their home cages until killed by decapitation. Brains were rapidly
removed and frozen on dry ice on aluminium foil. Frozen brains were stored at -70°C
until processed for in situ hybridisation. Trunk blood was collected into Eppendorf
tubes on ice containing 100pl 5% EDTA. Plasma was separated by centrifugation
and stored at -20°C until hormone assay. [This experiment was performed in
collaboration with Drs. A. J. Douglas and I.D. Neumann],
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7.2.3. In situ hybridisation
Brains were sectioned coronally at 15 pm and mounted on slides as previously
described in the General Methods Chapter (2). To detect nur77 mRNA expression a
36-mer oligonucleotide probe was used [MWG-Biotech], The sequence of the nur77
mRNA oligo-probe used is given below. It is complementary to bases 201-236 of the
mouse nur77 gene (Hazel et al, 1988).
5'- GTC TCG GGG CTG GCC AGG TCC ATG GTA GGC TTG CCG -3'
Probe labelling and hybridisation were performed as previously described (Chapter
2). The post-hybridisation washes were performed in the usual way (Chapter 2). The
melting temperature of the nur77 mRNA oligo-probe is 80°C, therefore the heated
SSC washes were performed at 60°C. Once dry, the sections were exposed to
autoradiographic film for 28 days at room temperature. The slides were then dipped
in autoradiographic emulsion (see Chapter 2) and exposed for 12 weeks. Nur77
mRNA expression in the pPVN was quantified from emulsion dipped sections using
a computer based image analysis system as described in the General Methods
Chapter. Data are presented as number of nur77 mRNA expressing cells per PVN
section (unilateral).
7.2.4. Radioimmunoassays
Plasma concentrations of ACTH were measured using a commercially available
immunoradiometric kit (Euro-Diagnostica) as before. The sensitivity of the assay
was 1 pg/ml and the intra-assay variation was < 10%. Plasma corticosterone
concentrations were determined using a commercially available radioimmunoassay
kit (ICN Pharmaceuticals) at the Max Planck Institute for Psychiatry in Munich. The
sensitivity of the assay was <10 ng/ml and the intra- and inter-assay variations were
< 7 and < 10%, respectively.
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7.2.5. Statistical Analysis
Two way analysis of variance (2-way ANOVA) followed by Student-Newman-Keuls
multiple comparison test was used to analyse the nur77 mRNA, plasma ACTH and
plasma corticosterone data. P values less than 0.05 were considered statistically
significant.
7.3. Results
7.3.1. Effects of forced swimming on plasma ACTH concentrations
Basal plasma concentrations of ACTH did not differ between the virgin and pregnant
groups (figure 7.1.). Exposure to forced swimming evoked a significant increase in
plasma ACTH concentration in both the virgin (p < 0.001) and the late pregnant
group (p<0.03; two-way ANOVA), however this response was significantly
attenuated in the pregnant mice (5.2-fold increase in the virgin group compared with
a 2-fold increase in the pregnant group; figure 7.1.)
7.3.2. Effects of forced swimming on plasma corticosterone concentrations
Plasma corticosterone concentration was significantly higher under basal conditions
in the pregnant group compared with the virgin group (figure 7.2.). Following forced
swimming corticosterone levels were significantly increased in the virgin group (9.3-
fold increase), however in the late pregnant group plasma corticosterone
concentration was significantly lower following 10 min forced swimming compared
with control levels, but not different from the post-swim concentration in virgin mice
(figure 7.2.).
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Figure 7.1. Effects of forced swimming on plasma ACTH concentrations in
virgin and pregnant mice.
Virgin and pregnant mice were exposed to 10 min forced swimming in water at
17°C. Immediately after exposure to the stressor mice were decapitated and trunk
blood was collected. Plasma ACTH concentration was determined using an
immunoradiometric assay. Values are plotted as group means ± SEM. Group
numbers: virgin/control, n = 11; pregnant/control, n = 10; virgin/forced swim, n = 11;
pregnant/forced swim, n = 4. Two-way ANOVA followed by Student Newman-
Keuls multiple comparison test was used for statistical analysis of the data: *p <
0.001 vs basal values in the same group; +p < 0.03 vs basal values in the same group;
#p < 0.001 vs all other groups.
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Figure 7.2. Effects of forced swimming on plasma corticosterone concentrations
in virgin and pregnant mice.
Virgin and pregnant mice were exposed to 10 min forced swimming in water at
17°C. Immediately after exposure to the stressor mice were decapitated and trunk
blood was collected. Plasma corticosterone concentration was determined by
radioimmunoassay. Values are plotted as group means ± SEM. Group numbers:
virgin/control, n = 11; pregnant/control, n = 10; virgin/forced swim, n = 11;
pregnant/forced swim, n = 4. Two-way ANOVA followed by Student Newman-
Keuls multiple comparison test was used for statistical analysis of the data: *p <
0.001 vs basal values in the virgin group; #p < 0.02 vs pregnant control group.
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7.3.3. Effects of confinement in a glass jar on plasma ACTH concentrations
Plasma ACTH concentrations were not significantly different between the virgin and
pregnant control groups (figure 7.3.). Following confinement in ajar for 10 min the
virgin group demonstrated a significant increase in ACTH secretion (3.7-fold;
p<0.001, two-way ANOVA). ACTH secretion in the pregnant group also showed a
tendency to increase (2-fold), however this increase was not significant (figure 7.3.).
7.3.4. Effects of confinement in a glass jar on plasma corticosterone
concentrations
As already described above plasma corticosterone concentrations were significantly
higher in the pregnant group under basal conditions compared with the virgin group
(figure 7.4.). Confinement in the jar for 10 min evoked a significant increase in
corticosterone secretion in the virgin group, however this stressor failed to have any
effect in the pregnant group (the difference between control and post-stress plasma
corticosterone concentrations in the virgin group was 211.8 ± 25.3 ng/ml vs 67.6 ±
78.5 ng/ml in the pregnant group).
7.3.5. Effects of confinement in a glass jar on nur77 mRNA expression in the
pPVN
Quantification of emulsion-dipped sections revealed that nur77 mRNA expression in
the pPVN was not significantly different between the virgin and the pregnant groups
under basal conditions (figure 7.5.). Confinement to the jar (10 min) evoked a
significant increase in nur77 mRNA expression in the virgin group, however this
response was absent in the pregnant group (53.4 ± 3.7 vs 35.4 ± 3.5 positive cells,
respectively; figure 7.5.). The level of nur77 mRNA expression in the PVN was 1.5-
fold greater in the virgin/stress group compared with the pregnant/stress group
(figure 7.5.).
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Figure 7.3. Effects of confinement in a glass jar on plasma ACTH
concentrations in virgin and pregnant mice.
Virgin and pregnant mice were exposed to 10 min confinement in a glass jar.
Immediately after exposure to the stressor mice were decapitated and trunk blood
was collected. Plasma ACTH concentration was determined by an
immunoradiometric assay. Values are plotted as group means ± SEM. Group
numbers: virgin/control, n = 11; pregnant/control, n = 10; virgin/jar, n = 11;
pregnant/jar, n = 9. Two-way ANOVA followed by Student Newman-Keuls multiple
comparison test was used for statistical analysis of the data: *p < 0.001 vs all other
groups.
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Figure 7.4. Effects of confinement in a glass jar on plasma corticosterone
concentrations in virgin and pregnant mice.
Virgin and pregnant mice were exposed to 10 min confinement in a glass jar.
Immediately after exposure to the stressor mice were decapitated and trunk blood
was collected. Plasma corticosterone concentration was determined by
radioimmunoassay. Values are plotted as group means ± SEM. Group numbers:
virgin/control, n - 11; pregnant/control, n = 10; virgin/jar, n = 11; pregnant/jar, n = 9.
Two-way ANOVA followed by Student Newman-Keuls multiple comparison test
was used for statistical analysis of the data: *p < 0.001 vs basal values in the virgin
group; #p < 0.001 vs all other groups.
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Figure 7.5.(a) Effects of confinement in a glass jar on nur77 mRNA expression
in the pPVN in virgin and pregnant mice.
Virgin and pregnant mice were exposed to 10 min confinement in a glass jar.
Immediately after exposure to the stressor mice were decapitated and brains were
rapidly removed and frozen on dry ice. Brain sections (15pm) were hybridised with
an [35S] oligo-probe complementary to nur77 mRNA. Autoradiography were
analysed and data are presented as number of positive cells (expressing nur77
mRNA) per PVN section (unilateral). Values are plotted as group means ± SEM.
Group numbers: virgin/control, n = 9; pregnant/control, n = 9; virgin/jar, n = 13;
pregnant/jar, n = 8. Two-way ANOVA followed by Student Newman-Keuls multiple
comparison test was used for statistical analysis of the data: *p < 0.001 vs all other
groups.
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Figure 7.5.(b) Effects of confinement in a glass jar on nur77 mRNA expression
in the pPVN in virgin and pregnant mice: Photomicrographs.
Brightfield photographs of autoradiographic film exposed for 28 days to coronal
brain sections hybridised with a ,5S-labelled oligo-probe complementary to nur77
mRNA from: A, virgin/control; B, virgin/jar; C, pregnant/control; D, pregnant/jar.
3 V, third ventricle; pPVN, parvocellular division of PVN. Scale bar = 100pm.
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Figure 7.5.(c) Effects of confinement in a glass jar on nur77 mRNA expression
in the pPVN: Photograph of Cellular Distribution.
Brightfield photograph of an emulsion-dipped section hybridised with a 35S-labelled
oligo-probe complementary to nur77 mRNA showing cellular distribution in the
pPVN. This is a representative section from a virgin mouse confined to ajar for 10
minutes. The solid arrows indicate nur77 mRNA expressing cells ("positive cells")
and the open arrows indicate cells which are not expressing nur77 mRNA. 3V
indicates direction of third ventricle. Scale Bar: 50 pm.
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7.4. Discussion
The present experiments demonstrate that ACTH secretion in response to
confinement in a glass jar (emotional stressor) and forced swimming (a combined
emotional and physical stressor) is increased in female mice as it is to other stressors
in male mice (Delrue-Perollet et al , 1995; Chesnokova et al , 1998; Dunn &
Swiergiel, 1999; Neveu & Liege, 2000). In pregnant mice the ACTH secretory
response to both of these stressors was significantly attenuated, consistent with the
findings in pregnant rats (Chapter 3-6). The attenuated ACTH secretory response in
the pregnant mice seems to be a result of reduced drive by CRH and/or AVP since
the parvocellular PVN neurones were activated less (indicated by reduced activation
of nur77 mRNA expression) following confinement to the jar in the pregnant group
than in the virgin group.
Nur77 binds to a response element (NBRE) in the promoter region of both the CRH
and the POMC gene and can regulate CRH and POMC gene transcription (Murphy et
al , 1995; Philips et al , 1997). In the pregnant mice nur77 mRNA expression was
markedly reduced following exposure to stress compared with the virgin mice. Thus
in pregnancy reduced activation of nur77 in response to stress may be involved in
reduced activation of the HPA axis. However studies with mice which carry a
targeted mutation in the nur77 gene (nur77 -/-) respond normally to changes in HPA
axis stimulation (with LPS, metyrapone and dexamethasone) (Crawford et al, 1995).
One explanation is that a functionally redundant transcription factor, such as nurrl
may compensate for the loss of nur77 in these mice. Nurrl encodes a product which
is highly homologous to nur77 and modulates gene transcription through the same
response element, NBRE (Wilson et al, 1993a).
Plasma corticosterone concentrations were significantly elevated in pregnancy under
basal conditions. This was not a consequence of enhanced ACTH signalling in
pregnancy, since plasma ACTH concentrations were not significantly different
between the virgin and pregnant groups. It may be a that sensitivity of the adrenal
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gland to circulating ACTH increases during pregnancy in mice. This may be an
effect of the priming effects of oestrogen on the adrenal gland, as has previously
been described in rats (Carr et al, 1981; Burgess & Handa, 1992). Basal levels of
circulating corticosterone are increased over the last few days of pregnancy in rats
(Atkinson & Waddell, 1995) and Cortisol levels have been shown to increase in the
last trimester of pregnancy in women (Magiakou et al, 1996) and in late pregnant
sheep (Keller-Wood & Wood, 1991). However, the rise in plasma corticosterone
concentration observed here in the pregnant mice is much greater than levels
normally observed in rats (1.3-fold increase in rats compared with a massive 19-fold
increase in mice).
If the adrenal gland is more sensitive to circulating basal levels of ACTH in pregnant
mice, then it should follow that the adrenal gland will also be more sensitive to
stress-induced increases in plasma ACTH, however this does not seem to be the case.
Both forced swimming and confinement to the jar induced modest increases in
ACTH secretion in the pregnant mice, however this increased ACTH signalling to
the adrenal gland did not result in hypersecretion of corticosterone. Instead, the
increase in plasma concentrations of ACTH in response to confinement to the jar had
little effect on plasma corticosterone concentrations in the pregnant mice and
moreover, corticosterone secretion in response to the increase in circulating ACTH
evoked by forced swimming was actually significantly reduced in the pregnant mice.
This finding is difficult to explain. It may be that on exposure to stress in pregnant
mice the already elevated basal levels of circulating corticosterone acts to restrain
further secretion of ACTH. An alternative explanation is that the corticosterone
originates from the foetal adrenals. Secretion of corticosterone by the foetal adrenals
begins between day 14-15 of pregnancy in the mouse (Montano et al, 1993). In rats,
llp-HSD-2 would be expected to limit the passage of corticosterone across the
placenta (Seckl, 1994), however in mice placental lip-HSD-2 activity and mRNA
expression are highest on day 13-14 of pregnancy but then decline progressively and
are undetectable by term (Condon et al, 1997). Thus it is plausible that the increase
in maternal plasma concentrations of corticosterone in the late pregnant mice is a
consequence of increased corticosterone secretion from the foetal adrenal glands.
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Whether the corticosterone detected is free or bound to CBG has not been
determined as yet.
Thus in pregnant mice the responsiveness of the HPA axis to the stressors tested here
is reduced at all levels, as it is during pregnancy in rats. Whether the precise
mechanisms are the same in rats and mice cannot be determined from these
experiments, though reduced central drive to the CRH and/or AVP neurones in
response to stress is likely to play a key role in maintaining the hyporesponsiveness
of the HPA axis in mice at this time. The finding that mice, as well as rats show
reduced HPA axis responses to stressors (i) shows that the findings in rats are not
species-specific (although the mechanisms may not be the same) and (ii) provides a
foundation for exploration of the mechanisms involved using transgenic mice.
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General Discussion
Remarkable physiological adaptations occur in pregnancy including changes in
metabolism, feeding behaviour and the cessation of ovarian cycling. The
responsiveness of the HPA axis and magnocellular oxytocin neurones to stress is also
altered in pregnancy. Previous studies have demonstrated that responsiveness of the
HPA axis to stress is decreased progressively as term approaches (Neumann et al,
1998) and persists through lactation until weaning (Windle et al, 1997). In lactation
the suckling stimulus is important for maintenance of reduced neuroendocrine
responses to stress, since the responsiveness of the HPA axis returns to "normal"
within two days of removal of the pups from their mother (Lightman & Young,
1989). The factor(s) involved in initiating reduced HPA axis responses in late
pregnancy are not known (possibilities are discussed later) and the mechanisms
underlying these attenuated responses are not fully understood. Changes at the
adenohypophysis, including reduced reactivity of pituitary corticotrophs to CRH and
decreased CRH receptor density (Neumann et al , 1998) have been shown to play a
role, however other mechanisms are likely to be involved. The aim of this thesis was
to investigate changes in central mechanisms underlying reduced stress responses in
pregnancy, with particular focus at the level of the hypothalamus.
In Chapter 3, experiments were designed to test whether the HPA axis is less
responsive to other emotional stressors in pregnancy and to establish whether these
attenuated HPA axis responses to stress in pregnancy are a consequence of reduced
activation of parvocellular PVN neurones. Pregnant rats demonstrated attenuated
ACTH and corticosterone secretory responses to maternal aggression (see figures
3.5. and 3.6.) and reduced ACTH secretion after exposure to restraint (see figure
3.1.). Decreased NGFI-B mRNA expression in the pPVN of late pregnant rats
following restraint stress indicates that the pPVN neurones are stimulated less
strongly by the stressor in pregnancy (see figure 3.2.). Since a NGFI-B response
element has been identified in the promoter region of the CRH gene (Wilson et al,
1991), NGFI-B is a putative regulator of CRH gene transcription in late pregnant
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rats. Thus exposure to restraint stress is less effective in activating CRH neurones,
and hence CRH gene transcription in late pregnant rats. AVP hnRNA expression in
the pPVN was also significantly lower in the pregnant rats after restraint stress (see
figure 3.4.). Together the data indicate that reduced activation of the HPA axis
following exposure to an emotional stressor in pregnancy is a consequence of
reduced stimulation of CRH and/or AVP neurones in the pPVN.
In Chapter 4 experiments were performed to investigate whether the HPA axis is also
less responsive to peripheral immune challenge in pregnancy. The ACTH secretory
response to i.v. LPS was strongly attenuated in pregnant rats (see figure 4.2.).
Similarly there was a striking reduction in ACTH and corticosterone secretion in
response to systemic IL-ip in the late pregnant rats (see figures 4.3. and 4.4.). These
findings appear to be a result of reduced CRH and/or AVP drive to the anterior
pituitary, since CRH mRNA expression in the pPVN was not stimulated by i.v. IL-
1P in the pregnant rats, as it was in the virgin rats (see figure 4.6.), indicating failure
of IL-ip to activate the CRH neurones in pregnancy. If it is assumed that activation
of CRH gene transcription reflects stimulation of the CRH cell bodies, which
simultaneously triggers CRH release from the nerve terminals, then it follows that
less CRH is released at the median eminence in the pregnant group in response to
stimulation with i.v. IL-ip. The differences in activation of the pPVN neurones
between virgin and pregnant rats following systemic IL-ip are not as a result of
differential activation of the brainstem input to the PVN from the A2 cell region of
the NTS, since Fos expression in this region was similar in the virgin and pregnant
groups after IL-ip administration (see figure 4.7.). These data indicate that signalling
between the NTS and the pPVN following IL-ip administration is interrupted in
pregnancy, resulting in reduced activation of the HPA axis. The precise mechanism
involved is not clear though several possibilities exist (these are summarised in
figure 8.1.).
Ascending noradrenergic projections from the NTS in the brainstem to the PVN are
important in relaying information from the periphery to the PVN neurones following
activation of the immune system (Wilson et al, 1991). If NA release is blocked pre-
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or post-synaptically in pregnancy, this may explain the reduced responsiveness of the
HPA axis to immune challenge with i.v. IL-lp. Furthermore, signalling via limbic
forebrain structures including the CeA and the BNST has recently been shown to be
important (Buller et al, 2001) in mediating activation of the HPA axis following
systemic administration of IL-ip. This signalling pathway was not studied here,
however interruption of signalling through these structures may contribute to the
hyporesponsiveness of the HPA axis in pregnancy.
Endogenous opioids are involved in restraining HPA axis responses to IL-ip in
pregnancy, since blocking the actions of opioids with the opioid receptor antagonist,
naloxone, largely reinstated an ACTH secretory response to systemic IL-ip (see
figure 4.8.). Moreover, naloxone pretreatment restored a response to i.v. IL-ip at the
level of the CRH neurones in the pregnant rats, as indicated by increased pPVN CRH
mRNA expression. However naloxone resulted in an attenuated pPVN CRH mRNA
response to IL-ip in the virgin group, resulting in CRH mRNA responses that were
not different between virgin and pregnant rats (see figure 4.10.). These data indicate
that the effects of endogenous opioids on the HPA axis switch from being excitatory
in virgin rats to being inhibitory in pregnant rats and strongly support a role for
endogenous opioids in attenuated HPA axis responses to peripheral administration of
IL-ip. It is feasible that endogenous opioids may be acting at the level of the
noradrenergic nerve terminals to restrain NA release and thus limit excitatory input
to the pPVN.
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The oxytocin secretory response to immune challenge with systemic IL-ip was also
markedly less in the pregnant group compared with the virgin group. However
pretreatment with naloxone revealed an exaggerated oxytocin secretory response to
IL-ip in the pregnant rats (see figure 4.9.), indicating that in pregnancy, oxytocin
secretion following immune challenge is restrained by endogenous opioids. This may
be an effect of opioids acting either directly on the oxytocin cell bodies or on their
presynaptic inputs, possibly their noradrenergic inputs. Previous studies using
cholecystokinin (CCK) to stimulate the noradrenergic projection from the A2 cell
group in the brainstem NTS to oxytocin neurones have indicated that central opioid
inhibition of this system is enhanced in late pregnancy (Douglas et al, 1995).
Furthermore, naloxone potentiates the CCK-induced firing rate of oxytocin neurones
in late pregnant rats but has no effect on basal activity suggesting that endogenous
opioids are acting presynaptically to restrain activity of the oxytocinergic system and
thus oxytocin release.
Further studies employing specific receptor antagonists are necessary to establish the
specific receptor type involved in mediating the inhibition over the CRH and
oxytocin neurones. Also combined immunohistochemical and retrograde tracing
studies are necessary to establish the origin of the endogenous opioids responsible
for restraining activity of the CRH and oxytocin neurones. Two candidate sites are
the arcuate nucleus and the NTS. The arcuate nucleus is home to a population of P-
endorphin cells which project to both the PVN (Drolet et al, 2001) and the SON
(personal communication with S.L. Meddle). The number of arcuate neurones
expressing POMC and p-endorphin is significantly increased by day 21 of pregnancy
(Redmond et al, 1996). Furthermore, expression of pro-enkephalin (pENK) and p-
opioid receptor mRNA increases in the NTS neurones in late pregnancy (Meddle et
al, 2001). Hence opioids from the arcuate nucleus and/or the NTS may be involved
in modulating the activation of CRH and/or oxytocin neurones by stress in
pregnancy.
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Thus in pregnancy, the responsiveness of the HPA axis to the physical stressor,
immune challenge is greatly reduced as it is following exposure to emotional
stressors. To determine whether the CRH neurones were also non-responsive to other
excitatory stimuli in pregnancy, specifically those involved in regulating metabolism
and arousal, the effects of orexin-A on HPA activity was measured. I.e.v.
administration of orexin-A evoked an increase in PVN CRH mRNA expression,
ACTH and corticosterone secretion in virgin rats (see figures 5.1., 5.2., and 5.3.).
However in pregnant rats, orexin-A failed to evoke any such effects. The failure of
orexin-A to induce an increase in CRH mRNA expression indicates that the CRH
neurones are not activated. This together with the previous findings suggests that in
pregnancy there is a "global reduction" in the responsiveness of the CRH neurones
(and hence the HPA axis) to all excitatory stimuli (though the mechanisms involved
might not be the same for all stimuli).
In Chapter 6 evidence was sought for altered glucocorticoid feedback sensitivity in
pregnancy. Removal of the glucocorticoid inhibitory feedback signal by phADX over
48h resulted in an increase in both CRH and AVP mRNA expression in the pPVN of
both virgin and pregnant rats (see figure 6.1. and 6.2.), however phADX induced a
significantly greater increase in CRH and AVP mRNA expression in the pregnant
group under basal conditions. This suggests that in late pregnancy the slow feedback
signal is enhanced or that the PVN neurones are more sensitive to slow
glucocorticoid negative feedback. There was a concomitant rise in basal ACTH
secretion in both the virgin and the pregnant rats following 48h phADX (see figure
6.3.), however in contrast to CRH and AVP mRNA expression in the PVN, the
increase in ACTH secretion after phADX was significantly greater in the virgin
group, suggesting altered sensitivity of the anterior pituitary to CRH and/or AVP in
pregnancy. Alternatively, despite the increase in pPVN CRH and AVP mRNA
expression following removal of glucocorticoid feedback it is possible that reduced
forward drive still restrains CRH and/or AVP secretion in pregnancy, resulting in
reduced ACTH secretion.
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The ACTH and corticosterone secretory response normally observed in response to
restraint stress was absent in both the virgin and the pregnant rats following 24h
phADX (see figure 6.9. and 6.10). Whether this was a result of the rats being non-
responsive and unaware of their environment or a consequence of a build-up of
neuroactive steroids (as a result of blocking the final step in corticosterone
biosynthesis, and the consequent build-up in corticosterone precursors) which may
affect HPA activity is not clear, though it is an unexpected result of the phADX
process.
Enhancing the rapid negative feedback signal with acute administration of exogenous
corticosterone resulted in a dramatic reduction in stress-induced (forced swimming)
ACTH secretion in intact virgin rats, whereas corticosterone administration had no
effect in the pregnant group (see figure 6.12.). The results are consistent with a loss
of rapid corticosteroid feedback in pregnancy. Thus it seems that enhanced rapid
negative feedback is not involved in the reduced responsiveness of the HPA axis to
acute stress in pregnancy, instead it seems more likely that if corticosterone feedback
is involved it is a consequence of more prolonged exposure to elevated
corticosterone levels associated with slow feedback mechanisms. Increased
sensitivity to slow glucocorticoid negative feedback in pregnancy has previously
been suggested from a study demonstrating increased GR mRNA expression in the
dentate gyrus and increased lip-HSD activity in the PVN on day 21 of pregnancy,
concomitant with reduced levels of basal CRH and AVP mRNA expression in the
PVN (Johnstone et al, 2000a).
Finally a comparative study was performed to determine whether the HPA axis is
also hyporesponsive in another rodent species, namely the mouse. Forced swim
stress and confinement to a glass jar evoked significant increases in ACTH secretion
in the virgin mice, an effect that was markedly attenuated in the late pregnant mice
(see figure 7.1. and 7.3.). The reduced pituitary response to these stressors in the
pregnant mice is likely to be an effect of reduced drive by CRH and/or AVP (like it
is in rats), since the pPVN neurones were activated by the stress less in the pregnant
mice (indicated by reduced nur 77 mRNA expression in this region; see figure 7.5.).
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The greatly enhanced basal levels of plasma corticosterone compared with those in
rats, suggests that other mechanisms (not present in rats, possibly involving rapid
glucocorticoid feedback mechanisms) may contribute to attenuated HPA axis
responses to stress in mice.
What is it aboutpregnancy that triggers these central changes?
Pregnancy is accompanied by a large increase in progesterone and oestrogen
secretion, which in the rat are produced by the ovaries. The ovaries are essential for
the maintenance of pregnancy and the collapse in progesterone secretion on the last
two days of pregnancy is an important trigger for parturition (Csapo & Wiest, 1969).
Studies have shown that sex steroids can modify the stress response. Opioid
inhibition of oxytocin secretory responses to stress is greater in female than male rats
(Carter et al, 1986). The development of the endogenous opioid tone in pregnancy
may partly be due to the concomitant rise in plasma oestrogen and progesterone.
Progesterone increases P-endorphin content of the hypothalamus and enhances
POMC expression in the arcuate nucleus (Bridges & Ronsheim, 1987), similar to that
observed in pregnancy (Redmond et al, 1996).
Virgin rats implanted subcutaneously with oestrogen and progesterone ( over 17 days
to mimic levels observed in pregnancy (Bridges, 1984)) demonstrate a modest
decrease in the oxytocin secretory response to forced swimming compared with
control animals (Douglas et al, 2000), similar to the response observed in pregnancy
(Douglas et al, 1998). However the oxytocin secretory response to forced swimming
was strongly enhanced in sex steroid-treated virgin rats in the presence of naloxone,
revealing strong opioid inhibition of oxytocin neuronal activity. Thus oestrogen and
progesterone treatment induces opioid inhibition over oxytocin neurones, similar to
that observed in pregnancy (Douglas et al, 1998).
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In contrast, the ACTH and corticosterone secretory response to swim stress are not
affected by sex steroids either alone or in the presence of naloxone (Douglas et al ,
2000). These data suggest that increasing circulating sex steroids are important in
inducing opioid restraint over oxytocin neurones in pregnancy, however do not
appear to be sufficient to induce the increased opioid tone over HPA secretory
responses to stress in pregnancy.
Another factor that may be involved in restraining the HPA axis in pregnancy is the
progesterone metabolite, allopregnanolone. Allopregnanolone is a "neuroactive
steroid" which is synthesised from cholesterol by glial cells within the brain (for
reviews see (Paul & Purdy, 1992; Majewska, 1992)). Although the brain has the
capacity to synthesise allopregnanolone the majority present in the brain is derived
from circulating progesterone (Corpechot et al, 1993; Cheney et al, 1995). During
pregnancy when circulating progesterone levels increase there is a concomitant rise
in brain levels of allopregnanolone (Paul & Purdy, 1992), reaching peak
concentrations on day 19 (Concas et al, 1998). Allopregnanolone can act upon
neurones expressing GABAa receptors to enhance inhibitory GABA transmission
(Majewska, 1992; Lambert et al, 1995; Rupprecht & Holsboer, 1999). This action of
allopregnanolone has been shown to be important in regulating oxytocin neurones
(Fenelon & Herbison, 1996; Fenelon & Herbison, 2000). Brussaard and colleagues
have shown that in late pregnancy, allopregnanolone can directly enhance oxytocin
neurone GABAa receptor signalling resulting in a powerful inhibitory influence upon
the neurone (Brussaard et al, 1997; Brussaard et al, 1999; Brussaard & Herbison,
2000).
The effects of allopregnanolone on HPA activity in pregnancy have recently been
investigated. Treatment of pregnant rats with the 5a-reductase (one of the enzymes
involved in the conversion of progesterone to allopregnanolone) inhibitor, 4-MA
fully reinstates an ACTH secretory response to forced swimming such that levels are
not significantly different from virgin control rats (personal communication with S.
Ma). These data strongly suggest a role for allopregnanolone in reduced HPA axis
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responses to stress in pregnancy. Whether allopregnanolone also has a role in
attenuated HPA axis responses to other stressors requires further investigation.
As well as the increased levels of sex steroids (and their metabolites) in pregnancy,
there are also increased amounts of various peptide hormones in the maternal
circulation, including relaxin and lactogenic hormones.
Relaxin is a polypeptide hormone produced by the corpora lutea. In the pregnant rat,
circulating levels of relaxin become detectable around day 10 and steadily increase
until a surge prepartum (Goldsmith et al, 1995). The actions of relaxin on the
reproductive tract and its role in osmoregulation via actions on the central nervous
system have been well documented (Kakouris et al, 1993; Goldsmith et al , 1995).
Since levels of circulating relaxin progressively increase during the second half of
gestation, at a time when attenuated HPA axis responses to stress are manifested in
pregnant rats, relaxin is a possible candidate for initiating central changes. Relaxin
secretion from the corpora lutea in pregnancy has previously been shown to be
important for endogenous opioid inhibition of oxytocin neurones (Way et al, 1993).
However, to date no study has investigated a role for relaxin in reduced HPA axis
responses in pregnancy. Relaxin is a relatively large polypeptide (molecular weight
is ~ 6000 Daltons) and would not be expected to cross the BBB. Instead relaxin is
thought to exert its actions on the brain via circumventricular organs. Indeed
autoradiographic studies have localised relaxin binding sites in the SFO and OVLT
(Heine et al, 1997; McKinley et al, 1997). The SFO sends afferent projections to
both the SON and the PVN (McKinley et al, 1996), hence it is not unreasonable to
think that circulating relaxin may be capable of influencing the activity of CRH
neurones via this pathway from the SFO. However relaxin binding sites have also
been demonstrated in the PVN, SON, arcuate nucleus, amygdala and hippocampus
(Heine et al , 1997; McKinley et al , 1997). Although it has yet to be shown, it is
conceivable that the brain itself is capable of synthesising relaxin which may act at
these binding sites to influence the responsiveness of CRH neurones to excitatory
stimuli in pregnancy.
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In rodents prolactin secretion during early pregnancy is induced by the mating
stimulus and is characterised by twice daily surges (Gunnet & Freeman, 1983). At
day 10 of pregnancy, pituitary prolactin secretion is inhibited when placental
lactogen levels begin to increase (Voogt & De Greef, 1989). There are two forms of
placental lactogen in rats (rPL) and both can bind to the prolactin receptor
(Robertson et al, 1982). rPL-I is only present for a few days around mid-gestation
(Robertson et al , 1982). The second, rPL-II begins to be detected in the blood
shortly after the appearance of PL-I and progressively increases throughout the
second half of pregnancy reaching peak levels by ~ day 20 (Robertson & Friesen,
1981). Prolactin is a fairly large polypeptide (197-199 amino acids) and would not be
expected to cross the BBB, however there is evidence that systemic prolactin gains
access to the CSF from where it can diffuse to numerous brain regions (Login. I.S &
MacLeod, 1977; Nicholson et al, 1980; Kalin et al, 1981). It has been suggested that
prolactin binding sites in the choroid plexus are involved in the transport of prolactin
from the blood into the aCSF (Nicholson et al , 1980). Receptors for prolactin are
present in the SON and PVN (Pi & Grattan, 1998) and RT-PCR studies (in the whole
brain) have shown dramatic increases in expression of prolactin receptor mRNA
during pregnancy (Sugiyama et al, 1994). In pregnancy and lactation prolactin
mRNA expression in the hypothalamus is significantly increased (Torner et al,
2001). Furthermore, antagonising the prolactin receptor with i.e.v. antisense
oligonucleotides increases stress-induced ACTH secretion in lactating rats (Torner et
al, 2001). In light of the evidence above it seems possible that prolactin may play a
role in the adaptations of HPA axis responses that occur in pregnancy.
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What is the functional significance of these adaptations that occur in
pregnancy?
Pregnancy clearly represents a conflict between the mother's need to maintain her
own health and meet the demands from the developing offspring in order to
maximise their potential. Therefore during pregnancy the mother must provide a safe
environment with adequate nutrition and limit the exposure of the foetuses to
damaging agents. So, are the changes in responsiveness of the HPA axis beneficial to
both the mother and her offspring or does the mother compromise herself in order to
protect the foetuses? Despite the presence of 11 (3-HSD in the placenta,
glucocorticoids can still gain access to the foetus. In pregnancy the
hyporesponsiveness of the HPA axis to stressors limits exposure of the foetus to
excessive levels of corticosterone in utero. As discussed in Chapter 1 the developing
foetus can be programmed by glucocorticoids which can have life-long detrimental
consequences and predispose the offspring to various diseases throughout their life
(see Chapter 1).
Restraining the maternal HPA axis may also have metabolic advantages to the
pregnant mother. During late pregnancy rats increase their food intake during the
dark phase (Cripps & Williams, 1975) and unsurprisingly this is associated with an
increase in maternal fat and body weight (Shirley, 1984). Plasma leptin concentration
increases in the dark phase, however it has recently been reported that there is no
further increase in pregnant rats, as would be expected due to the increase in adipose
tissue in pregnancy. Furthermore, in pregnancy there appears to be a resetting of the
central mechanisms regulating appetite, since central leptin administration is less
effective in reducing food intake in late pregnant rats (Johnstone & Higuchi, 2001).
Thus in pregnancy reduced sensitivity to central actions of leptin will result in a
decreased satiety effect and therefore produce a state of hyperphagia, thus allowing
for adequate energy intake to meet the increasing demands of the foetus. Since
glucocorticoids are catabolic compounds it would seem that limiting their production
in pregnancy in response to stress would be beneficial to the mother. This in
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association with increased food intake and reduced actions of leptin will help
maintain a positive energy balance.
Here the responsiveness of the HPA axis to orexin-A was markedly attenuated in late
pregnancy. No direct measure of food intake was made (as the experiment was
performed early in the light phase when feeding is usually minimal), however, crude
observations indicated increased "oral motor activity" in both the virgin and the
pregnant orexin-treated rats. This suggests that the pregnant rats are still able to
respond behaviourally to the orexigenic signal, however the pPVN neurones are
stimulated less by this signalling in pregnancy. It is not known whether in pregnancy
the centrally projecting CRH neurones (that project to feeding centres) respond in a
similar way to those which project to the median eminence. It would be beneficial to
the mother for these neurones to also be less responsive to excitatory stimuli since
centrally acting CRH is known to inhibit food intake (Schwartz et al, 2000).
In conclusion, the responsiveness of the HPA axis to stressors is dramatically
attenuated in pregnancy. The reduced responses observed in late pregnancy seem to
persist irrespective of the nature of the stressor, be it a mild 'emotional' stressor or a
more severe 'physical' stressor, indicating a "global reduction" in the responsiveness
of the HPA axis to stress in pregnancy. Changes in central drive to the pPVN CRH/
AVP neurones and their responsiveness to excitatory inputs seems to be the most
important factors in the reduced responsiveness of the HPA axis to stressors in late
pregnancy, although enhanced slow glucocorticoid negative feedback may also
contribute. What triggers these changes to occur is not known, however increased
levels of pregnancy associated hormones and neuroactive steroids may be involved.
This remarkable phenomenon, peculiar to pregnancy, will limit exposure of the
foetuses to excessive levels of glucocorticoids, protect them from permanent
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